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“Those who do not want to imitate anything, produce nothing” 
- Salvador Dalí 
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Résumé 
Deux principaux sujets ont été décrits dans ce manuscrit. La première partie traite de la 
réaction de Michael organocatalique et énantiosélective de différents donneurs de Michael 
avec la phenyl vinyl selenone. D’un côté les nitroacetates -substitués ont été utilisés comme 
donneurs de Michael. En présence de dérivés d’alkaloides du quinquina comme 
organocatalyseur, la synthèse de dérivés d’amino-acides quaternaires enantioenrichis a été 
possible. D’un autre côté, les nitroamides -substitué ont aussi été utilisés comme partenaires 
dans cette réaction. Avec eux, une séquence d’addition de Michael organocatalytique suivie 
d’une SN2 intramoléculaire et d’une hydrolyse a été développée pour la synthèse de -lactone 
avec une enantiosélectivité modérée. La deuxième partie est focalisée sur l’insertion de 
différent isocyanures catalysés par des métaux de transition pour la synthèse de produits 
naturels et d’heterocycles variés. Dans un premier temps nous avons développé la synthèse de 
imidazolones-3,5,5-trisubstitués en utilisant l’insertion de ,-dibenzyl -isocyanoacetate 
avec une amine primaire catalysée par du nitrate d’argent. Avec cette même méthodologie, 
evodiamine et rutaecarpine, deux produits naturels, ont été synthétisés à partir de l’o-
isocyanobenzoate de méthyle. La synthèse de imidazolones-2,3,5,5-tetrasubstitués a aussi été 
reportée par l’utilisation de la réaction trois-composantes de ,-dibenzyl -isocyanoacetate, 
d’une amine primaire et d’iodure d’aryle en présence d’un système bimetallique 
palladium/cuivre. Dans un second temps, l’insertion d’isocyanure catalysé par du palladium a 
été étudiée. La réaction multicomposante d’une amine primaire, d’un iodure d’aryle et de l’o-
cyanobenzonitrile catalysée par du palladium a permis l’élaboration de quinazolin-4-one 2-
substitué. Finalement, le procédé domino catalysé par du palladium entraine l’insertion 
d’isocyanure et l’activation C(sp)3-H du 3-cyclopropyl-2-isocyanopropanoate pour fournir un 
azaspiro[2.4]hept-4-ene C-2 arylé. 
 
Mots clés: organocatalyse, phenyl vinyl selenone, amino acide quaternaire, 
nitroacetate, nitroamide,  alkaloide du quinquina, insertion d’isonitrile, , ,-disbustittued 
isocyanoacetate, imidazolone, quinazolin-4-one, reaction multicomposantes, procédé domino.  
9 
 
Abstract 
This manuscript covers two main topics. The first part dealt with the organocatalytic 
conjugate addition of Michael donors to phenyl vinyl selenone. The enantioselective 
Cinchona alkaloid-catalyzed Michael addition using -substituted -nitroacetates has been 
developed. The synthesis of various -dialkyl -nitroacetates has been accomplished in 
excellent yield and good enantioselectivity which were subsequently converted to cyclic and 
acyclic quaternary amino acids, taking advantage of the rich functionalities of the adducts. 
-Substituted -nitroamides have also been utilized as nucleophile. With them, an 
organocatalytic Michael addition/intermolecular SN2/hydrolysis sequence have been 
developed for the synthesis of -lactones in moderate enantioselectivity. The second part of 
the manuscript focused on the transition-metal-catalysed insertion of isocyanides bearing 
participating functional group for the synthesis of heterocycles and natural product. On the 
one hand, the synthesis of 3,5,5-trisubstituted imidazolones using silver-catalyzed reaction of 
,-disubstituted -isocyanoacetate with primary amine have been developed. To illustrate 
this methodology, evodiamine and rutaecarpine, two natural products, have been synthesized 
using methyl o-isocyanobenzoate. The synthesis of 2,3,5,5-tetrasubstituted imidazolones have 
been also reported using the 3-CR reaction of ,-dibenzyl -isocyanoacetate, primary amine 
and aryl iodide in the presence of a palladium/copper bimetallic system. On the other hand, 
palladium catalysed isocyanide insertion have been explored. The Pd-catalyzed 
multicomponent reaction of primary amine, aryl halide and o-cyanobenzonitrile has permitted 
the construction of 2-substituted quinazolin-4-one. Finally, the Pd-catalyzed domino process 
isocyanide insertion/C(sp)
3
-H activation of 3-cyclopropyl-2-isocyanopropanoate furnished C-
2 arylated azaspiro[2.4]hept-4-ene.  
 
Key words: Organocatalysis, phenyl vinyl selenone, quaternary amino acids, nitroacetate, 
nitroamide, cinchona, isocyanide insertion, ,-disbustittued isocyanoacetate, imidazolone, 
quinazolin-4-one,  multicomponent reaction, domino process.  
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conv   Conversion  
CR (3-CR)  Component reaction  
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d  Day  
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Coming through the project 
From isocyanide… 
Isocyanide, named also as isonitrile, is an important reactive group in chemistry. With 
its resonance forms,
1
 the isocyanide group has been generally represented as a polarized triple 
bond (Scheme 1, I-2) or as carbene-like molecule with a free lone pair on the carbon (Scheme 
1, I-3). This particular hybridization has offered to this moiety the ability of reacting rapidly 
with an electrophile and a nucleophile almost simultaneously. 
 
Scheme 1: isocyanide classical reactivity. 
Firstly isolated by Lieke in 1859,
2
 the isocyanide was popularized in the middle of the 
20
th
 century with the discovery of multicomponent reactions. In 1921, Passerini described the 
three component reaction (P-3CR, Scheme 2 (a))
 3
 of carboxylic acid I-5, carbonyl I-4 and 
isocyanide I-1 whereas Ugi reported in 1961 the four component reaction (U-4CR, Scheme 2 
(b))
4
 where an amine I-7 reacted with the same adducts used in the P-3CR to give bis-amides 
I-8.
5
 With the multiple possibilities of adducts association, various complex molecules could 
be constructed in one step from readily available starting material.
6
 
 
Scheme 2: (a) Passerini three component reaction, (b) Ugi four component reaction. 
 Application of the isocyanide chemistry has been largely investigated. From 
hetereocycle synthesis to polymer construction, through to carbene-ligand design and natural 
product synthesis;
7
 numerous fields have been impacted by this chemistry. In organic 
                                                 
1
 R. Ramozzi, N. Chéron, B. Braida, P. C. Hiberty, P. Fleurat-Lessard, New J. Chem. 2012, 36, 1137. 
2
 W. Lieke, Justus Liebigs Ann. Chem. 1859, 112, 316. 
3
 (a) M. Passerini, Gazz. Chim. Ital. 1921, 51, 126; (b) M. Passerini, Gazz. Chim. Ital. 1921, 51, 181; (c) M. 
Passerini, G., Ragni, ibid. 1931, 61, 964. 
4
 (a) I. Ugi, C. Steinbrückner, Chem. Ber. 1961, 94, 734-742; (b)  I. Ugi, C. Steinbrückner, Chem. Ber. 1961, 
94, 2802; (c) I. Ugi, Angew. Chem. Int. Ed. Engl. 1962, 1, 8. 
5
 For more details on the history of isocyanide chemistry, see: I. Ugi, B. Werner, A Dömling, Molecules 2003, 8, 
53. 
6
 (a) A. Dömling, I. Ugi Angew. Chem. Int. Ed. 2000, 39, 3168; (b) J. Zhu, Eur. J. Org. Chem. 2003, 2003, 1133; 
(c) J. Zhu, H. Bienaymé, Multicomponent Reactions, Wiley-VCH, Weinheim, Germany, 2005; J. Zhu, Q. Wang, 
M.X. Wang, Multicomponent Reactions in Organic Synthesis, Wiley-VCH, 2014. 
7
 V. G. Nenajdenko, Isocyanide Chemistry: Application in Synthesis and Material Science, Wiley-VCH, 2012. 
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chemistry, the art of retrosynthesis using isocyanide-based MCR has been challenging but 
several research groups have developed impressive total synthesis with this isocyanide 
chemistry. 
The total synthesis of Eurystatin A (I-9) by Semple and coworkers in 2001 is a good 
example of isocyanide-based MCR utilization.
8
 This natural macrocycle was synthesized with 
a late peptide coupling of I-10. This linear peptide precursor I-10 was formed via N-acyl 
migration of the ester intermediate I-11. I-11, was constructed concisely using the Passerini-
3CR of alaninal I-12, leucine isonitrile I-13, and ornithine derivative I-14 (Scheme 3). 
 
Scheme 3: Semple’s retrosynthesis for the total synthesis of Eurystatin A starting from P-3CR. 
Ecteinascidin 743 (I-15), also known as Trabectedin, is an anti-tumor drug. Firstly 
synthesized by Corey,
9
 Fukuyama has also highlighted the use of the isocyanide chemistry in 
the beautiful total synthesis of this natural product.
10
 Ecteinascidin 743 was obtained using the 
same end-game strategy as Corey reported involving oxidation and Pictet Spengler reaction of 
I-16. The ten-membered sulfide was constructed by a sequential Friedel-Craft, esterification 
and macrocyclization of the intermediate I-18 with the cysteine derivative I-19. The aldehyde 
I-18 was isolated from the key intermediate I-20 after an intramolecular Heck reaction and 
functional group modification (Scheme 4). 
                                                 
8
 T. D. Owens, G.-L. Araldi, R. F. Nutt, J. E. Semple, Tetrahedron Lett. 2001, 42, 6271. 
9
 E. J. Corey, D. Y. Gin, R. S. Kania, J. Am. Chem. Soc. 1996, 118, 9202. 
10
 A. Endo, A., Yanagisawa, M., Abe, S., Tohma, T., Kan, T. Fukuyama, J. Am. Chem. Soc. 2002, 124, 6552. 
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Scheme 4: Fukuyama’s retrosynthesis approach for the Total Synthesis of Ecteinascidin 743. 
The key framework I-20 was synthesized in few steps via an Ugi 4 component 
reaction (Scheme 5). Ethanal, 1-isocyano-4-methoxybenzene I-22, amine I-21 and amino acid 
I-23 reacted in methanol under reflux to deliver I-24 in 90% yield. After 
deprotection/protection/cyclization sequence, the key cyclic dipeptide I-20 was isolated in 
72% yield over 4 steps. 
 
Scheme 5: Synthesis of the key intermediate via U-4CR. 
Our group has been exploring the isocyanide reactivity for years and with a common 
affection for natural product total synthesis, some potent synthetic targets have been 
architected using isonitrile properties. The most recent example is the efficient 7 steps first 
total synthesis of (+)-Peganumine A (I-25) which was reported last year.
11
 (+)-Peganumine A 
was accomplished via a one pot enantioselective Pictet-Spengler/Brønsted acid-catalyzed 
transannular cyclization of the commercially available 6-methoxytriptamine I-26 and the 
                                                 
11
 C. Piemontesi, Q. Wang, J. Zhu, J. Am. Chem. Soc. 2016, 138, 11148. 
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tetracyclic intermediate I-27. This tetracyclic core was synthesized by an isocyanide-base 
MCR of the isonitrile compound I-28 which was obtained from the Liebesking-Srogl 
coupling of I-29 and the isocyanide derivative of 6-methoxytriptamine I-30 (Scheme 6). 
 
Scheme 6: (+)-Peganumine A: our retrosynthesis. 
Two different multicomponent reactions to synthesize the key intermediate I-27 have 
been developed. The Passerini reaction of I-28, TFA and pyridine in DCM at room 
temperature offered the ten-membered lactam I-30. After transannular cyclization of the 
amide group on the carbonyl, the tetracyclic structure was formed to give the molecule I-31. 
Deprotection followed by a Corey-Kim oxidation on the alcohol lead to the desired compound 
I-27. The second approach engaged the isocyanide I-28, methylhydroxylamine and acetic acid 
to deliver the macrolactam I-32. After -elimination with released of AcOH, the imine I-33 
underwent spontaneously hydrolysis and transannular cyclization to afford the key product I-
27 (Scheme 7). 
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Scheme 7: Formation of the tetracyclic skeleton from two isocyanide-based MCR approaches. 
The total synthesis of (±)-Trigonolimine B (I-34) has also been intensively 
investigated by our group through isocyanide chemistry. The first retrosynthesis approach 
envisioned the application of the Ugi-4CR as an initial step. With this proposal only four steps 
were required for the synthesis of (±)-Trigonolimine B (Scheme 8). However, after numerous 
experiments on this first step, this retrosynthesis analysis has shown to be unfruitful.
12
 
 
Scheme 8: First unsuccessful retrosynthesis approach: Ugi-4MCR. 
…through isocyanoacetate… 
 To synthesize the challenging quaternary carbon present in the natural product, we 
decided to use the reactivity of -isocyanoacetate as alternative. With two electron 
withdrawing groups on the same carbon, this small molecule possesses strong nucleophilic 
                                                 
12
 T. Buyck, J. Zhu, Isocyanoacetates as Synthetic Platform Towards Natural Products and Biologically 
Relevant Scaffolds, PhD Thesis, 2014. 
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properties. The double functionalization of this camouflaged glycine template has allowed the 
easy construction of fully substituted carbon. With this approach depicted in Scheme 9, the 
total synthesis of (±)-Trigonolimine B was accomplished with the Bischler-Napieralski 
reaction on the spiro compound I-35 as end-game step. I-36 was made via two ring-closing on 
compound I-39. The indole I-39 was synthesized from the reductive amination of 2-(6-
(methoxy)indol)-acetaldehyde I-40 and the ,-disubstituted -aminoester I-41. An aromatic 
nucleophilic substitution and an alkylation with the -isocyanoacetate formed the desired 
compound I-41 which contain the quaternary carbon.
13
  
 
Scheme 9: Our successful retrosynthesis approach for the total synthesis of (±)-Trigonolimine B: -
isocyanoacetate approach. 
After the racemic 7 steps-total synthesis of (±)-Trigonolimine B, we envisaged the 
enantioselective synthesis of another member of this indole alkaloid family, Trigonolimine A 
(I-45). The retrosynthetic analysis for the synthesis of (+) or (-)-Trigonolimine A has been 
very similar to the one previously described (Scheme 10). This natural product could be 
disconnected to three parts: trimethyl orthoformate I-46, a chiral quaternary -aminoester I-
47 and an aldehyde derivative of tryptamine I-48. To install the chiral quaternary carbon of 
the compound I-47, we decided to develop an enantioselective Michael addition of -aryl -
isocyanoacetate I-49 to phenyl vinyl selenone I-50.
14
  
                                                 
13
 T. Buyck, Q. Wang, J. Zhu, Org. Lett. 2012, 14, 1338. 
14
 T. Buyck, Q. Wang, J. Zhu, Angew. Chem. Int. Ed. 2013, 52, 12714. 
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Scheme 10: Enantioselective retrosynthesis approach for the total synthesis of Trigonolimine A 
 After intensive reaction conditions screening (catalyst, solvent, temperature, 
additives…), the optimized enantioselective Michael addition of -substituted -
isocyanoacetate I-49 and phenyl vinyl selenone occurred smoothly using 10 mol% of 
Cinchona alkaloid as organocatalyst in toluene at -40 °C during 3 days. Good yields and 
enantioselectivities were obtained and various substituted aromatics (with donating or 
withdrawing group in ortho, meta and para position) and heterocycles on the -aryl 
isocyanoacetate were tolerated (Scheme 11). With this methodology, the synthesis of 
enantioenriched quaternary -amino acids derivatives, important building blocks massively 
used in organic chemistry and biochemistry, has been possible. However, it is important to 
notice that the scope of the Michael addition was limited. Effectively, when alkyl groups were 
used as substituent on the -substituted -isocyanoacetate, the Cinchona alkaloid-catalyzed 
enantioselective Michael addition was inhibited. 
 
Scheme 11: Enantioselective Michael addition of -aryl -isocyanoacetate to phenyl vinyl selenone 
developed in our group. 
…up to nitroacetate 
 With the hope of overcoming the scope limitation encountered in our previous 
enantioselective methodology for the synthesis of quaternary amino acids, we decided to 
change our approach from isocyanide chemistry to other reactive synthetic synthon. The first 
chapter will focus on the work investigated on -substituted -nitroacetate I-53 as Michael 
donor in the enantioselective Michael addition with phenyl vinyl selenone I-50 (Scheme 12).  
30 
 
 
Scheme 12: From -isocyanoacetate to -nitroacetate. 
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Introduction 
Background on the enantioselective synthesis of quaternary -amino acid  
The interest for the synthesis of quaternary -amino acids has been growing during the 
last decades in the biological, biochemical and pharmaceutical fields.
15
 Due to the presence of 
an additional substituent on the -carbon, the fully substituted amino acid is more persistent 
in-vivo and the racemization of the chiral center is thereby avoided. This tetrasubstituted 
amino acid, when integrated in a peptide, modified the secondary structure of the proteins 
which could generate the denial of a problematic enzyme-linked receptor. With this 
alternative to the twenty well-known natural amino-acids, the fully -substituted -amino 
acids have become relevant building blocks for the synthesis of unnatural and natural 
compounds and for the design of proteins and peptidomimetics. Therefore, numerous efficient 
enantioselective syntheses of quaternary -amino acids have been developed.16 
Retrosynthetically, different disconnections has been described for the synthesis of 
quaternary -amino acids I-52 (Scheme 13). The first possibility could be the cleavage of the 
C-N bond; this disconnection would correspond to the electrophilic amination of ,-
disubstituted ester I-54 to a nitrogen unit (Scheme 13, d.1). The second possible could be the 
C-C bond connected to the ester group, this breaking would match with the Strecker reaction 
of a cyanide to a ketimine I-55 (Scheme 13, d.2). The third approach could be the carbon-
carbon disconnection d.3. This bond would be formed via nucleophilic addition of 
nucleophiles to -ketiminoesters I-56 (Scheme 13, d.3). After breaking d.4, the fully 
substituted -amino acid could also be synthesized by reacting a glycine template I-57 which 
would play the role of nucleophile on an electrophilic specie (Scheme 13, d.4). 
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 (a) S. Omura, T. Fujimoto, K. Otaguro, K. Matsuaki, R. Moriguchi, H. Tanaka, Y. Sasaki, J. Antibiot. 1991, 
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Scheme 13: Possible disconnection for the synthesis of enantoenriched quaternary -amino acid 
1- Enantioselective electrophilic amination – (disconnection d.1) 
Generally introduced by the addition of an amine on an electrophile, the nitrogen unit 
has been also incorporated via the less conventional electrophilic amination. In 2003, 
Jørgensen described an enantioselective synthesis of quaternary -amino acid by a 
Cu(OTf)2/Box ligand-catalyzed reaction of -ketoester I-61 and dibenzyl azodicarboxylate I-
62 (Scheme 14 (a)).
17a
 Organocatalysis induced also this asymmetric transformation and 
cinchona alkaloids have been described to give high yields and enantioselectivities when -
substituted -cyanoacetate I-64 and azodicyarboxylate I-65 reacted together (Scheme 14 
(b)).
17b
 Primary -alkoxycarbonyl amides I-67 and azodicarboxylate I-65 with lanthanum-
based ternary catalyst described by Shibazaki offered also highly enantioenriched fully 
substituted -amino acids in good yields (Scheme 14 (c)).17c 
                                                 
17
 With azadicarboxylate (a) M. Marigo, K. Juhl, K. A. Jørgensen, Angew. Chem. Int. Ed. 2003, 42, 1367; (b) S. 
Saaby, M. Bella, K. A. Jørgensen, J. Am. Chem. Soc. 2004, 126, 8120; (c) T. Mashiko, N. Kumagai, M. 
Shibasaki,  J. Am. Chem. Soc. 2009, 131, 14990. 
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Scheme 14: Enantioselective electrophilic amination with azadicarboxylate. 
N-hydroxycarbamate has been another suitable electrophilic nitrogen donor. In 2014, 
the group of Luo reported the unprecedented asymmetric organocatalytic α-amination of -
substitued β-ketoester I-69 with N-hydroxycarbamate I-70 (Scheme 15, (a)).18a The same 
year, Yamamoto and coworkers described the Lewis acid-catalyzed asymmetric 
hydroxyamination of -substituted β-ketoester I-72 (Scheme 15, (b)). In these two reports, 
the N-hydroxycarbamate
 
I-73 was converted in situ to a reactive nitroso species which was 
mandatory for the electrophilic -amination.18b 
 
Scheme 15: Enantioselective electrophilic amination with N-hydroxycarbamate. 
                                                 
18
 With N-hydroxycarbamate (a) C. Xu, L. Zhang, S. Luo, Angew. Chem. Int. Ed. 2014, 53, 4149; (b) B. Maji, 
M. Baidya, H. Yamamoto, Chem. Sci. 2014, 5, 3941. 
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2- Enantioselective Strecker reaction - (disconnection d.2) 
Several cyanation reactions have been developed but it has been the Strecker reaction 
which was the mostly studied.
19
 This 3-component reaction involving a carbonyl, an amine 
and a cyanide was originally developed in 1850 by Adolph Strecker when acetaldehyde, 
ammonia and hydrogen cyanide were mixed together to deliver -substituted -
cyanoamine.
20
 The subsequent hydrolysis of the nitrile group permited the formation of the 
desirable -amino acid.  
The use of ketimines with cyanide for the asymmetric synthesis of quaternary -amino 
acid has been preliminarily reported by Jacobsen. Reaction of HCN with N-benzyl protected 
ketimine in the presence of a thiourea as organocatalyst at -78 °C in toluene, the ,-
disubstituted -cyanoamines I-76 were obtained in excellent yield and enantioselectivity 
(Scheme 16 (a)).
21a
 In 2009, Yamamoto reported the use of cyanoformate as cyanide source in 
the enantioselective addition of cyanide to ketimine with an aluminium complex Cat*I-6 as 
Lewis acid catalyst. This less toxic and less volatile cyanide source has been a good 
alternative and easier-to-handle reagent (Scheme 16 (b)).
21b
 
 
Scheme 16: Enantioselective Strecker reaction. 
                                                 
19
 Review on catalytic asymmetric cyanation reactions : N. Kurono, T. Ohkuma, ACS Catal. 2016, 6, 989. 
20
 A., Strecker Ann. Chem. Pharm. 1850, 75, 27. 
21
 First Strecker reaction with ketimine: P. Vachal, E. N. Jacobsen, Org. Lett. 2000, 2, 867; P. Vachal, E. N. 
Jacobsen,  J. Am. Chem. Soc. 2002, 124, 10012; (b) ethyl cyanoformate as cyanide source J. P. Abell, H. 
Yamamoto, J. Am. Chem. Soc. 2009, 131, 15118. 
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The enantioselective cyanation of other substrates such as -trifluoromethyl ketimine 
I-80 or isatin ketimine I-82 derivative has also been described with the Strecker reaction 
using TMSCN and the adapted organocatalyst (Scheme 17, (a) & (b)).
22
  
 
Scheme 17: Enantioselective Strecker reaction with other substrates. 
3- -Ketiminoester for enantioselective synthesis of quaternary -amino acid - (disconnection 
d.3)  
-Ketiminoesters I-56 have been used in different enantioselective nucleophilic 
addition.
23
 Asymmetric Mannich reaction, enantioselective alkylation, allylation or 
alkynylation have been developed for the elaboration of quaternary amino acids. In 2003, 
Jørgensen and coworkers reported the first enantioselective Mannich reaction with cyclic 
ketimine I-85, silyl ketene acetal I-86 and zinc-(Py)box L*I-4 as chiral complex. This 
methodology allowed the formation of tetrasubstituted amino acid with yield up to 99% and 
95% enantioselective excess (Scheme 18 (a)).
24a
 Vinylogous Mannich reaction has also been 
described by Hoveyda. This diastereo and enantioselective Ag-catalyzed reaction of -
ketiminoesters I-88, a commercially available siloxyfuran I-89, silver acetate and a chiral 
ligand L*I-5 offered quaternary amino acids where two asymmetric contiguous stereocenters 
have been created (Scheme 18 (b)).
24b
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Scheme 18: Enantioselective Mannich reaction with -ketiminoester. 
Transition metal-catalyzed reactions with -ketiminoesters have been another 
approach for the synthesis of tetrasubstituted quaternary amino acids. In 2014, Kozlowski 
developed the enantioselective 3-CR reaction  between α-iminoesters I-91, Grignard reagents, 
and cinnamyl acetate. Using the umpolung N-addition on -iminoesters developed by Kagan 
and Fiaud;
25
 the alkyl Grignard attacked first the nitrogen of the ketimine to generate a 
stabilized enamine intermediate. After, this intermediate reacted with the palladium –allyl 
electrophile to afford α-allyl-α-aryl-α-amino acids I-92 (Scheme 19, (a)).26a Recently, 
Ohshima et al have described enantioselective alkynylation of -ketiminoester I-93 with 
terminal alkynes I-95 and adaptable rhodium (III) complexes as chiral catalyst. It was notable 
that this transformation using (trimethylsilylethynyl)rhodium(III) as precatalyst with a loading 
of 0.5 mol% could accomplish the formation of highly enantioenriched quaternary amino 
acids in good yield (Scheme 19, (b)).
26b
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 Fiaud, J. C.; Kagan, H. Tetrahedron Lett. 1970, 11, 1813. 
26
 (a) J. M. Curto, J. S. Dickstein, S. Berritt, N. C. Kozlowski, Org. Lett. 2014, 16, 1948; (b) K. Morisaki, M. 
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Scheme 19: Enantioselective metal-catalyzed transformations with -ketiminoester. 
4- Glycine templates for enantioselective synthesis of quaternary -amino acid -
(disconnection d.4) 
Among the possible manner of synthesizing quaternary -amino acids, the use of 
glycine template has been intensively investigated (Scheme 20). -substituted 
(arylideneamino)acetate I-97,
27
 oxazolones I-98,
28
 -substituted -isocyanoacetates I-49 29 
and -substituted -nitroacetates I-53 have shown to be good glycine masks for the 
development of enantioenriched reaction. As many asymmetric alkylation, allylation and 
Michael addition have been reported over the year for the synthesis of highly enantioenriched 
tetrasubstituted -amino acid with the different glycine templates, we have chosen to describe 
only the literature background of -substituted nitroacetate for the synthesis of 
enantioenriched quaterny -amino acids. 
 
Scheme 20: Glycine template used for the synthesis of enantioenriched quaternary -amino acids . 
-nitroacetate as privileged partner 
Synthesis of nitroacetate derivative 
-Nitroacetate is a small molecule enormously studied by the chemistry community. 
The easy modification of the functional groups
30
 and the high acidity of the  proton31 has 
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38 
 
given to this glycine template attractive properties for the development of new synthetic 
transformation. Steinkopf was the first to isolate alkyl -nitroacetate in moderate yield by 
adding carefully nitromethane in a saturated aqueous solution of potassium hydroxide under 
air atmosphere at reflux.
32
 Esterification of the subsequent dipotassium salt using sulfuric acid 
in methanol offered the desired methyl nitroacetate. It was noteworthy that this reaction was 
reproducible and has been optimized to the mole scale.
32c
  
 
Scheme 21: -Nitroacetate synthesis 
-Substituted -nitroacetate, derivative of -nitroacetate needed for the 
enantioselective synthesis of quaternary -amino acid, could be synthesized by alkylation, 
Pd-catalyzed allylation or Michael addition (Scheme 22 (a)).
33
 To avoid the double alkylation 
which was competing in some cases with the mono alkylation, the Knoevenagel condensation 
of aldehyde with -nitroacetate has been a good alternative. (Scheme 22 (b)).34 It was also 
possible to synthesize -aryl -nitroacetate I-100 with a direct palladium-catalyzed arylation 
of -nitroacetate developed by Kozlowski in 2012.31 Finally the simple -bromination of 
alkyl ester I-101 followed by a SN2 reaction to introduce the nitro group using sodium nitrite 
has permited the access to various -alkyl -nitroacetate.35 
 
Scheme 22: -Substituted -nitroacetates syntheses. 
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Enantioselective transformation with -substituted -nitroacetate 
Over the years, different asymmetric methods have been developed for the 
enantioselective synthesis of ,-disubstituted nitroacetates. One of the most established 
approach have been the nitro Mannich (or aza-Henry) reaction. This reaction involved the 
nucleophilic addition of -substituted nitroacetate I-53 to the protected imine I-102 leading to 
the corresponding -nitro -aminoester I-103. Chiral catalysts or chiral ligand were the key 
for the stereocontrol of the chiral center (Scheme 23). 
 
Scheme 23: Enantioselective nitro Mannich reaction for the synthesis of -nitro -amino ester. 
Jørgensen and coworkers reported in 2005 the catalytic enantioselective nitro Mannich 
reaction using -substituted nitroacetates as nucleophiles.36 In the presence of Cu(OTf)2 as 
Lewis acid, (R)-Ph-Box as chiral ligand and quinine as Brønsted base, the formation of -
nitro -amino ester I-103 was done in 98% yield with a dr of 14:1 and an ee of 75%. 
Another way of ,-disubstituted nitroacetate synthesis was the asymmetric allylic 
alkylation of -substituted nitroacetate I-53 with allylic carbonate I-104. This method was 
highlighted by Shibasaki et al. in 2007 and Ooi et al. in 2012 (Scheme 24).
37 
To perform this 
asymmetric transformation for the construction of -disubstitued nitroacetates I-105 and I-
107, chiral ligand such as phosphinooxazoline L*I-7 or the ammonium-phosphine ion pair 
ligand L*I-8 were needed.  
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Scheme 24: Enantioselective allylic alkylation of -substituted nitroacetate. 
In 2007, Togni and coworkers designed the synthesis of -fluoro -substituted 
nitroacetate I-108 by the asymmetric electrophilic fluorination of -substituted nitroacetate I-
53 (Scheme 25).
38
 The fluorinating reagent was made in situ by combining a Cinchona 
alkaloid derivative and Selectfluor.  However, the best result was obtained using 
acetylquinine as organocatalyst to give product in 98% yield and only 40% ee.  
 
Scheme 25: -Fluorination of -substituted nitroacetate. 
More recently, Maruoka’s group reported the catalytic asymmetric aldol reaction of -
substituted nitroacetate I-53 with aqueous formaldehyde (Scheme 26).
39
 This reaction was 
performed with a bifunctional chiral phase-transfer catalyst Cat*I-10 which allowed the 
formation of -alkyl serine derivatives I-109.  
 
Scheme 26: Catalytic asymmetric aldol reaction of -substituted nitroacetate to aqueous formaldehyde. 
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 J. Ramírez, D. P. Huber, A. Togni, Synlett, 2007, 1143. 
39
 S. Shirakawa, K. Ota, S. J. Terao, K. Maruoka, Org. Biomol. Chem. 2012, 10, 5753. 
41 
 
The asymmetric conjugated addition of -substituted nitroacetate I-53 to various 
Michael acceptors has been also a good method for the synthesis of quaternary amino acid 
derivatives.
40
 ,-unsaturated ketones I-110 41, nitro olefins I-111,42 -unsaturated sulfones 
I-112,
43
 ethylidenebisphosphonate I-113,
44
 -trifluoromethylated acrylamide I-114,45 or 
maleimide I-115
46
 were used as Michael acceptors (Scheme 27).  Different organocatalysts 
were used to perform these transformations in good enantioselectivity. 
  
Scheme 27: Michael addition of -substituted nitroacetate to various Michael acceptor partners. 
The asymmetric conjugated addition of -substituted nitroacetate I-53 has permited 
the formation of a wide range of quaternary -amino acid derivatives (I-116 to I-121). But 
some interesting Michael acceptors have still not been investigated with -substituted -
nitroacetate, such as phenyl vinyl selenone. 
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Reactivity and synthesis of phenyl vinyl selenone 
Phenyl vinyl selenone (I-50) is a small molecule where the phenyl selenonyl group 
acts as electron-withdrawing group and leaving group. With this double ability, the organic 
compound can play firstly the role of Michael acceptor with one nucleophile. A second 
nucleophile can be incorporated with displacement of the -SeO2Ph group which permits the 
rapid formation of complex molecules and the development of numerous domino processes. 
Synthetically, the phenyl vinyl selenone can be considered as an ethane dication moiety I-124 
(Scheme 28).     
 
Scheme 28: Phenyl vinyl selenone reactivity. 
The synthesis of phenyl vinyl selenone could be achieved in two steps from diphenyl 
diselenide I-125 using a Grignard reaction with vinyl magnesium bromide I-126 as first step. 
After the double oxidation of the subsequent selenide I-127 with m-CPBA, the phenyl vinyl 
selenone I-150 could be isolated in 80% yield.  
 
Scheme 29: Phenyl vinyl selenone synthesis. 
Cyclopropane synthesis 
Due to this dicationic reactivity pattern, vinyl selenone has been used for the 
cyclopropanation of malonate derivative. Dialkyl malonate, -ketoester, -ketoamide, -
cyanoacetate or nitromethane could act as double nucleophile on phenyl vinyl selenone when 
sodium hydride was used (Scheme 30, (a)).
47a
 Oxindole derivatives I-131 have also been used 
with vinyl selenone in basic aqueous medium to form spiro compounds I-132 (Scheme 30 
(b)).
47b
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Scheme 30: Cyclopropanation with phenyl vinyl selenone. 
 A first trial of the diastereoselective cyclopropanation using chiral auxiliary, (-)-
dibornyl or (-)-dimenthyl malonate, has been explored by Tiecco and Bagnoli (Scheme 31 
(a)).
 48a
 Unfortunately, low diastereoselectivity was observed with the chiral malonates I-133. 
It was still possible to separate by column chromatography the diastereoisomers which, after 
removal of the bornyl or menthyl groups, allowed the isolation of highly enantioenriched 
cyclopropanes. Marini and Tiecco reported also the asymmetric cyclopropanation of -aryl -
cyanoacetate I-135 with phenyl styryl selenone I-136. After a cinchona alkaloid-catalyzed 
Michael addition of the nucleophile I-135 to the styryl selenone I-136, Michael adducts I-138 
were obtained in good yield and moderate enantioselectivity. When treated with sodium 
ethanoate, a decarboxylation/SN2 sequence occured on intermediate I-138 to afford the 
cyclopropane I-137 with a complete conservation of the diastereoselectivity and a little 
erosion of the enantioselectivity (Scheme 31 (b))
 48b
 
 
Scheme 31: Trial of disastereoselective cyclopropanation with vinyl selenone. 
Double nucleophilic addition 
The double nucleophilic addition of heteroatom on phenyl vinyl selenone was also 
possible. For example, when primary amines I-7 were mixed with phenyl vinyl selenone, the 
smooth formation of aziridine I-139 was occurring (Scheme 32 (a)). Chiral amino alcohol, 
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diol and diamine could be used with phenyl alkenyl selenone I-129 for the synthesis of non-
aromatic heterocycles I-141 (Scheme 32 (b)).
49
 This chemistry has been applied on 
nucleoside and sugar selenonyl derivatives (I-142 & I-143) and different modifications of 
these biomolecules have been described.
50
 
 
Scheme 32: Heterocycle synthesis using vinyl selenone. 
With the electron-withdrawing ability of the phenylselenonyl group, the carbon C 
could be deprotonized. Different reactions have been developed by Krief in 1988 where the 
-deprotonation followed by a SN2 reaction was occurring. The reaction of cyclopropyl 
phenyl selenone I-151 with a carbonyl and tBuOK as base afforded 1-oxaspiro[2.2]pentane 
derivative I-152 (Scheme 34 (a)).  The Michael addition of the -deprotonated alkyl phenyl 
selenone I-154 on the methyl acrylate I-155 permited the formation of cyclopropyl ester 
compounds I-156 using a similar sequence (Scheme 34 (b)).
51
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Scheme 33: -Deprotonation of alkyl phenyl selenone. 
Rearrangement 
Different rearrangements have been reported using phenyl vinyl selenone. Kuwajima 
reported in 1983, the Michael addition of -benzyl -ketoester I-158 with alkenyl phenyl 
selenone I-159. Due to the absence of a second acidic -proton on the substrate, the resulting 
negative charge was suggested to attack intramolecularly the ketone to afford the cyclobutane 
intermediate I-161. The alkoxy of the intermediate I-161 was converted to the ketone with the 
opening of the 4-membered ring to give the linear enolate I-162. After SN2 of the enolate to 
display the phenyl selenonyl group, 2-acetylcyclopropane-1-carboxylates I-160 could be 
isolated in moderate yield (Scheme 34).
52 
 
Scheme 34: Rearrangement with -ketoester and phenyl vinyl selenone. 
Ring expansion 
A really nice ring expansion of cyclic compound using alkenyl phenyl selenone has 
been noticed by Kuwajima in 1985. Ethyl cyclohexanone-2-carboxylate I-168, when reacted 
with the Z isomer of phenyl prop-1-ene selenone I-170, offered the 7-membered ring I-171 
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bearing vinyl group. Interestingly, when this alkenyl selenone was replaced by (E)-prop-1-ene 
phenyl selenone I-159, the bicyclo[5.1.0]octanone I-169 was formed. The proposed 
mechanism to rationalize the two structures started with the Michael addition which afforded 
the adduct I-172. After cyclization to form the 4-membered ring of the compound I-173, a 
ring opening was occurring to deliver I-161. Then, the bicyclic molecule I-175 was obtained 
after SN2 of the enolate I-174 to the phenyl selenonyl group. In the case of Z-isomer the 
conformation of the bicyclic structure allowed the intramolecular hetero-ene reaction of the 
ketone with the methyl cyclopropane to give the vinyl compound I-177.
53
  
 
Scheme 35: Ring expansion of ethyl cyclohexanone-2-carboxylate with phenyl vinyl selenone. 
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Fragmentation 
The peculiar reactivity of alkenyl selenone derivative has allowed also the 
fragmentation of some compounds. 3-(phenylselenonyl)cyclohex-2-en-1-ol I-178 could afford 
two distinct linear products after fragmentation in function of the reaction condition applied. 
When NaH was used, the deprotonation of the alcohol promoted the ring opening of the 6-
membered ring to deliver the alkyne I-179. On another hand, if a nucleophile was used, the 
Michael addition occurred and the resulting alkoxylate I-182 would give the linear alkene I-
180 after fragmentation with release of benzeneseleninic acid.
 54
  
 
Scheme 36: Fragmentation of 1-substituted 3-(phenylselenonyl)cyclohex-2-en-1-ol. 
Domino process 
Other domino processes have been developed using the property of the 
organoselenium chemistry. Cascade reaction could be initiated by the oxidation of the 
selenide to afford the selenone derivative which could undergo a nucleophilic substitution 
when an internal nucleophile was present in the molecule. With this kind of domino reaction, 
oxetane I-184 or cyclic amine I-189 could be obtained (Scheme 37 (a) & (b)).
55
  
 
Scheme 37: Domino promoted by oxidation for the synthesis of cyclic amines and cyclic ethers. 
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The synthesis of triazole has been described by Pathak in 2014. The [3+2] 
cycloaddition of the cyclic phenyl selenone I-162 and alkyl azide I-164 afforded the byclic 
compound I-166. After rearomatization with release of phenyl seleninic acid and hydrolysis 
of the cyclic acetal, densely functionalized triazoles I-165 could be formed in moderate yield 
(Scheme 38).
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Scheme 38: [3+2] Cycloaddition/hydrolysis sequence of selenosugar. 
In view of elaborating enantioenriched domino sequences promoted by oxidation of 
selenide compound, it is important to stress that an enantioselective selenide incorporation 
was possible. Effectively, Melchiorre and Marini described the enantioselective 
organocatalytic -selenation of aldehyde using N-(phenylseleno)phthalimide I-191 and a 
chiral amine Cat*I-11 as catalyst. This reaction gave -seleno aldehyde I-192 in good yield 
and enantioselectivity and several optically active compounds could be synthesize using the 
versatile reactivity of selenium such as the oxidative domino process (Scheme 39 (c)).
57
 
 
Scheme 39: Enantioselective -selenation of aldehyde. 
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 Some various heterocyclic compounds have also been synthesized using the oxidative 
domino process. Protected aziridine I-195, oxazolone I-196, protected pyrrolidine I-197 or 
cyclic carbamate I-199 could be isolated by this method (Scheme 40).
58
 
 
Scheme 40: Domino promoted by oxidation for the synthesis of heterocycles. 
Multicomponent reaction 
Multicomponent reactions using alkenyl selenone derivative have been likewise 
depicted. It was in 2014 that our group reported the multicomponent reaction of -substituted 
-isocyanoacetate I-49, phenyl vinyl selenone I-50 and water in the presence of a Brønsted 
base followed by the addition of PTSA. In this transformation the phenyl selenonyl group has 
played three specific roles which were 1) an activator for the Michael addition, 2) a leaving 
group 3) the less common role, an oxidant.  
The reaction pathway proposed for the one pot synthesis of 1,3-oxazinan-2-one began 
with the Michael addition and gave the adduct I-201, followed by the hydrolysis of the 
isonitrile which offered the formamide I-203. The formamide I-203 displaced the phenyl 
selenonyl group which delivered the 5,6-dihydro-4H-1,3-oxazine I-204 and benzenseleninic 
acid I-207. The benzeneseleninic acid I-203 could dimerize to benzeneseleninic anhydride 
(BSA) I-208. A second addition of water gave 1,3-oxazinan-2-ol I-205 which reacted with the 
benzeneseleninic anhydride to afford the seleninate I-206. After oxidation with elimination of 
benzeneselenenic acid I-209 the desired oxazinan-2-one I-200 was obtained (Scheme 41).
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Three molecules of benzeneselenenic acid permited the formation of two molecules of 
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diphenyl diselenide, benzeneseleninic acid and water. This oxidation process with BSA has 
been reported in the 80s independently by Barton and Kuwajima.
 60 
It was notable that this 
example was the first time to describe phenyl vinyl selenone I-50 with this triple role in the 
same reaction. With these abilities, complexity could be installed quickly on different 
scaffolds. 
 
Scheme 41: Multicomponent reaction for the synthesis of cyclic carbamate. 
 Recently, Tiwari reported the multicomponent component reaction of aldehydes I-210, 
ketone I-4 and phenyl vinyl selenone I-50 in the presence of a base and NHC Cat*I-12 as 
catalyst. In the suggested mechanism, the NHC Cat*I-12 was catalyzing the reaction of two 
aldehydes I-210 to produce the benzoin compound I-214. In the presence of a base this 
compound reacted with vinyl selenone to give the Michael adduct I-215. The alcohol group of 
this intermediate could attack the ketone I-4 which after a cascade reaction afforded the 
bicyclic compound I-211 (Scheme 42). An eventual deprotection of the acetal was possible by 
treating the cyclic acetal with DIBAL-H followed by a aqueous workup to isolate dihydroxy 
2,3-tetrahydrofurane derivative I-216.
61
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Scheme 42: Multicomponent reaction using NHC and phenyl vinyl selenone. 
 Enantioselective transformation 
Enantioselective transformation using phenyl vinyl selenone I-50 has been established 
and Marini and coworkers were the first to describe this Michael acceptor in an asymmetric 
conjugate addition (Scheme 43).
62
 The 1,4-addition of -aryl cyanoacetate I-217 to phenyl 
vinyl selenone I-50 in the presence of the bifunctional organocatalyst Cat*I-13 lead to -aryl 
-substituted cyanoacetate I-218 with good yield and enantioselectivity.  
 
Scheme 43: Asymmetric Michael addition of -aryl -substituted cyanoacetate to vinyl selenone. 
Chen and coworkers have shown in 2011 the asymmetric Michael addition of 3-
substituted oxindole I-219 to phenyl vinyl selenone I-50 (Scheme 44). 
63
 In the presence of 
Cinchona alkaloid thiourea organocatalyst Cat*I-14, the reaction afforded I-220 in good yield 
and enantioselectivity. 
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Scheme 44: Asymmetric Michael addition of 3-substituted oxindole to vinyl selenone. 
The same year, Marini’s group developed an enantioselective synthesis of 
spirolactones I-223 by an organocatalyzed Michael-addition/cyclization sequence.
64
 This 
reaction occured firstly with the conjugated addition of cyclic tert-butyl -ketoester I-221 to 
phenyl vinyl selenone I-50. Then, by taking advantages of the leaving group properties of the 
phenylselenonyl group, the desired spirolactones I-223 were formed (Scheme 45 (a)). The 
synthesis of polycyclic pyrrolidines I-225 was also possible by using an intramolecular 
Staudinger reaction/reduction sequence on the azide compound I-224 (Scheme 45 (b)).  
 
Scheme 45: Asymmetric Michael addition of cyclic tert-butyl -ketoester to vinyl selenone. 
In 2013 our group described the catalytic asymmetric conjugate addition of -aryl--
isocyano acetate I-49 to vinyl selenone I-50 for the synthesis of quaternary -amino acid 
derivatives.
14
  
 
Scheme 46: Asymmetric Michael addition of -aryl -isocyanoacetate and phenyl vinyl selenone. 
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 The last report has been depicted by Mukherjee last year where butenolides was used 
I-226 as Michael donor in the enantioselective organocatalyzed conjugate addition with 
phenyl vinyl selenone I-50 and thiourea-amine bifunctional organocatalyst Cat*I-16.
 65
 
 
Scheme 47: Asymmetric Michael addition of butenolides and phenyl vinyl selenone. 
Cinchona alkaloids as bifunctional organocatalyst. 
Among the catalytic asymmetric approaches for the synthesis of enantioenriched 
compound, the organocatalysis has shown to be extremely attractive since the beginning of 
this century.
66
 Environmentally friendly (low toxicity of the organocatalyst, development of 
metal free reaction), this type of catalyst has shown to be robust and not expensive which 
made them extremely popular to elaborate mild methodologies for the synthesis of potent 
bioactive molecules.  
The family of Cinchona alkaloids, have been particularly employed in the 
organocatalyst field. Quickly introduced by Bredig and Fiske in 1912 for the hydrocyanation 
of aldehydes, this family of molecules were actually recognized as precious organocatalyst in 
the end of the seventies when Pracejus followed by Wynberg described the first 
enantioselective transformation using cinchona alkaloids in ketene chemistry or conjugated 
addition.
67
  
Quinidine Cat*I-17 and quinine Cat*I-18, two natural products from this alkaloid 
family, possessed the opposite stereocenters at the C8 and C9 position respectively (Scheme 
48).
68
 With this particularity, quinine and quinidine are considered as pseudoenantiomer.  
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Scheme 48: Cinchona alkaloids, a bifunctional organocatalyst. 
Cinchona alkaloids have been considered as bifunctional organocatalysts. They 
possess a basic nitrogen on the quinuclidine part which played the role of Lewis or Brønsted 
base to activate nucleophile and an hydroxyl group on the carbon C9 which allows the 
activation of electrophile by hydrogen bonding (Scheme 48).
69
  
The easy modification of this organic molecule (especially on the C6’ and the C9 
position)  and the presence of 5 stereogenic centers (N1, C4, C3, C8, C9) on the cinchona 
alkaloids give to this compound a tuneable chiral environment. Different H-bond donor such 
as alcohol, amine, amide, thioruea, or squaramide have been installed at the C6’ or C9 position 
of the organocatalyst. With them, high degree of chiral induction has been reached and 
various methodologies have been developed to achieve the synthesis of important optically 
active molecules (Scheme 49).
70
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Scheme 49: Modification of Cinchona alkaloid over the years 
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Results & Discussion 
Reaction Optimization 
In order to answer to the scope restriction observed in the methodology developed 
with -aryl -isocyanoacetate I-49 and phenyl vinyl selenone I-50,14 we started to study the 
racemic condition of the Michael addition with methyl nitrobutyrate I-53a, phenyl vinyl 
selenone I-50 and triethylamine at room temperature in toluene (Scheme 50). After 10 min of 
reaction, 70% of the phenyl vinyl selenone was converted to the desired product I-228a, 
which was isolated in 60% yield. After 2 hours and full conversion of the reagents, the 
product was isolated in 89% yield. 
 
Scheme 50: Racemic Michael addition of methyl nitrobutyrate to phenyl vinyl selenone. 
To perform the reaction in a catalytic enantioselective way, the Cinchona alkaloid-
based organocatalyst Cat*I-24 with a free OH in C6’ position was used. This organocatalyst 
firstly introduced by Deng and co-worker
71
 appeared also to be one of the best catalyst for our 
synthesis of ,-disubstituted -isocyanoacetate I-51.14 Using 10 mol% of the organocatalyst 
in toluene at room temperature, the desired product I-228a was isolated with a yield of 88% 
and an enantiomeric ratio of 28:78 (Scheme 51). 
 
Scheme 51: First hit for the asymmetric Michael addition of methyl nitrobutyrate to phenyl vinyl 
selenone. 
With this promising result in hand, the optimization of ,-disubstituted -
nitroacetate I-228 synthesis was investigated by varying the different parameters of the 
reaction. 
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Solvents 
Different solvents were screened. Polar solvent such as THF gave poor enantioselectivity. 
Apolar solvents gave better er and toluene appeared to be the best solvent (Table 1). 
Table 1: Solvent screening. 
 
Entry Catalyst Conditions Isolated Yield (%) er 
1 Cat*I-24 Toluene, 2 h. 88 % 28:72 
2 Cat*I-24 THF, 16 h. 81 % 44:56 
3 Cat*I-24 DCM, 16 h. 72 % 34:66 
4 Cat*I-24 Xylene, 2 h. 95 % 31:69 
Temperature screening 
The temperature of the reaction was explored (Table 2). When the temperature was 
reduced, the enantioselectivity of the catalytic Michael addition increased, but the conversion 
of the reaction was slower. It was also important to note that the pseudoenantiomer quinine 
derivative Cat*I-1 gave better enantiomeric ratio in comparison with quinidine derivative 
Cat*I-24 with an inversion of the major enantiomer. 
Table 2: Temperature screening. 
 
Entry catalyst Condition Isolated Yield (%) er 
1 Cat*I-24 0 °C, 4 h. 92 20:80 
2 Cat*I-24 - 15 °C, 16 h. 88 16:84 
3 Cat*I-24 - 30 °C, 48 h. 92 12:88 
4 Cat*I-24 - 40 °C, 24 h. 30 12:88 
5 Cat*I-1 R.T., 2 h. 94 85:15 
6 Cat*I-1 - 30 °C, 48 hours 96 92:8 
7 Cat*I-1 - 40 °C, 72 hours 82 93:7 
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Finally, after 48 hours of reaction with the organocatalyst Cat*I-15 at - 30 °C, the ,-
disubstituted -nitroacetate I-228a was synthesized with a yield of 96 % and an 
enantioselective ratio of 92:8 (Entry 6).  
Catalyst screening 
The synthesis of different organocatalysts has been depicted in the Scheme 52. 
Starting from Quinine Cat*I-18, the OH on the C9 position could be convert to NH2 using a 
one pot Mitsunobu/Staudinger reaction. The subsequent C9-aminoquinine Cat*I-21 could be 
converted to the thiourea cinchona alkaloid Cat*I-8 using 3,5-bis(trifluoromethyl)phenyl 
isothiocyanate.  
Quinine Cat*I-18 could also be converted to C9-O-substituted derivatives. C9-O-
alkylated Cat*I-25 was made by SN2 with alkyl halide. C9-O-arylated Cat*I-25 was 
elaborated with Ullmann coupling.  
The C6’ position could also be modified after deprotection of the alcohol (Scheme 
52,step d). Triflation of the C6’ alcohol of Cat*I-19 allowed the insertion of amine or thiourea 
at this position and offered quinine derivative Cat*I-27 and Cat*I-28 respectively.  
-isocupreine Cat*I-2, a twistane-like structure, has shown to be a good 
organocatalyst candidate in some transformation due to its constrained tricyclic cage. -ICPD 
Cat*I-2 could be synthesized from quinidine using KBr in concentred H3PO4.  
Finally the C9-epi-quinine Cat*I-29 could be obtained using a Mitsunobu reaction 
with para-(nitro)benzoic acid. After the hydrolysis of the subsequent ester, the epi-quinine 
Cat*I-29 could be isolated with an invertion of the stereocenter C9.
70,72
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Jouannetaud, J.-C. Jacquesy, A. Cousson, Tetrahedron 2005, 61, 2065. 
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Scheme 52: Synthesis of Cinchona alkaloids derivatives 
A first serie of Cinchona alkaloid were investigated (Table 3). Whereas quinine Cat*I-
18 and thiourea derivative Cat*I-8 gave low enantioselectivity (entries 1 and 3); cupreine 
Cat*I-30, -isocupreidine Cat*I-2, amino derivative Cat*I-21 and Cat*I-15 lead to good 
enantiomer ratio (entries 1, 2, 4 and 6). However, the yield obtained with cupreine Cat*I-30 
and Cat*I-21 are low (65 and 25% respectively) (entries 2 and 3). 
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Table 3: Catalyst screening. 
 
Entry Catalyst Time Isolated Yield (%) er 
1 Cat*I-18 72 h. 84 56:46 
2 Cat*I-30 48 h. 65 87:13 
3 Cat*I-21 72 h. 25 90:10 
4 Cat*I-2 48 h. 96 20:80 
5 Cat*I-8 48 h. 15 34:66 
6 Cat*I-15 48 h. 84 94:6 
 
This first organocatalyst screening gave Cat*I-2 as the best catalyst which produced I-
228a in 84% with 94:6 er (Entry 6). 
Concentration screening 
The concentration of the reaction was then investigated (Table 4). Even if the 
concentration was increased, no big changes were observed for the yield and the 
enantioselectivity of the reaction. We have fixed the concentration to 0.1 M for the 
subsequent study. 
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Table 4: Concentration screening. 
 
Entry Catalyst Concentration Isolated Yield (%) er 
1 Cat*I-15 0.1 M 84 6:94 
2 Cat*I-15 0.25 M 86 6:94 
3 Cat*I-15 0.5 M 72 7:93 
Fine tuning catalyst  
Other organocatalysts were used (Table 5). After varying the group at C6’-position 
with OMe, OH, NH2 or thiourea (Entry 1 to 4), the phenol group at this position (Entry 1) 
appeared to be an efficient catalyst for our enantioselective Michael addition. The Cinchona 
alkaloid derivative Cat*I-34, where the vinyl double bond of the catalyst was reduced, did not 
impact the enantioselectivity and gave similar yield and er as the catalyst Cat*I-15 (Entry 5).  
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Table 5: Other catalysts screening. 
 
Entry Catalyst Isolated Yield (%) er 
1* Cat*I-15 88 94:6 
2 Cat*I-31 60 51:49 
3 Cat*I-32 10 57:43 
4 Cat*I-33 27 74:26 
5 Cat*I-34 80 90:10 
6 Cat*I-35 58 82:18 
7 Cat*I-36 99 94:6 
8 Cat*I-37 87 95.5:4.5 
9 Cat*I-38 96 96:4 
10 Cat*I-39 97 95:5 
11 Cat*epi(I-1) 99 95:5 
12 Cat*epi(I-37) 90 95:5 
13 Cat*epi(I-38) 74 94:6 
 
The 9-phenanthryl moiety at the C9 position of the organocatalyst was then replaced 
by different bulky aryl and alkyl groups (Entries 6 to 10). Except catalyst Cat*I-35 which 
possessed an OBn on C9, all the orgacatalysts gave high enantioselectivity. Intriguingly, the 
absolute configuration at C9 seemed not to be important for the catalytic activities of the 
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catalysts since the Cat*epi(I-15), Cat*epi(I-37) and Cat*epi(I-38) were all efficient catalysts 
affording the adduct in good to excellent yields with er higher than 94:6 (entries 13–15). 
Overall, the best conditions consisted to perform the reaction of I-53a and I-50 in toluene at -
30 °C for 48 h in the presence of catalyst Cat*I-38. Under these conditions, the Michael 
adduct I-228a was isolated in 96% yield with an er of 96:4.  
Ester screening 
The effect of the alkyl residue of ester was evaluated under the optimum conditions 
(Table 6). While comparable enantioselectivities were observed with the methyl and ethyl 
esters (Entry 1 & 2), the reaction of the tert-butyl ester I-53c with I-50 afforded the Michael 
adduct I-228c with significantly reduced er (Entry 3). 
Table 6: Effect of the ester size on the enantioselectivity of the reaction. 
 
Entry CO2R Isolated Yield (conv.) er 
1 CO2Me (I-228a) 96%  96:4 
2 CO2Et (I-228b) 93% 95:5 
3 CO2t-Bu (I-228c) 76% 54:46 
 
It is notable that some additives (Na2SO4, molecular sieves…) were added in the 
reaction but no influence on the yield or enantioselectivity was noticed. Finally, the best 
conditions for this catalytic enantioselective Michael Addition on phenyl vinyl selenone were 
with methyl -substituted nitroacetate at – 30 °C in toluene in the presence of 10 mol% of 
bifunctional organocatalyst Cat*I-38. 
Scope 
To determine the possible variation allowed on the Michael acceptor, different alkenyl 
aryl selenone derivative were synthesized. The introduction of other aryl group on the 
selenone was made from arylbromide I-229 which was firstly converted to a Grignard 
reagent. After selenation with pure selenium the reaction was quenched with HCl to afford the 
aryl selenol which dimerized few hours later to the diaryl diselenide I-230. The diaryl 
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diselenide I-230 was converted to the aryl vinyl selenone I-232 using the same procedure than 
with phenyl vinyl selenone I-50.
73
   
For the alkenyl part, different approaches have been reported. The most common 
method was with the Grignard reaction of an alkenyl magnesium bromide to phenylselenyl 
bromide or diphenyl diselenide and gave alkenyl phenyl selenide I-235. Another possibility 
was the hydrozirconation of terminal alkyne I-95 with the Schwartz’s reagent. The zirconium 
species was treated with phenylselenyl bromide to afford derivative I-235.
74
 Finally, the 
synthesis of alkenyl phenyl selenide could also be performed using alkynes I-234, diphenyl 
diselenide, zinc and a biphasic acidic medium.
75
 The alkenyl phenyl selenides I-235 were 
converted to alkenyl phenyl selenone I-236 using 2 equivalents of m-CPBA (Scheme 53). 
 
Scheme 53: Synthesis of different alkenyl aryl selenones 
With the new Michael acceptors and our optimal conditions in hand, the scope of the 
reaction was next examined. For the aryl group attached to the selenium, The presence of 
electron-donating group such as para-methoxy or bulky aryl such as 3,5-dimethylphenyl did 
not influence the reaction and gave similar yield and enantioselectivity. However, electron-
withdrawing group such as trifluoromethyl in para position gave slightly lower 
enantioselectivity and yield.  
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Scheme 54: Scope of the aryl vinyl selenone. 
Different alkenyl phenyl selenone I-236 were also tried as Michael acceptor for the 
asymmetric conjugate addition of -substituted nitroacetate (Scheme 55). When the reaction 
was run with a  or  substituted alkenyl phenyl selenone (I-236a, I-236b and I-236c) and 
even if the reaction was heated to 60 °C no transformation was observed. If the reaction was 
heated to 80 °C the slight degradation of starting materials was detected (Entries 1-3). Other 
substrates such as (E)-(2-(phenylselenonyl)vinyl)benzene I-236d and 2-(phenylselenonyl)-
1H-indene I-236e were also used as Michael acceptor partner. Similar results were obtained, 
no reaction occurred between – 30 °C and 60 °C (or 40 °C for I-236e). The same observation 
was also noted and when the reaction mixture was heated too much, the starting materials 
started to decompose.
 
Scheme 55: Other alkenyl phenyl selenone as Michael acceptor. 
To continue our investigation on the scope of the catalytic enantioselective Michael 
addition, the variation of the -substituted nitroacetate was studied. It appears that various 
types of alkyl, with or without functionalities were tolerated. Simple linear alkyl group (I-
228a, I-228g and I228h) or branched alkyl group (I-228i) gave good enantioselectivity and 
yield. A variety of functionalities were compatible with our reaction conditions such as ketone 
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(I-228k), cyano (I-228n), phenylsulfonyl (I-228o), double bond (I-228p) and ester (I-228l 
and I-228m). Remarkably, some of our compounds (I-228l, I-228m, I-228m, I-228o) were 
clear precursors of -substituted analogues such as aspartic acid, asparagine, glutamic acid, 
glutamine, arginine, methionine and proline. Benzyl substituent and its functionalized ones 
were compatible with the reaction to afford I-228q-s, surrogates for -substituted 
phenylalanine and tyrosine. However, when methyl -phenyl -nitroacetate I-53t or methyl 
-isopropyl -nitroacetate I-53j was used in the enantioselective Michael addition almost no 
selectivity was observed. We supposed that the presence of a tertiary carbon in  of the -
nitroacetate I-53 impeded a good chiral induction of the organocatalyst.  
 
Scheme 56: Scope of the enantioselective Michael addition 
To determine the stereochemistry of the major enantiomer, a crystalline compound 
was mandatory to perform an X-ray analysis. For that, treatment of I-228s with NaN3 
followed by aza-Wittig reaction of the resulting azido compound with 4-nitrobenzaldehyde 
and reductive cyclization afforded gratefully the crystalline pyrrolidinone I-237. The structure 
of I-237 was solved by X-ray crystal structural analysis and the absolute configuration of the 
quaternary center was determined to be (S) unambiguously. Consequently, stereoselectivity of 
the precursor I-228s and the Michael adducts I-228 obtained with the methodology were 
assigned accordingly. 
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Scheme 57: Synthesis and X-ray structure of the pyrrolidinone I-237. 
 
The quinidine derivative Cat*I-39, pseudoenantiomer of the quinine derivative Cat*I-
38, was used as the organocatalyst under the same reaction conditions. As expected, the 
formation of the other enantiomer ent(I-228g) was favoured with similar yield and a slightly 
lower enantioselectivity (Scheme 58).  
 
Scheme 58: Michael addition catalyzed by quinidine-derived catalyst. 
Performing the reaction of I-53q with I-50 in a gram scale afforded the Michael 
adduct I-228q in similar yield and enantioselectivity (Scheme 59). In this case, it was notable 
that almost all the catalyst Cat*I-38 was easily recovered (96 %) and could be re-used without 
diminishing the catalytic efficiency. 
 
Scheme 59: Gram scale enantioselective Michael addition. 
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The large scope of this asymmetric Michael addition of -substituted -nitroacetate I-
53 to phenyl vinyl selenone I-50 has shown the possibility of synthesizing various optically 
active precursors of tetrasubstituted -amino acids. Even if -aryl -nitroacetates gave low 
enantioselectivity under our reaction condition, this methodology appeared to be a 
complementary tool to the method based on -aryl -isocyanoacetates I-49 previously 
developed.
 14
 With both of these methodologies, the access to a broad range of quaternary -
amino I-52 acids is possible (Scheme 60). 
 
Scheme 60: Development of two complementary methodologies for the synthesis of enantioenriched 
quaternary -amino acids 
Transition state 
In this transformation, organocatalysts with a free OH group at C6’ have induced high 
enantioselectivity. This result implied that hydrogen bonding might take place with the 
substrate. Since nitro group was known to have a strong tendency to form hydrogen bonds 
with even a slightly acidic proton,
76
 a stereochemical model (Figure 1) implicating an enolate 
of methyl -substituted -nitroacetate was proposed following the transition state and the 
computational studies reported on bifunctional organocatalysts
77
 and C6’OH-cinchona 
alkaloid derivative (Scheme 61).
 14,71,78
 In the proposed transition state I-238, we suggested 
that the protonated cinchona alkaloids would adopted, in nonpolar solvent, an anti-open 
conformer.
79
 The positioning of the two reactants was also fixed by the hydrogen bond 
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formed between the OH group at C6’ and the nitro and the selenonyl group respectively. A 
pseudo-intramolecular Si-face attack of enolate to the vinyl selenone would deliver, after 
protonation, the Michael adduct I-228 with an absolute configuration of S. In this proposal, 
the alkyl residue of the ester could have a steric interaction with the quinoline subunit of the 
catalyst. Therefore, increasing the size of the R group would destabilize this transition state, 
thus leading to a diminished enantioselectivity which was described on the Table 6. The O-
naphyl group present on the C9 seemed also to shield the substrates and induce chiral 
interaction. 
 
Scheme 61: A proposed transition-state model with the stereoselectivity observed 
Post-transformation 
To reach important enantioenriched building blocks, chemical transformations of -
disubstituted -nitroacetate were envisaged by taking advantage of the reactivity of the nitro 
and phenylselenonyl groups (Scheme 107).
30,80,81
 Reaction of I-228q with NaN3 afforded the 
azido derivative I-239 which, upon Staudinger reduction and lactamization cascade, furnished 
the pyrrolidinone I-240. The latter was further reduced to the amino derivative I-241, a 
constrained analogue of phenylalaninamide, the enantioselective synthesis of which remained 
unknown.
82
 Substitution of the phenylselenonyl group by iodide proceeded smoothly to 
furnish iodide derivative I-242, which was reduced (Raney Ni, H2 , MeOH, RT) to methyl 2-
ethyl phenylalanate I-243 in 65% yield.
 83
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Scheme 62: Chemical transformations of the enantioenriched Michael adduct I-228q.  
In the course of this study, different reductive conditions were explored to convert the 
nitro to amine. Unexpectively, hydrogenation of I-228q in the presence of Adam’s catalyst 
reduced the phenyl selenone to phenyl selenide (confirmed by HRMS, 
1
H, 
13
C and 
77
Se NMR) 
I-244q in a quantitative yield (Scheme 63). This new reaction, which was serendipitously 
discovered, is chemoselective to the phenylselenonyl group, the nitro group was stable under 
these conditions. To the best of our knowledge, there was only one example on the reduction 
of phenyl selenone to phenyl selenide (PI3 , CHCl3 , 0 °C) accomplished in a simple 
substrate.
84
 Treatment of I-244q with sodium periodate followed by Grieco elimination 
produced the vinyl substituted derivative I-245q in 95% yield. The reduction of the nitro 
group of the compound I-245q was possible with elemental Zn in a solution of AcOH/MeOH 
(1:1) at 50 °C and furnished then the methyl -vinyl phenylalanate I-246q.85 The conversion 
of I-228q to I-245q could be realized in a one-pot fashion in 91% yield. This one-pot process 
was compatible with a number of functions such as cyano, phenylsulfonyl, ester and carbonyl 
groups as illustrated by the successful synthesis of compounds I-245n, I-245o, I-245l and I-
245k. We note that this two-steps sequence represented formally an enantioselective 
vinylation of an enolate. Inspite of the clear synthetic potentials, only few methods exist for 
accomplishing such transformation.
86
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Scheme 63:  chemoselective reduction of phenylselenonyl group - one pot reduction/oxidation sequence for 
the synthesis of enantioenriched vinyl derivative. 
Reduction of I-228q with Raney nickel under 40 bars of H2 in MeOH afforded directly 
the methyl 2-ethyl (R)-phenylalanate I-243 in which both nitro and phenylselenonyl groups 
were reduced (Scheme6). This represented, to the best of our knowledge, the first example of 
reduction of alkyl phenylselenone to alkane. 
 
Scheme 64: Reduction of alkyl phenyl selenone to alkanes 
Applying this protocol to I-228l allowed a one-pot synthesis of methyl (R)-2-ethyl 
pyroglutamate I-248 by a reduction/lactamizaiton sequence. To further illustrate the 
versatility of our approach, compound I-228l was successfully converted to methyl (S)-2-
vinylpyroglutamate I-247 using the chemistry detailed in Scheme 63.We stressed that 
examples of quaternary -amino acids (I-241, I-243, I-246q, I-247, I-248) presented herein 
are all difficultly accessible otherwise. 
 
Scheme 65: Synthesis of enantioenriched -lactam 
 With all the transformations depicted previously, we could consider the phenyl vinyl 
selenone I-50 as a synthetic equivalent of "+CH2CH2N", "+CH2CH2I", "+CH2CH3" and 
"+CH=CH2". We believe that none of the other known Michael acceptors could be as versatile 
as phenyl vinyl selenone. 
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Scheme 66: phenyl vinyl selenone as a switchable synthetic synthon 
Unexpected transformation: 
The synthesis of other interesting building blocks has also been envisaged. The 
enantioenriched 4-ester-4-nitrocyclohex-2-en-1-one I-253 could be a good example. The 
racemic version of this 6-membered ring has been made via Diels-Alder reaction using the 
Danishefsky diene.
87
 The considered sequence was an ozonolysis/intramolecular aldolisation 
starting from I-228k. Unfortunatly, only methyl 2-nitro-5-oxohexanoate I-53k was isolated in 
60% yield. Due to the presence of two electron-withdrawing groups in  position of the vinyl, 
the deformylation after ozonolysis was easy. To avoid this fragmentation, the preliminary 
reduction of the nitro to the amine could have been a solution. 
 
Scheme 67:  Fragmentation of I-228k 
 In order to substitute the phenyl selenonyl group by an alkoxy group, sodium hydride 
was added to a solution of I-228h in methanol. Surprisingly, instead of the expected ether 
derivative I-258 the isoxazoline N-oxide I-259 was isolated. The formation of this compound 
could be rationalized by a decarboxylation of I-228h followed by the intramolecular 
displacing of the selenieted group with the nitro group to offer the 5-membered heterocycle I-
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259. The synthesis of isoxazoline N-oxyide I-259 has been mostly described by [3+2] 
cycloaddition of olefin and nitronate.
88
 
 
Scheme 68: Unexpected synthesis of isoxazoline N-oxide 
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Conclusion 
The novel organocatalytic enantioselective Michael addition of - substituted -
nitroacetate to phenyl vinyl selenone was successfully accomplished. The Michael adducts 
were isolated in good to excellent yields and enantioselectivities. The reaction was carried out 
in the presence of bifunctional Cinchona alkaloid derivative as organocatalyst. The resulting 
-dialkyl -nitroacetates were subsequently converted to cyclic and acyclic quaternary 
amino acids, taking advantage of the rich functionalities of these adducts. This 
methodology complements our previous work developed for the synthesis of -aryl -
substituted isocyanoacetates. Novel protocols allowing chemoselective reduction of phenyl 
selenone to phenyl selenide and reduction of alkyl phenyl selenones to alkanes have also been 
reported. We believed that these chemoselective reductions would find applications in organic 
synthesis.
89
 
 
Scheme 69: Development of Cinchona alkaloid-catalyzed enantioselective Michael addition of - 
substituted nitroacetate to phenyl vinyl selenone 
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Chapter 2: -Substituted -
Nitroacetamide as Michael Donor 
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Introduction 
Preliminary idea 
Interested by the triple role of the phenyl vinyl selenone (activator for conjugated 
addition, leaving group and oxidant) which have been highlighted in our group,
59
 we 
imagined the synthesis of 5-membered ring derivatives using the phenyl selenonyl abilities in 
a multicomponent reaction where -substituted -electron-withdrawing amide I-261, phenyl 
vinyl selenone I-50 and a nucleophile were reacting together  (Scheme 70).  
We hypothesized that the reaction of amide I-261 with phenyl vinyl selenone would 
afford -lactam via a sequence of Michael addition and SN2 displacement of phenyl selenonyl 
group by the amide nitrogen. Oxidation of amide by in situ generated BSA would provide N-
acyl imine I-266 which could be trapped by a nucleophile to give I-262. 
 
Scheme 70: Preliminary idea for the synthesis of -lactam 
-Lactam synthesis 
 In the literature, the synthesis of -lactam I-267 has been massively reported. This was 
not surprising; this 5-membered ring is present in many natural product, drugs and bioactive 
compounds which have shown to be important in medicinal chemistry.
90
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 Several way of synthetizing -lactam has been exploited using the classical bond 
disconnection between the carbonyl and the nitrogen atom (Scheme 71, d.1). With that, 
intramolecular peptide coupling with an amine and an activated carboxyl group or the 
reduction of amine mask (nitro, azide or imine) has been an easy method to make the 5-
membered heterocycle. Cleaving the C-N bond could be also a good approach (Scheme 71, 
d.2).
91
 This bond could be made by N-alkylation of -halide-amide.92 The C-C bond 
disconnection d.3 has also been envisaged to construct the cyclic 5-membered amide. 
Dieckmann condition, radical cyclization or even Grubbs metathesis have been possible by 
this way.
93
 
 
Scheme 71: classical way for the synthesis -lactam synthesis 
 [4+1] Annulations, [3+2] annulations and also transition metal-catalyzed 
methodologies have been developed for the synthesis of -lactams. These approaches were 
less describes in the literature and have been a bit more detailed in this introduction. 
[4+1] Annulation:  
The [4+1] annulation has permited the construction of different N-protected 2-
pyrrolidinone I-272 by using the required primary amine I-7 and 4-iodobutanoyl chloride I-
271 (Scheme 72, (a)).
94a
 Fused 5-5 or 6-5 rings I-275 could also be synthesized if amino 
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alcohol I-273 were used with 4-oxobutanoic acid I-274 in the presence of PTSA in toluene at 
reflux (Scheme 72, (b)).
94b
  
 
Scheme 72: [4+1] annulation for -lactam synthesis 
Interestingly, the Ugi type three-component reaction using a primary amine I-7, an 
isocyanide I-1 and the carboxylic acid I-274 bearing a -carbonyl group afforded also -
lactam I-276.
95a
 After the trapping of the reactive nitrilium intermediate by the internal 
carboxylate to afford the intermediate I-277, the intramolecular attack of the amine to the 
carboxyl group gave the bridged compound I-278. The fragmentation of the bridged system 
delivered finally the -lactam I-276 (Scheme 73, (a)). Last year, an asymmetric version of this 
Ugi type reaction using 2-formylbenzoic acid I-279 in the presence of Cat*I-40 as 
organocatalyst has been developed to produce enantioenriched 3-oxoisoindoline-1-
carboxamides I-270 (Scheme 73, (b)).
95b
 
 
Scheme 73: Ugi type reaction for -lactam synthesis 
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[3+2] Annulation: 
 Different [3+2] annulations exist for the synthesis of this 5-membered heterocycle. 
The three-atoms unit containing the nitrogen could be played by azomethine ylide. After de-
silylation of the ammonium salt I-281, the reactive azomethine ylide generated in situ reacted 
with electron poor dipolarophile I-282 to afford, after the deprotection of the dithiolane, the -
lactam I-283 (Scheme 74, (a)).
96a
 Three-atoms motif containing nitrogen such as 2-iodo-N-
substituted acetamide I-286 has been also a good partner in the [3+2] annulation. After 
generating the stabilized enolate of the ketone I-285 with dimethyl carbonate I-284 and 
sodium hydride, the 2-iodoacetamide I-286 was added to the mixture to afford the fused 
lactam I-287 (Scheme 74, (b)).
96b 
 
Scheme 74: [3+2] annulation -lactam synthesis with 3-atom unit containing nitrogen 
Two-atoms partners containing nitrogen have also allowed the formation of -lactam. 
Shenvi and Corey described the diastereoselective synthesis of this kind of cyclic amide using 
a chiral glycine derivative I-289 and dimethylmalonyl dichloride I-288 for the total synthesis 
of (−)-7-methylomuralide (Scheme 75, (c)).96c Finally, the addition of an alkyl zinc bromide 
derivative to an imine, another two-atoms unit containing a nitrogen, followed by an 
intramolecular nucleophilic addition to the ester afforded the 3-methylenepyrrolidin-2-one 
derivative I-293 (Scheme 75, (d)).
96d
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Scheme 75: [3+2] annulation -lactam synthesis 2-atom unit containing nitrogen 
Metal-catalyzed -lactam synthesis: 
The design of specific metal-catalyzed reactions for the synthesis of -lactams have 
also been reported. Some transformations have been arbitrarily selected and depicted in the 
following schemes (Scheme 76, Scheme 77, Scheme 78). For example, the conversion of 
lactone I-294 to lactam I-295 has been described by Hong in 2015 using iridium complex and 
primary amine I-7 (Scheme 76). In the suggested mechanism of this reaction, the ring opening 
of lactone I-294 with a primary amine gave the linear hydroxyamide I-296 which was 
oxidized by the iridium complex by hydrogen transfer to the 4-oxobutanamide I-297. This 
aldehyde was trapped by another molecule of primary amine I-7 and reduced by the iridium 
complex to offer 4-aminobutanamide I-298. Finally the desired cyclic amide was formed after 
transamidation I-295.
97
 
 
Scheme 76: Iridium-catalyzed -lactam synthesis 
The synthesis of -lactam I-300 was also possible using gold-catalyzed tandem 
cycloisomerization/oxidation on enantiopure homopropargylic sulfonamides I-299 (Scheme 
77).
98 
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Scheme 77: Gold-catalyzed -lactam synthesis 
Enantioselective metal-catalyzed syntheses of chiral -lactam were also known 
(Scheme 78, (a) & (b)).
99
 Krische has highlighted the asymmetric rhodium-catalyzed 
cyclization of acetylenic aldehydes I-301 where a chiral diphosphine ligand L*I-9 
coordinated to a rhodacycle intermediate I-303 was involved and afforded after reductive 
cyclization the enantioenriched -lactam I-302. The palladium(0)-catalyzed C-H activation of 
cyclopropyl chloroacetamide I-304 described by Cramer and Pedroni in 2015 permited also 
the access to enantioenriched pyrrolidines I-305. In this transformation where a C(sp
3
)-C(sp
3
) 
bond formation was constructed, bulky TADDOL phosphonite ligand L*I-10 has been 
specially elaborated to induced high degree of chirality.  
It is notable that for some of these metal-catalyzed -lactam syntheses, a well 
elaborated starting material was needed which could take, sometimes, several steps to be 
constructed. 
 
Scheme 78: enantioselective metal-catalyzed -lactam synthesis 
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Literature precedent with phenyl vinyl selenone and -substituted -electron withdrawing-
amide 
 Only few example of asymmetric transformation using N-non protected amide have 
been developed by the scientific community.
 18c,100
 The difficulties encountered due to the 
relatively high pKa of the -C-H, the possible deprotonation of the labile N-H proton and the 
multiple coordination site of the substrate for the chiral catalyst were the plausible arguments 
which rendered hard the induction of enantioselectivity.
18c
 
In 2003, Yamada reported an enantioselective reduction of (E)-2-methyl-3-
phenylacrylamide I-306 using NaBH4 and the cobalt complex Cat*I-41. In this reaction 
primary and secondary unsaturated amide could be reduced albeit with a maximum of 60% of 
enantioselective excess (Scheme 79).
 101
 
 
Scheme 79: enantioselective 1,4-reduction of unsaturated primary amide 
Enzymatic kinetic resolution appeared to be an excellent tool for the synthesis of 
enantiopure ,-disubstituted amide. With amidase Rhodococcus sp. AJ270, enantiopure (R)-
amides I-309 could be separated from the highly enantioenriched (S)-carboxylic acid I-310. It 
was also important to note that is possible to convert cyano compound to enantioenriched 
amide derivative by using nitrile hydratase (Scheme 80).
102
 
 
Scheme 80: Enzyme kinetic resolution 
 In 2007, the enantioselective -fluorination of unprotected -tert-butoxycarbonyl 
lactams I-311 has been described by Sodoeka. The in situ formation of the chiral active 
complex was obtained when palladium chloride, chiral ligand L*I-11 and AgOTf were mixed 
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together which offered the fluorinated lactam I-312 in 58% yield and excellent 
enantioselectivity if NFSI was used as fluorine source and 2,6-lutidine as base.
103
  
  
Scheme 81: enantioselective -fluorination of N-unprotected tert-butoxycarbonyl lactams 
The use of N-unprotected amide have been also explored in diastereoselective 
transformations
104
 but finally, the most relevant utilization has been described by Shibasaki 
and coworkers with the enantioselective electrophilic amination of -substituted -
amidoacetate I-67. In this reaction, -substituted -amidoacetate I-67 reacted with 
azodicarboxylate I-65 in the presence of La(NO3)3•6H2O, the peptide-based ligand L*I-2 and 
O-tertbutyl valine to give highly enantioenriched -quaternary amide in excellent yield 
(Scheme 82).
18c105
 
 
Scheme 82: enantioselective electrophilic amination for -lactam synthesis 
Combination of phenyl vinyl selenone and amide 
The combination of N-unprotected amide and phenyl vinyl selenone has already been 
described. It was in 2013 that Marini and coworkers reported the reaction between phenyl 
vinyl selenone and -substituted -electron-withdrawing acetamide I-261 (-substituted -
ketoacetamides,-substituted -malonylacetamides, or -substituted -cyanoacetamides) for 
the synthesis of N-protected -disubstituted -lactam I-264. This racemic [3+2] annulation 
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between phenyl vinyl selenone I-50 and secondary amides occurred in the presence of 2 
equivalents of DBU in DCM at room temperature.
106
 
 
Scheme 83: [3+2] annulation using phenyl vinyl selenone for the synthesis of -lactam. 
 Inspired by their approach, we decided to use phenyl vinyl selenone I-50 and different 
-substituted -electron-withdrawing acetamides I-261 in the hope of developing an 
enantioselective version of this transformation and a 3-component reaction exploiting the 
triple role of the phenyl vinyl selenone (Scheme 84). 
 
Scheme 84: Our approach for the synthesis of enantioenriched -lactam 
Results & Discussion 
-Substituted -amidoacetate as starting material 
Brønsted base activation 
To start the investigation, 2-substituted methyl 3-amino-3oxo-propanoate I-313 and 
phenyl vinyl selenone I-50 were used as test substrate and different bases were tried to 
promote the 1,4-nucleophilic addition.  2 equivalents of base, 1 equivalent of I-313 and 1.2 
equivalent of pheny vinyl selenone were mixed together in DCM (Table 7). If the -
substituent of the -amidoacetate was a methyl (I-313a), Et3N and t-BuOK lead to messy 
reactions. Traces of the desired lactam I-314 were observed when NaH, DBU and Cs2CO3 
were used. Surprisingly, the lactone I-315 was isolated in 45% when TMG was used as strong 
organic base. In order to develop an enantioselective transformation, quinine Cat*I-18 was 
chosen as chiral organocatalyst. Unfortunately, only the starting materials were recovered. 
Methyl -phenyl amidoacetate I-313b was also used as substrate to render the -CH proton 
more acidic. With 2 equivalents of NaH, the reaction was messy. In the presence of 2 
equivalents of KOH the formation of lactam I-314 was possible in 25% yield but the lactone 
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I-315 was also formed in 40% NMR yield. Reducing the amount of base to 1.3 equivalent 
lead, in the case of NaH, to the formation of 40% of lactam I-314 and  45% of lactone I-315. 
With KOH, the reaction was complicated and only trace amount of lactone I-315 were 
detected. 
Table 7: Brønsted base screening. 
 
Entry R Base Temperature Observation 
1 I-313a Et3N RT, 40 °C Messy reaction 
2 I-313a NaH RT, 40 °C Messy, traces of I-314 
3 I-313a Cs2CO3 RT, 40 °C Messy, traces of I-314 
4 I-313a t-BuOK RT, 40 °C Messy reaction 
5 I-313a DBU RT Messy, traces of I-314 
6 I-313a TMG RT 45% of I-315 
7 I-313a quinine RT, 40 °C No reaction 
8 I-313b NaH RT Messy reaction 
9 I-313b KOH RT 20% yield of I-314 + 30% yield of I-315 
 10 I-313b NaH (1.3 equiv) RT 30% yield of I-314 + 35% yield of I-315 
11 I-313b KOH (1.3 equiv) RT trace of I-315 
12 I-313b Quinine (Cat*I-18) RT No reaction 
 
 Methanol was used as solvent with the expectation that methanol could play the 
external nucleophile for the formation of the 3-CR adduct I-316. However, by changing the 
base, (Et3N, NaH or KOH), the -substituent (R = Me or Ph), only messy reaction were 
observed (Scheme 85).   
 
Scheme 85: MeOH as solvent and partner in the 3-CR. 
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Lewis acid activation 
When the nitrogen of the amide is playing the nucleophile the lactam is formed 
whereas if the oxygen attack the phenyl selenonyl group, the cyclic imidate is formed which 
afford, after hydrolysis the lactone. Due to poor results obtained with Brønsted base we 
decided to utilize Lewis acids as catalyst. Excited by the enantioselective reaction described 
by Shibasaki and coworkers where rare earth metal complexes were used as catalyst 
system,
18c
 we decided to explore this approach. 
Different Lewis acids and ligands were screened (Table 8). When 30 mol% of 
La(OTf)3, La(NO3)3.6H2O, GaBr3, Er(OTf)3 or EuCl3 were used respectively with 30 mol% of 
terpyridine, the formation of lactone I-315a was obtained. The best result was obtained with 
La(OTf)3 (30 mol%), terpyridine (30 mol%), in toluene at RT leading to 48% NMR yield of 
the lactone I-315a. LaBr3, FeBr3 and YbCl3 (entry 3, 5 and 7) however, were not able to 
promote the 1,4-addition. The presence of a Lewis acid was mandatory has shown in entry 9. 
Shibasaki’s condition were also used (entry 10) but failed to catalyze this transformation. 
Table 8: Lewis acid screening. 
 
Entry Conditions Observation 
1 La(OTf)3 terpyridine, toluene I-315a (48% NMR yield) 
2 La(NO3)3.6H2O terpyridine, toluene 55% conv. in I-315a (28% yield) 
3 LaBr3, terpyridine, toluene No reaction 
4 GaBr3, terpyridine, toluene Full conv. in I-315a (42% yield) 
5 FeBr3, terpyridine, toluene, R.T. to 40 °C No reaction 
6 Er(OTf)3, terpyridine, toluene Full conv. in I-315a (48% yield) 
7 YbCl3, terpyridine, toluene, R.T. to 40 °C No reaction 
8 EuCl3, terpyridine, toluene R.T. 67% conv. in I-315a (17% yield) 
9 No L.A., terpyridine, toluene R.T. to 40 °C No reaction 
10 La(NO3)3.6H2O, L*I-2, H-D-Val-OtBu, AcOEt,  No reaction 
 
La(OTf)3 seems to be the most promising Lewis acid to catalyse the formation of the 
lactone I-315a even if moderate yield was obtained. Therefore, we decided to modify our 
preliminary idea which was the synthesis ofdisubstituted lactam and focused on the 
enantioselective synthesis disubstituted lactone I-317 (Scheme 86). 
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Scheme 86: Enantioselective lactone synthesis. 
After a preliminary screening of different parameters (ratio Lewis acid/ligand, ligand 
and temperature) using La(OTf)3 as Lewis acid, the best conditions to form the lactone I-314a 
were with 30 mol% of terpyridine as ligand, 30 mol% of Lewis acid at room temperature in 
DCM (Table 9). Under these conditions I-314a was obtained in 48% yield.   
Table 9: Condition screening when La(OTf)3 is used as Lewis acid. 
  
Entry Ratio Lewis 
acid/Ligand (X:Y) 
Ligand Temperature Observation 
1 1 :1 (30 :30 mol%) LI-12 R.T. 48% NMR yield 
2 1 :0 (30 :0 mol%) None R.T. 44% NMR yield 
3 1 :1 (30 :30 mol%) LI-13 R.T. 36% NMR yield 
4 1 :1 (30 :30 mol%) L*I-14 R.T. 25% NMR yield 
5 1 :1 (100 :100 mol%) LI-12 R.T. 12% NMR yield 
6 1 :2 (30 :60 mol%) LI-12 R.T. 46% NMR yield 
7 1 :3 (30 :90 mol%) LI-12 R.T. 46% NMR yield 
8 2 :1 (30 :15 mol%) LI-12 R.T. 36% NMR yield 
9 1 :1 (30 :30 mol%) LI-12 -40 °C No reaction 
10 1 :1 (30 :30 mol%) LI-12 -20 °C No reaction 
11 1 :1 (30 :30 mol%) LI-12 0 °C 45% Conv., 29% NMR yield 
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 To render the reaction enantioselective, bis(oxazoline)pyridine derivatives, a class of 
chiral tridentate ligand, have been studied (Table 10). The -substituted amidoacetate was 
replaced by methyl -benzyl -amidoacetate I-313c which was more easily separable and 
gave a greater UV signal strength on chiral SFC. When the reaction was run at room 
temperature, the conversion was very slow (Entries 1 to 6). The reaction was then heated to 
40 °C and (Inda)pyBox and (tBu)pyBox afforded the lactone I-314c in low yield and low 
enantioselectivity (Entries 8 and 9). The methyl -phenyl amidoacetate I-313b was also used 
as starting material for this enantioselective Michael addition, however, low yield and er 
where obtained in this transformation (Entries 10 to 15). L*I-17 and L*I-18 allowed the 
formation of the lactone I-314c (64:36 er, 24% yield and 72:28, 20% yield respectively). The 
yields were low and the rest of the starting material was not converted to the desired product 
even after 72h of reaction time.  
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Table 10: Chiral ligand screening. 
 
Entry R Ligand T °C yield er 
1 R = Bn L*I-12 R.T. 20% NMR yield - 
2 R = Bn L*I-13 R.T. 11% NMR yield - 
3 R = Bn L*I-16 R.T. No reaction - 
4 R = Bn L*I-4 R.T. No reaction - 
5 R = Bn L*I-17 R.T. Low conversion - 
6 R = Bn L*I-14 R.T. Low conversion - 
7 R = Bn None 40 °C No reaction - 
8 R = Bn L*I-17 40 °C 20% yield 55:45 
9 R = Bn L*I-14 40 °C 20% yield 66:34 
10 R = Ph L*I-16 40 °C 19% yield 55:45 
11 R = Ph L*I-4 40 °C 26% yield 64:36 
12 R = Ph L*I-17 40 °C 24% yield 54:46 
13 R = Ph L*I-14 40 °C 17% yield 54:46 
14 R = Ph L*I-15 40 °C 10% yield 52:48 
15 R = Ph L*I-18 40 °C 20% yield 72:28 
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Brønsted acid activation & dual catalysis 
Brønsted acids have also been explored to develop this enantioselective reaction 
(Table 11). Unfortunately, 10 mol% of phosphoric acid Cat*I-42 or sulfonyl phosphoramide 
Cat*I-43 at room temperature or at 60 °C was not promoting the transformation (Entry 1 to 
4).  
The dual catalysis approach has been tried. By mixing a Lewis acid, a ligand and a 
Brønsted acid, several powerful reactions have been reported.
107
 When La(OTf)3, ligand L*I-
4 and TFA were used together, no reaction was observed even at 60 °C. Finally, in the 
presence of lanthanim complex and Cat*I-42 or Cat*I-43 at 60 °C, the lactone I-314b was 
formed albeit with low yields and enantioselectivities (36-38% yield & 60:40 er). 
Table 11: Brønsted acid screening. 
 
Entry R T (°C) Acid (10 mol%) Lewis Acid/Ligand Observation 
1 R = Ph R.T., 60 °C Cat*I-42 None No reaction 
2 R = Ph R.T., 60 °C Cat*I-43 None No reaction 
3 R = Bn R.T., 60 °C Cat*I-42 None No reaction 
4 R = Bn R.T., 60 °C Cat*I-43 None No reaction 
5 R = Ph R.T. TFA La(OTf)3, L*I-4 (1:1) No reaction 
6 R = Ph R.T. Cat*I-42 La(OTf)3, L*I-4 (1:1) No reaction 
7 R = Ph R.T. Cat*I-43 La(OTf)3, L*I-4 (1:1) No reaction 
8 R = Ph 60 °C TFA La(OTf)3, L*I-4 (1:1) No reaction 
9 R = Ph 60 °C Cat*I-42 La(OTf)3, L*I-4 (1:1) 35% conv., 60:40 er 
10 R = Ph 60 °C Cat*I-43 La(OTf)3, L*I-4 (1:1) 38% conv., 61:39 er 
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Other -substituted -(electron-withdrawing)acetamide 
With these unfruitful results, we decided to replace the -substituted-amidoacetate 
by other -substituted -(electron-withdrawing) acetamides which could have a better affinity 
with the catalyst and a better reactivity. Therefore, we decided to change the ester group to 
carbonyl (I-318), cyano (I-319) or nitro (I-320) group on the Michael donor in this reaction. 
Each of the three different -(electron-withdrawing)acetamides were used separately 
with lanthanum-ligand complexes (Table 12). The La(OTf)3-pyBox system or Shibasaki’s 
complex gave no reaction for the three Michael donors even if the reaction was heated to 60 
°C. When trimethylamine was added in the reaction, degradation of -butyl -ketoacetamide 
I-318, was observed. In the case of -butyl -cyanoacetamide I-319, a trace amount of the 
imidate I-321 was detected. Nonetheless, the presence of an organic base with -butyl -
nitroacetamide I-320 allowed the full conversion of the starting material to the imidate I-321 
in 81% yield. 
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Table 12: Screening of other electron-withdrawing group on the starting material. 
 
Entry EWG Ligand Temperature Base Observation 
1 C(O)Me L*I-4 R.T., 60 °C None No reaction 
2 C(O)Me L*I-2 R.T., 60 °C None No reaction 
3 C(O)Me L*I-4 R.T. Et3N Degradation 
4 C(O)Me L*I-2 R.T. Et3N Degradation 
5 CN L*I-4 R.T., 60 °C None No reaction 
6 CN L*I-2 R.T., 60 °C None No reaction 
7 CN L*I-4 R.T. Et3N Trace of I-321 
8 CN L*I-2 R.T. Et3N Trace of I-321 
9 NO2 L*I-4 R.T., 60 °C None Trace of the imidate at 60 °C 
10 NO2 L*I-2 R.T., 60 °C None No reaction 
11 NO2 L*I-4 R.T. Et3N Full conv. to I-321, 81% yield 
  12 NO2 L*I-2 R.T. Et3N Full conv. to I-321 
 
 With the high yield obtained for the synthesis of the imidate I-321 when the-electron 
withdrawing group was a nitro group, we focused our investigation on -substituted -
nitroacetamide I-320 as substrate. 
-Substituted -nitroacetamide as partner of choice 
The first test reactions with -substituted -nitroacetamide I-320 were performed in 
the presence of Brønsted base. To discriminate the presence of La(OTf) or ligand; the 
reaction was run without the rare earth-ligand complex. Indeed, when trimethylamine was 
used as organic base, the Michael addition occurred to afford a mixture of imidate/lactone. It 
was interesting to note that the imidate was stable in this condition whereas previously the 
imidate was fully hydrolyzed to lactone. It appeared also that quinine Cat*I-18, -
isocupreidine Cat*I-2, thiourea derivative Cat*I-8 and Cat*I-38 triggered also the Michael 
addition/SN2 sequence. The conversion of the starting material to the product was good but 
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the enantioselectivity of this transformation could not be recorded. Effectively, the product 
was not UV active and the UV detector of the SFC could not detect the lactone I-323 as well 
as the imidate I-324. 
Table 13: Base screening. 
 
Entry Catalyst lactone/imidate ratio Isolated yield of lactone 
1 Et3N 10:90  78% 
2 Cat*I-18 45:55 35% 
3 Cat*I-2 16:84 59% 
4 Cat*I-8 35:65 57% 
5 Cat*I-38 50:50 47% 
 
 In order to fully convert the imidate I-324 to the lactone I-323, we tried several 
hydrolysis conditions on the cyclic imidate I-324. The best result was obtained when acetic 
acid was added to a solution of I-324 in a (1:1) mixture of DCM and water at room 
temperature. The desired cyclic compound I-323 was isolated in 94% isolated yield (Scheme 
87, (a)). A one pot synthesis combining the [3+2] annulation and the imidate hydrolysis has 
been also developed to give I-323 in 90% yield (Scheme 87, (b)).  
 
Scheme 87: Imidate hydrolysis to lactone. 
 To measure the enantioselective ratio of the reaction, other -substituted -
nitroacetamides containing aromatic group for a better UV signal strength needed to be 
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elaborated. To reach this goal, the unprecedented syntheses of primary, secondary and tertiary 
-substituted -nitroacetamides have been developed. 
 The primary amide I-328 has been synthesized by -bromination of 3-
phenylpropanenitrile I-325 followed by SN2 with sodium nitrate and hydrolysis of the nitrile 
to the amide I-328 in 22% yield over three steps. 
 
Scheme 88: Primary amide synthesis. 
For the secondary amides I-329, the first approach envisaged was the transamidation 
of -benzyl -nitroacetate I-53q with primary amine I-57. This reaction gave good yield only 
in the case of not bulky primary amine. The other approach for the synthesis of I-329 started 
with the Passerini 3-CR of 2-phenylacetaldehyde I-330, isonitrile I-1 and acetic acid which 
afforded after deprotection the N-substituted -benzyl -hydroxyacetamide I-331. By 
continuing the sequence with an Appel reaction and a nucleophilic substitution, the secondary 
-nitroacetamide I-329 could be generally isolated in moderate to good yield. 
 
Scheme 89: Secondary amide synthesis. 
 Finally, the tertiary amide was synthesized from 3-phenylpropanoic acid I-333 by a 
one pot sequence acyl chloride formation/-bromination/nucleophilic addition of N,N-
dimethylamine sequence to deliver I-334 in low yield. The final SN2 with sodium nitrate 
offered the -nitroacetamide I-335 in 72% yield.  
 
Scheme 90: Tertiary amide synthesis. 
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 With this various amides in hands, we decided to use N-butyl -benzyl -
nitroacetamide I-329a as model substrate and Cat*I-1 as organocatalyst. After screening the 
solvent and the temperature, we observed that all the solvent gave good yields and the 
temperature was not influencing the er with DCM as solvent. It was notable that toluene gave 
the best result with 90% yield and 60:40 er for I-336 (Table 14). 
Table 14: Solvent screening. 
 
Entry solvent T (°C) yield er 
1 DCM R.T. 94% 50:50 
2 DCM -40 °C 92% 50:50 
3 AcOEt R.T. 87% 51:49 
4 Toluene R.T. 90% 60:40 
5 THF R.T. 91% 53:47 
6 MeCN R.T. 88% 58:42 
  
 The influence of the N-substituents of the amide was then studied (Table 15). Cat*I-1, 
Cat*I-35 and Cat*I-7 were selected as organocatalyst for a preliminary screening due to the 
difference of chiral environment and H-bond donors. When N-unsubstituted amide I-328 was 
utilized as substrate, moderate yield and low er were observed (Entry 1 & 2). Moreover, no 
reaction  has been detected when Cat*I-7 is the catalyst (Entry 3). The tertiary amide I-335 
also gave poor result. Only no reaction or low yield/er were obtained (Entry 4 to 6). When 
secondary amides were used, the convertion toward the lactone was excellent and isolated 
yields were very good. For the enantioselectivity, moderate er (around 60:40) were obtained 
with I-329a (R = n-Bu) (Entry 7 to 9). The nitroacetamide I-329b (R = t-Bu) however gave 
interesting outcome with Cat*I-35 and Cat*I-7 (64:36 er and 61:39 er respectively) (Entry 11 
& 12). N-(2,6-(dimethyl)phenyl) secondary amide I-329c was used but low induction where 
observed with the three selected catalysts (Entry 13 to 15). Surprisingly, we also observed that 
the best catalyst Cat*I-38 developed for the previous methodology gave poor 
enantioselectivety regardless of the nature of the N-substituent (Entry 16 to 19).  
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Table 15: N-Substitients screening. 
 
Entry -N(R
1
R
2
) Catalyst Isolated Yield er 
1 -NH2 (I-328) Cat*I-1 50% 51:49 
2 -NH2 (I-328) Cat*I-35 65% 51:49 
3 -NH2 (I-328) Cat*I-7 No reaction - 
4 -N(Me)2 (I-335) Cat*I-1 25% 52:48 
5 -N(Me)2 (I-335) Cat*I-35 No reaction - 
6 -N(Me)2 (I-335) Cat*I-7 No reaction - 
7 -NH(n-Bu) (I-329a) Cat*I-1 90%. 60:40 
8 -NH(n-Bu) (I-329a) Cat*I-35 91% 60:40 
9 -NH(n-Bu) (I-329a) Cat*I-7 89% 59:41 
10 -NH(t-Bu) (I-329b) Cat*I-1 94% 55:45 
11 -NH(t-Bu) (I-329b) Cat*I-35 92% 64:36 
12 -NH(t-Bu) (I-329b) Cat*I-7 95% 61:39 
13 -NH(m-xyl) (I-329c) Cat*I-1 93% 55:45 
14 -NH(m-xyl) (I-329c) Cat*I-35 94% 59:41 
15 -NH(m-xyl) (I-329c) Cat*I-7 92% 56:44 
16 -NH(n-Bu) (I-329a) Cat*I-38 89% 55:45 
17 -NH(tBu) (I-329b) Cat*I-38 88% 53:47 
18 -NH(Bn) (I-329d) Cat*I-38 91% 54:46 
19 -NH(Me) (I-329e) Cat*I-38 87% 54:46 
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Because N-t-butyl secondary amide I-329b gave best results in our preliminary 
screening, further organocatalysts were tried using this structure (Table 16). To summarize 
this large screening of organocatalyst, the yields observed for the transformation were good 
for almost all the catalysts, only Cat*I-45 could not promote the reaction (Entry 8). The 
enantioselectivity ratio oscillates around 60:40 but the catalysts which possessed a free OH on 
C9 gave the most interesting enantioselectivity (Entry 6, entry 13, entry 18 and entry 19). 
Notably, Cat*I-49 where the C9 was OH and C6’ was OiPr afforded the best enantioselective 
ratio of 71:29 (entry 18). Other modification around the double bond or the use of other H-
bond donor on C6’ or C9 of the organocatalyst did not lead to good chiral induction.  
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Table 16: Cinchona alkaloid screening. 
 
Entry Catalyst Isolated yield er 
1* Cat*I-1 94% 55:45 
2* Cat*I-35 92% 64:36 
3* Cat*I-7 95% 61:39 
4 Cat*I-14 80% 52:48 
5 Cat*I-44 92% 59:41 
6 Cat*I-18 85% 67:33 
7 Cat*I-45 89% 60:40 
8 Cat*I-46 No reaction - 
9 Cat*I-30 87% 52:48 
10 Cat*I-47 92% 60:40 
11 Cat*I-18 90% 60:40 
12 Cat*I-48 81% 62:38 
13 Cat*I-49 86% 67:33 
14 Cat*I-50 88% 55:45 
15 Cat*I-51 90% 57:43 
16 Cat*I-38 84% 53:47 
17 Cat*I-52 94% 51:49 
18 Cat*I-53 94% 71:29 
19 Cat*I-54 90% 66:34 
20 Cat*I-55 89% 56:44 
21 Cat*I-56 85% 51:49 
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After an intensive screening of various reaction parameters with the hope of reaching 
highly enantioenriched ,-disubstituted -lactone, no better results were obtained. The 
difficulty of inducing the enantioselectivity could probably be explained by the presence of 
two H-bond sites on the substrate (N-H of the secondary amide, and the -acidic proton) and 
two strong coordinating functional groups (nitro and amide) which complicate the electronic 
interaction with the Cinchona alkaloid  for a good transition state. To answer this problematic, 
one of the solution could have been to try other family of organocatalysts such as Jacobsen's  
thiourea derivatives
108
 or phosphoric acid derivatives.  
Nonetheless, we decided to put this enantioselective Michael addition/SN2 sequence in 
stand-by. The optimum conditions found consisted of performing the reaction of I-329b and 
I-50 in the presence of Cat*I-53 in toluene at -20 °C.Under these conditions lactone I-336 
was isolated, after acidic treatment, in 94% yield with an er of 71:29. 
 
Scheme 91: Best result for the Cinchona alkaloid-catalyzed enantioselective conjugated addition. 
 
Other interesting product isolated during the study 
 During this project, some interesting building blocks have been isolated. By varying 
the Brønsted base, we observed that N-substituted -substituted -nitroacetamide could be 
exclusively converted to lactam I-337. By adding 2 equivalents of DBU in the presence of -
nitroacetamide I-329a and phenyl vinyl selenone I-50 in DCM, the racemic lactam I-337 was 
obtained with the excellent yield of 90% (Scheme 92). This result was in accord with the 
work described by Marini and coworkers.
106
 
 
Scheme 92: ,-Disubstituted lactam synthesis. 
 Interestingly, we also noticed that the imidate I-338 can be hydrolyzed to 2-benzyl-N-
butyl-4-hydroxy-2-nitrobutanamide I-339 in the presence of wet DCM and SiO2. The linear 
product was formed in 60% yield (Scheme 93). 
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 M. S. Sigman, E. N. Jacobsen, J. Am. Chem. Soc. 1998, 120, 4901. 
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Scheme 93: Unexpected ring opening of the cyclic imidate I-338. 
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Conclusion 
In conclusion, the organocatalytic Michael addition/intramolecular SN2 sequence 
between N-substituted substituted nitroacetamide I-329 and phenyl vinyl selenone I-50 
has been developed. In the presence of Cinchona alkaloid Cat*I-53, the formation of cyclic 
imidate I-338 was possible and could be converted after hydrolysis to the ,-disubstituted -
lactone I-336 in excellent yield and moderate enantioselectivity. This domino process could 
afford the linear product I-339 if the imidate I-338 was treated with SiO2 and wet DCM. The 
racemic synthesis of ,-disubstituted -lactam I-337 was also feasible in excellent yield 
using DBU. In this methodology, the careful choice of the reaction conditions allowed the 
formation of different important building blocks which could be used later for the design of 
potent bioactive molecules (Scheme 94). 
 
Scheme 94: Alkyl nitroacetamide and phenyl vinyl selenone for the synthesis of -lactone or -
lactam. 
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Part II: Transition Metal-Catalyzed 
Insertions of Isocyanides Bearing 
Participating Functional Group 
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Chapter 3: Lewis Acid-Catalyzed 
Insertions of ,-Disubstituted -
Isocyanoacetate and Methyl o-
Isocyanobenzoate 
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Introduction 
Isocyanide as nucleophile 
The unique electronic configuration of isocyanide affords to this functional group a 
peculiar reactivity.
 109
 Classically, due to the free lone pair located on the carbon, isocyanide 
II-1 acts as a nucleophile with electrophiles. The resultant nitrilium II-2 reacts quickly with 
an external nucleophile which leading to the ketimine II-3 (Scheme 95).
 
 
 
Scheme 95: Classical reactivity of isocyanide. 
The use of Lewis acids has been described for years to enhance the electrophilicity of 
functionalities such as carbonyl, imine, carboxylate or nitrile groups and numerous 
transformations like Diels-Alder,
110
 or Friedel-Craft
111
 reactions have been developed using 
Lewis acid catalysis. 
To introduce nucleophilic isocyanides in unreactive substrate, different functionalities 
have been activated by Lewis acid. In the beginning of this century, Chatani and coworkers 
have reported the Ga(Cl)3-catalyzed  [4+1] cycloaddition of ,-unsaturated ketones II-4 with 
aryl isocyanides II-5 (Scheme 96, (a)). This reaction offered various cyclic imidates II-6 
which could be converted in -lactones.112a Other Michael acceptors such as 2-aryl 2-
cyclohexen-1-ones II-7 lead to [4+1] cycloaddition with isocyanide when La(OTf)3 was used 
as catalyst (Scheme 96, (b)). Two different products (II-9 or II-10) could be isolated 
depending on the internal heterocycle attached to the cyclic enone.
112b
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Scheme 96: Lewis acid-catalyzed transformation of ,-unsaturated enone and isocyanide.  
Zhao and coworkers have shown that gallium-(III) could also catalyze the double 
insertion of isocyanide II-5 into substituted epoxide II-11 for the synthesis of ,-unsaturated 
-iminolactones II-12.113 In this transformation, the Lewis acid activated the epoxide which 
facilitated the ring opening by nucleophilic addition of an isocyanide. The subsequent 
nitrilium II-13 reacted with a second isocyanide to afford, after closing the 5-membered ring, 
the desired cyclic compound II-12 in good yield (Scheme 97, (a)). Similarly, Meijere et al 
have reported the Pr(OTf)3-catalyzed double insertion of isocyanide II-5 into electron 
deficient cyclopropane II-14 to afford the cyclic enamine II-15 in low to moderate yield 
(Scheme 97, (b)).
114
  
 
Scheme 97: Lewis acid-catalyzed double isocyanide insertion into epoxide or activated cyclopropane.  
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Recently, our group reported the silver-(I)-catalyzed 3-CR reaction of primary 
homopropargylamine II-17, isocyanide II-8 and carboxylic acid II-18 for the synthesis of N-
acyl proline -amides II-19 (Scheme 98, (a)).115 For this reaction, the suggested mechanism 
which followed our experimental observations started with a silver-catalyzed 5-endo-dig 
cyclization of the amine II-20 to the internal alkyne. After expulsion of the silver complex 
linked on II-22, II-22 was converted to the dihydropyrrole II-24. With the presence of the 
isocyanide II-8 and the carboxylic acid II-18, this cyclic compound II-24 which was in 
equilibrium with the iminium intermediate II-25 underwent an Ugi-Jouillé reaction to afford 
the desired pyrrolidine derivative II-28.  
It was important to note that in the absence of carboxylic acid II-18 and if the primary 
homopropargylamine II-17 was replaced by the secondary amine II-29, the transformation 
stoped at the protected dihydropyrrole II-31. The 3-CR reaction between the intermediate II-
32, water and isocyanide occurred only if the reaction mixture was submitted to FCC on silica 
gel and lead to the N-protected proline -amides II-30 (Scheme 98, (b)). 
 
Scheme 98: Silver-catalyzed 3-CR with isocyanide.  
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Isocyanide as electrophile 
By taking advantage of the carbene-like nature of isonitrile II-1, this functional group 
could also react as an electrophile when a specific metal was present in the reaction (Scheme 
99). Ito and Saegusa, the pioneers in this type of isocyanide insertion to nucleophiles, have 
developed this chemistry at the end of the sixties. Amine,
116
 trialkylsilane,
117
 alcohol,
118
 
thiol
119
 and dialkylphosphine
120
 have been used in copper-(I) or copper-(II)-catalyzed 
isocyanide insertion reaction.  
 
Scheme 99: Electrophilic isocyanide: activation with Lewis acid. 
Later, it has been highlighted that the isocyanide insertion into nucleophile was also 
possible without external activation if strong metalated nucleophiles such as Grignard reagent, 
organolithium or organozinc compounds were used (Scheme 100).
121
 
 
Scheme 100: Organometallic as strong nucleophile. 
In the field of polymer chemistry, Lewis acids have been utilized to promote the 
isocyanide polymerization (Scheme 101).
122
 With this type of activation and by playing with 
the temperature and the alkyl/aryl residue of the isocyanide, different oligomers with various 
physical and chemical properties have been elaborated. 
 
Scheme 101: Polymerization of isocyanide. 
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In 1999, Ito and coworkers reported the isocyanide insertion into organic nucleophile 
such as dialkyl amine and alcohol without external activation (Scheme 102).
123
 In this 
particular case, the nucleophile reacted with the o-alkynylisocyanobenzenes II-40 to afford 
the imdoyl anion II-42 which directly underwent a fast 6electrocyclization. After 
rearomatization and protonation, the quinoleine II-41 was formed in good yield. Normally, 
the nucleophilic addition on isocyanide was delicate without catalyst but the favored 
6electrocyclization allowed the trapping of the intermediate II-42 to drive the reaction to 
the final product II-41.     
 
Scheme 102: Isocyanide insertion of nucleophiles followed by 6- electrocyclization 
 The isocyanide insertion of indole II-45 was also possible and has been described by 
Chatani and coworkers in 2007 if aluminum trichloride was used as Lewis acid (Scheme 103).
 
124
 
 
Scheme 103: Isocyanide insertion of indole. 
More recently, our group described the 4-CR reaction where three molecules of 
isocyanide II-8 reacted with carboxylic acid II-18 in the presence of zinc bromide as Lewis 
acid (Scheme 104, (a)).
 125
 Mechanistically, this transformation could start with isocyanides 
II-8 coordinated to the Lewis acid. After isocyanide insertion of carboxylic acid II-18 to give 
II-48, two other isocyanide insertions occured to afford the oligomer II-52 containing three 
isocyanides unit. Then, metal-salt elimination lead to the ketenimine intermediate II-54 which 
delivered after cyclization and dealkylation the heterocycle II-47 in moderate to good yields. 
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Scheme 104: Lewis acid-catalyzed reaction of isocyanides with carboxylic acid 
Thiocarboxylic acid II-56 could replace carboxylic acid II-18 and allowed the similar 
formation of amino-4-carboxamidothiazole II-57 (Scheme 105).
126
 Interestingly, this type of 
heterocycles was able to emit fluorescence at long wavelengths due to the double excited-state 
intramolecular proton transfer (ESIPT) process. 
 
Scheme 105: Lewis acid-catalyzed reaction of isocyanides with thiocarboxylic acid and double ESIPT 
process. 
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 The syntheses of imidazolium salts II-63 and imidazoles II-64 by using Lewis acids, 
isocyanide II-8 and propargylamine II-62 have also been developed in our laboratory 
(Scheme 106).
127
 In this reaction, the isocyanide II-8 acted as a polarized triple bond which 
was uncommon and rare for this type of functionality. For the mechanism, we suggested that 
the propargylamine II-62 would attack the Lewis acid-activated isocyanide II-37 to afford the 
metalated species II-66. After salt metathesis, the compound II-67, where the triple bond was 
activated by the silver salt, would afford the cyclic compound II-68 after 5-exo-dig type 
reaction. Silver salt regeneration permited the formation of the desired imidazolium salt II-63. 
If the residue carried by the nitrogen was a tert-butyl group, a dealkylation was occurring to 
give the imidazolone II-64 after salt metathesis. 
 
Scheme 106: Lewis acids-catalyzed reaction of isocyanide and propargylamine. 
Isocyanide synthesis 
To synthesize isocyanides, several methods have been developed over the years. 
Preliminary studies from Lieke and later Meyer and Gauthier separately described the 
formation of isonitrile II-8 by reacting alkyl halide II-71 with silver cyanide (Scheme 107 
(a)).
128
 Primary amines II-72 were a partner of choice for the preparation of isocyanide II-8. 
Excess of KOH and CHCl3 in the presence of the primary amine II-72 afforded the isonitrile 
compound II-8 (Scheme 107 (b)).
129
 However, the most common method used to construct 
isocyanide II-8 was the two steps sequence formylation/dehydration of primary amine II-72. 
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With different formylating agent (ethylformate, acetic formic anhydride, ammonium formiate 
or even trifluoromethanesulfonic anhydride to activate the amine) and numerous conditions of 
dehydration (with POCl3, COCl2, PPh3 & CCl4, Burgess reagent etc.) a broad scope of 
isocyanides II-8 has been reported.
130
 
Alcohol II-74, a versatile starting material, is also convertible in isocyanide II-8. Hard 
Lewis acids, such as ZnBr2 or TiCl4, in present of TMSCN could be used to transform tertiary 
protected and non-protected alcohol. Recently, Shenvi and co-worker have reported milder 
condition where the reaction of TFA-protected alcohol II-73 with 20 mol% of Sc(OTf)2 and 
TMSCN at room temperature lead to the isocyanation with high stereo-inversion (Scheme 
107, (c)).
131
 With this method, the late installation of isocyanide in elaborated molecules was 
possible with good chemo- and stereoselectivities. Other methods to convert free alcohol II-
74 to isocyanide II-8 have also been described by the group of Kitano and Mukayaima 
respectively (Scheme 107, (d)).
132
 Gassman et al have shown that the opening of cyclic ethers 
II-75 using ZnI2 and TMSCN permited the preparation of  or isocyanoalcohol II-76 
(Scheme 107, (e)).
133
 Finally, isocyanate II-77 could be modified to isocyanide II-8 under 
reductive condition (Scheme 107, (f)).
134
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Scheme 107: Different approaches for the synthesis of isocyanide. 
Preliminary idea 
 With the isocyanide insertion into nucleophile in mind, we envisaged to develop the 
Lewis acid-catalyzed [3+3] cycloaddition of -EWG isocyanide II-78 and -amino acetate 
II-79 for the synthesis of  1,6-dihydropyrimidin-5(4H)-one derivative II-80 (Scheme 108). In 
this transformation, we imagined that the mechanism could start with the isocyanide 
coordination of the Lewis acid which promoted the nucleophilic attack of the -amino acetate 
II-79 to offer the amidine II-82. Sequential salt metathesis and deprotonation gave the 
intermediate II-83 which underwent cyclization to deliver the desired 6-membered ring II-80. 
This unprecedented domino process involving isocyanide insertion/cyclization could allow 
the formation of one C-N and one C-C bonds rapidly to furnish unusual building blocks. 
 
Scheme 108: Preliminary idea - Lewis acid-catalyzed [3+3] cycloaddition. 
  
116 
 
Results & Discussion 
Preliminary resutls 
To start our investigation on the Lewis acid-catalyzed formal [3+3] cycloaddition we 
decided to use methyl -isocyanoacetate II-84 and L-phenylalanine methyl ester II-85 as 
partners. Different parameters (Lewis acid, base, solvent, temperature) were intensively 
screened but, unfortunately, only the dimer II-86 was observed which comes from the [3+2] 
cycloaddition of two isocyanoacetate molecules II-84. This was not surprising, Yamamoto 
and coworkers have already described this type of transformation where one of the isocyanide 
was playing the role of a 1,3-dipole due to the presence of a base or a Lewis acid (Scheme 
109).
135
 
 
Scheme 109: [3+2] Cycloaddition of -isocyanoacetates. 
 During this preliminary exploration, we have also isolated the 2-imidazoline derivative 
II-87 when acetone was used as solvent. This compound II-87 results from the 3-CR reaction 
of -isocyanoacetate II-84, -aminoester II-85 and acetone. This multicomponent reaction 
was known and has been depicted by Orru, Ruijter and coworkers in 2007.
 136
  
   
Scheme 110: 3-CR reaction for the synthesis of imidazolines derivatives. 
 Methyl -phenyl -isocyanoacetate has been used as -isocyanoacetate alternative 
with the hope of developing this Lewis acid-catalyzed [3+3] cycloaddition. This time, only 
degradation of the starting materials was observed whatever the Lewis acid, base, temperature 
or solvent used. These observations drove us to conclude that the presence of an acidic -
proton was problematic in the design of our reaction. 
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-Metalated isocyanide 
With the well-known electron withdrawing ability of the isocyanide functionality, the 
deprotonation of the -proton was possible with a strong base (BuLi) or even with a softer 
base when another EWG is carried by the -carbon. This was the case for the isocyanoacetate 
II-78 and lot of methodologies have been developed by taking advantage of this 
property.
137,109a
  It was also possible to incorporate a Lewis acid in the reaction condition to 
activate the isocyanide which enhanced the acidity of the -CH and facilitated the 
deprotonation to form the intermediate II-88. A 1,3-metal shift could occurred on II-88 to 
afford the -metalated species II-89 (Scheme 111). This two forms were in equilibrium and 
could be considered as a reactive 1,3-dipole used in different cycloadditions. 
 
Scheme 111: -Metalated isocyanoacetate, formation of a 1,3 dipole. 
 The first example of -metalated isocyanide in organic synthesis has been reported by 
Schöllkopf
 
and Gerhart in 1968 for the synthesis of oxazoline II-92 (Scheme 112).
138
 In this 
reaction butyl lithium was mandatory to deprotonate alkyl isocyanide II-90. 
 
Scheme 112: First [3+2] cycloaddition using -metalated isocyanide. 
Over the years various syntheses of 5 membered heterocycles have been elaborated by 
taking advantage of the -metalated -EWG isocyanide (Scheme 113). Pyrroles II-94 (with 
Michael acceptor or alkyne)
139
, pyrrolines II-95 (with Michael acceptors),
140
 oxazoles II-96 
(with aldehyde),
141
 oxazolines II-97 (with aldehyde or ketone),
142
 imidazoles II-98 (with 
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isocyanide, aldimine),
135,143
 imidazoline II-99 (with aldimine or ketimine),
 141a,144
 thiazole II-
100 (with thiono ester or carbone disulphide)
145
 and triazolines II-101 (with 
azodicarboxylates)
146
 could be made with this approach. 
  
Scheme 113: [3+2] Cycloaddition for heterocycles syntheses using -methalated isocyanide. 
Several asymmetric methodologies have been developed with the -metalated 
isocyanoacetate II-73 to synthesize enantioenriched non-aromatic 5 membered heterocycles. 
For example, Dixon and coworkers have highlighted the highly enantio- and 
diastereoselective synthesis of oxazolines II-103a using silver salt as Lewis acid and a 
phosphinated cinchona alkaloid derivative L*II-2 as precatalyst (Scheme 114). In this 
asymmetric aldol reaction where the isocyanoacetate II-78 acted as a nucleophile on a 
carbonyl compound II-102a, the cooperative Brønsted base/Lewis acid catalyst system was 
the key to get the hetereocycles in excellent yields and ee. By changing the carbonyl 
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compound II-102a to an imine derivative II-102b, highly enantio- and diastereoselective 
Mannich reactions were also possible and furnished enantioenriched imidazolines II-103b.
 147
 
 
Scheme 114: Enantioselective and diastereoselective [3+2] cycloaddition of isocyanoacetate and carbonyl 
compounds. 
 Some obscurities on the mechanism of the Lewis acid-catalyzed [3+2] cycloaddtion 
using isocyanoacetate were still remaining and intriguingly, the groups of Bi and Lei reported 
separately the same year two different mechanistic approaches for the same silver carbonate-
catalyzed [3+2] cycloaddition of phenylacetylene II-105 and isocyanoacetate II-106 (Scheme 
115). In the Bi’s suggested mechanism, the first step was the isocyanide insertion into 
metalated alkyne II-108 whereas in the proposed mechanism of Lei, the 1,3-dipole II-110 
reacted with the silver-alkyne II-108 via a concerted [3+2] cycloaddition.  
Two years later, Lan, Liu and Meng observed after DFT calculation that the most 
favorable pathway should give the dimetalated heterocycle II-111 proposed by Lei after a 
double 1,5-silver migration. This computational study discriminated the proposal of Bi and 
justified the high nucleophilicity of the -carbon of the isocyanoacetate.148 
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Scheme 115: Silver-catalyzed [3+2] cycloaddition of isocyanoacetate and phenylacetylene. 
Other partner than 2-atom units have been utilized in the cycloaddition with -
metalated isocyanide. Indeed, it has been shown that the Lewis acid-catalyzed [3+3] 
cycloaddition of -acidic isocyanide II-113 with azomethine imine II-114 was possible. With 
this reaction 1,2,4-triazine derivatives II-115 and II-118 could be elaborated in moderate to 
good yield.
149
 
 
Scheme 116: Lewis acid-catalyzed [3+3] cycloaddition of -acidic isocyanide and azomethine imine. 
 Fulvenes II-119 could also be associated with isocyanoacetate II-78 in a silver-
catalyzed [6+3] annulation/isomerization.
150
 In this transformation fused dihydropyridine 
derivatives II-120 were obtained in good yields and perfect regioselectivities. 
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Scheme 117: Silver-catalyzed [6+3] annulation/isomerization of isocyanoacetate and fulvene. 
 In our preliminary failed experiments, the presence of the -acidic proton on the -
isocyanoacetate II-78 facilitated the -metalation of the isocyanide which rendered the 
isocyanide insertion into the nucleophile impossible. To overcome this problem, we decided 
to use ,-disubstituted isocyanoacetate II-122 instead of -mono or non-substituted 
isocyanoacetate II-78 and avoided the formation of the 1,3-dipole (Scheme 118).  
With this type of isocyanide as starting material, we hoped to develop a novel Lewis 
acid-catalyzed isocyanide insertion of ,-disubstituted isocyanoacetate II-122 into primary 
amine II-72. In this unprecedented domino sequence, lactamization should occur after the 
isocyanide insertion to afford 3,5,5-trisubstituted imidazolone derivatives II-123. 
 
 
Scheme 118: Alternative to the -metalated isocyanide. 
 
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,-Disubstituted isocyanoacetate as partner 
 With the goal of developing an efficient method to construct imidazolones, we decided 
to use ,,-dibenzyl isocyanoacetate II-122a and benzyl amine II-22a as starting materials 
and toluene as solvent for the beginning of our investigation. Firstly, different Lewis acids 
were examined (Table 17). Copper-(II) oxide, ytterbium-(III) triflate or copper-(II) triflate 
gave no reaction at 60 °C or 80 °C. At 100 °C, no or slow reaction were observed for cupric 
salts whereas with Yb(OTf)3, decomposition of the starting materials was observed. 
Impressively, silver-(I) triflate delivered the desired imidazole II-123a in 76% isolated yield. 
In the case of copper-(II) chloride, the formation of imidazole was observable at 80 °C in only 
30% NMR yield.  
Table 17: Lewis acid screening. 
 
Entry Lewis Acid T (°C) Observation 
1 CuO (0.1 equiv.) 60 °C, 80 °C, 100 °C No reaction 
2 CuO (0.2 equiv.) 100 °C No reaction 
3 Yb(OTf)
3 
(0.1 equiv.) 60 °C, 80 °C No reaction 
4 Yb(OTf)
3 
(0.1 equiv.) 100 °C Messy reaction 
5 Cu(OTf)
2 
(0.1 equiv.) 60 °C, 80 °C No reaction 
6 Cu(OTf)
2 
(0.1 equiv.) 100 °C Slow conv. 
7 Ag(OTf) (0.1 equiv.) 60 °C Full conv., 76% isolated yield 
8 CuCl
2 
(0.1 equiv.) 60 °C No reaction 
9 CuCl
2 
(0.1 equiv.) 80 °C 38% conv., 30% NMR yield 
With this good result observed with the silver-(I) salt, we decided to  continue our 
screening of different Lewis acids which possessed an oxidation state of +1 (Table 18). At 40 
°C, the Cu-(I) salts (Cu2O and CuCl) did not allow the formation of the heterocycle. However 
at this same temperature, AgNO3, AgOAc and AgOTf delivered the imidazolone in low to 
moderate yield. Increasing the temperature to 60 °C gave better outcome and the silver-(I) 
salts afforded particularly good results. It was not surprising as silver salts have already 
shown to be powerful catalysts in isocyanide chemistry.
151
 After a quick screening of the 
catalyst loading (Entry 11 to 15), 10 mol% of silver-(I) nitrate gave the best result and offered 
the imidazole II-123a in 90% isolated yield. 
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Table 18: Lewis acid screening, second round. 
 
Entry Lewis acid Temperature Yield (%) 
1 Cu2O 40 °C No reaction 
2 CuCl 40 °C No reaction 
3 AgNO3 40 °C 71% conv., 58% NMR yield 
4 AgOAc 40 °C 40% conv., 28% NMR yield 
5 AgOTf 40 °C 83% conv. 51% NMR yield 
6 Cu2O 60 °C full conv., 48% NMR yield 
7 CuCl 60 °C full conv., 47% NMR yield 
8 AgNO3 60 °C full conv., quant. NMR yield, (90% isolated) 
9 AgOTf 60 °C full conv., quant. NMR yield, (76% isolated) 
 10 Ag2O 60 °C full conv., quant. NMR yield 
11 AgNO3 (5 mol%) 60 °C full conv.. 83% NMR yield 
12 AgOTf (5 mol%) 60 °C full conv.. 80% NMR yield 
13 Ag2O (5 mol%) 60 °C 75% conv.; 73% NMR yield 
14 AgNO3 (1 mol%) 60 °C 80% conv. 67% NMR 
15 AgOTf (1 mol%) 60 °C 38% conv. 37% NMR 
Different solvents were also used in this transformation and AcOEt appeared to give 
similar results as toluene (Table 19). Increasing the concentration did not impact the reaction 
and adding molecular sieves was not beneficial for the synthesis of imidazolone II-123a.  
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Table 19: Solvent screening. 
 
Entry solvent Observation 
1 toluene Full conv., quant. NMR yield (90% isolated) 
2 dioxane Full conv., 88% NMR yield 
3 DCM 74% conv., 69% NMR yield 
4 THF 91% conv., 84% NMR yield  
5 DMF 78% conv., 75% NMR yield 
6 AcOEt Full conv., quant. NMR yield (90% isolated) 
7 toluene + 4 Å MS 83% conv., 81% NMR yield 
8 toluene (conc = 0.2 mol.L
-1
) Full conv., quant. NMR yield (84% isolated) 
9 toluene (conc = 0.5 mol.L
-1
) Full conv., quant. NMR yield 
With this mild conditions in hand (toluene, 10 mol% AgNO3, 60 °C), the synthesis of 
imidazolones II-123, important five-membered non-aromatic heterocycles, was possible. 
These heterocycles are structural motifs found in bioactive natural products
152
 and are key 
elements responsible for the luminescent properties of green fluorescent proteins (GFP) 
(Scheme 119).
153
 Compounds containing this non-aromatic cyclic scaffold display potent 
inhibitory activities against fatty acid synthases
154
 and are angiotensin II receptor 
antagonists.
155
 Indeed, it is the key motif found in the marketed drug Irbesartan II-127 for the 
treatment of hypertension.
156
  
 
Scheme 119: Important compounds containing imidazolone motif. 
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Previous C-2 unsubstituted imidazolone synthesis 
Different synthetic routes have been developed for the synthesis of C-2 unsubstituted 
imidazoles. One of the current methods was the cyclization of -isocyanoacetamide II-126 
(Scheme 120).
157
 By using BuLi, the deprotonation of the N-H occured and promoted the 
formation of the 5 membered-ring. 
 
Scheme 120: Cyclization of -isocyanoacetamide for the imidazolone synthesis. 
Ito and Saegusa reported the synthesis of imdazolone II-123 via the cyclization of 
amino acid derived formamidine II-130.
158
 In this approach, the reagent II-128 was 
synthesized beforehand with imidazole II-127 and alkyl isocyanide II-8 in the presence of 
silver chloride. By mixing aldimine derivative II-128 with the amino acid II-129, the 
formamidine II-130 could be isolated. After activation of the carboxylic group with pyridine 
and acetic anhydride, the C-2 naked 5 or 6-membered heterocycle II-131 was formed 
(Scheme 121). 
 
Scheme 121: Cyclization of amino acid derived formamidine for the imidazolone synthesis. 
 It has also been shown that the conversion of azlactone II-132 to imidazolone II-123 
was possible. In the presence of an amine in basic condition at reflux, the opening of the 
azlactone II-132 was occuring which afforded consequently the imidazolone II-123.
 159
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Scheme 122: Azlactone to imidazolone. 
,-Disubstituted isocyanoacetate synthesis 
In order to construct different imidazolones with our silver-(I) nitrate-catalyzed 
reaction with ,-disubstituted isocyanoacetate II-12 and primary amine II-72, different ,-
disubstituted isocyanoacetates (II-134, II-136 and II-122) were synthesized. By simply 
converting natural or unnatural -amino acids to -isocyanoacetates with an 
esterification/formylation/dehydration sequence, alkylation of -monosubstituted or -
unsubstituted isocyanoacetate was possible under appropriate conditions (Scheme 123). 
 
Scheme 123: Alkylation of mono or non -substituted isocyanoacetate. 
Scope of the reaction 
With the optimal conditions previously described, the scope and the functional-group 
tolerance of the reaction were inspected (Scheme 124). Various alkyl amines, linear, branched 
including sterically demanding tert-butylamine, reacted with methyl ,-dibenzyl--
isocyanoacetate II-122a to afford the corresponding imidazolones in excellent yields (II-123a 
to II-123f) Functionalized amines such as allylamine (II-123c), tryptamine (II-123j), 
enantioenriched -amino esters (II-123l and II-123s), chiral amine (II-123g), unprotected 
amino alcohols (II-123h and II-123m) participated well in this reaction. Note that even 
thioether, known to have high affinity with silver, was compatible with our reaction 
conditions (II-123s). Different functional groups (CO2Me, CN, N3, olefin) on the -
isocyanoacetates were well tolerated (II-123o to II-123q, II-123u). Spiroimidazolones (II-
123m and II-123v) can also be prepared without event. Interestingly, reaction of 4-
aminobenzyl amine with II-122a was highly chemoselective to afford II-123i (94% yield) in 
which the aniline nitrogen was untouched. 5-Diphenylmethylene imidazolone II-123r, an 
127 
 
analogue of GFP chromophore, can also be prepared from methyl 2-isocyano-3,3-
diphenylacrylate. 
 
Scheme 124: Scope of the silver-catalyzed isocyanide insertion. 
Aniline II-137 derivatives have been tested as amine partner in our optimal condition 
reaction but no reaction was observed. However, by performing the reaction at higher 
temperature (120 °C) with 20 mol% of AgNO3, the anilines II-137 regardless its electronic 
nature participated in the reaction to afford the corresponding N-arylated imidazolones, albeit 
in moderate yields (II-123w to II-123z) (Scheme 125). 
 
Scheme 125: Scope of the reaction with aniline as primary amine. 
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Reaction of diamines was also possible if two equivalents of disubstituted -
isocyanoacetate were used which afforded bis-imidazolones (II-123aa and II-123ab) in good 
yields (Scheme 126, (a)). 
Finally, the protocol could also be applied to complex natural products. Thus, 3--
amino-5-cholestene II-139 and 9-amino quinidine II-140 were converted to their imidazolone 
derivatives (II-123ac and II-123ad) in yields of 73% and 70%, respectively (Scheme 126 (b) 
& (c)). Derivatives of 3-amino-5-cholestene were important cellular probes with potential 
medical applications.
160
 We believed that such a late stage functionalization protocol could be 
a useful synthetic tool in medicinal chemistry. 
 
Scheme 126: Late stage imidazolone synthesis on complex molecules. 
The synthesis of enantioenriched 3,5,5-trisubstituted imidazolone II-123q has been 
achieved by following two methodologies developed in our lab (Scheme 127).
14
 Firstly, the 
enantioselective organocatalytic Michael addition/SN2 sequence offered the azide compound 
II-143 in 83% yield over two steps with 94% ee. Then, the application of our silver catalyzed 
transformation allowed the formation of the enantioenriched 3,5-(R)-5-imidazolone derivative 
II-123q in 95% yield with 94% ee. 
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 S. Boonyarattanakalin, J. Hu, S. A. Dykstra-Rummel, A. August, B. R. Peterson, J. Am. Chem. Soc. 2007, 
129, 268. 
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Scheme 127: Enantioenriched ,-disubstituted imidazolone synthesis. 
Suggested mechanism 
A possible reaction pathway was shown in Scheme 128. Coordination of isocyanides 
and amine to silver would afford the complex II-145. Migratory insertion from II-145 would 
afford II-146 and HX which would undergo salt metathesis to produce amidine II-148 with 
concurrent regeneration of the silver salt. Intramolecular lactamization of II-148 would then 
furnish the observed product II-123. Another pathway where the metalated amidine II-146 
underwent amidation followed by salt metathesis to afford the desired compound could also 
be considered.  
We note that no reaction took place in the absence of silver nitrate and that the 
formation of amidine II-149 was clearly observed by 
1
H NMR when the reaction was 
performed at 40 °C under otherwise standard conditions. 
 
Scheme 128: Suggested mechanism of silver-catalyzed isocyanide insertion/lactamization. 
Methyl o-isocyanobenzoate as partner 
Methyl o-isocyanobenzoate II-150, another isocyanide substrate without -acid 
proton, has been used in the presence of a catalytic amount of AgNO3 and primary amine II-
72 (Scheme 129). Unsurprisingly, 3-substituted quinazolin-4(3H)-one II-151, a privileged 
scaffold in medicinal chemistry, was obtained in good yield. For example, when benzylamine 
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II-72a or tryptamine II-152 were mixed with methyl o-isocyanobenzoate II-150, the 
respective quinazolin-4(3H)-one II-151 and II-153 were isolated in 86% and 82% yield. 
 
Scheme 129: Application of the silver-catalyzed isocyanide insertion for quinazolin-4-one synthesis. 
Application for natural product synthesis 
Evodiamine II-154 and rutaecarpine II-155 are quinazolinecarboline alkaloids isolated 
from the dried fruit of evodia rutaecarpa, a plant used in traditional Chinese medicine against 
headache, dysentery, cholera, etc.
161
 Due to the medicinal importance of these alkaloids, 
various synthetic routes have been developed.
162
 With the presence of quinazolin-4(3H)-one 
moiety in the two natural products, the syntheses of evodiamine II-154 and rutaecarpine II-
155 have been chosen to illustrate our methodology (Scheme 130).  
 
Scheme 130: Retrosynthesis of evoadiamine and rutaecarpine. 
Silver nitrate-catalyzed condensation of tryptamine II-152 with methyl 
isocyanobenzoate II-150 afforded quinazolinone II-153. Compound II-153, without 
purification, was methylated with methyl triflate to afford N-methylated intermediate II-156. 
Adding HMPA to the reaction mixture and heating the solution to 120 °C promoted the 
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 T. Wang, Y. Wang, Y. Kontani, Y. Kobayashi, Y. Sato, N. Mori, H. Yamashita, Endocrinology. 2008, 149, 
358. 
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Pictet-Spengler reaction and furnished (±)-evodiamine II-154 in 49% overall yield. On the 
other hand, treatment of II-153 with TFAA afforded II-157 which, upon treatment with 
hydrogen peroxide under basic conditions for an oxidation and deprotection step, provided 
rutaecarpine II-155 in 53% overall yield (Scheme 131).  
 
Scheme 131: Rutaecarpine & (±)-Evodiamine synthesis. 
2,3,5,5-Tetrasubstituted imidazolone synthesis 
  The 2,3,5,5-tetrasubstituted imidazolone cores are important compound with 
fluorescent properties. Contained in the Kaede protein,
163
 a photoactivatable fluorescent 
macromolecule, or in the BODIPY-like Burgess fluorophore,
155c
 this moiety has been 
synthetized by means of different synthetic methodologies. 
 One of the approaches has been reported via an aza-Wittig cyclization/Knoevenagel 
condensation and afforded C-2 substituted imidazole II-159 in good yield (Scheme 132, (a)). 
Knoevenagel condensation could also happen before the aza-Wittig cyclization to deliver the 
same type of heterocycle II-159 (Scheme 132, (b)).
 164,155c,165
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 I. V. Yampolsky, A. A. Kislukhin, T. T. Amatov, D. Shcherbo, V. K. Potapov, S. Lukyanov and K. A. 
Lukyanov, Bioorg. Chem. 2008, 36, 96. 
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 H. Takeuchi, S. Hagiwara, S. Eguchi, Tetrahedron 1989, 45, 6375; (b) Y. A. Ortiz Barbosa, D. J. Hart, N. A.  
Magomedov, Tetrahedron 2006, 62, 8748. 
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Scheme 132: Aza-Wittig cyclization. 
 Three-component reaction of of -aminoester II-162, carboxylic acid II-18 and 
primary amine II-72 under microwave irradiation afforded compound II-163. the compound 
II-163 was formed via diamide II-164 or azlactone II-165 intermediate in moderate to good 
yield (Scheme 133).
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Scheme 133: Microwave 3-CR using ,-disubstituted aminoester, primary amine and carboxylic acid. 
 Recently, Pirali et al have developed a convergent one-pot synthesis of 2-arylated 
imidazolones II-167 from the reaction of -isocyanoacetamides II-126 with benzynes II-166. 
This [4+1] heteroannulation involved the in situ formed aryne intermediate (Scheme 134).
167
 
 
Scheme 134: [4+1] Cyclization if -isocyanoamide and arynes. 
 Hoarau, Bischoff and coworkers have also reported a direct C2-H functionalization of 
imidazolones II-123 using palladium-(0) and copper-(I) as bimetallic catalytic system. In their 
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reaction, the presence of a base was primordial and DBU gave the best result to afford the 
2,3,5,5-tetrasubstituted imidazole II-167  (Scheme 135).
168
 
 
 
Scheme 135: C-H activation of C-2 unsubstituted imidazole. 
Development of three component reaction 
 In our suggested mechanism (Scheme 128), we depicted two possible metalated 
species (II-147 and II-146) where the metal was carried by the carbon of the former 
isocyanide. By taking advantage of II-147 and II-146, we hoped to design a three component 
reaction where one of the intermediate could be trapped for the rapid C-2 functionalization of 
the imidazolone compound. 
 
Scheme 136: Suggested metalated intermediates in the silver-catalyzed transformation. 
 Keeping this in mind, we thought to develop a synthesis of 2,3,5,5-tetrasubstituted 
imidazolone II-167 by reaction of ,-disubstituted--isocyanoacetate II-122, primary amine 
II-72 and aryl halide II-168 (Scheme 137).  
 
Scheme 137: 3-CR for the synthesis of 2,3,5,5-tetrasubstituted imidazolone. 
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Optimization of the 3-CR reaction 
We chose II-122a (R1 = R2 = Bn), benzylamine II-72a and 4-methylphenyliodide II-
168a as test substrates. Initial screening using Pd(OAc)2 as transition metal catalyst, DBU as 
base and PPh as ligand in DMF at 130 °C (Table 20). Combining this conditions with 
AgNO3 afforded a complex reaction mixture (Entry 1). AgOTf and Yb(OTf)3 afforded the 
desired product in low yield (Entry 2 and 3) whereas the combination of copper-(I) salt and 
Pd(OAc)2 turned out to be more rewarding. The conditions used by Hoarau
168a
, where copper 
iodide was used, gave the imidazolone II-168a in 68% NMR yield (Entry 5). Without DBU, 
the formation of imidazolone was still occurring and finally, the imidazolone II-167a could 
be formed in 72% isolated yield (75% NMR yield, Entry 7) when 1 equivalent of Cu
I
2O was 
mixed with Pd(OAc)2. It was notable that, with copper-(II) salt or without Lewis acid (Entry 
12 & 13), the yield of the desired heterocycle II-167a has decreased drastically. 
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Table 20: Lewis acid screening. 
 
Entry Lewis Acid Base NMR yield 
1 AgNO3 DBU degradation 
2 AgOTf DBU 33% 
3 Yb(OTf)3 DBU 23% 
4 Cu
I
I DBU 68% 
5 Cu
I
I - 57% 
6 Cu
I
Cl - 55% 
7 Cu
I
2O - 75% (72%) 
8 [Cu
I
OTf]2.toluene (0.5 equiv) - 58% 
9 Cu
I
OAc - 21% 
10 [(MeCN) 4Cu
I
]PF6 - 51% 
11 [(MeCN)4Cu
I
]BF4 - 50% 
12 Cu
II
(OTf)2 - 6% 
13 None - 21% 
Different bases were used (Table 21, Entry 1 to 4). None of them were able to increase 
the yield of the reaction. Other palladium sources and ligands were also screened (Entry 5 to 
8). Palladium-(0) complexes such as Pd(dba)2 or Pd(Ph3)4 gave good outcome even if the 
Pd(OAc)2/PPh3 combination offered the best result. Unfortunately, only a complex mixture 
was obtained with phenanthroline as ligand (Entry 7). With (Py)-Box as ligand, imidazolone 
II-167a was obtained in 63% NMR yield (Entry 8).  
Decreasing the Pd loading to 2 mol% under otherwise identical conditions afforded 
trisubstituted inidazolone II-123a in 26% yield accompanied by a trace amount of 2,3,5,5-
tetrasubstituted imidazolone II-167a. 
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Table 21: Base/Palladium source screening. 
 
Entry Pd source Ligand Base NMR yield 
1* Pd(OAc)2 (5 mol%) PPh3 (10 mol%) - 75% 
2 Pd(OAc)2 (5 mol%) PPh3 (10 mol%) DBU 28% 
3 Pd(OAc)2 (5 mol%) PPh3 (10 mol%) Et3N 57% 
4 Pd(OAc)2 (5 mol%) PPh3 (10 mol%) Cs2CO3 27% 
5 Pd(dba)2 (5 mol%) - - 66% 
6 Pd(PPh3)4 (5 mol%) - - 64% 
7 Pd(OAc)2 (5 mol%) LII-2 (10 mol%) - messy 
8 Pd(OAc)2 (5 mol%) L*II-3 (10 mol%) - 63% 
9 Pd(OAc)2 (2 mol%) PPh3 (4 mol%) - 7% + 26% X 
10 Pd(OAc)2 (10 mol%) PPh3 (20 mol%) - 63% 
 
Finally, the temperature, the solvent and the amount of copper-(I) oxide were 
examined (Table 22). 130 °C, DMF and 1 equivalent of copper salt gave the best result 
leading to the imidazolone II-167a in 75% yield. 
Table 22: Fine tuning of the reaction. 
 
Entry T (°C) Solvent Cu2O (X equiv) NMR yield 
1* 130 °C DMF 1 equiv 75% 
2 110 °C DMF 1 equiv 66% 
3 150 °C DMF 1 equiv 66% 
4 130 °C DMSO 1 equiv 41% 
5 130 °C DMF 0.1 equiv 34% 
6 130 °C DMF 0.25 equiv 54% 
7 130 °C DMF 0.5 equiv 69% 
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Scope of the 3-CR reaction 
 The novel three-component reaction displayed a broad application scope (Scheme 
138). Aryl iodides bearing electron-donating (OMe II-167c, II-167e and II-167g) and 
electron-withdrawing groups (F II-167d; CO2Me II-167m; CF3 II-167p; NO2 II-167q) were 
appropriate substrates for this reaction. Compound II-167j containing -naphtyl at the C-2 
position of the heterocycle could also be made by this methodology. Note that the position 
(ortho, meta or para) of the substituent on the C-2 aryl counterpart was not affecting the 
reaction. 
Functionalized amines such as tryptamine (II-167r), linear (II-167a and II-167c), 
branched (II-167b) and cyclic amine (II-167j, II-167k and II-167m) participated in this 
reaction without event. Reaction of (R)- and (S)-1-phenylethylamine with II-122 and II-168 
afforded chiral imidazolones II-167e and II-167f, respectively, without epimerization. Chiral 
primary amine derived from the chiral pool such as the amino-cholesterol derivative II-139 
and phenylalanine t-Bu ester, were also accepted in this reaction and gave enantiopure 
scaffolds in one step in 52% (II-167s) and 63% (II-167t) isolated yield respectively. 
The use of cyclohexyl -isocyanonacetate II-122 in this reaction allowed the 
formation of C-2 substituted spiroimidazolones II-167o and II-167p. Finally, aryl and alkyl 
chain with functionalities (-OPh, -CO2Me, -NMeBn) on the ,-disubstituted -
isocyanoacetate partner were also allowed in this transformation (II-167g, II-167h, II-167j, 
II-167l and II-167u). 
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Scheme 138: Scope of the three component reaction with aryl iodide. 
Vinylbromides, including 1,2-disubstituted, 1,1-disubstituted and tetra-substituted 
ones, reacted smoothly with II-122 and II-169 to provide 2-vinyl substituted imidazolones II-
167v, II-167w and II-167x in good yields (Scheme 139). 
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Scheme 139: Scope of the three-component reaction with alkenyl halide. 
In order to reach different interesting scaffolds, the reaction conditions have been 
applied to methyl o-isocyanobenzoate II-150. Unfortunally, degradation of the starting 
materials was observed (Scheme 140). This was probably due to the easy and known 
polymerization of this type of isocyanide. 
 
Scheme 140: 2,2-Disubstituted-2,5-dihydro-3H-imidazo[2,1-a]isoindol-3-one synthesis. 
Based on this novel reaction sequence, more complex domino processes could be 
designed for the one-pot synthesis of polyheterocyclic compounds. For example, reaction of 
(2-bromophenyl)methanamine II-172 with methyl isocyanoacetate II-171furnished tricyclic 
compounds II-173a and II-173b, respectively (Scheme 141).  
 
Scheme 141: Bimetallic catalyzed 3-CR with methyl o-isocyanobenzoate. 
Mechanistic study 
 In this 3 component reaction, several pathways were possible to reach the desired 
2,3,5,5-tetrasubstituted imidazolone II-167. As initial step, we suggested that the reaction 
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started with isocyanide insertion. Palladium and copper, the two metals present in our 
reaction, are known to promote this type of reaction. Without copper, the yield for the 
imidazolone formation dropped considerably which highlighted the importance of the Lewis 
acid (Scheme 142, (a)).  
 If a base was added in our standard conditions, an important drop of the yield was also 
observed (Scheme 142, (b)). With DBU, the heterocycle was formed in 28% yield. In the 
methodology developped by Hoarau (Scheme 135),
168
 the presence of a base was primordial 
to promote the C-H activation of the 3,5,5-trisubstituted imidazolone II-123. In our case 
however, the base seemed to poison the bimetallic catalytic system. 
 
Scheme 142: Importance of the reagents. 
 In the absence of palladium and triphenylphosphine, the formation of the C-2 
substituted II-167a was not observed (Scheme 143). Unsurprisingly, with only Cu2O as 
catalyst, the product II-123a was formed via isocyanide insertion/lactamization process in 
43% yield. 
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Scheme 143: Importance of the palladium acetate. 
Two plausible mechanisms were depicted in Scheme 144 and Scheme 145 
respectively. In the Scheme 144, the mechanism began with a coordination/isocyanide 
insertion sequence to afford the metalated amidine II-176. After lactamization to deliver II-
177, the transmetallation of the copper-(I) species II-178 with the palladium-(II) II-180 gave 
the cyclic intermediate II-178 with regeneration of the copper-(I) salt II-174. Final reductive 
elimination offered the tetrasubstituted imidazolone II-167 and the recovery of the palladium-
(0) II-179. In this mechanism, we suggested that the isocyanide insertion set the copper on the 
molecule which permited the transmetallation with the palladium intermediate II-180. 
 
Scheme 144: Transmetalation pathway. 
 For the mechanism proposed in Scheme 145, the first catalytic cycle correspond to the 
suggested Lewis acid-catalyzed cycle described for the synthesis of trisubstituted imidazolone 
II-123 (Scheme 128). Then, a C-H activation of the C-2 position (generally in the presence of 
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a base and a Lewis acid) of II-123 gave the compound II-177. After metal exchange, the 
palladated intermediate II-178 was formed. Reductive elimination delivered the product II-
167 and the regeneration of II-179. In this pathway, basic conditions were needed to 
deprotonate the C-2 of the imidazolone II-123 (organic base or the counter anion of the salt). 
 
Scheme 145: C-H activation pathway. 
 In order to legitimate one pathway to the other in this mechanism, the reaction 
conditions (1 equiv Cu2O, 5 mol% Pd(OAc)2, 10 mol% PPh3, 130 °C, DMF) were applied to 
the unsubstituted C-2 imidazolone II-123a and p-iodotoluene II-168a. Interestingly, no 
reaction was observed and the trisubstituted imidazolone II-123a was fully recovered even 
after 12 hours (Scheme 146, (a)). The same experiment was run with 1.5 equivalent of benzyl 
amine. This time, the reaction offered the tetrasubstituted II-167a  in 47% NMR yield with 
26% NMR yield of II-123a  (Scheme 146, (b)).  
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Scheme 146: Other experiment on the C-H pathway. 
These two experiments have shown that a base was needed to activate the C-H bond of 
the C2 of the imidazolone II-123a. Without base, the C-H activation proposed in the Scheme 
145 could not occur and rendered impossible the C-2 metalation of the imidazolone 
(intermediate II-177).  
These observations did not allow the discrimination of one of the two pathways. The 
reaction could go via the C-H activation pathway (Scheme 145) if the benzyl amine was 
playing the role of base. The mechanism described in Scheme 144 could also occur and the 
copper-catalyzed isocyanide insertion into the amine could deliver the C-2 metalated 5-
membered heterocycle II-177 for the transmetalation step with II-180. 
  
144 
 
Conclusion 
The syntheses of various 3,5,5-trisubstituted imidazolones II-123 and 2,3,5,5-
tetrasubstituted imidazolones II-167 have been achieved. Two different methodologies have 
been developed by taking advantage of the rich chemistry of the isocyanide group. Firstly, 
-disubstituted isocyanoacetate II-122 with primary amines II-72 in the presence of a 
catalytic amount of AgNO3 afforded 3,5,5-trisubstituted imidazolones II-123 in good to 
excellent yields. This unprecedented domino isocyanide/amine insertion followed by 
lactamization occurred under mild condition (toluene, 60 °C). Secondly, reaction of -
disubstituted isocyanoacetate II-122 with primary amines II-72 and aryl halide II-168 in the 
presence of Cu
I
/Pd
II
 bimetallic system provided 2,3,5,5-tetrasubstituted imidazolone II-167 
via formation of one C-C bond and two C-N bonds in moderated to good yield. Finally the 
concise synthesis of two natural product, rutaecarpine II-154 and (±) evodiamine II-155, have 
been accomplished to illustrate the utility of this chemistry.
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Scheme 147: Summary of the isocyanide insertion of -disubstituted isocyanoacetate into primary 
amine - Development of 3 CR reaction and application in natural product synthesis. 
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Chapter 4:  Palladium-Catalyzed 
Insertions of o-Isocyanobenzonitrile and 
2-Substituted 3-Cyclopropyl-2-
Isocyanopropanoate 
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Introduction 
 Since the explosion of palladium catalysis at the end of the last century, this type of 
chemistry has become one of the most prolific research areas in organic chemistry. In 2010 
Heck, Negishi and Suzuki were even awarded by the Nobel Prize for their work on palladium-
catalyzed cross couplings in organic synthesis. Today, this field is commonly applied at the 
industrial scale for the synthesis of important drugs by creating C-C, C-O or C-N bonds which 
where complicated to form before.
170 
Inspired by the previous work on palladium-catalyzed carbon monoxide insertion, 
Kosugi and Migita reported in 1986 the first palladium-catalyzed isocyanide insertion where 
tert-butyl isocyanide, bromobenzene and an organotin compound reacted together in the 
presence of Pd
0
(Ph3)4.
171
 More than ten years after, Whitby and coworkers observed that the 
use of non-toxic nucleophiles (amines, alcoholates, thiolates) instead of the organotin reagent 
was possible and offered different ketimine derivatives II-182 in moderate to good yield using 
similar chemistry (Scheme 148).
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Scheme 148: Palladium-catalyzed isocyanide insertion. 
 Over the years, different methodologies have been developed taking advantage of this 
insertion step. In the palladium-catalyzed isocyanide insertion, the formation of aryl imidoyl-
palladium intermediate II-181, which reacts further with a nucleophile, is the major difference 
with the Lewis acid-catalyzed isocyanide insertion in which a direct insertion into the 
heteroatom-H bond of the nucleophile is observed.  
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Trapping of  imidoyl-Pd intermediates with other nucleophiles 
In 2011, it has been reported that water could act as nucleophile to trap the imidoyl-
palladium intermediate and afforded amides II-184 in good yield.
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Scheme 149: Pd-catalyzed isocyanide insertion with water was nucleophile. 
Palladium-catalyzed isocyanide insertion in the presence of terminal alkyne as 
nucleophile II-186 was also developed. The subsequent alkynyl imine II-187 could then be 
easily hydrolyzed to afford the ketone II-188.
174
  
 
Scheme 150: Pd-catalyzed isocyanide insertion with terminal alkyne as nucleophile. 
Bisnucleophiles have also been used with palladium and isocyanides. In the presence 
of aryl bromide II-168, the oxidative addition of the palladium followed by isocyanide 
insertion afforded the imidoyl-palladium intermediate. Then, the bisnucleophile II-190 was 
incorporated after reductive elimination. Finally, the release of tert-butyl amine II-192 at 
reflux gave C-2 arylated heterocycles II-193 (Scheme 151, (a))
175a
.  
In the absence of aryl halide II-168 and base, Ruitjer and Orru reported the synthethis 
of C-2 aminated heterocycles using bisnucleophile II-190 via Pd-catalyzed isocyanide 
insertion. In this case, it was proposed that the double oxidative addition in the bisnucleophile 
II-190 gave the 5-membered palladacycle II-194, where at least two molecules of isocyanide 
were coordinated to the palladium. A sequence of isocyanide insertion and reductive 
elimination furnished finally various heterocycles II-195 depending on the bisnucleophile 
used (Scheme 151, (b)).
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Scheme 151: Pd-catalyzed isocyanide insertion with bisnucleophile. 
Domino reaction after classical Pd-isocyanide insertion 
The inventiveness of the organic chemists and the broad applicability of Pd-catalyzed 
isocyanide insertions have allowed the design of different domino processes. An example has 
been described in 2011 with the palladium-catalyzed reaction of isocyanide II-1, methyl o-
bromobenzoate II-196 and hydrazine II-197. After Pd-catalyzed isocyanide insertion, the 
imidoyl palladium reacted with hydrazine. Then, the final lactamization delivered 4-
aminophthalazin-1(2H)-ones II-198.
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Scheme 152: Pd-catalyzed domino reaction involving isocyanide insertion for the synthesis of 4-
aminophthalazin-1(2H)-ones. 
The Pd-catalyzed domino reaction of isocyanide II-1, o-iodophenol II-199 and 
aziridine II-200 has also been reported. In this transformation the imidoyl palladium was 
attacked by the nitrogen atom of the aziridine. The subsequent 3-membered ring opening gave 
the uncommon 7-membered ring II-201 (Scheme 153).
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Scheme 153: Pd-catalyzed domino reaction involving isocyanide insertion and aziridine. 
Another example of cascade transformation where bromoalkyne II-202, isocyanide II-
1 and o-aminophenol II-203 were used together is depicted in Scheme 154. This reaction was 
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presumably occurring via a vinyl palladium intermediate II-205 which underwent isocyanide 
insertion. The final reductive elimination with incorporation of the amine offered the 7-
membered heterocycle II-204.
179
 
 
Scheme 154: Pd-catalyzed domino reaction involving isocyanide insertion involving bromoalkyne. 
 Palladium chemistry has been also applied for the activation of C-H bond. Several 
domino processes involving palladium-catalyzed isocyanide insertion and C-H activation 
reactions have been reported.
109g  
In this type of transformation, after formation of the imidoyl 
palladium intermediate II-206, a C-H activation gave the palladacycle II-207. Final reductive 
elimination produced the product II-208 with regeneration of Pd-(0) (Scheme 155). Examples 
of C-H activation with acidic proton,
180
 C(sp
2
)-H activation,
181
 and C(sp
3
)-H activation
182
 
have been reported. 
 
Scheme 155: Pd-catalyzed isocyanide insertion followed by C-H activation. 
Palladium insertion into other bonds than C-X 
Pd-catalyzed isocyanide insertion has been mostly described with oxidative addition as 
first step when the palladium-(0) is incorporated into a C-X bond of an alkenyl or aryl halide. 
However, insertion of palladium into other types of bonds is also known. In 2013, Jiang and 
Wu reported the palladium-catalyzed synthesis of 4-halo-2-aminoquinolines II-210 using 
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isocyanide II-1, o-(alkynyl)aniline II-209 and lithium halide. It has been suggested that the 
first step of this reaction was a trans-halopalladation of Pd-(II) species which afforded the 
intermediate II-211 before isocyanide insertion (Scheme 156).
183
 
 
Scheme 156: Pd-catalyzed isocyanide insertion via trans-halopalladation as initial step. 
Later, Reddy illustrated the Pd-catalyzed domino process of isocyanide II-1 and 
phenyl propargyl alcohol derivative II-212. In this reaction it was proposed that the first step 
was an via oxy/amino palladation (depending of the heteroatom X of compound II-212) in 
anti and 5-exo-dig fashion to produce intermediate II-213. After a reductive 
elimination/oxidative addition/protodepalladation sequence, the heterocycles II-214 or II-215 
were isolated in moderate to good yields (Scheme 157)
184
 
 
Scheme 157: Pd-catalyzed isocyanide insertion via 5-exo-dig cyclization as initial step. 
 The palladium catalyzed 5-exo-trig cyclization/isocyanide insertion reaction using N-
sulfonyl-2-allylaniline and isocyanide has also been described by Jiang and Wu. Interestingly, 
the imidoyl palladium II-217 resulting from the isocyanide insertion could be converted in 
amides II-218 or cyanides II-219 depending on the additive (Scheme 158)
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Scheme 158: Pd-catalyzed isocyanide insertion via 5-exo-trig cyclization as initial step. 
It is also possible to synthesize 3-(imino)isoindolin-1-ones II-221 via palladium-
catalyzed isocyanide insertion of isocyanide I-1 and triazine II-220. In this transformation the 
denitrogenation of the triazine II-220 gave the 5-membered azapalladacycle II-222 which 
delivered the desired heterocycle II-221 after isocyanide insertion (Scheme 159).
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Scheme 159: Pd-catalyzed isocyanide insertion via N2 extrusion as initial step. 
 More recently, our group and the group of Jiang reported almost simultaneously the 
palladium-catalyzed multicomponent reaction for the synthesis of pyrroles (II-224 or II-225) 
and iminopyrrolones (II-226). In this reaction, the first intermediate was the (σ-
allenyl)palladium-(II) II-229. Incorporation of two or three isocyanide II-1 was possible 
depending on the temperature (Scheme 160).
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Scheme 160: Pd-catalyzed isocyanide insertion via (σ-allenyl)palladium-(II) species. 
Ketenimine formation via Pd-catalyzed isocyanide insertion 
 In 2001, Yamamoto reported the unprecedented palladium catalyzed 3-CR of aryl 
isocyanide II-230, allyl carbonate II-231 and TMSN3 II-232. The proposed mechanism of this 
reaction started with the formation of the [-(allyl)PdN] complex. After isocyanide insertion 
in the Pd-N3 bond and Curtius type rearrangement, the carbodiimide intermediate II-235 was 
formed. Final 1,3-palladium migration and reductive elimination produced the allyl 
cyanamides II-233. (Scheme 161).
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Scheme 161: Allyl cyanamide formation via Pd-carbodiimide intermediate 
 Inspired by the initial work of Yamamoto, our group described in 2016 the facile 
ketenimine II-238 synthesis using isocyanide II-1 and allyl carbonate II-237 with palladium. 
This reaction was initiated by the formation of the -allyl complex, which presumably 
adopted the 1-allyl form. After isocyanide insertion into the Pd-allyl bond and -hydride 
elimination, the ,-unsaturated ketenimine II-238 was obtained in good yield. This 
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ketenimine II-238 could quickly be converted in amides II-239 or tetrazoles II-240 
depending of its further treatment (Scheme 162).
189a
 
  
Scheme 162: Ketenimine formation via -allyl complex. 
It has also been illustrated that -halo methylphosphonate II-241a and -haloketones 
II-241b furnished -EWG ketenimine II-242 (Scheme 163). Further modifications of the 
ketenimine functionality afforded -EWG amides II-243, tetrazoles II-244, 5-aminopyrazoles 
II-245 or -EWG enamines II-246 .189b,c 
 
Scheme 163: Ketenimine formation via Pd-enolated intermediate. 
Pd-catalyzed insertion of isocyanides bearing participating functional group 
To explore the various possibilities of the palladium-catalyzed isocyanide insertion, 
modified isocyanides have also been used instead of the classical alkyl isocyanides. In 2002, 
Takahashi used o-alkenylphenyl isocyanide II-247 with aryl iodide II-168 and diethylamine 
for the synthesis of indoles derivative II-248. This Pd-catalyzed isocyanide insertion/5-exo-
trig/reductive elimination sequence afforded the heterocycle II-248 in moderate yields (40-
60% yield) (Scheme 164).
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Scheme 164: Palladium-catalyzed isocyanide insertion of o-alkenylphenyl isocyanide, aryl iodide and a 
secondary amine. 
 o-Alkynyl isocyanobenzene can also be used as isocyanide partner. For example, 
Yamamoto described the divergent synthesis of allyl cyanamide II-252 and N-cyanoindole II-
253 using the isocyanide II-250 (Scheme 165).
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Scheme 165: Palladium catalyzed isocyanide insertion of o-Alkynyl isocyanobenzene, allyl carbonate and 
TMSN3. 
  In 2013, o-alkynyl isocyanobenzene II-250 has been used with aryl iodide II-254 in a 
palladium-catalyzed isocyanide insertion. After formation of the imidoyl palladium 
intermediate II-255, incorporation of water afforded the 3-acyl-2-arylindole II-256. If a 
heteroatom was present in ortho of the aryl iodide, tetracyclic derivative II-257 were formed 
in good yield. It is important to note that the isocyanide II-250 was added dropwise to obtain 
decent yield of the products (Scheme 166).
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Scheme 166: Palladium catalyzed isocyanide insertion of o-alkynyl isocyanobenzene 
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Our idea 
We reported previously in the Chapter 3 that the 3-CR reaction involving methyl o-
isocyanobenzoate II-150, primary amine II-72 and aryl iodide II-168 in presence of 
copper/palladimum bimetallic system did not permit the formation of C-2 substituted 
quinazolin-4-ones II-170. 
In order to perform the synthesis of this heterocycle II-170, we hoped to develop the 
palladium-catalyzed isocyanide insertion/lactamization sequence using o-isocyanobenzonitrle 
II-258, primary amine II-72 and aryl halide II-168. This methodology could allow the 
formation of luotonin A II-259, a natural product found in the Chinese herbal medicinal plant 
Paganum niggelastrum, which possesses cytotoxic activity towards murine leukemia cell line 
(Scheme 167).
193
  
 
Scheme 167: Proposed Pd-catalyzed 3-CR reaction for the synthesis of 2-substituted quinazolin-4-one. 
Results & Discussion 
o-Isocyanobenzonitrile as starting material 
 In this approach we decided to use the more stable o-isocyanobenzonitrile II-258 
instead of methyl o-isocyanobenzoate II-150, which is known to polymerize when the 
reaction mixture is heated.  
o-Isocyanobenzonitrile II-258 has been described only once by Ito in 1999 in the 
isocyanide insertion/6-electrocyclization reaction for the synthesis of 2,3-disubstituted 
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quinolines (Scheme 102).
123
 This starting material could be easily synthesized using the 
classic formylation/dehydration sequence of o-cyanoaniline II-260 (Scheme 168). 
 
Scheme 168: o-Isocyanobenzonitrile synthesis. 
Background on 2-substituted quinazolin-4-one synthesis 
Quinazolinone is a motif found in several bioactive compounds. Possessing anti-
bacterial, antifungal, antiviral and enzyme inhibitor properties, this potent heterocycle has 
been extensively studied.
194
 Synthetically, many different strategies have been designed for 
the 2-substituted quinazolin-4-ones II-170 formation.
 195
 
 Anthranilic acid II-263 has been used as starting material for the synthesis of C-2 
quinazolin-4-ones II-266. After formation of the quinazoline-2,4(1H,3H)-dione II-264 with 
potassium cyanate, double dehydration offered the 2,4-dichloroquinazoline II-265. Treatment 
with water in basic conditions followed by addition of primary amine give the desired 
aminated heterocycle II-266 (Scheme 169, (a)).
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C-2 substituted quinazolin-4-ones II-170 could be made from anthranilic acid II-263 
via the formation of the cyclic carbamic anhydride II-267. Addition of amine followed by 
acyl chloride or orthoester afford the desired quinazolin-4-one II-170 (Scheme 169, (b)). 
 
Scheme 169: Quinazolinones synthesis from anthranilic acid. 
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 La Rosa and coworkers described the synthesis of C-2 substituted quinazolin-4-one II-
271 via [4+2] cycloaddition/[2+2] cycloaddition/ring expansion sequence from the 
uncommon dienophile II-269 and phenylisocyanate II-270 (Scheme 170). 
197
 
Scheme 170: Diels-Alder type reaction for the quinazolin-4-ones synthesis. 
It was also possible to synthesize C-2 substituted quinazolin-4-one II-170 via copper 
catalyzed-amidation of o-bromo benzamide II-273 with primary amide II-274 (Scheme 171).
 
198
 
 
Scheme 171: Copper catalyzed-aryl amidation for quinazolin-4-ones synthesis. 
 Palladium-catalyzed isocyanide insertion of isocyanide II-1 and N-methyl o-
(amino)benzylamine II-275 gave C-2 aminated quinazolin-4-one II-276. In this reaction, a 
further benzylic oxidation occured under oxygen atmosphere (Scheme 172).
 176b
 
 
Scheme 172: Pd-catalyzed isocyanide insertion for the C-2 aminated quinazolin-4-ones synthesis. 
The lithiation of o-bromobenzoisonitrile II-277 gave the heterocycle II-278 in 
moderate to good yield after reactions with alkyl isocyanate and an electrophile (Scheme 
173).
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Scheme 173: ortho lithiation from o-bromobenzoisonitrile for C-2 substituted quinazolin-4-one synthesis. 
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Condition optimization 
 In order to develop another method to synthetize 2-substituted quinazolin-4-one II-
170, we started our investigation with o-isocyanobenzonitrile II-258, p-idodotoluene II-168a 
and benzyl amine II-72a as starting materials.  All the reactions were set up in the glovebox 
and all the reagents were mixed together before heating. Unfortunately, after the screening of 
palladium sources, ligands, solvents and temperatures, only the C-2 unsubstituted quinazolin-
4-one II-151 was obtained (Scheme 174). With these conditions, the imidoyl palladium 
intermediate was not formed. 
 
Scheme 174: Preliminary screening for the Pd-catalyzed 3-CR. 
Inspired by the work of Takemoto (Scheme 166),
192
 we tried to add the isocyanide II-
258 dropwise in the reaction mixture. In this case, the incorporation of the aryl iodide II-168a 
was possible and the desired product II-170a was formed in 9% yield accompanied with the 
amide II-279 in 33% yield (Scheme 175, (a)). Benzyl amine and isocyanide were also added 
dropwise simultaneously but similar results were observed (Scheme 175, (b)).  
 
Scheme 175: Pd-catalyzed 3-CR with dropwise addition of isocyanide. 
As the latter encouraging result suggested the succesfull formation of the imidoyl 
palladium intermediate, different parameters were modified (Table 23). 2 equivalents of 
benzyl amine gave 25% yield of II-170a and 31% of  II-279 (Entry 2). Toluene as solvent or 
P(Ad)2Bu as ligand were not promising for this reaction (Entries 3 and 4). An excess of 
160 
 
benzyl amine furnished the mixture of undesired product II-151 and II-280 in 19% and 39% 
yield respectively (Entry 5). 
Table 23: Initial screening. 
 
The addition rate of isocyanide was examined (Table 24). Addition of the isocyanide 
in only 20 min gave a mixture of II-170a, II-279 and II-151 in poor yield (Entry 4). Slower 
additions (0.01, 0.02 & 0.05 mL/min) gave better results and an addition rate of 0.02 mL.min
-
1
 was chosen (Entries 1 to 3).  
Table 24: Addition rate of the isocyanide adding screening. 
 
Entry Flow of the adding NMR yield 
1 0.01ml/min (addition of 2mL over 200 min) 23% yield  of II-170a  + 24% yield II-279 + 5% yield of II-151 
2 0.02ml/min (addition of 2mL over 100 min) 24% yield of II-170a  + 34% yield of II-279 
3 0.05ml/min (addition of 2mL over 40 min) 21% yield of II-170a  + 31% yield of II-279 
4 0.1ml/min (addition of 2mL over 20 min) 15% yield of II-170a  + 18% yield of II-279 + 15% yield of II-151 
 
By varying the equivalents of isocyanide and p-iodotoluene II-168a (Table 25, entry 1 
to 4), we observed that 1.5 equivalent of isocyanide with 1 equivalent of p-iodotoluene and 2 
equivalents of amine gave the best hit with 57% NMR yield of products resulting from the 
imidoyl palladium intermediate (II-170a & II-279).  The temperature had an important 
impact on the formation of II-170 (entries 5 to 7). Indeed, when the temperature was fixed to 
80 °C, the desired 2-substituted quinazolin-2one II-170a was produced in 48% NMR yield.  
Entry Modification of the initial condition NMR yield 
1* - 9% of  II-170a  + 33% of  II-279 
2 2 equiv of Bn-NH
2
 25% of  II-170a  + 31% of  II-279 
3 2 equiv of Bn-NH
2
 + Toluene instead of DMF 20% of  II-170a   
4 2 equiv of Bn-NH
2
 + Pd(Ad)
2
Bu instead of P(Ph)
3
 14% of  II-170a  + 37% of  II-279 
5 10 equiv of Bn-NH
2
 19% of  II-151  + 39% of  II-280 
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Table 25: Equivalent and temperature screening. 
 
Entry T (°C) Equivalent (X, Y) NMR yield 
1* 100 °C (X = 1, X = 1) 24% yield of II-170a  + 34% of II-279 
2 100 °C (X = 1, Y = 1.5) 17% yield of II-170a  + 21% of II-279 
3 100 °C (X = 1.5, Y = 1) 27% yield II-170a  + 37% yield of II-279 + 32% yield of II-151 
4 100 °C (X = 2, Y = 1) 30% yield II-170a  + 27% yield II-279 + 40% yield II-151 
5 80 °C (X = 1.5, Y = 1) 48% yield of II-170a  +31% yield of II-279 
6 120 °C (X = 1.5, Y = 1) 31% yield of II-170a  + 34% yield of II-279 
7 60 °C (X = 1.5, Y = 1) 21% yield of II-170a + 44% of II-151 
 
Starting from this so far best reaction conditions (Entry 1), different other parameters 
were screened (Table 26). The use of 3Å molecular sieves avoided the formation of the amide 
II-279 but II-170a was obtained in 25% yield only (Entry 2). 2 mol% of Pd(OAc)2 with 4 
mol% of PPh3 furnished only the quinazolin-4one II-151 (Entry 3). The ligand P(Ad)2Bu 
instead of PPh3 furnished low yield of the desired II-170a (Entry 4). 3 equivalents of Cs2CO3 
or heating to 100 °C did not favor the reaction (Entries 5 and 6). Increasing the loading of 
Pd(OAc)2 and PPh3 (10 and 20 mol% respectively) gave a complex mixture of II-170a, II-
279 and II-151. 
Table 26: Further screening. 
 
Entry Modification of the condition NMR yield 
1* - 48% yield of II-170a   +31% yield of II-279 
2 3Å MS 25% yield of II-170a   + 28% yield of II-151 
3 Pd(OAc)
2
 (2 mol%), PPh
3 
(4 mol% ) 40% yield of II-151 
4 P(Ad)
2
Bu instead of PPh
3
 13% yield of II-170a   + 44% yield of II-151 
5 Cs
2
CO
3
 (3 equiv) 27% yield of II-170a   + 24% yield of II-151 
6 100 °C, 3 Å MS, Cs
2
CO
3
 (3 equiv) 20% yield of II-170a   + 11% yield of II-151 
7 100 °C, Pd(OAc)
2
 (10 mol%), PPh
3 
(20 mol% ) 29% yield of II-170a  + 11% yield of II-279 + 38% yield of II-151 
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 Several Lewis acids were added as additives in order to activate the cyanide for the 
final cyclization. Regrettably, the degradation of the starting materials was observed when 1 
or 0.2 equivalent of different Lewis acids were used (Table 27). 
Table 27: Lewis acid screening 
 
Entry Lewis acid NMR yield 
1* CuCl
2 
 (1 equiv) Degradation 
2 CuI  (1 equiv) Degradation 
3 BF
3
.Et
2
O (1 equiv) Degradation 
4 AlCl
3 
 (1 equiv) Degradation 
5 AlCl
3
 (20 mol%) Degradation 
6 CuI (20 mol%) Degradation 
7 FeCl
3
 (20 mol%) Degradation 
8 ZnCl
2
 (20 mol%) degradation 
9 InCl
3
 (20 mol%) degradation 
10 SnCl
4
 (20 mol%) degradation 
 
Other bases and solvents were screened (Table 28). Degradation of the starting 
material was observed in toluene (Entry 1 & 2). With DMF or dioxane as solvent, CsOPiv and 
the combination of Cs2CO3 and pivalic acid lead to unfruitful results (Entry 3 to 6). Without 
base, the product II-151 was formed in 21% yield (Entry 7). The use of other aromatic 
solvents such as p-xylene or mesytelene afforded II-170a in only 11% and 16% yield 
respectively (Entries 8 and 9). 
Table 28: Base/solvent screening. 
 
Entry solvent Condition NMR yield 
1 toluene CsOPiv (2 equiv) Degradation 
2 toluene Cs
2
CO
3
 (2 equiv), PivOH (0.3 equiv) Degradation 
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3 dioxane CsOPiv (2 equiv) 14% of II-170a  + 5% of II-151 
4 dioxane Cs
2
CO
3
 (2 equiv), PivOH (0.3 equiv) 6% of II-170a  + 14% of II-151 
5 DMF CsOPiv (2 equiv) 15% of II-279 
6 DMF Cs
2
CO
3
 (2 equiv), PivOH (0.3 equiv) 15% of II-151 
7 DMF No base 21% yield II-151 
8 p-xylene - Messy, 11% of II-170a  
9 mesytelene - Messy, 16% of II-170a  
   
 Before putting this project in stand-by because of the lack of results, we finally 
quickly focused on the synthesis of a scaffold close to Luotonin A (Scheme 176). At 100 °C 
with 5 mol% of Pd(OAc)2,  10 mol% PPh3 and 2 equivalents of Cs2CO3, o-
isocyanobenzonitrile II-258 and o-bromobenzylamine II-172 furnished a complex reaction 
mixture. Decreasing the temperature to 80 °C, gave only traces amount of the product II-281 
and 15% NMR yield of the C-2 unsubstituted quinazolin-2-one II-282. 
 
Scheme 176: Pd-catalyzed isocyanide insertion with o-bromo benzylamine. 
 The best result obtained during the investigation on the Pd-catalyzed 3-CR of o-
isocyanobenzonitrile, benzyl amine and p-iodotoluene, was obtained with 5 mol% of 
Pd(OAc)2, 10 mol% of PPh3, 2 equiv of Cs2CO3 in DMF at 80 °C and afforded the 2-arylated 
quinazolin-4-one II-170a in 48% yield. This project was put on hold to explore another Pd-
catalyzed transformation involving isocyanide insertion. 
Alternative idea: Pd-catalyzed isocyanide insertion/C(sp
3
)-H activation sequence with 
cyclopropanes. 
At the beginning of this year, Zhu and coworkers developed the enantioselective 
desymmetrization of ,-dibenzylisocyanoacetate II-122a. In this transformation, the 
isocyanide insertion furnished the imidoyl palladium intermediate, followed by an 
enantioselective C(sp
2
)-H activation. The resulting 7-membered palladacycle II-284 
underwent reductive elimination to deliver the enantioenriched 3,4-dihydroisoquinolines II-
283. The ligand SPINOL-derived phosphoramidite L*II-2 was important to reach high 
enantioselectivies (Scheme 177).
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Scheme 177: Desymmetrization of ,-dibenzyl isocyanoacetate via Pd-catalyzed isocyanide insertion/C-H 
activation 
C(sp
3
)-H activation is an important method to introduce complexity in molecules. The 
incorporation of the palladium in unactivated C(sp
3
)-H bond has been particularly studied. 
Generally, an appropriate directing group is needed to favor the selective C-H activation of 
the transition metal.
201
   
In 2012, Takemoto et al. reported the first Pd-catalyzed isocyanide insertion/C-H 
activation sequence for the synthesis of C-2 arylated indoles derivatives II-285. In this 
transformation, they have also shown that the slow addition of isocyanide is important to 
obtain good yields (Scheme 178).
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Scheme 178: Pd-catalyzed isocyanide insertion/C(sp
3
)-H activation of o-isocyanotoluene 
The cyclopropane ring is commonly present in potent molecules. Due to the strain of 
this small ring, which gives a slight acidity to the proton, the C(sp
3
)-H bond of the 3-
membered ring can be functionalized. Recent reports of cyclopropane (Csp
3
)-H activation 
found enantioselective applications for the synthesis of interesting building blocks.
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 By taking advantage of the cyclopropane and the isocyanide reactivities, we proposed 
to develop a Pd-catalyzed isocyanide insertion/C(sp
3
)-H activation reaction of methyl 2-
isobutyl 3-cyclopropyl-2-isocyanopropanoate II-288. In this transformation, we suggested 
that the formation of the imidoyl palladium II-291 could then follow two different pathways 
depending on the nature of R
2
. If R
2
 ≠ H, the 7-membered pallacycle II-292 could give the 
azabicyclo[4.1.0]hept-2-ene II-289 after reductive elimination. In the case of R
2
 = H, the 6-
membered palladacycle II-293 could be formed and should afford the C-2 arylated 
azaspiro[2.4]hept-4-ene II-290 (Scheme 179). 
 
Scheme 179: Pd-catalyzed isocyanide insertion/ C-H activation of methyl 2-substituted 3-cyclopropyl-2-
isocyanopropanoate. 
Methyl 2-isobutyl 3-cyclopropyl-2-isocyanopropanoate as starting material 
 The investigation on this transformation was performed with methyl 2-substituted 3-
cyclopropyl-2-isocyanopropanoate II-288a and p-iodotoluene II-168a as starting material 
(Table 29). When Cs2CO3 was used as base in toluene, only degradation was observed 
regardless of the palladium source and the ligand used (Entry 1 to 3). If DMF was used with 
Cs2CO3 (2 equiv), Pd(OAc)2 (5 mol%) and PPh3 (10 mol%), the amide II-294 was produced 
in 50% NMR yield (Entry 4). Interestingly, by replacing the base with CsOPiv, 20% NMR 
yield of the desired spiro compound II-290a was obtained (Entry 5). Heating to 110 °C gave 
II-290a in 30% NMR yield (Entry 7). Note that the combination Cs2CO3 and PivOH gave 
only 17% NMR yield of the azaspiro[2.4]hept-4-ene II-290a (Entry 6). 
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Table 29: Preliminary screening 
 
Entry Pd /Ligand  
(5 mol%/10 mol%) 
base solvent T (°C) NMR yield 
1 Pd(OAc)
2
/PPh
3
 
 
Cs
2
CO
3 
 (2 equiv) toluene 100 °C Slight degradation 
2 Pd(OAc)
2
/P(Ad)
2
Bu 
 
Cs
2
CO
3 
 (2 equiv) toluene 100 °C Slight degradation 
3 PdCl
2
/PPh
3
 
 
Cs
2
CO
3 
 (2 equiv) toluene 100 °C Slight degradation 
4 Pd(OAc)
2
/PPh
3
 
 
Cs
2
CO
3
 (2 equiv) DMF 90 °C 50% of II-294 
5 Pd(OAc)
2
/PPh
3
 
 
CsOPiv (1.2 equiv) toluene 90 °C 20% of II-290a 
6 Pd(OAc)
2
/PPh
3
 
 
Cs
2
CO
3
 (1.5 equiv),  
PivOH (0.3 equiv) 
toluene 110 °C 17% of II-290a 
7 Pd(OAc)
2
/PPh
3
 
 
CsOPiv (1.5 equiv) toluene 110 °C 30% of II-290a 
 
 The catalyst loading was also optimized (Table 30). By decreasing the amount of 
palladium and ligand (2 mol% and 4 mol% respectively), no reaction was observed (Entry 3). 
Lower yield of II-290a was obtained when 10 mol% of palladium acetate and 20 mol% of 
triphenylphosine were used (Entry 2). Finally, the starting materials were recovered when the 
the reaction mixture was diluted or when the isocyanide was added in one portion (Entry 4 & 
5). 
Table 30: Catalyst loading/dropwise addition 
 
Entry Catalyst loading Modification NMR yield 
1* 5mol%/10 mol% - 30% of II-290a 
2 10mol%/20 mol% - 12% of II-290a 
3 2mol%/4 mol% - No reaction (starting material recovered) 
4 5mol%/10 mol% Conc.  [0.025M] No reaction (starting material recovered) 
5 5mol%/10 mol% One portion of isocyanide No reaction (starting material recovered) 
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The screening of the solvents was then explored. Toluene (110 °C), dioxane (90 °C) or 
mesitylene (130 °C) gave similar yield of the spiro compound II-290a. The best result was 
obtained with p-xylene at 130 °C and gave the desired product in 42% yield II-290a.  
Table 31: solvent screening 
 
Entry solvent T (°C) NMR yield 
1* toluene 110 °C 30% of II-290a 
2 dioxane 90 °C 33% of II-290a 
3 p-xylene 130 °C 42% of II-290a 
4 p-xylene 120 °C 33% of II-290a 
5 mesitylene 130 °C 34% of II-290a 
 
Cesium pivalate as base and p-xylene as solvent lead to a significant yield of 42% of 
the desired product. To further increased the yield of II-290a, different ligands were studied 
(Table 32). Monodentate phosphine such as XPhos, CyJohnPhos and RuPhos gave a complex 
reaction mixture (Entries 2, 5 and 7) whereas Xantphos and SEGPHOS were not suitable 
ligand for this reaction (Entries 2 and 8). PhDavephos and P(Ad)2nBu permited to form II-
290a albeit in low yield (24-25%, Entries 4 and 9). It is notable that tBuPhox favoured the 
formation of the unexpected azlactone II-295 in 24% yield (Entry 6). 
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Table 32: Ligand screening. 
 
Entry Ligand NMR yield 
1* PPh3 42% of II-290a 
2 XPhos Degradation of the starting material 
3 XantPhos Degradation of the starting material 
4 PhDavePhos 25% of II-290a 
5 CyJohnPhos Degradation of the starting material 
6 tBuPhox 24% of a new product II-295 
7 RuPhos Degradation of the starting material 
8 (R)-DM-SEGPhos Messy 
9 P(Ad)
2
nBu 24% of II-290a 
 
Different sources of palladium were also tried (Table 33). Palladium tetrakis and 
P(Cy)3.HBF4 gave a complex reaction mixture (Entry 3 and 4). NHC palladium complex lead 
to II-290a in only 15% NMR yield (Entry 5). Palladium halide complexes were also screened 
and interestingly PdCl2 afford the azaspiro[2.4]hept-4-ene II-290a in 44% yield (Entry 2). 
However, by changing the chloride to bromide (PdBr2), II-290a was formed in 12% yield 
only. 
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Table 33: Palladium source screening. 
 
Entry Palladium source NMR yield 
1* Pd(OAc)
2
 42% of II-290a 
2 PdCl
2
 44% of II-290a 
3 Pd(Ph
3
)
4
 Degradation of the starting material 
4 P(Cy)
3
.HBF
4
 Slight degradation, starting material only 
5 PEPPSI-IPr catalyst 15% of II-290a 
6 Pd(Br)
2
 22% of II-290a 
7 Pd(TFA)
2
 39% of II-290a 
8 Pd(dba)
2
 35% of II-290a 
  
 The azaspiro[2.4]hept-4-ene derivative II-290a has been synthesized in 44% yield 
when methyl 2-isocbutyl 3-cyclopropyl-2-isocyanopropanoate and p-iodotoluene reacted in 
the presence of  PdCl2 (5 mol%), PPh3 (10 mol%) and CsOPiv (2 equiv) in p-xylene at 130 
°C. With this promising result, further optimizations are currently ongoing.  
By modifying the isocyanoacetate starting material II-288, other nitrated heterocycles 
(II-289, II-290 or II-296) might be synthesized via the similar Pd-catalyzed isocyanide 
insertion/C(sp
3
)-H activation sequence. These different scaffolds could be potent bioactive 
compound used in medicinal chemistry (Scheme 180). 
 
Scheme 180: Other potential scaffold via the Pd-catalyzed isocyanide insertion/C(sp
3
)-H activation 
isocyanoacetate. 
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Conclusion 
 Palladium-catalyzed reactions involving isocyanide bearing participating functional 
group have been investigated. On one hand, the three component reaction of o-
isocyanobenzonitrile II-258, p-iodotoluene II-168a and benzyl amine II-72a in the presence 
of a catalytic amount of Pd(OAc)2, PPh3 and 2 equivalents of Cs2CO3 afforded the 2-
substituted quinazolin-4-one II-170a in moderate yield (Scheme 181). On the other hand, the 
palladium-catalyzed isocyanide insertion/C(sp
3
)-H activation of methyl 2-isobutyl 3-
cyclopropyl-2-isocyanopropanoate II-295 and p-iodotoluene II-168a in the presence of a 
catalytic amount of PdCl2 and triphenylphosphine in xylene at 130 °C deliver the C-2 arylated 
azaspiro[2.4]hept-4-ene II-290a in 44% yield. We also noticed that changing the ligand to 
tBuPhox leads to the azlactone II-295 in 24% yield. In these two projects, a further 
optimization of the reaction condition would be necessary to reach higher yield of these 
different important heterocycles.  
 
Scheme 181: Palladium catalyzed reaction involving o-isocyanobenzonitrle and 2-substituted 3-
cyclopropyl-2-isocyanopropanoate 
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General Conclusion 
During this PhD, we have initially focused our effort on the development of 
enantioselective organocatalytic conjugate addition of different Michael donors to phenyl 
vinyl selenone. As initial acceptor, -substituted nitroacetate have been used in this reaction. 
In the presence of Cinchona alkaloid derivative as organocatalyst, the formation of -
dialkyl -nitroacetates has been accomplished in excellent yield and good enantioselectivity. 
The resulting Michael adducts have been converted to linear and cyclic quaternary amino 
acids by taking advantage of their rich functionalities. -Substituted nitroamides were 
subsequently used as nucleophiles with phenyl selenone. In the presence of Cinchona 
alkaloid, the organocatalytic Michael addition/intramolecular SN2/hydrolysis sequence 
afforded -lactone in good yield and moderate enantioselectivity. The formation of racemic -
lactam has also been reported following a similar sequence when DBU was used as base 
(Scheme 182).  
 
Scheme 182: Organocatalyzed Michael addition to phenyl vinyl selenone. 
In the second part of this PhD, we have concentrated our attention on the design of 
transition metal-catalyzed insertions of isocyanides bearing participating functional group for 
the synthesis of heterocycles and natural products. On the one hand, the silver-catalyzed 
isocyanide insertion of -disubstituted isocyanoacetate with primary amine furnished 3,5,5-
trisubstituted imidazolones in good to excellent yield. This methodology has been applied on 
methyl o-isocyanobenzoate for the synthesis of two natural products, evodiamine and 
rutaecarpine. Then, a copper/palladium-catalyzed 3-CR reaction of ,-disubstituted 
isocyanoacetate, primary amide and aryl iodide have been developed to afford 2,3,5,5-
tetrasubstituted imidazolones in moderate to good yield. On the other hand, palladium-
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catalyzed isocyanide insertion has been explored. The Pd-catalyzed 3-CR of o-
isocyanobenzonitrile, aryl iodide and primary amine produced 2-substituted quinazolin-4-one 
in moderate yield. We have also investigated the Pd-catalyzed isocyanide insertion/C(sp
3
)-H 
activation of methyl 2-isobutyl 3-cyclopropyl-2-isocyanopropanoate with aryl iodide which 
delivered C-2 arylated azaspiro[2.4]hept-4-ene in moderate yield (Scheme 183). 
 
Scheme 183: Transition metal-catalyzed isocyanide insertion of unusual isocyanide. 
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Part III: Experimental data 

175 
 
General information 
Reagents and solvents were purchased from commercial sources (Aldrich, Acros, Merck, Fluka and VWR 
international) and preserved under argon. More sensitive compounds were stored in a desiccator or glove-box if 
required. Reagents were used without further puriﬁcation unless otherwise noted. 
All reactions were performed under argon (or nitrogen) unless otherwise noted. When needed, glassware was 
dried overnight in an oven (T > 100 °C) or under vacuum with a heat gun (T > 200 °C). 
When solvents are indicated as dry they were either purchased as such, distilled prior to use or were dried by a 
passage through a column of anhydrous alumina or copper using a Puresolv MD 5 from Innovative Technology 
Inc., based on the Grubb’s design.1  
Reactions heated by microwave irradiation are performed in a CEM Discover SP microwave instrument. 
Flash column chromatography was performed using Silicycle P60 silica: 230-400 mesh (40-63 µm) silica. 
Reactions were monitored using Merck Kieselgel 60F254 aluminium or glass backed plates. TLC’s were 
visualized by UV ﬂuorescence (254 nm) then stained with one of the following TLC stains: KMnO4, 
phosphomolybdic acid, ninhydrin, pancaldi, p-anisaldehyde, vanillin. 
NMR spectra were recorded on a Brüker AvanceIII-400, Brüker Avance-400 or Brüker DPX-400 spectrometer 
at room temperature, 
1
H frequency is at 400.13 MHz, 
13C frequency is at 100.62 MHz. Chemical shifts ( δ ) were 
reported in parts per million (ppm) relative to residual solvent peaks rounded to the nearest 0.01 MHz for proton 
and 0.1 MHz for carbon ( ref: CHCl3 [
1
H: 7.26 ppm, 
13
C: 77.2 ppm] , MeOH [
1
H: 3.31 ppm, 
13
C 49.0 ppm], 
DMSO [
1
H: 2.50 ppm, 
13
C 39.5 ppm] ). Coupling constants ( J ) were reported in Hz to the nearest 0.1 Hz. Peak 
multiplicity was indicated as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet) and br (broad). 
IR spectra were recorded in a Jasco FT/IR-4100 spectrometer outﬁtted with a PIKE technology MIRacleTM 
ATR accessory as neat ﬁlms compressed onto a Zinc Selenide window. The spectra are reported in cm −1. 
Abbreviations used are: w (weak), m (medium), s (strong) and br (broad). 
Mass spectra were obtained with a Waters ACQUITY H-class UPLC/MS ACQ- SQD by electron ionisation (EI 
positive and negative) or a Finnigan TSQ7000 by electrospray ionization (ESI + ). The accurate masses were 
measured by the mass spectrometry service of the EPFL by ESI-TOF using a QTOF Ultima from Waters.  
Enantiomeric ratios were determined with a Thar SFC Investigator system using chiral stationary phase. 
Optical rotations αD were obtained with a Jasco P-2000 polarimeter (589 nm). 
Melting points were determined using a Stuart SMP30. 
When a rigorously inert and dry atmosphere was needed reactions were carried out in a PureLab HE 4GB 2500 
Glove-box System from Innovative Technologies inc. 
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Part I 
Chapter 1 
For all general procedures the order of addition of reagents has to be respected. 
Phenyl vinyl selenone (2a)
[203]
, alkyl -alkyl nitroacetates 4a-4e, [204] 4g,[205] 4h-4k,[206] 4l,[207] 4m-4o,[208] 
Cinchona alkaloid-based organocatalysts QN-2, QN-3, QD-3, QN-5, QN-8, QN-9, QN-10, QN-11, QN-12 -
iCD and epiQN-3 were synthesized according to the literature procedures.
[209]
 
General procedures 
General procedure A:
 
 
 
Preparation of -alkyl -bromoacetate: 
To the carboxylic acid (1 equiv) was added dropwise PBr3 (1.1 equiv) at room temperature during 0.5 hour. To 
the resulting mixture was added dropwise Br2 (1.1 equiv) during 0.5 hour (HBr gas was trapped with an exit 
tubing which was connected to a saturated aqueous solution of NaHCO3) and the reaction mixture was heated to 
60 °C for 2 additional hours. The reaction mixture was cooled to room temperature and MeOH was added 
dropwise over 1h. The reaction mixture was then concentrated under reduced pressure to give the -
bromoacetate which was used in the next reaction without further purification. 
Preparation of -alkyl -nitroacetate: [205] 
To a solution of -bromoacetate (1 equiv) and phloroglucinol (1.2 equiv) in DMF (0.2 M) at 0 °C was added 
NaNO2 (1.5 equiv). The reaction mixture was slowly warmed to room temperature and stirred until complete 
consumption of the starting material (TLC monitoring, around 1 hour). The reaction mixture was diluted with a 
saturated aqueous solution of NH4Cl and extracted with EtOAc (3 times). The combined organic layers were 
washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product was 
purified by flash chromatography on silica gel to afford the pure product 4f. 
General procedure B: 
Synthesis of
 
aryl vinyl selenone:
[210],[211],[212]
 
 
To a suspension of magnesium (729 mg, 30.0 mmol, 1 equiv) in Et2O (60 mL, 0.5 M) was added dropwise aryl 
bromide (30.0 mmol, 1 equiv) at such a rate that the reflux was maintained during 1 hour. Selenium metal (2.37 
g, 30.0 mmol, 1 equiv) was then added portionwise (4-5 portions, caution: the reaction is exothermic). The 
reaction mixture was vigorously stirred at 40 °C for 2 hours. The reaction mixture was cooled to  0 °C and 
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diluted slowly with cold water. Concentrated HCl (20 mL) was added slowly and the reaction mixture was 
extracted with Et2O (3 x 30 mL). The combined organic layers were dried over Na2SO4, filtered and 
concentrated under reduce pressure. The residue was diluted with ethanol (50 mL) and a flow of O2 gas was 
bubbled to the reaction mixture during 12 hours. The reaction mixture was concentrated and the crude product 
was filtered through silica gel to afford the diaryl diselenide. 
To a solution of the diaryl diselenide (1 equiv) in THF (0.1 M) was added and vinyl magnesium bromide (2.2 
equiv) at 0 °C. The reaction mixture was warmed to room temperature and stirred during 4 hours. The reaction 
mixture was diluted with water and extracted with EtOAc (3 times). The combined organic layers were dried 
over Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by flash 
chromatography on silica gel to (pure PE as eluent) afford the pure product. 
To a solution of the aryl vinyl selenide (1 equiv) in DCM (0.1 M) at 0 °C was added portionwise mCPBA (4 
equiv) during 10 min. The reaction mixture was warmed to room temperature and stirred until complete 
consumption of the starting material (TLC monitoring, around 2 hours). The reaction mixture was diluted with 
water and extracted with EtOAc (3 times). The combined organic layers were washed with brine, dried over 
Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by flash 
chromatography on silica gel to afford the desired aryl vinyl selenone 2. 
General procedure C:[213] 
 
To a suspension of quinine (1.5 equiv), CuI (10 mol%), phenanthroline (20 mol%) and Cs2CO3 (1.2 equiv) in dry 
toluene (0.2 M) was added aryl iodide (1 equiv). The resulting mixture was heated to 60 °C and stirred for 12 
hours. The reaction mixture was cooled to room temperature, diluted with a saturated aqueous solution of 
NaHCO3 and extracted with AcOEt (3 times). The combined organic layers were washed with brine, dried over 
Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by flash 
chromatography on silica gel to afford the pure product. 
General procedure D: [214] 
 
To a solution of NaH (1.5 equiv) in dry DMF (0.1 M) at 0 °C was added dropwise EtSH (1.5 equiv) during 10 
min. To the reaction mixture was added a solution of Cinchona alkaloid derivative (1 equiv) in dry DMF (0.1) 
and the resulting mixture was quickly heated to 110 °C. The reaction mixture was stirred until complete 
consumption of the starting material (TLC monitoring, around 5 hours). The reaction mixture was cooled to 
room temperature, diluted with water and extracted with EtOAc (3 times). The combined organic layers were 
washed with brine, dried over Na2SO4 and concentrated under reduced pressure. The crude product was purified 
by flash chromatography on silica gel to afford the pure product. 
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General procedure E: 
 
To a solution of aryl vinyl selenone 2 (0.05 mmol, 1 equiv) and QN-7 (0.005 mmol, 0.1 equiv) in toluene (0.1 
mL) at - 30 °C was added -substituted nitroacetate 4 (0.06 mmol, 1.2 equiv). The reaction mixture was stirred 
at - 30 °C until complete consumption of the starting material (TLC monitoring, around 48 hours). The reaction 
mixture was warmed to room temperature and concentrated under reduced pressure. The crude product was 
purified by flash chromatography on silica gel to afford the pure product. 
General procedure F: Synthesis of (±)-5 
 
To a solution of phenyl vinyl selenone (2a) (0.05 mmol, 1 equiv) and -substituted nitroacetate 4 (0.06 mmol, 
1.2 equiv) in toluene (0.5 mL) was added Et3N (0.06, 1.2 equiv). The reaction mixture was stirred until complete 
consumption of the starting material (TLC monitoring, around 12 hours) and concentrated under reduced 
pressure. The crude product was purified by flash chromatography on silica gel to afford the pure product. 
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Characterization data 
 
Procedure A:  
Yield: 155 mg, 32% (2 steps) Eluent: AcOEt/PE, 0:100 to 85:15 
Aspect: colorless oil 
1
H NMR (400.13 MHz, CDCl3): δ 5.20 (dd, J = 10.0, 5.1 Hz, 1H), 3.83 (s, 3H), 2.28 (ddd, J = 14.3, 10.0, 5.6 
Hz, 1H), 1.94 (ddd, J = 14.3, 8.6, 5.1 Hz, 1H), 1.70 – 1.58 (m, 1H), 0.97 (d, J = 6.6 Hz, 6H). 
13
C NMR (100.62 MHz, CDCl3): δ 165.5, 86.8, 53.7, 39.0, 25.2, 22.6, 21.5. 
IR: 2961 (w), 1755 (s), 1561 (s), 1373 (w), 1272 (w), 1207 (w). 
HRMS: (ESI) calcd for C7H12NO4 [M+H] 174.0766; found 174.0779. 
Aryl vinyl selenones 
 
Procedure B:  
Yield: 8.03 g, 91% from the corresponding diselenide, Eluent: AcOEt/PE, 80:20 to 90:10 
Aspect: white solid 
1
H NMR (400.13 MHz, CDCl3): δ 8.00 – 7.92 (m, 2H), 7.74 – 7.68 (m, 1H), 7.67 – 7.61 (m, 2H), 6.99 (dd, J = 
16.6, 9.1 Hz, 1H), 6.72 (dd, J = 16.6, 2.0 Hz, 1H), 6.45 (dd, J = 9.1, 2.0 Hz, 1H). 
13
C NMR (100.62 MHz, CDCl3): δ 141.3, 139.0, 134.5, 131.3, 130.5, 127.1. 
77
Se NMR (76.31 MHz, Se(Me)2): δ 966.8 
IR: 3043 (w), 1448 (w), 1370 (w), 1221 (w), 1064 (w), 980 (m), 929 (s), 880 (s), 761 (s), 685 (m). 
HRMS: (ESI) calcd for C8H8NaO2Se
+
 [M+Na]
+
 238.9582; found 238.9591. 
Melting point: 109.5-111.5 °C 
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Procedure B:  
Yield: 130 mg, 20% (over 3 steps) Eluent: AcOEt/PE, 70:30 to 90:10 
Aspect: white solid 
1
H NMR (400.13 MHz, CDCl3): δ 7.96 – 7.77 (m, 2H), 7.12 – 7.06 (m, 2H), 6.97 (dd, J = 16.5, 9.1 Hz, 1H), 
6.67 (dd, J = 16.5, 1.9 Hz, 1H), 6.40 (dd, J = 9.1, 1.9 Hz, 1H), 3.89 (s, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 164.4, 139.4, 132.0, 130.6, 129.2, 115.7, 56.0. 
77
Se NMR (76.31 MHz, Se(Me)2): δ 966.1 
IR: 3040 (w), 2902 (w), 1587 (m), 1575 (w), 1494 (m), 1259 (s), 1073 (m), 926 (s), 876 (s), 830 (s). 
HRMS: (ESI) calcd for C9H11O3Se
+
 [M+H]
+
 246.9868; found 246.9873. 
Melting point: 112.5-114.5 °C 
 
Procedure B:  
Yield: 1.60 g, 28% (over 3 steps) Eluent: AcOEt/PE, 70:30 to 90:10 
Aspect: white solid 
1
H NMR (400.13 MHz, CDCl3): δ  8.12 (d, J = 7.9 Hz, 2H), 7.91 (d, J = 7.9 Hz, 2H), 7.02 (dd, J = 16.4, 9.0 Hz, 
1H), 6.80 (dd, J = 16.4, 2.1 Hz, 1H), 6.52 (dd, J = 9.0, 2.1 Hz, 1H). 
13
C NMR (100.62 MHz, CDCl3) δ 144.9, 138.6, 136.3 (q, J = 32.3 Hz), 132.4, 127.9, 127.6 (q, J = 3.8 Hz), 
123.0 (q, J = 272.7 Hz). 
77
Se NMR (76.31 MHz, Se(Me)2): δ 946.7 
IR: 2922 (w), 1601 (m), 1398 (w), 1320 (s), 1164 (m), 1119 (s), 1072 (s), 1011 (s), 824 (s). 
HRMS: (ESI) calcd for C9F3H8O2Se
+
 [M+H]
+
 284.9636; found 284.9642. 
Melting Point: 101-103 °C 
 
 
 
Procedure B:  
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Yield: 715 mg, 16% (over 3 steps), Eluent: AcOEt/PE, 70:30 to 90:10 
Aspect: white solid 
1
H NMR (400.13 MHz, CDCl3): δ 7.56 – 7.55 (m, 2H), 7.31 – 7.30 (m, 1H), 6.97 (dd, J = 16.5, 9.1 Hz, 1H), 
6.71 (dd, J = 16.5, 1.9 Hz, 1H), 6.42 (dd, J = 9.1, 1.9 Hz, 1H), 2.42 (s, 6H). 
13
C NMR (100.62 MHz, CDCl3): δ 140.9, 140.8, 139.2, 136.2, 131.0, 124.4, 21.5. 
77
Se NMR (76.31 MHz, Se(Me)2): δ 968.0 
IR: 3091 (w), 3044 (w), 2337 (w), 1718 (w), 1458 (w), 1362 (w), 1008 (m), 929 (s), 882 (s), 850 (m), 677 (m).  
HRMS: (ESI) calcd for C10H13O2Se
+
 [M+H]
+
 245.0075; found 245.0080. 
Melting point: 161-163 °C 
Catalysts 
 
Procedure: To a solution of quinine (1 equiv) and NaH (5 equiv) in DMF previously stirred at room temperature 
for 2 hours, was added 1-bromo-2-methylpropane (5 equiv). The resulting mixture was heated to 120 °C for 12 
hours. The reaction mixture was cooled to room temperature, diluted with water and extracted with AcOEt (3 
times). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated under 
reduced pressure. The crude product was purified by flash chromatography on silica gel to afford the pure 
product. 
Yield: 21%, Eluent: AcOEt/NH3, 99:1 to AcOEt/NH3/MeOH, 97:1:2 
Aspect: brown pale foam 
1
H NMR (400.13 MHz, CDCl3) δ 8.67 (d, J = 4.5 Hz, 1H), 7.96 (d, J = 9.3 Hz, 1H), 7.36 (d, J = 4.5 Hz, 1H), 
7.33 – 7.26 (m, 2H), 5.62 (ddd, J = 17.6, 10.3, 7.6 Hz, 1H), 5.22 – 5.12 (m, 1H), 4.93 – 4.78 (m, 2H), 3.89 (s, 
3H), 3.55 – 3.40 (m, 1H), 3.18 – 2.97 (m, 4H), 2.78 – 2.67 (m, 1H), 2.67 – 2.56 (m, 1H), 2.34 – 2.21 (m, 1H), 
1.90 – 1.71 (m, 4H), 1.57 – 1.38 (m, 2H), 0.90 (d, J = 6.6 Hz, 3H), 0.88 (d, J = 6.6 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3) δ 157.9, 147.5, 144.6, 144.6, 141.3, 136.5, 131.8, 127.3, 121.9, 118.6, 114.7, 
101.2, 80.4, 76.2, 60.1, 56.8, 56.0, 43.3, 39.6, 28.9, 27.8, 27.3, 21.4, 19.6, 19.5. 
IR: 2925 (m), 2870 (w), 1735 (w), 1677 (w), 1621 (m), 1508 (m), 1364 (w), 1240 (s), 1107 (s), 1029 (s), 914 
(m), 856 (s), 821 (m), 718 (m). 
HRMS: (ESI) calcd for C24H33N2O2
+
 [M+H]
+
 381.2537; found 381.2545. 
[𝜶]𝐃
𝟐𝟔 = - 74 (c 0.3, CHCl3) 
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Procedure C:  
Yield: 73%, Eluent: AcOEt/NH3, 99:1 to AcOEt/NH3/MeOH, 98:1:1) 
Aspect: brown pale foam 
1
H NMR (400.13 MHz, CDCl3): δ  8.60 (d, J = 4.5 Hz, 1H), 8.58 – 8.54 (m, 1H), 8.11 – 8.05 (m, 1H), 7.85 – 
7.80 (m, 1H), 7.63 – 7.58 (m, 1H), 7.58 – 7.51 (m, 1H), 7.48 – 7.39 (m, 3H), 7.36 (d, J = 8.1 Hz, 1H), 7.09 (t, J = 
8.1 Hz, 1H), 6.43 (d, J = 7.7 Hz, 1H), 6.23 (d, J = 2.9 Hz, 1H), 5.79 (ddd, J = 17.0, 10.3, 7.7 Hz, 1H), 5.06 – 
4.90 (m, 2H), 4.01 (s, 3H), 3.54 – 3.43 (m, 1H), 3.42 – 3.34 (m, 1H), 3.22 – 3.12 (m, 1H), 2.82 – 2.67 (m, 2H), 
2.39 – 2.30 (m, 1H), 2.30 – 2.20 (m, 1H), 2.04 – 1.94 (m, 2H), 1.82 – 1.72 (m, 1H), 1.68 – 1.57 (m, 1H). 
13
C NMR (100.62 MHz, CDCl3): δ 158.3, 152.3, 147.9, 144.8, 143.7, 142.1, 134.8, 132.3, 128.0, 126.6, 126.6, 
126.6, 125.9, 125.7, 122.0, 121.7, 120.8, 118.2, 114.6, 106.6, 100.9, 78.9, 60.6, 57.6, 56.0, 43.6, 40.3, 28.3, 28.3, 
22.0. 
IR: 3064 (w), 2937 (w), 2864 (w), 1621 (m), 1578 (m), 1508 (m), 1398 (m), 1265 (s), 1239 (s), 1102 (m), 914 
(w), 792 (m), 771 (s), 733 (m). 
HRMS: (ESI) calcd for C30H31N2O2
+
 [M+H]
+
 451.2380; found 451.2395. 
[𝜶]𝐃
𝟐𝟔 = + 249 (c 1.0, CHCl3)  
 
Procedure C:  
Yield: 64%, Eluent: AcOEt/NH3, 99:1 to AcOEt/NH3/MeOH, 98:1:1 
Aspect: brown pale foam 
1
H NMR (400.13 MHz, CDCl3): 8.68 (d, J = 4.5 Hz, 1H), 8.56 (d, J = 8.2 Hz, 1H), 8.05 (d, J = 9.3 Hz, 1H), 
7.78 – 7.71 (m, 1H), 7.64 (d, J = 2.8 Hz, 1H), 7.57 – 7.45 (m, 3H), 7.40 (dd, J = 9.2, 2.7 Hz, 1H), 7.32 (d, J = 8.3 
Hz, 1H), 7.07 (t, J = 8.0 Hz, 1H), 6.52 (d, J = 7.7 Hz, 1H), 5.93 (d, J = 7.5 Hz, 1H), 5.85 (ddd, J = 17.4, 10.4, 7.3 
Hz, 1H), 5.08 – 4.94 (m, 2H), 4.01 (s, 3H), 3.78 – 3.64 (m, 1H), 3.61 – 3.46 (m, 1H), 3.26 (dd, J = 13.9, 10.0 Hz, 
1H), 2.99 – 2.77 (m, 2H), 2.41 – 2.27 (m, 1H), 1.85 – 1.73 (m, 2H), 1.70 – 1.53 (m, 2H), 1.40 – 1.28 (m, 1H). 
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13
C NMR (100.62 MHz, CDCl3): δ 158.1, 153.4, 147.8, 144.9, 142.8, 141.7, 134.7, 132.3, 127.7, 127.5, 126.6, 
126.1, 125.6, 125.6, 122.5, 121.6, 121.0, 120.5, 114.7, 106.9, 101.6, 78.2, 60.7, 56.7, 55.8, 42.6, 39.7, 28.1, 27.9, 
24.8. 
IR: 3062 (w), 2937 (w), 2864 (w), 1621 (m), 1578 (m), 1508 (s), 1265 (s), 1239 (s), 1097 (m), 913 (m), 854 (m), 
772 (s), 732 (m). 
HRMS: (ESI) calcd for C30H31N2O2
+
 [M+H]
+
 451.2380; found 451.2384. 
[𝜶]𝐃
𝟐𝟔 = - 195 (c 1.0, CHCl3) 
 
Procedure C:  
Yield: 63%, Eluent: AcOEt/NH3, 99:1 to AcOEt/NH3/MeOH, 98:1:1 
Aspect: brown pale foam 
1
H NMR (400.13 MHz, CDCl3): δ  8.66 (d, J = 4.5 Hz, 1H), 8.09 (d, J = 10.0 Hz, 1H), 7.75 – 7.69 (m, 2H), 
7.49 – 7.42 (m, 4H), 7.35 – 7.27 (m, 2H), 7.21 (dd, J = 9.0, 2.5 Hz, 1H), 6.89 (d, J = 2.5 Hz, 1H), 6.18 – 6.12 
(m, 1H), 5.76 (ddd, J = 17.0, 10.3, 7.6 Hz, 1H), 5.05 – 4.89 (m, 2H), 4.03 (s, 3H), 3.49 – 3.40 (m, 1H), 3.36 – 
3.29 (m, 1H), 3.18 (dd, J = 13.7, 10.2 Hz, 1H), 2.81 – 2.68 (m, 2H), 2.38 – 2.31 (m, 1H), 2.12 – 2.05 (m, 1H), 
2.01 – 1.95 (m, 1H), 1.94 – 1.90 (m, 1H), 1.67 – 1.57 (m, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 158.4, 154.9, 147.8, 144.8, 143.6, 141.7, 134.4, 132.3, 129.8, 129.3, 127.7, 
127.0, 126.6, 126.5, 124.1, 122.1, 118.6, 118.6, 114.7, 109.2, 101.0, 79.1, 60.4, 57.4, 56.1, 43.6, 40.0, 28.2, 27.8, 
21.5. 
IR: 2938 (w), 1621 (m), 1600 (w), 1509 (s), 1467 (m), 1255 (s), 1216 (s), 1178 (s), 1029 (w), 911 (m), 837 (m), 
733 (s). 
HRMS: (ESI) calcd for C30H31N2O2
+
 [M+H]
+
 451.2380; found 451.2379. 
[𝜶]𝐃
𝟐𝟔 = + 216 (c 1.1, CHCl3) 
 
Procedure C:  
Yield: 47%, Eluent: AcOEt/NH3, 99:1 to AcOEt/NH3/MeOH, 98:1:1 
Aspect: brown pale foam 
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1
H NMR (400.13 MHz, CDCl3): δ  8.72 (d, J = 4.5 Hz, 1H), 8.04 (d, J = 9.3 Hz, 1H), 7.75 (d, J = 2.7 Hz, 1H), 
7.68 – 7.60 (m, 2H), 7.53 (d, J = 4.5 Hz, 1H), 7.47 – 7.38 (m, 2H), 7.32 – 7.27 (m, 1H), 7.25 – 7.21 (m, 2H), 
7.02 (d, J = 2.5 Hz, 1H), 5.86 – 5.73 (m, 2H), 5.08 – 4.91 (m, 2H), 4.03 (s, 3H), 3.70 – 3.56 (m, 1H), 3.43 – 3.36 
(m, 1H), 3.36 – 3.29 (m, 1H), 2.94 – 2.86 (m, 1H), 2.86 – 2.79 (m, 1H), 2.37 – 2.25 (m, 1H), 1.76 – 1.67 (m, 
2H), 1.66 – 1.56 (m, 1H), 1.47 – 1.34 (m, 1H), 1.18 – 1.07 (m, 1H). 
13
C NMR (100.62 MHz, CDCl3): δ 158.1, 155.5, 147.6, 144.9, 142.7, 141.6, 134.1, 132.2, 129.4, 129.2, 127.6, 
127.6, 126.8, 126.3, 123.9, 121.7, 121.2, 119.5, 114.6, 109.7, 101.8, 78.6, 60.3, 56.3, 55.8, 41.9, 39.7, 28.2, 27.7, 
25.0. 
IR: 2939 (w), 2864 (w), 1621 (m), 1509 (m), 1254 (m), 1215 (s), 1033 (m), 909 (m), 836 (m), 730 (s). 
HRMS: (ESI) calcd for C30H31N2O2
+
 [M+H]
+
 451.2380; found 451.2374. 
[𝜶]𝐃
𝟐𝟓 = - 1 (c 1.1, CHCl3) 
 
Procedure C:  
Yield: 68%, Eluent: AcOEt/NH3, 99:1 to AcOEt/NH3/MeOH, 97:1:2  
Aspect: brown pale foam 
1
H NMR (400.13 MHz, CDCl3): δ  8.66 (d, J = 4.5 Hz, 1H), 8.14 – 8.04 (m, 1H), 7.79 – 7.65 (m, 2H), 7.52 – 
7.39 (m, 4H), 7.36 – 7.23 (m, 2H), 7.25 – 7.21 (m, 1H), 6.88 (d, J = 2.5 Hz, 1H), 6.25 (ddd, J = 16.9, 10.4, 7.5 
Hz, 1H), 6.16 (d, J = 3.0 Hz, 1H), 5.23 – 5.09 (m, 2H), 4.01 (s, 3H), 3.38 (m, 1H), 3.29 – 3.19 (m, 1H), 3.06 – 
2.91 (m, 2H), 2.88 – 2.75 (m, 1H), 2.44 – 2.22 (m, 2H), 1.89 – 1.82 (m, 1H), 1.64 – 1.47 (m, 2H), 1.35 – 1.18 
(m, 1H). 
13
C NMR (100.62 MHz, CDCl3): δ 158.3, 155.0, 147.8, 144.8, 143.7, 140.9, 134.3, 132.3, 129.8, 129.2, 127.6, 
127.0, 126.6, 126.5, 124.0, 122.0, 118.8, 118.6, 114.8, 109.1, 100.9, 79.7, 60.0, 55.9, 50.6, 50.0, 40.3, 28.5, 26.7, 
21.3. 
IR: 3060 (w), 2936 (w), 2872 (w), 1621 (s), 1509 (s), 1467 (m), 1254 (s), 1216 (s), 1178 (s), 998 (m), 910 (m), 
836 (s), 732 (s). 
HRMS: (ESI) calcd for C30H31N2O2
+
 [M+H]
+
 451.2380; found 451.2374. 
[𝜶]𝐃
𝟐𝟔 = - 150 (c 1.1, CHCl3) 
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Procedure D:  
Yield: 65%, Eluent: AcOEt/NH3, 99:1 to AcOEt/NH3/MeOH, 97:1:2 
Aspect: brown pale foam 
1
H NMR (400.13 MHz, CDCl3): δ  8.69 (d, J = 4.5 Hz, 1H), 8.31 (br s, 1H), 8.13 – 8.07 (m, 1H), 8.00 (d, J = 
9.0 Hz, 1H), 7.39 (d, J = 4.4 Hz, 1H), 7.32 (dd, J = 9.1, 2.4 Hz, 1H), 5.61 (ddd, J = 17.5, 10.3, 7.5 Hz, 1H), 5.46 
– 5.35 (m, 1H), 4.97 – 4.82 (m, 2H), 3.75 – 3.59 (m, 1H), 3.32 – 3.16 (m, 1H), 3.07 (d, J = 6.3 Hz, 2H), 3.04 – 
2.96 (m, 1H), 2.95 – 2.86 (m, 1H), 2.69 – 2.57 (m, 1H), 2.46 – 2.32 (m, 1H), 2.13 – 2.01 (m, 1H), 1.98 – 1.89 
(m, 1H), 1.89 – 1.82 (m, 1H), 1.70 – 1.56 (m, 1H), 1.50 – 1.38 (m, 1H), 0.93 (d, J = 6.6 Hz, 3H), 0.91 (d, J = 6.6 
Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 157.0, 146.8, 144.2, 143.9, 140.7, 131.4, 128.1, 123.4, 118.0, 115.3, 107.3, 
78.2, 76.1, 59.7, 56.4, 43.5, 39.4, 29.0, 27.9, 27.0, 19.8, 19.7, 19.6. 
IR: 2952 (w), 2935 (w), 2871 (w), 1618 (m), 1510 (w), 1467 (s), 1403 (w), 1240 (s), 1106 (s), 1060 (m), 855 (s), 
822 (s), 763 (m). 
HRMS: (ESI) calcd for C23H31N2O2
+
 [M+H]
+
 367.2380; found 367.2388. 
[𝜶]𝐃
𝟐𝟔 = - 81 (c 0.1, CHCl3) 
 
Procedure D:  
Yield: 57%, Eluent: AcOEt/NH3, 99:1 to AcOEt/NH3/MeOH, 98:1:1 
Aspect: brown pale foam 
1
H NMR (400.13 MHz, CDCl3): δ  8.54 – 8.48 (m, 2H), 8.47 – 8.42 (m, 1H), 7.80 (d, J = 9.0 Hz, 1H), 7.74 (d, J 
= 8.1 Hz, 1H), 7.62 – 7.55 (m, 1H), 7.54 – 7.48 (m, 1H), 7.33 (d, J = 4.5 Hz, 1H), 7.23 (dd, J = 9.1, 2.4 Hz, 1H), 
7.11 (d, J = 8.3 Hz, 1H), 6.37 (s, 1H), 6.21 – 6.09 (m, 1H), 5.83 – 5.68 (m, 2H), 5.18 – 4.92 (m, 2H), 3.75 – 3.57 
(m, 1H), 3.51 – 3.41 (m, 1H), 3.39 – 3.28 (m, 1H), 3.02 – 2.87 (m, 2H), 2.59 – 2.45 (m, 2H), 2.31 – 2.16 (m, 
1H), 2.14 – 2.08 (m, 1H), 1.85 – 1.71 (m, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 157.0, 151.2, 147.2, 144.1, 142.1, 140.4, 134.7, 132.1, 128.1, 127.1, 126.5, 
125.8, 125.7, 125.7, 124.0, 121.2, 120.9, 117.7, 115.8, 108.0, 106.3, 76.0, 59.4, 56.4, 43.7, 39.2, 28.0, 27.3, 20.4. 
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IR: 2934 (w), 1629 (m), 1599 (m), 1510 (m), 1466 (m), 1253 (s), 1215 (s), 1177 (s), 1001 (w), 835 (s), 812 (s), 
745 (s). 
HRMS: (ESI) calcd for C29H29N2O2
+
 [M+] 437.2224; found 437.2221. 
[𝜶]𝐃
𝟐𝟔 = + 243 (c 0.09, CHCl3) 
 
Procedure D:  
Yield: 55%, Eluent: AcOEt/NH3, 99:1 to AcOEt/NH3/MeOH, 98:1:1 
Aspect: brown pale foam 
1
H NMR (400.13 MHz, CDCl3): δ  8.45 (d, J = 4.5 Hz, 1H), 8.42 – 8.35 (m, 1H), 8.28 – 8.17 (br s, 1H), 7.88 (d, 
J = 9.1 Hz, 1H), 7.77 – 7.71 (m, 1H), 7.58 – 7.42 (m, 2H), 7.33 – 7.20 (m, 3H), 6.83 – 6.50 (m, 2H), 6.24 (d, J = 
7.8 Hz, 1H), 5.65 (ddd, J = 17.3, 10.3, 7.0 Hz, 1H), 5.09 – 4.96 (m, 2H), 3.84 – 3.68 (m, 1H), 3.66 – 3.53 (m, 
1H), 3.47 – 3.32 (m, 1H), 3.19 – 3.07 (m, 1H), 3.06 – 2.93 (m, 1H), 2.66 – 2.49 (m, 2H), 2.38 – 2.22 (m, 1H), 
2.19 – 2.10 (m, 1H), 1.91 – 1.80 (m, 1H), 1.80 – 1.71 (m, 1H). 
13
C NMR (100.62 MHz, CDCl3): δ 157.0, 150.8, 147.0, 144.2, 140.4, 138.7, 134.8, 132.3, 128.4, 126.7, 126.5, 
126.1, 125.9, 125.6, 123.4, 121.6, 120.9, 117.7, 116.9, 107.1, 105.7, 74.4, 59.8, 55.7, 43.8, 38.2, 27.6, 26.1, 19.8. 
IR: 2940 (w), 1620 (w), 1574 (w), 1509 (w), 1463 (w), 1396 (w), 1264 (w), 1236 (w), 1096 (w), 906 (s), 726 (s). 
HRMS: (ESI) calcd for C29H29N2O2
+
 [M+H]
+
 437.2224; found 437.2224. 
[𝜶]𝐃
𝟐𝟔 = - 171 (c 0.7, CHCl3) 
 
Procedure D:  
Yield: 83%, Eluent: AcOEt/NH3, 99:13 to AcOEt/NH3/MeOH, 97:1:2 
Aspect: brown pale foam 
1
H NMR (400.13 MHz, CDCl3): δ  8.57 (d, J = 4.5 Hz, 1H), 8.41 (d, J = 2.5 Hz, 1H), 7.88 (d, J = 9.0 Hz, 1H), 
7.62 (d, J = 8.1 Hz, 1H), 7.57 (d, J = 9.0, 1H), 7.39 (d, J = 4.5 Hz, 1H), 7.27 – 7.23 (m, 1H), 7.19 (m, 1H), 7.15 
– 7.07 (m, 2H), 7.03 (d, J = 8.1 Hz, 1H), 6.70 (d, J = 2.5 Hz, 1H), 6.32 (s, 1H), 5.68 (ddd, J = 17.5, 10.3, 7.5 
Hz, 1H), 5.02 – 4.90 (m, 2H), 3.64 – 3.52 (m, 1H), 3.36 – 3.29 (m, 1H), 3.29 – 3.20 (m, 1H), 2.91 – 2.78 (m, 
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1H), 2.77 – 2.69 (m, 1H), 2.45 – 2.36 (m, 1H), 2.34 – 2.25 (m, 1H), 2.20 – 2.10 (m, 1H), 2.00 – 1.95 (m, 1H), 
1.74 – 1.65 (m, 1H), 1.64 – 1.53 (m, 1H). 
13
C NMR (100.62 MHz, CDCl3) δ 157.1, 154.2, 147.0, 143.9, 142.5, 140.5, 134.2, 131.8, 129.8, 129.2, 127.5, 
127.1, 126.9, 126.5, 124.1, 123.6, 118.2, 118.0, 115.4, 109.1, 107.5, 76.9, 59.3, 56.5, 43.5, 39.4, 28.0, 27.0, 20.1 
IR: 2934 (w), 2866 (w), 1733 (w), 1629 (m), 1599 (m), 1510 (s), 1466 (s), 1253 (s), 1177 (s), 1001 (w), 835 (s), 
812 (s), 751 (s). 
HRMS: (ESI) calcd for C29H29N2O2
+
 [M+H]
+
 437.2224; found 437.2235. 
[𝜶]𝐃
𝟐𝟔 = + 263 (c 0.1, CHCl3) 
 
Procedure D:  
Yield: 61%, Eluent: AcOEt/NH3, 99:1 to AcOEt/NH3/MeOH, 98:1:1 
Aspect: brown pale foam 
1
H NMR (400.13 MHz, CDCl3): δ 8.69 (d, J = 4.4 Hz, 1H), 8.12 – 7.96 (m, 2H), 7.55 – 7.47 (m, 2H), 7.39 – 
7.28 (m, 3H), 7.24 – 7.14 (m, 2H), 7.14 – 7.07 (m, 1H), 7.05 – 6.97 (m, 1H), 5.63-5.56 (m, 2H), 5.02 – 4.86 (m, 
2H), 3.90 – 3.69 (m, 1H), 3.31 – 3.13 (m, 2H), 2.83 – 2.65 (m, 2H), 2.30 – 2.12 (m, 1H), 1.69 – 1.61 (m, 1H), 
1.61 – 1.51 (m, 1H), 1.48 – 1.34 (m, 2H), 1.18 – 1.07 (m, 1H). 
13
C NMR (100.62 MHz, CDCl3): δ 157.2, 155.5, 146.2, 143.8, 142.4, 140.9, 134.0, 131.7, 129.4, 129.3, 128.4, 
127.5, 126.8, 126.3, 124.0, 123.4, 122.5, 121.6, 119.6, 115.3, 109.6, 105.2, 60.4, 56.0, 41.2, 39.5, 27.5, 27.5, 
24.6. 
IR: 2936 (w), 1732 (w), 1629 (w), 1619 (w), 1600 (w), 1510 (m), 1467 (m), 1244 (s), 1215 (s), 1176 (m), 1044 
(m), 990 (m), 836 (s), 748 (s). 
HRMS: (ESI) calcd for C29H29N2O2
+
 [M+H]
+
 437.2224; found 437.2203. 
[𝜶]𝐃
𝟐𝟓 = - 2 (c 1.0, CHCl3) 
 
Procedure D:  
Yield: 88%, Eluent: AcOEt/NH3, 99:1 to AcOEt/NH3/MeOH, 97:1:2 
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Aspect: brown pale foam 
1
H NMR (400.13 MHz, CDCl3): δ 8.55 (d, J = 4.5 Hz, 1H), 8.18 (d, J = 3.1 Hz, 1H), 7.83 (d, J = 9.0 Hz, 1H), 
7.59 (d, J = 8.2 Hz, 1H), 7.53 (d, J = 9.0 Hz, 1H), 7.36 (d, J = 4.5 Hz, 1H), 7.25 – 7.22 (m, 1H), 7.19 – 7.14 (m, 
1H), 7.11 – 7.02 (m, 2H), 6.98 – 6.89 (m, 1H), 6.71 – 6.63 (m, 1H), 6.39 – 6.34 (m, 1H), 6.34 – 6.23 (m, 1H), 
5.37 – 5.01 (m, 2H), 3.64 – 3.46 (m, 1H), 3.35 – 3.15 (m, 1H), 3.11 – 2.92 (m, 2H), 2.88 – 2.73 (m, 1H), 2.64 – 
2.48 (m, 1H), 2.38 – 2.24 (m, 1H), 1.93 – 1.84 (m, 1H), 1.66 – 1.53 (m, 1H), 1.52 – 1.41 (m, 1H), 1.32 – 1.16 
(m, 1H). 
13
C NMR (100.62 MHz, CDCl3): δ 157.1, 154.4, 146.9, 144.0, 142.4, 140.1, 134.1, 131.9, 129.7, 129.1, 127.4, 
127.0, 126.9, 126.4, 124.0, 123.6, 118.2, 118.2, 115.6, 109.1, 106.8, 77.6, 58.9, 50.0, 49.4, 39.7, 28.2, 26.0, 20.0. 
IR: 3061 (w), 2939 (w), 1630 (m), 1600 (m), 1510 (m), 1467 (m), 1254 (s), 1216 (s), 1178 (s), 998 (w), 910 (m), 
836 (s), 732 (s). 
HRMS: (ESI) calcd for C29H29N2O2
+
 [M+H]
+
 437.2224; found 437.2219. 
[𝜶]𝐃
𝟐𝟔 = - 174 (c 1.0, CHCl3) 
-disubstituted -nitroacetates 
 
Procedure E:  
Yield: 17.4 mg, 96% Eluent: AcOEt/PE, 20:80 to 80:20 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 8.02 – 7.95 (m, 2H), 7.78 – 7.73 (m, 1H), 7.71 – 7.65 (m, 2H), 3.82 (s, 3H), 
3.56 – 3.45 (m, 2H), 2.81 – 2.73 (m, 2H), 2.37 – 2.17 (m, 2H), 0.95 (t, J = 7.5 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 166.1, 141.0, 134.9, 130.7, 127.1, 95.0, 54.1, 54.1, 28.9, 26.7, 8.2. 
IR: 3056 (w), 2941 (w), 1784 (m), 1751 (m), 1552 (s), 1443 (m), 1253 (w), 1183 (w), 884 (m), 842 (m), 744 (s), 
688 (m). 
HRMS: (ESI) calcd for C13H17NNaO6Se
+
 [M+Na]
+
 386.0113; found 386.0120. 
e.r.: 95.8:4.2, [𝜶]𝐃
𝟐𝟔= - 37 (c 0.12, CHCl3) 
 
Procedure E:  
Yield: 35 mg, 93% Eluent: AcOEt/PE, 20:80 to 80:20 
Aspect: yellow oil 
189 
 
1
H NMR (400.13 MHz, CDCl3): δ  8.06 – 7.92 (m, 2H), 7.79 – 7.73 (m, 1H), 7.72 – 7.65 (m, 2H), 4.28 (q, J = 
7.2 Hz, 2H), 3.61 – 3.44 (m, 2H), 2.86 – 2.65 (m, 2H), 2.40 – 2.12 (m, 2H), 1.28 (t, J = 7.2 Hz, 3H), 0.95 (t, J = 
7.5 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 165.5, 141.0, 134.9, 130.7, 127.1, 95.0, 63.6, 54.2, 28.9, 26.7, 14.0, 8.2. 
IR: 2997 (w), 2362 (w), 1746 (s), 1552 (s), 1446 (w), 1250 (m), 941 (s), 887 (m), 747 (m), 685 (w). 
HRMS: (ESI) calcd for C14H19NNaO6Se
+
 [M+Na]
+
 400.0270; found 400.0259. 
[𝜶]𝐃
𝟐𝟔= - 11 (c 1.30, CHCl3) 
e.r.: 94.7:5.3 
 
Procedure E:  
Yield: 30.9 mg, 76% Eluent: AcOEt/PE, 20:80 to 80:20 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 8.07 – 7.96 (m, 2H), 7.80 – 7.73 (m, 1H), 7.72 – 7.66 (m, 2H), 3.54-3.47 (m, 
2H), 2.85 – 2.61 (m, 2H), 2.32 – 2.13 (m, 2H), 1.46 (s, 9H), 0.94 (t, J = 7.5 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 164.3, 141.0, 134.9, 130.7, 127.2, 95.4, 85.6, 54.3, 28.7, 27.8, 26.6, 8.2. 
IR: 2927 (w), 2362 (s), 2336 (s), 1740 (w), 1442 (w), 1065 (w), 855 (w), 744 (m), 672 (m), 640 (m).  
HRMS: (ESI) calcd for C16H23NNaO6Se
+
 [M+Na]
+
 428.0583; found 428.0581. 
 
Procedure E: Yield: quant., Eluent: AcOEt/PE, 20:80 to 80:20  
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.89 (d, J = 9.0 Hz, 2H), 7.12 (d, J = 9.0 Hz, 2H), 3.91 (s, 3H), 3.82 (s, 3H), 
3.50 – 3.42 (m, 2H), 2.86 – 2.60 (m, 2H), 2.44 – 2.06 (m, 2H), 0.94 (t, J = 7.5 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 166.0, 164.5, 131.6, 129.0, 115.7, 94.9, 55.9, 54.1, 53.9, 28.7, 26.6, 8.1. 
IR: 2954 (w), 1751 (m), 1588 (m), 1554 (s), 1494 (m), 1262 (s), 1023 (w), 938 (w), 886 (m), 834 (w).  
HRMS: (ESI) calcd for C9H13O3
+
 [M+H]
+
 169.0859; found 169.0858. 
[𝜶]𝐃
𝟐𝟔= - 42 (c 0.36, CHCl3) 
e.r.: 95.4:4.6 
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Procedure E: Yield: 67%, Eluent: AcOEt/PE, 20:80 to 80:20  
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): 8.15 (d, J = 8.2 Hz, 2H), 7.96 (d, J = 8.3 Hz, 2H), 3.84 (s, 3H), 3.63 – 3.56 (m, 
2H), 2.80 – 2.76 (m, 2H), 2.32 – 2.17 (m, 2H), 0.97 (t, J = 7.5 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): 165.9, 144.3, 136.5 (q, J = 33.5 Hz), 127.9, 127.6 (q, J = 3.7 Hz), 122.8 (q, J 
= 273.5 Hz), 94.8, 54.6, 54.0, 28.9, 26.5, 8.1. 
IR: 2927 (w), 2325 (m), 2103 (w), 1906 (w), 1558 (w), 1325 (m), 1137 (m), 1048 (s), 889 (w), 667 (m).  
HRMS: (ESI) calcd for C14H16F3NO6Se [M+] 431.0095; found. 
[𝜶]𝐃
𝟐𝟔= - 50 (c 0.31, CHCl3) 
e.r.: 90.8:9.2 
 
Procedure E: Yield: 90%, Eluent: AcOEt/PE, 20:80 to 80:20  
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl): δ 7.57 – 7.55 (m, 2H), 7.35 – 7.34 (m, 1H), 3.83 (s, 3H), 3.56 – 3.39 (m, 2H), 
2.87 – 2.69 (m, 2H), 2.43 (s, 6H), 2.37 – 2.16 (m, 2H), 0.95 (t, J = 7.5 Hz, 3H).  
13
C NMR (100.62 MHz, CDCl3): δ 166.1, 141.1, 140.6, 136.6, 124.3, 95.1, 54.0, 53.9, 28.9, 26.7, 21.5, 8.2. 
IR: 2960 (w), 2922 (w), 1752 (m), 1555 (s), 1440 (w), 1255 (w), 945 (w), 890 (m). 
HRMS: (ESI) calcd for C15H21NO6Se [M+] 391.0534; found. 
[𝜶]𝐃
𝟐𝟔= - 36 (c 0.41, CHCl3) 
e.r.: 93.9:6.1 
e.r.: 54.3:45.7 
 
Procedure E:  
Yield: 16.5 mg, 95%, Eluent: AcOEt/PE, 20:80 to 80:20 
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Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 8.03 – 7.95 (m, 2H), 7.80 – 7.72 (m, 1H), 7.72 – 7.63 (m, 2H), 3.82 (s, 3H), 
3.62 – 3.52 (m, 2H), 2.87 – 2.68 (m, 2H), 1.85 (s, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 166.5, 141.0, 134.9, 130.7, 127.1, 91.0, 54.2, 54.1, 29.5, 22.4. 
IR: 2957 (w), 1750 (s), 1554 (s), 1447 (m), 1271 (m), 1065 (w), 938 (m), 886 (m), 747 (w), 686 (w).  
HRMS: (ESI) calcd for C12H15NNaO6Se
+
 [M+Na]
+
 371.9957; found 371.9955. 
e.r.: 97.9:2.1, [𝜶]𝐃
𝟐𝟔= - 38 (c 0.1, CHCl3) 
 
e.r.: 95.4:4.6, [𝜶]𝐃
𝟐𝟔= + 7 (c 1.66, CHCl3) 
 
Procedure E:  
Yield: 19.5 mg, quantitative yield Eluent: AcOEt/PE, 20:80 to 80:20 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 8.02 – 7.93 (m, 2H), 7.78 – 7.72 (m, 1H), 7.71 – 7.64 (m, 2H), 3.81 (s, 3H), 
3.57 – 3.43 (m, 2H), 2.84 – 2.70 (m, 2H), 2.29 – 2.11 (m, 2H), 1.37 – 1.32 (m, 2H), 1.16 – 1.26 (m, 2H), 0.90 (t, 
J = 7.3 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 166.2, 141.0, 134.9, 130.7, 127.1, 94.6, 54.2, 54.0, 35.2, 27.1, 25.7, 22.5, 
13.7. 
IR: 2960 (w), 2934 (w), 1751 (m), 1553 (s), 1446 (w), 1255 (w), 1221 (w), 1066 (w), 941 (m), 887 (m), 746 (w), 
686 (w). 
HRMS: (ESI) calcd for C15H21NNaO6Se
+
 [M+Na]
+
 414.0426; found 414.0441. 
[𝜶]𝐃
𝟐𝟓= - 14.46 (c 0.74, CHCl3) 
e.r.: 96.5:3.5 
 
Procedure E:  
Yield: 19.5 mg, quantitative yield, Eluent: AcOEt/PE, 20:80 to 80:20 
Aspect: yellow oil 
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1
H NMR (400.13 MHz, CDCl3): δ 8.02 – 7.94 (m, 2H), 7.80 – 7.71 (m, 1H), 7.73 – 7.64 (m, 2H), 3.81 (s, 3H), 
3.57 – 3.38 (m, 2H), 2.88 – 2.72 (m, 2H), 2.29 – 2.09 (m, 2H), 1.72– 1.64 (m, 2H), 0.90 (m, 6H). 
13
C NMR (100.62 MHz, CDCl3): δ 166.4, 141.0, 134.9, 130.7, 127.2, 94.4, 54.3, 54.0, 43.4, 27.4, 24.2, 23.4, 
23.3.  
IR: 2963 (w), 1751 (m), 1554 (s), 1446 (w), 1244 (w), 941 (m), 887 (m), 747 (w), 685 (w). 
HRMS: (ESI) calcd for C15H21NNaO6Se
+
 [M+Na]
+
 414.0426; found 414.0433. 
e.r.: 92.1:7.9, [𝜶]𝐃
𝟐𝟔= - 32 (c 0.47, CHCl3) 
 
Procedure E: Yield: quantitative, Eluent: AcOEt/PE 20:80 to 80:20 
1
H NMR (400.13 MHz, CDCl3): δ 8.02 – 7.95 (m, 2H), 7.80 – 7.71 (m, 1H), 7.72 – 7.63 (m, 2H), 3.82 (s, 3H), 
3.65 – 3.51 (m, 2H), 2.82 – 2.71 (m, 2H), 2.70 – 2.63 (m, 1H), 1.06 (d, J = 6.8 Hz, 3H), 1.03 (d, J = 6.8 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 165.7, 141.1, 134.8, 130.6, 127.1, 98.3, 54.8, 53.8, 35.1, 26.2, 18.0, 17.7. 
IR: 2977 (w), 2956 (w), 1749 (m), 1551 (s), 1446 (w), 1258 (m), 940 (m), 887 (m), 747 (w), 686 (w).  
HRMS: (ESI) calcd for C14H19NNaO6Se
+
 [M+Na]
+
 400.0270; found 400.0276. 
[𝜶]𝑫
𝟐𝟓= + 2 (c 1.1, CHCl3) 
e.r.: 45.4:54.6 
 
Procedure E:  
Yield: 20.0 mg, 84%, Eluent: AcOEt/PE, 20:80 to 80:20 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 8.04 – 7.95 (m, 2H), 7.79 – 7.72 (m, 1H), 7.69 (m, 2H), 3.82 (s, 3H), 3.57 – 
3.49 (m, 2H), 2.83 – 2.71 (m, 2H), 2.60 – 2.53 (m, 2H), 2.53 – 2.46 (m, 2H), 2.15 (s, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 205.3, 165.8, 141.0, 134.9, 130.7, 127.2, 93.7, 54.3, 53.9, 37.6, 30.1, 28.6, 
27.6. 
IR: 3063 (w), 2956 (w), 1750 (s), 1717 (m), 1555 (s), 1446 (m), 1358 (w), 1260 (w), 941 (m), 887 (m), 747 (w), 
687 (w). 
HRMS: (ESI) calcd for C15H19NNaO7Se
+
 [M+Na]
+
 428.0219; found 428.0221. 
e.r.: 95.8:4.2, [𝜶]𝐃
𝟐𝟔= - 22 (c 0.55, CHCl3) 
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Procedure E:  
Yield: 21.0 mg, quantitative yield, Eluent: AcOEt/PE, 20:80 to 80:20 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 8.01 – 7.95 (m, 2H), 7.78 – 7.73 (m, 1H), 7.73 – 7.65 (m, 2H), 3.83 (s, 3H), 
3.69 (s, 3H), 3.58 – 3.49 (m, 2H), 2.80 – 2.72 (m, 2H), 2.61 – 2.53 (m, 2H), 2.41 (m, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 171.8, 165.6, 141.0, 134.9, 130.7, 127.2, 93.6, 54.3, 53.9, 52.4, 30.1, 28.5, 
27.5. 
IR: 2956 (w), 1738 (s), 1555 (s), 1445 (m), 1350 (w), 1266 (m), 1205 (m), 939 (s), 886 (s), 747 (m), 687 (w).  
HRMS: (ESI) calcd for C15H19NNaO8Se
+
 [M+Na]
+
 444.0168; found 444.0169. 
[𝜶]𝐃
𝟐𝟔= + 2 (c 2.1, CHCl3) 
e.r.: 92.7:7.3 
 
Procedure E: Yield: 95%, Eluent: AcOEt/PE, 20:80 to 80:20  
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 8.04 – 7.93 (m, 2H), 7.80 – 7.73 (m, 1H), 7.73 – 7.65 (m, 2H), 3.85 (s, 3H), 
3.71 (s, 3H), 3.65 – 3.59 (m, 2H), 3.36 (d, J = 17.1 Hz, 1H), 3.30 (d, J = 17.1 Hz, 1H), 3.00 – 2.91 (m, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 168.0, 165.0, 140.9, 134.9, 130.7, 127.2, 91.2, 54.6, 54.2, 52.9, 39.6, 27.8. 
IR: 2957 (w), 1742 (s), 1561 (s), 1440 (m), 1370 (w), 1213 (m), 941 (m), 887 (m), 748 (w), 686 (w). 
HRMS: (ESI) calcd for C14H17NNaO8Se
+
 [M+Na]
+
 430.0012; found 430.0009. 
[𝜶]𝐃
𝟐𝟔= + 20 (c 0.8, CHCl3) 
e.r.: 86.8:13.2 
 
Procedure E:  
Yield: 16.6 mg, 86%, Eluent: AcOEt/PE, 20:80 to 80:20 
Aspect: yellow oil 
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1
H NMR (400.13 MHz, CDCl3): δ 8.00 – 7.88 (m, 2H), 7.73 – 7.67 (m, 1H), 7.65-7.61 (m, 2H), 3.83 (s, 3H), 
3.60 – 3.36 (m, 2H), 2.90 – 2.69 (m, 2H), 2.62 – 2.39 (m, 4H). 
13
C NMR (100.62 MHz, CDCl3): δ 164.8, 140.9, 134.9, 130.7, 127.2, 117.4, 91.2, 54.6, 54.2, 52.9, 39.6, 27.8. 
IR: 2957 (w), 2927 (w), 2359 (w), 2252 (w), 1749 (s), 1556 (s), 1446 (m), 1260 (m), 1220 (m), 938 (s), 885 (s), 
746 (m), 685 (m). 
HRMS: (ESI) calcd for C14H16N2NaO6Se
+
 [M+Na]
+
 411.0066; found 411.0063. 
[𝜶]𝐃
𝟐𝟔= + 2 (c 1.3, CHCl3) 
e.r.: 91.3:8.7 
 
Procedure E:  
Yield: 22.6 mg, 90% yield Eluent: AcOEt/PE, 20:80 to 80:20 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 8.02 – 7.96 (m, 2H), 7.96 – 7.90 (m, 2H), 7.80 – 7.73 (m, 1H), 7.72 – 7.67 
(m, 3H), 7.65 – 7.58 (m, 2H), 3.83 (s, 3H), 3.61 – 3.42 (m, 2H), 3.27 – 3.14 (m, 2H), 2.86 – 2.75 (m, 2H), 2.71 – 
2.60 (m, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 165.0, 140.9, 138.2, 135.0, 134.6, 130.8, 129.8, 128.2, 127.2, 92.7, 54.6, 
53.4, 50.8, 28.3, 27.6. 
IR: 3063 (w), 1751 (s), 1558 (s), 1447 (m), 1309 (m), 1149 (s), 1088 (w), 940 (m), 887 (m), 745 (m), 687 (m).  
HRMS: (ESI) calcd for C19H21NNaO8SSe
+
 [M+Na]
+
 526.0045; found 526.0046. 
e.r.: 87.0:13.0, [𝜶]𝐃
𝟐𝟔= + 2 (c 1.43, CHCl3) 
 
Procedure E:  
Yield: 18.1 mg, 97%, Eluent: AcOEt/PE, 20:80 to 80:20 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ  8.02 – 7.94 (m, 2H), 7.79 – 7.73 (m, 1H), 7.72 – 7.65 (m, 2H), 5.58 (ddt, J = 
16.6, 10.4, 7.3 Hz, 1H), 5.28 – 5.20 (m, 2H), 3.83 (s, 3H), 3.60 – 3.48 (m, 2H), 3.07 – 2.89 (m, 2H), 2.78 – 2.68 
(m, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 165.7, 141.0, 134.9, 130.7, 128.3, 127.2, 123.0, 93.8, 54.2, 54.0, 40.0, 27.1. 
IR: 2960 (w), 2927 (w), 1752 (m), 1555 (s), 1446 (m), 1258 (w), 940 (s), 887 (m), 747 (w), 686 (w).  
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HRMS: (ESI) calcd for C14H17NNaO6Se
+
 [M+Na]
+
 398.0113; found 398.0109. 
[𝜶]𝐃
𝟐𝟓= - 25 (c 0.31, CHCl3) 
e.r.: 95.1:4.9 
 
Procedure E: Yield: 95%, Eluent: AcOEt/PE, 20:80 to 80:20  
Gram scale procedure: To a solution of phenyl vinyl selenone (2a) (1.23 g, 5.7 mmol, 1 equiv) and QN-7 (250 
mg, 0.057 mmol, 0.1 equiv) in toluene (5 mL) at - 30 °C was added a solution of -substituted nitroacetate 4m 
(1.31 g, 6.3 mmol, 1.1 equiv) in toluene (1 mL). The reaction mixture was stirred at - 30 °C until complete 
consumption of the starting material (TLC monitoring, around 72 hours). The reaction mixture was warmed to 
room temperature and concentrated under reduced pressure. The crude product was purified by flash 
chromatography on silica gel to afford the pure product. The catalyst was recovered in 96% yield (240 mg) by 
using AcOEt/MeOH/NH3 100:2:1 as eluent. 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl): δ 7.98 – 7.87 (m, 2H), 7.78 – 7.68 (m, 1H), 7.69 – 7.60 (m, 2H), 7.33 – 7.25 (m, 
3H), 7.07 – 6.99 (m, 2H), 3.84 (s, 3H), 3.62 (d, J = 14.3 Hz, 1H), 3.50 (d, J = 14.3 Hz, 1H) 3.50 – 3.46 (m, 2H) 
2.71 – 2.57 (m, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 165.8, 140.8, 134.8, 131.6, 130.6, 130.0, 129.3, 128.6, 127.2, 94.9, 54.2, 
54.2, 41.6, 26.9. 
77
Se NMR (76.31 MHz, Se(Me)2): 995.9 
IR: 2940 (w), 1749 (m), 1552 (s), 1438 (m), 938 (m), 885 (m), 744 (s), 683 (m). 
HRMS: (ESI) calcd for C18H19NNaO6Se
+
 [M+Na]
+
 448.0270; found 448.0269. 
[𝜶]𝐃
𝟐𝟔= - 10 (c 0.59, CHCl3) 
e.r.: 91.1:8.9 
 
Procedure E: Yield: 88%, Eluent: AcOEt/PE, 20:80 to 80:20 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl): δ 7.97 – 7.88 (m, 2H), 7.77 – 7.69 (m, 1H), 7.68 – 7.60 (m, 2H), 6.95 (d, J = 8.6 
Hz, 2H), 6.79 (d, J = 8.6 Hz, 2H), 3.83 (s, 3H), 3.79 (s, 3H), 3.57 (d, J = 14.5 Hz, 1H) 3.52 – 3.46 (m, 2H) 3.45 
(d, J = 14.5 Hz, 1H), 2.68 – 2.59 (m, 2H). 
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13
C NMR (100.62 MHz, CDCl3): δ 165.9, 159.7, 140.9, 134.8, 131.1, 130.6, 127.2, 123.4, 114.6, 95.0, 55.4, 
54.3, 54.1, 40.9, 26.8. 
IR: 2958 (w), 1752 (m), 1554 (s), 1514 (s), 1252 (s), 941 (s), 886 (s), 743 (m), 686 (m). 
HRMS: (ESI) calcd for C19H21NNaO7Se
+
 [M+Na]
+
 478.0375; found 478.0373.  
[𝜶]𝐃
𝟐𝟔= - 44.0 (c 0.49, CHCl3) 
e.r.: 90.5:9.5 
 
Procedure E: Yield: 85%, Eluent: AcOEt/PE, 20:80 to 80:20 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl): δ 7.94 – 7.84 (m, J = 8.3 Hz, 2H), 7.75 – 7.68 (m, 1H), 7.66 – 7.57 (d, J = 8.3 
Hz, 2H), 7.42 – 7.32 (m, 2H), 6.95 – 6.85 (m, 2H), 3.81 (s, 3H), 3.57 (d, J = 14.4 Hz, 1H), (3.55 – 3.50 (m, 2H), 
3.46 (d, J = 14.4 Hz, 1H), 2.68 – 2.49 (m, 2H). 
13
C NMR (100.62 MHz, CDCl3): = 165.5, 140.6, 134.8, 132.3, 131.6, 130.7, 130.6, 130.5, 130.5, 127.2, 127.1, 
127.0, 122.8, 94.5, 54.2, 53.9, 40.8, 26.7. 
IR: 2956 (w), 1751 (m), 1555 (s), 1446 (w), 1257 (w), 941 (m), 886 (s), 729 (s). 
HRMS: (ESI) calcd for C18H18BrNNaO6Se
+
 [M+Na]
+
 525.9375; found 525.9383. 
[𝜶]𝐃
𝟐𝟔=  - 31 (c 0.11, CHCl3) 
e.r.: 90.7:9.3 
 
Procedure E: Yield: 83%, Eluent: AcOEt/PE, 20:80 to 80:20  
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 8.03 – 7.91 (m, 2H), 7.79 – 7.72 (m, 1H), 7.72 – 7.63 (m, 2H), 7.51 – 7.40 
(m, 3H), 7.31 – 7.26 (m, 2H), 3.88 (s, 3H), 3.60 (m, 1H), 3.41 (m, 1H), 3.34 – 3.14 (m, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 166.0, 141.0, 134.9, 131.6, 130.7, 130.6, 129.4, 127.5, 127.2, 97.2, 54.7, 
54.4, 29.3. 
IR: 3061 (w), 2956 (w), 1748 (s), 1557 (s), 1446 (m), 1353 (w), 1253 (m), 939 (s), 885 (s), 741 (s), 686 (m).  
HRMS: (ESI) calcd for C17H17NNaO6Se
+
 [M+Na]
+
 434.0113; found 434.0121. 
e.r.: 60.6:39.4 
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Further chemical transformation of compounds I-228 
 
Procedure: To a solution of the selenone 5o (362.3 mg, 0.72 mmol, 1 equiv) in DMF (10 mL) was added  NaN3 
(61.1 mg, 0.94 mmol, 1.3 equiv). The reaction mixture was stirred at 60 °C until complete consumption of the 
starting material (TLC monitoring, around 2 hours). The reaction mixture was diluted with water and extracted 
with EtOAc (3 times). The combined organic layers were washed with brine, dried over Na2SO4, filtered and 
concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel to 
afford the pure product. 
Yield: 212 mg, 83%, Eluent: AcOEt/PE, 10:90 to 20:80  
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.51 – 7.38 (m, 2H), 7.01 – 6.90 (m, 2H), 3.85 (s, 3H), 3.63 (d, J = 14.4 Hz, 
1H), 3.50 – 3.42 (m, 3H), 2.39 – 2.18 (m, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 166.5, 132.3, 131.7, 131.5, 122.6, 94.4, 53.9, 46.7, 40.4, 32.8. 
IR: 2956 (w), 2100 (s), 1752 (m), 1553 (s), 1489 (w), 1260 (m), 1212 (m), 1075 (w), 1013 (w) 801 (w). 
HRMS: (ESI) calcd for C12H13N2O4Br+ [M-N2]+ 329.0131; found 329.0136. 
[𝜶]𝐃
𝟐𝟔= - 12 (c 0.17, CHCl3) 
 
Procedure: To a solution of azide 8o (121.4 mg, 0.34 mmol) in THF (4 mL) was added triphenylphosphine 
(98.1 mg, 0.37 mmol, 1.1 equiv). The reaction mixture was stirred at room temperature for 2 hours. p-
Nitrobenzaldehyde (77.0 mg, 0.51 mmol, 1.5 equiv) was added and stirring was continued at room temperature 
for another 2 hours. The reaction mixture was diluted with MeOH (1 mL) and NaBH3CN (42.7 mg, 0.68 mmol, 
2 equiv) was added. After being stirred at 70 °C for 16 hours, the reaction mixture was diluted with water and 
extracted with EtOAc (3 times). The combined organic layers were washed with brine, dried over Na2SO4, 
filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on 
silica gel to afford the pure product. 
Yield: 50 mg, 34% yield, Eluent: AcOEt/PE, 50:50 to 70:30  
Aspect: pale yellow solid 
1
H NMR (400.13 MHz, CDCl3): δ 8.21 – 8.14 (m, 2H), 7.47 – 7.40 (m, 2H), 7.24 – 7.19 (m, 2H), 7.17 – 7.11 
(m, 2H), 4.59 (d, J = 15.4 Hz, 1H), 4.50 (d, J = 15.4 Hz, 1H), 3.70 (d, J = 13.6 Hz, 1H), 3.47 (d, J = 13.6 Hz, 
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1H), 3.45 – 3.37 (m, 1H), 2.86 (ddd, J = 9.5, 8.8, 3.1 Hz, 1H), 2.69 (ddd, J = 14.7, 8.0, 3.1 Hz, 1H), 2.37 (ddd, J 
= 14.6, 8.9, 6.7 Hz, 1H). 
13
C NMR (100.62 MHz, CDCl3): δ 166.6, 147.9, 142.1, 132.3, 132.2, 132.2, 128.7, 124.3, 122.3, 93.7, 47.0, 
44.0, 38.4, 28.3. 
IR: 2922 (m), 2853 (w), 1708 (m), 1547 (s), 1520 (w), 1345 (s), 1262 (w), 1013 (m), 801 (m). 
HRMS: (ESI) calcd for C18H16N3O5BrNa+ [M+Na]+ 456.0166; found 456.0162. 
Melting point: 110-112 °C 
[𝜶]𝐃
𝟐𝟔= - 20 (c 0.42, CHCl3) 
 
Procedure: To a solution of selenone 5m (190 mg, 0.67 mmol, 1 equiv) in DMF (7 mL) was added NaN3 (57 
mg, 0.87 mmol, 1.3 equiv). The reaction mixture was stirred at 60 °C until complete consumption of the starting 
material (TLC monitoring, around 2 hours). The reaction mixture was diluted with water and extracted with 
EtOAc (3 times). The combined organic layers were washed with brine, dried over Na2SO4, filtered and 
concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel to 
afford the pure product. 
Yield: 152 mg, 83%, Eluent: AcOEt/PE, 5:95 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.26 – 7.22 (m, 3H), 7.01 (d, J = 3.5 Hz, 2H), 3.77 (s, 3H), 3.59 (s, 1H), 3.44 
(d, J = 14.4 Hz, 1H), 3.38 (t, J = 7.1 Hz, 1H), 2.40 – 2.11 (m, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 166.6, 132.3, 129.9, 129.0, 128.2, 94.5, 53.7, 46.6, 40.8, 32.6. 
IR: 2923 (w), 2099 (m), 1753 (m), 1553 (s), 1438 (w), 1212 (m), 1095 (w), 737 (w), 703 (m). 
HRMS: (ESI) C12H14N4NaO4 [M+Na] 301.0913; found 301.0915. 
[𝛂]𝐃
𝟐𝟔= - 32 (c 0.28, CHCl3) 
 
Procedure: To a solution of azide 8 (135 mg, 0.5 mmol, 1 equiv) in THF/H2O (9:1, 4.5 mL of THF + 0.5 mL of 
H2O) was added PPh3 (170 mg, 0.65 mmol, 1.3 equiv). The reaction mixture was stirred at room temperature for 
2 hours and heated at 70 °C for 24 hours. The reaction mixture was diluted with water and extracted with EtOAc 
(3 times). The combined organic layers were washed with brine, dried over Na2SO4, filtered and concentrated 
under reduced pressure. The crude product was purified by flash chromatography on silica gel to afford the pure 
product. 
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Yield: 59 mg, 54%, Eluent: AcOEt/PE, 30:70 to 50:50 
Aspect: amorphous white solid 
1
H NMR (400.13 MHz, CDCl3): δ 7.35 – 7.28 (m, 3H), 7.26 – 7.22 (m, 2H), 6.33 – 5.80 (m, 1H), 3.58 (s, 2H), 
3.52 – 3.43 (m, 1H), 2.94 (m 1H), 2.83 (ddd, J = 14.5, 7.8, 3.5 Hz, 1H), 2.46 (ddd, J = 14.7, 8.5, 6.4 Hz, 1H). 
13
C NMR (100.62 MHz, CDCl3): δ 169.4, 133.5, 130.4, 129.0, 128.0, 93.3, 39.2, 39.2, 30.5. 
IR: 3257 (w), 1717 (s), 1543 (s), 1456 (w), 1337 (w), 1283 (w), 1067 (w), 779 (w), 703 (m).  
HRMS: (ESI) calcd for C11H12N2NaO3
+
 [M+Na]
+
 243.0740; found 243.0746. 
[𝛂]𝐃
𝟐𝟔= - 42 (c 0.29, CHCl3) 
 
Procedure: To a solution of 9 (20 mg, 0.091 mmol, 1 equiv) in MeOH (1 mL) was added a suspension of Raney 
Nickel (0.5 mL) in H2O. The resulting mixture was stirred in an autoclave under 40 bar of H2 at room 
temperature for 16 hours. The reaction mixture was filtered through Celite and concentrated under reduced 
pressure. The crude product was purified by flash chromatography on silica gel to afford the pure product. 
Yield: 13 mg, 75% yield, Eluent: AcOEt/PE, 70:30 to 90:10 
Aspect: amorphous white solid 
1
H NMR (400.13 MHz, CDCl3): δ 7.39 – 7.19 (m, 5H), 5.71 (s, 1H), 3.21 – 3.10 (m, 1H), 2.97 (d, J = 13.2 Hz, 
1H), 2.80 (d, J = 13.2 Hz, 1H), 2.74 – 2.61 (m, 1H), 2.38 – 2.22 (m, 1H), 1.96 – 1.84 (m, 1H), 1.67 (br s, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 180.5, 136.3, 130.3, 128.5, 127.1, 59.4, 44.6, 38.2, 33.8. 
IR: 3224 (w), 2359 (w), 1495 (w), 1456 (w), 1292 (w), 780 (m), 703 (s). 
HRMS: (ESI) calcd for C11H15N2O
+
 [M+H]
+
 191.1179; found 191.1178. 
[𝛂]𝐃
𝟐𝟔= + 30 (c 0.68, CHCl3) 
 
Procedure: To a solution of 5m (255 mg, 0.6 mmol, 1 equiv) in acetone (6 mL) was added NaI (117 mg, 0.78 
mmol, 1.3 equiv). The reaction mixture was stirred at room temperature until complete consumption of the 
starting material (TLC monitoring, around 2 hours). The reaction mixture was diluted with water and extracted 
with EtOAc (3 times). The combined organic layers were washed with brine, dried over Na2SO4, filtered and 
concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel to 
afford the pure product. 
Yield: 193 mg, 88%, Eluent: AcOEt/PE, 5:95 
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Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.35 – 7.30 (m, 3H), 7.13 – 7.02 (m, 2H), 3.84 (s, 3H), 3.59 (d, J = 14.3 Hz, 
1H), 3.49 (d, J = 14.3 Hz, 1H), 3.18 – 3.03 (m, 2H), 2.65-2.63 (m, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 166.0, 132.2, 129.7, 129.0, 128.3, 96.7, 53.7, 40.5, 38.4, -5.8. 
IR: 2955 (w), 1750 (s), 1551 (s), 1436 (w), 1252 (m), 1192 (m), 741 (w), 702 (m). 
HRMS: C12H14INNaO4
+
 [M+Na]
+
 385.9860; found 385.9856. 
[𝛂]𝐃
𝟐𝟔= - 18 (c 0.50, CHCl3) 
 
Procedure: To a solution of iodide 11 (33 mg, 0.089 mmol, 1 equiv) in MeOH was (1 mL) added a suspension 
of Raney Nickel in H2O (0.5 mL). The resulting mixture was stirred under H2 atmosphere at room temperature 
for 16 hours. The reaction mixture was filtered through Celite and concentrated under reduced pressure. The 
crude product was used without further purification. 
Yield: 12 mg, 65%, Eluent: AcOEt/PE, 30:70 to 80:20 
 
Procedure: To a solution of selenone 5m (123 mg, 0.29 mmol, 1 equiv) in MeOH (3 mL) was added PtO2 (16 
mg, 0.06 mmol, 0.2 equiv). The resulting mixture was stirred under H2 atmosphere at room temperature for 16 
hours. The reaction mixture was filtered through Celite and concentrated under reduced pressure. The crude 
product was purified by flash chromatography on silica gel to afford the pure product. 
Yield: 102 mg, 91%, Eluent: AcOEt/PE, 5:95 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.44 – 7.41 (m, 2H), 7.23 – 7.21 (m, 3H), 7.17 – 7.14 (m, 3H), 6.85 – 6.83 
(m, 2H), 3.70 (s, 3H), 3.54 (d, , J = 14.3 Hz, 1H), 3.44 (d, J = 14.3 Hz, 1H), 2.75 – 2.70 (m, 2H), 2.38 – 2.34 (m, 
2H). 
13
C NMR (100.62 MHz, CDCl3): δ 166.6, 133.8, 132.6, 129.8, 129.4, 128.9, 128.8, 128.1, 127.8, 96.4, 53.6, 
40.1, 34.6, 20.9. 
77
Se NMR (76.31 MHz, Se(Me)2): δ 327.0 
IR: 2954 (w), 1753 (m), 1552 (s), 1437 (m), 1358 (w), 1256 (w), 1210 (w), 740 (m), 703 (m).  
HRMS: (ESI) calcd for C18H19NNaO4Se
+
 [M+Na]
+
 416.0371; found 416.0381. 
[𝛂]𝐃
𝟐𝟔= - 50 (c 0.27, CHCl3) 
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Procedure: To a solution of selenide 13m (84 mg, 0.21 mmol, 1 equiv) in MeOH/H2O (9:1, 1.8 mL of MeOH + 
0.2 mL of H2O) was added  NaHCO3 (27 mg, 0.32 mmol, 1.5 equiv) and NaIO4 (49 mg, 0.23 mmol, 1.1 equiv). 
The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with water 
and extracted with EtOAc (3 times). The combined organic layers were washed with brine, dried over Na2SO4, 
filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on 
silica gel to afford the pure product. 
Yield: 42 mg, 83%, Eluent: AcOEt/PE, 5:95 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.29 – 7.27 (m, 3H), 7.11 – 7.09 (m, 2H), 6.22 (dd, J = 17.7, 11.1 Hz, 1H), 
5.51 (d, J = 11.1 Hz, 1H), 5.35 (d, J = 17.7 Hz, 1H), 3.84 (s, 3H), 3.78 (d, J = 14.1 Hz, 1H), 3.58 (d, J = 14.1 Hz, 
1H). 
13
C NMR (100.62 MHz, CDCl3): δ 166.3, 132.5, 131.5, 130.4, 128.7, 128.1, 119.5, 96.9, 53.8, 43.1. 
IR:  2956 (w), 2359 (w), 1754 (m), 1556 (s), 1438 (w), 1355 (w), 1254 (w), 704 (w).  
HRMS: (ESI) calcd for C12H13NNaO4
+
 [M+Na]
+
 258.0737; found 258.0733. 
[𝛂]𝐃
𝟐𝟔= - 15 (c 0.49, CHCl3) 
 
Procedure: To a solution of 14m (31 mg, 0.13 mmol, 1 equiv) in AcOH/MeOH (1:1, 1 mL of AcOH + 1 mL of 
MeOH) was added zinc powder (170 mg, 2.6 mmol, 20 equiv). The reaction mixture was stirred at 50 °C for 16 
hours. The reaction mixture was cooled down to room temperature, diluted with water and extracted with DCM 
(3 times). The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure. The 
crude product was purified by flash chromatography on silica gel to afford the pure product. 
Yield: 22 mg, 85% yield, Eluent: AcOEt/PE, 70:30 to 90:10  
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.34 – 7.24 (m, 3H), 7.21 – 7.16 (m, 2H), 6.18 (dd, J = 17.3, 10.7 Hz, 1H), 
5.42 (d, J = 17.3 Hz, 1H), 5.26 (d, J = 10.7 Hz, 1H), 3.74 (s, 3H), 3.31 (d, J = 13.4 Hz, 1H), 2.95 (d, J = 13.4 Hz, 
1H), 2.59 (s, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 174.3, 139.1, 135.3, 130.3, 128.6, 127.4, 115.6, 64.0, 52.7, 45.4. 
IR: 2952 (w), 1736 (s), 1605 (w), 1496 (w), 1437 (w), 1201 (m), 929 (w), 744 (w), 705 (m).  
HRMS: (ESI) calcd for C12H16NO2
+
 [M+H]
+
 206.1176; found 206.1179. 
[𝛂]𝐃
𝟐𝟔= - 5 (c 0.2, CHCl3) 
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Procedure: To a solution of selenone 5i (86 mg, 0.22 mmol, 1 equiv) in MeOH (2.2 mL) was added PtO2 (10 
mg, 0.044 mmol, 0.2 equiv). The resulting mixture was stirred under H2 atmosphere at room temperature for 16 
hours. The reaction mixture was filtered through Celite and concentrated under reduced pressure. The crude 
product was purified by flash chromatography on silica gel to afford the pure product. 
Yield: 62 mg, 79% yield, Eluent: AcOEt/PE, 10:90 to 30:70 
Aspect: yellow oil 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.54 – 7.46 (m, 2H), 7.35 – 7.28 (m, 3H), 3.83 (s, 3H), 2.84 – 2.68 (m, 2H), 
2.64 – 2.46 (m, 4H), 2.44 – 2.26 (m, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 165.6, 133.5, 129.6, 128.5, 128.1, 117.6, 94.1, 54.1, 36.2, 30.4, 20.2, 12.8. 
IR: 2956 (w), 2358 (w), 1750 (s), 1554 (s), 1438 (m), 1308 (m), 1149 (s), 741 (m), 690 (m).  
HRMS: (ESI) calcd for C14H16N2NaO4Se
+
 [M+Na]
+
 379.0167; found 379.0165. 
 
Procedure: To a solution of selenide 13i (60 mg, 0.17 mmol, 1 equiv) in MeOH/H2O (9:1, 1.8 mL of MeOH + 
0.2 mL of H2O) was added  NaHCO3 (22 mg, 0.26 mmol, 1.5 equiv) and NaIO4 (41 mg, 0.19 mmol, 1.1 equiv). 
The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with water 
and extracted with EtOAc (3 times). The combined organic layers were washed with brine, dried over Na2SO4, 
filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on 
silica gel to afford the pure product. 
Yield: 22 mg, 64% yield, Eluent: AcOEt/PE, 10:90 to 30:70 
Aspect: yellow oil 
 
1
H NMR (400.13 MHz, CDCl3): δ 6.39 (dd, J = 17.6, 11.1 Hz, 1H), 5.65 (dd, J = 11.0, 0.6 Hz, 1H), 5.43 (dd, J 
= 17.7, 0.6 Hz, 1H), 3.87 (s, 3H), 2.83 – 2.64 (m, 2H), 2.58 – 2.37 (m, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 165.3, 130.1, 121.6, 117.8, 94.2, 54.3, 31.3, 12.8. 
IR: 2959 (w), 2358 (w), 1752 (s), 1651 (w), 1557 (s), 1438 (w), 1254 (m), 953 (w). 
HRMS: (ESI) calcd for C8H10N2NaO4
+
 [M+Na]
+
 221.0533; found 221.0528. 
[𝛂]𝐃
𝟐𝟔= + 3 (c 0.57, CHCl3) 
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Procedure: To a solution of selenone 5j (65 mg, 0.13 mmol, 1 equiv) in MeOH (1.3 mL) was added PtO2 (6 mg, 
0.026 mmol, 0.2 equiv). The resulting mixture was stirred under H2 atmosphere at room temperature for 16 
hours. The reaction mixture was filtered through Celite and concentrated under reduced pressure. The crude 
product was purified by flash chromatography on silica gel to afford the pure product. 
Yield: 50 mg, 82% yield, eluent: AcOEt/PE, 20:80 to 30:70 
Aspect: yellow oil 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.92 – 7.84 (m, 2H), 7.74 – 7.65 (m, 1H), 7.63 – 7.56 (m, 2H), 7.51 – 7.46 
(m, 2H), 7.32 – 7.28 (m, 3H), 3.76 (s, 3H), 3.08 – 2.98 (m, 2H), 2.74 – 2.65 (m, 2H), 2.59 – 2.53 (m, 2H), 2.53 – 
2.44 (m, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 165.8, 138.4, 134.4, 133.4, 129.7, 129.6, 128.5, 128.2, 128.0, 94.1, 54.1, 
51.0, 36.2, 27.6, 20.0. 
IR: 2957 (w), 2365 (w), 2343 (w), 1752 (m), 1554 (s), 1447 (m), 1308 (m), 1154 (m), 741 (m), 690 (m). 
HRMS: HRMS (ESI) calcd for C19H21NNaO6SSe
+
 [M+Na]
+
 494.0147; found 494.0150. 
 
Procedure: To a solution of selenide 13j (39 mg, 0.082 mmol, 1 equiv) in MeOH/H2O (9:1, 0.9 mL of MeOH + 
0.1 mL of H2O) was added  NaHCO3 (10 mg, 0.12 mmol, 1.5 equiv) and NaIO4 (19 mg, 0.090 mmol, 1.1 equiv). 
The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with water 
and extracted with EtOAc (3 times). The combined organic layers were washed with brine, dried over Na2SO4, 
filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on 
silica gel to afford the pure product. 
Yield: 18 mg, 70% yield Eluent: AcOEt/PE, 10:90 to 30:70 
Aspect: yellow oil 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.96 – 7.87 (m, 2H), 7.75 – 7.67 (m, 1H), 7.64 – 7.57 (m, 2H), 6.30 (dd, J = 
17.6, 11.1 Hz, 1H), 5.58 (dd, J = 11.1, 0.6 Hz, 1H), 5.37 (dd, J = 17.7, 0.6 Hz, 1H), 3.82 (s, 3H), 3.24 – 3.02 (m, 
2H), 2.80 – 2.70 (m, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 165.4, 138.4, 134.4, 130.1, 129.7, 128.2, 121.6, 94.2, 54.2, 51.2, 28.3. 
IR: 2924 (w), 2364 (w), 1750 (m), 1557 (s), 1447 (m), 1308 (m), 1240 (m), 1147 (s), 1087 (m), 741 (m), 688 (s). 
HRMS: (ESI) calcd for C13H15NNaO6S
+
 [M+Na]
+
 336.0512; found 336.0514. 
[𝛂]𝐃
𝟐𝟔= + 5 (c 1.48, CHCl3) 
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Procedure: To a solution of selenone 5k (85 mg, 0.20 mmol, 1 equiv) in MeOH (2 mL) was added PtO2 (9 mg, 
0.04 mmol, 0.2 equiv). The resulting mixture was stirred under H2 atmosphere at room temperature for 16 hours. 
The reaction mixture was filtered through Celite and concentrated under reduced pressure. The crude product 
was purified by flash chromatography on silica gel to afford the pure product. 
Yield: 61 mg, 78% yield, Eluent: AcOEt/PE, 10:90 to 30:70 
Aspect: yellow oil 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.54 – 7.45 (m, 2H), 7.32 – 7.27 (m, 3H), 3.78 (s, 3H), 3.67 (s, 3H), 2.81 – 
2.70 (m, 2H), 2.60 – 2.45 (m, 4H), 2.33 – 2.22 (m, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 171.7, 166.1, 132.9, 129.2, 128.4, 127.4, 94.7, 53.5, 51.9, 35.7, 29.1, 28.3, 
20.0. 
IR: 2955 (w), 1739 (s), 1551 (s), 1437 (m), 1255 (m), 1201 (m), 739 (m), 692 (m). 
HRMS: (ESI) calcd for C15H19NNaO6Se [M+Na] 412.0275; found 412.0279. 
 
Procedure: To a solution of selenide 13k (39 mg, 0.1 mmol, 1 equiv) in MeOH/H2O (9:1, 0.9 mL of MeOH + 
0.1 mL of H2O) was added  NaHCO3 (13 mg, 0.15 mmol, 1.5 equiv) and NaIO4 (24 mg, 0.11 mmol, 1.1 equiv). 
The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with water 
and extracted with EtOAc (3 times). The combined organic layers were washed with brine, dried over Na2SO4, 
filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on 
silica gel to afford the pure product. 
Yield: 14 mg, 61% yield, Eluent: AcOEt/PE, 10:90 to 30:70 
Aspect: yellow oil 
 
1
H NMR (400.13 MHz, CDCl3): δ 6.38 (dd, J = 17.6, 11.1 Hz, 1H), 5.56 (d, J = 11.1 Hz, 1H), 5.41 (d, J = 17.6 
Hz, 1H), 3.83 (s, 3H), 3.69 (s, 3H), 2.76 – 2.65 (m, 2H), 2.48 – 2.31 (m, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 172.2, 166.1, 130.8, 120.7, 95.1, 54.0, 52.2, 30.4, 28.7. 
IR: 2957 (w), 2361 (w), 1739 (s), 1438 (m), 1253 (s), 1202 (m), 983 (w).  
HRMS: (ESI) calcd for C9H13NNaO6
+
 [M+Na]
+
 254.0635; found 254.0635. 
[𝛂]𝐃
𝟐𝟔= + 6 (c 0.27, CHCl3) 
 
 
One pot conversion of 5 to 14: 
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Procedure: To a solution of selenone 5 (0.15 mmol, 1 equiv) in methanol was added added PtO2 (68 mg, 0.3 
mmol, 0.2 equiv). The reaction mixture was stirred under H2 atmosphere at room temperature for 16 hours. 
NaHCO3 (19 mg, 0.23 mmol, 1.5 equiv), NaIO4 (36mg, 0.17 mmol, 1.1 equiv) and water (0.1 mL) were then 
added. The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with 
water and extracted with EtOAc (3 times). The combined organic layers were washed with brine, dried over 
Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by flash 
chromatography on silica gel to afford the pure product. 
 
Procedure: To a solution of selenone 5m (35 mg, 0.082 mmol, 1equiv) in MeOH (1 mL) was added a 
suspension of Raney Nickel (0.5 mL) in H2O. The resulting mixture was stirred in an autoclave under 40 bar of 
H2 at room temperature for 16 hours. The reaction mixture was filtered through Celite and concentrated under 
reduced pressure. The crude product was purified by flash chromatography on silica gel to afford the pure 
product. 
Yield: 17mg, 68% yield, Eluent: AcOEt/PE 30:70 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): 7.32 – 7.21 (m, 3H), 7.17 – 7.10 (m, 2H), 3.71 (s, 3H), 3.18 (d, J = 13.2 Hz, 1H), 
2.76 (d, J = 13.2 Hz, 1H), 2.02 – 1.89 (m, 1H), 1.77 – 1.67 (br s., 2H), 1.68 – 1.58 (m, 1H), 0.89 (t, J = 7.5 Hz, 
3H). 
13
C NMR (100.62 MHz, CDCl3): 177.1, 136.6, 130.0, 128.5, 127.1, 62.8, 52.1, 46.0, 33.4, 8.6. 
IR: 2930 (w), 2359 (w), 1733 (s), 1456 (w), 1237 (m), 1197 (m), 867 (w), 742 (w), 703 (s).  
HRMS: (ESI) calcd for C12H18NO2
+
 [M+H]
+
 208.1332; found 208.1339. 
[𝜶]𝐃
𝟐𝟔= + 4 (c 0.42, CHCl3) 
Synthesis of-disubstituted -lactams 16k and 17k: 
 
Procedure: To a solution of 5k (95 mg, 0.23 mmol, 1equiv) in MeOH (2.3 mL) was added a suspension of 
Raney Nickel in H2O (0.5 mL). The resulting mixture was stirred in an autoclave under 40 bar of H2 at room 
temperature for 16 hours. The reaction mixture was filtered through Celite and concentrated under reduced 
pressure. The crude product was purified by flash chromatography on silica gel to afford the pure product. 
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Yield: 23 mg, 59% yield, Eluent: AcOEt/PE, 60:40 to 80:20 
Aspect: yellow oil 
 
1
H NMR (400.13 MHz, CDCl3): δ 5.97 (s, 1H), 3.76 (s, 3H), 2.49 (ddd, J = 12.7, 9.1, 6.5 Hz, 1H), 2.41 – 2.35 
(m, 2H), 2.15 – 2.02 (m, 1H), 1.94 – 1.84 (m, 1H), 1.81 – 1.72 (m, 1H), 0.90 (t, J = 7.5 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 176.9, 174.1, 66.2, 52.8, 32.4, 30.2, 29.8, 8.5. 
IR: 2954 (w), 1737 (m), 1701 (s), 1436 (w), 1253 (w), 1163 (w). 
HRMS: (ESI) calcd for C8H14NO3
+
 [M+H]
+
 172.0968; found 172.0969. 
[𝛂]𝐃
𝟐𝟔= - 15 (c 0.02, CHCl3) 
 
Procedure: To a solution of 13k (106 mg, 0.27 mmol, 1 equiv) in AcOH/MeOH (1:1, 1.5 mL of AcOH + 1.5 
mL of MeOH) was added zinc powder (353 mg, 5.4 mmol, 20 equiv). The reaction mixture was stirred at 50 °C 
for 16 hours. The reaction mixture was cooled down to room temperature, diluted with water and extracted with 
DCM (3 times). The combined organic layers were dried over Na2SO4 and concentrated under reduced pressure. 
The crude product was purified by flash chromatography on silica gel to afford the pure product. 
Yield: 84 mg, 95% 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.52 – 7.43 (m, 2H), 7.31 – 7.24 (m, 3H), 6.77 (s, 1H), 3.74 (s, 3H), 2.83 – 
2.74 (m, 2H), 2.49 – 2.39 (m, 1H), 2.39 – 2.32 (m, 2H), 2.31 – 2.21 (m, 1H), 2.14 – 2.08 (m, 1H), 2.06 – 1.99 
(m, 1H). 
13
C NMR (100.62 MHz, CDCl3): δ 177.3, 173.5, 133.0, 129.4, 129.3, 127.5, 66.1, 53.0, 39.8, 30.8, 29.6, 21.2. 
IR: 2953 (w), 1734 (m), 1696 (s), 1435 (w), 1258 (m), 1197 (m), 1167 (m), 737 (m), 692 (m).  
HRMS: (ESI) calcd for C14H18NO3Se
+
 [M+H]
+
 328.0446; found 328.0442. 
 
Procedure: To a solution of selenide S1 (75 mg, 0.23 mmol, 1 equiv) in MeOH/H2O (9:1, 1.8 mL of MeOH + 
0.2 mL of H2O) was added  NaHCO3 (29 mg, 0.35 mmol, 1.5 equiv) and NaIO4 (53 mg, 0.25 mmol, 1.1 equiv). 
The reaction mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with water 
and extracted with EtOAc (3 times). The combined organic layers were washed with brine, dried over Na2SO4, 
filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on 
silica gel to afford the pure product. 
Yield: 25 mg, 63% yield Eluent: AcOEt/PE, 60:40 to 80:20 
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Aspect: yellow oil 
 
1
H NMR (400.13 MHz, CDCl3): δ 6.21 (s, 1H), 6.07 (dd, J = 17.2, 10.5 Hz, 1H), 5.33 (d, J = 17.2 Hz, 1H), 
5.25 (d, J = 10.5 Hz, 1H), 3.78 (s, 3H), 2.63 – 2.47 (m, 1H), 2.41 – 2.31 (m, 2H), 2.23 – 2.12 (m, 1H). 
13
C NMR (100.62 MHz, CDCl3): δ 177.0, 172.5, 137.3, 115.3, 66.9, 53.1, 32.3, 29.2. 
IR: 2925 (s), 1739 (s), 1710 (s), 1462 (w), 1439 (w), 1263 (w), 1164 (w).  
HRMS: (ESI) calcd for C8H12NO3
+
 [M+H]
+
 170.0812; found 170.0811. 
[𝛂]𝐃
𝟐𝟔= -8 (c 0.05, CHCl3) 
 
Procedure: To a solution of PtO2 (0.1 equiv) in MeOH was added methyl 2-nitro-2-(2-
(phenylselenonyl)ethyl)hexanoate (33e) (1 equiv). The resulting mixture was stirred under H2 atmosphere until 
complete consumption of the starting material (TLC monitoring, around 2 hours). The reaction mixture was 
filtered through a Celite pad and concentrated under reduced pressure. The crude product was used without 
further purification. 
Yield: quantitative
 
1
H NMR (400.13 MHz, CDCl3): δ 7.53 – 7.45 (m, 2H), 7.33 – 7.26 (m, 3H), 3.77 (s, 3H), 2.85 – 2.63 (m, 2H), 
2.59 – 2.48 (m, 2H), 2.46 – 2.37 (m, 4H), 2.11 (s, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 205.6, 166.6, 133.4, 129.5, 128.8, 127.8, 95.2, 53.7, 37.7, 36.4, 30.1, 28.1, 
20.4. 
IR: 2955 (w), 1750 (m), 1719 (m), 1551, (s), 1438 (m), 1357 (w), 1256 (w), 740 (m), 692 (w). 
HRMS: (ESI) calcd for C15H19NO5SeNa+ [M+Na]+ 396.0321; found 396.0325. 
 
Procedure: To a solution of NaIO4 and NaHCO3 in MeOH/H2O (9:1) was added the selenide XX (). The 
reaction mixture was stirred 2 hours at room temperature and heated to 50 °C during 12 hours. The reaction 
mixture was diluted with water and extracted with EtOAc (3 times). The combined organic layers were washed 
with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified 
by flash chromatography on silica gel to afford the pure product. 
Yield: 95%, Eluent: AcOEt/PE 10:90 to 20:80
 
1
H NMR (400.13 MHz, CDCl3): δ 6.36 (dd, J = 17.6, 11.1 Hz, 1H), 5.54 (d, J = 11.0 Hz, 1H), 5.38 (d, J = 17.6 
Hz, 1H), 3.83 (s, 3H), 2.69 – 2.58 (m, 2H), 2.56 – 2.48 (m, 2H), 2.15 (s, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 205.8, 166.2, 131.2, 120.5, 95.4, 53.9, 37.9, 30.1, 28.9. 
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IR: 2922 (w), 2853 (m), 1751 (m), 1718 (m), 1554 (s), 1252 (m), 1170 (w).  
HRMS: (ESI) calcd for C9H13NO5Na+ [M+Na]+ 238.0686; found 238.0690. 
 
1
H NMR (400.13 MHz, CDCl3): 4.41 (t, J = 8.7 Hz, 2H), 3.17 – 2.98 (m, 2H), 2.45 – 2.35 (m, 2H), 1.58 – 1.47 
(m, 2H), 1.44 – 1.32 (m, 2H), 0.94 (t, J = 7.3 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): 115.8, 63.2, 33.2, 27.7, 26.0, 22.6, 13.8. 
IR: 2959 (w), 2930 (w), 2873 (w), 1639 (s), 1466 (w), 1381 (w), 1269 (w), 1186 (w), 1088 (w), 863 (w). 
Crystallographic data of compound 7 
 
Summary of Data CCDC 1496191 
--------------------------------------------------------------- 
Compound Name: (S)-3-(4-bromobenzyl)-3-nitro-1-(4-nitrobenzyl)pyrrolidin-2-one 
Formula: C18 H16 Br1 N3 O5 
Unit Cell Parameters: a 13.044(3) b 9.5725(6) c 14.578(3) Ia 
Check cif of CCDC 1496191 
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Chapter 2 
Characterization data 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.35 – 7.27 (m, 3H), 7.22 – 7.18 (m, 2H), 6.14 (s, 1H), 5.20 (dd, J = 8.2, 6.8 
Hz, 1H), 3.56 – 3.46 (m, 2H), 3.34 – 3.20 (m, 2H), 1.52 – 1.40 (m, 2H), 1.34 – 1.23 (m, 2H), 0.91 (t, J = 7.3 Hz, 
3H). 
13
C NMR (100.62 MHz, CDCl3): δ 162.6, 134.4, 129.1, 127.9, 91.1, 40.1, 37.4, 31.3, 20.0, 13.8. 
IR: 3299 (w), 2954 (w), 2934 (w), 2864 (w), 1666 (s), 1553 (s), 752 (w), 701 (w). 
HRMS: (ESI) calcd for C13H18N2NaO3
+
 [M+Na]
+
 273.1210; found 273.1214. 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.44 – 7.26 (m, 4H), 7.23 – 7.09 (m, 2H), 6.24 (s, 1H), 5.22 (dd, J = 8.0, 6.9 
Hz, 1H), 3.51 (d, J = 7.5 Hz, 2H), 2.86 (d, J = 4.8 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 163.3, 134.4, 129.1, 129.0, 128.0, 91.1, 37.4, 27.0. 
IR: 3302 (w), 1667 (s), 1553 (s), 1414 (w), 1374 (w), 759 (w), 700 (m). 
HRMS: (ESI) calcd for C10H12N2NaO3
+ [M+Na]+ 231.0740; found 231.0748. 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.37 – 7.28 (m, 6H), 7.23 – 7.12 (m, 4H), 6.42 (s, 1H), 5.24 (dd, J = 8.1, 6.9 
Hz, 1H), 4.45 (d, J = 5.6 Hz, 2H), 3.66 – 3.37 (m, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 162.6, 136.7, 134.2, 129.2, 129.1, 129.0, 128.1, 128.0, 127.9, 91.0, 44.3, 
37.3.IR: 3288 (w), 3063 (w), 1665 (s), 1553 (s), 1456 (w), 1360 (w), 1240 (w), 748 (m), 736 (w), 698 (s). 
HRMS: (ESI) calcd for C16H16N2NaO3
+
 [M+Na]
+
 307.1053; found 307.1054. 
 
1
H NMR (400.13 MHz, Methanol-d4) δ 7.39 – 7.33 (m, 4H), 7.33 – 7.25 (m, 1H), 7.12 – 7.05 (m, 1H), 7.04 – 
6.94 (m, 2H), 5.71 (dd, J = 9.6, 6.1 Hz, 1H), 4.86 (s, 6H), 3.64 (dd, J = 13.5, 6.1 Hz, 1H), 3.51 (dd, J = 13.6, 9.7 
Hz, 1H). 
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13
C NMR (100.62 MHz, CDCl3): δ 164.2, 136.8, 135.8, 134.3, 130.7, 129.9, 129.1, 128.8, 128.6, 89.8, 36.7, 
18.0. 
IR: 2359 (s), 2335 (m), 1666 (m), 1558 (s), 767 (w), 703 (w). 
HRMS: (ESI) calcd for C17H17N2O3 [M+H-1] 297.1239; found 297.1239. 
 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.32 – 7.28 (m, 2H), 7.27 – 7.22 (m, 3H), 4.60 (dd, J = 8.0, 6.7 Hz, 1H), 3.59 
(dd, J = 14.0, 8.0 Hz, 1H), 3.26 (dd, J = 14.0, 6.6 Hz, 1H), 2.96 (s, 3H), 2.95 (s, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 168.4, 137.9, 129.6, 128.7, 127.2, 43.7, 41.2, 37.6, 36.5. 
IR: 2926 (w), 1656 (s), 1557 (m), 1496 (w), 1404 (w), 1361 (w), 1259 (w), 1138 (w), 750 (w), 702 (w).  
HRMS: (ESI) calcd for C11H15N2O3
+
 [M+H]
+
 223.1077; found 223.1078. 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.41 – 7.29 (m, 2H), 7.27 – 7.22 (m, 3H), 6.16 (s, 1H), 5.71 (s, 1H), 4.47 
(dd, J = 7.9, 5.7 Hz, 1H), 3.55 (dd, J = 14.4, 5.7 Hz, 1H), 3.26 (dd, J = 14.4, 7.9 Hz, 1H). 
13
C NMR (100.62 MHz, CDCl3): δ 170.6, 137.0, 129.6, 128.7, 127.4, 50.5, 41.7. 
IR: 3436 (w), 3301 (w), 3196 (w), 1674 (s), 1607 (m), 1411 (w), 1207 (w), 1045 (w), 745 (w), 700 (s). 
HRMS: (ESI) calcd for C9H10BrNNaO+ [M+Na]+ 249.9838; found 249.9840. 
 
1
H NMR (400.13 MHz, CD3OD): δ 7.32 – 7.05 (m, 5H), 5.37 (dd, J = 8.4, 6.9 Hz, 1H), 3.47 – 3.37 (m, 1H), 
3.32 – 3.23 (m, 1H). 
13
C NMR (100.62 MHz, CD3OD): δ 166.5, 134.9, 128.8, 128.3, 127.0, 89.2, 35.7. 
IR: 3435 (w), 3311 (w), 3201 (w), 1701 (s), 1619 (w), 1542 (s), 1416 (w), 1242 (w), 749 (w), 702 (m). 
HRMS: (ESI) calcd for C11H11NNaO4
+
 [M+Na]
+
 244.0580; found 244.0581. 
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1
H NMR (400.13 MHz, CDCl3): δ 7.51 – 7.39 (m, 2H), 7.39 – 7.28 (m, 3H), 6.49 (s, 1H), 5.33 (s, 1H), 1.40 (s, 
9H). 
13
C NMR (100.62 MHz, CDCl3): δ 166.1, 138.1, 129.1, 128.4, 52.3, 28.6. 
IR: 3297 (w), 2980 (w), 1656 (s), 1639 (m), 1556 (m), 1452 (w), 1364 (w), 1259 (w), 1223 (w), 714 (w).  
 
1
H NMR (400.13 MHz, CDCl3): δ 7.37 – 7.27 (m, 3H), 7.25 – 7.14 (m, 2H), 5.87 (s, 1H), 5.09 (dd, J = 7.9, 7.1 
Hz, 1H), 3.53 – 3.39 (m, 2H), 1.31 (s, 9H). 
13
C NMR (100.62 MHz, CDCl3): δ 161.5, 134.5, 129.2, 129.1, 127.9, 91.5, 52.6, 37.2, 28.4. 
IR: 3324 (w), 2973 (w), 1669 (s), 1557 (s), 1367 (m), 1222 (m), 752 (m), 699 (m). 
HRMS: (ESI) calcd for C13H18N2NaO3+ [M+Na]+ 273.1210; found 273.1210. 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.54 – 7.38 (m, 5H), 6.09 (s, 1H), 5.98 (s, 1H), 1.36 (s, 9H). 
13
C NMR (100.62 MHz, CDCl3): δ 161.9, 130.8, 130.4, 129.6, 129.5, 129.3, 128.0, 93.2, 52.8, 28.5. 
IR: 3323 (w), 2973 (w), 1671 (m), 1561 (s), 1457 (w), 1368 (m), 1222 (w), 704 (w). 
HRMS: (ESI) calcd for C12H17N2O3
+
 [M+H]
+
 237.1234; found 237.1232. 
 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.41 – 7.31 (m, 3H), 7.25 – 7.19 (m, 2H), 4.46 – 4.32 (m, 1H), 3.94 (td, J = 
8.8, 4.0 Hz, 1H), 3.69 – 3.59 (m, 2H), 2.94 (ddd, J = 14.6, 7.5, 4.0 Hz, 1H), 2.59 (ddd, J = 14.5, 8.5, 7.7 Hz, 1H). 
13
C NMR (100.62 MHz, CDCl3): δ 169.1, 132.3, 130.3, 129.4, 128.5, 92.0, 66.0, 39.5, 31.8. 
IR: 1781 (s), 1552 (s), 1456 (w), 1349 (w), 1222 (w), 1174 (m), 1151 (w), 1023 (m), 702 (s).  
HRMS: (ESI) calcd for C11H11NNaO4
+
 [M+Na]
+
 244.0580; found 244.0581. 
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1
H NMR (400.13 MHz, CDCl3): δ 7.33 – 7.27 (m, 3H), 7.24 – 7.20 (m, 2H), 3.65 (d, J = 13.7 Hz, 1H), 3.50 (d, 
J = 13.7 Hz, 1H), 3.44 (ddd, J = 9.6, 8.1, 6.1 Hz, 1H), 3.36 – 3.15 (m, 2H), 2.81 (ddd, J = 9.6, 8.6, 3.7 Hz, 1H), 
2.70 (ddd, J = 14.4, 8.1, 3.7 Hz, 1H), 2.34 (ddd, J = 14.6, 8.6, 6.1 Hz, 1H), 1.49 – 1.35 (m, 2H), 1.28 – 1.13 (m, 
2H), 0.89 (t, J = 7.3 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 166.4, 133.6, 130.5, 128.9, 127.8, 94.6, 44.2, 43.4, 39.4, 28.9, 28.4, 19.9, 
13.8. 
IR: 2959 (w), 2932 (w), 2869 (w), 1705 (s), 1545 (s), 1456 (w), 1275 (w), 702 (w). 
HRMS: (ESI) calcd for C15H20N2NaO3
+
 [M+Na]
+
 299.1366; found 299.1375. 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.33 – 7.27 (m, 3H), 7.25 – 7.19 (m, 2H), 4.35 – 4.25 (m, 1H), 4.11 – 3.98 
(m, 1H), 3.73 (d, J = 14.0 Hz, 1H), 3.50 (d, J = 14.0 Hz, 1H), 3.42 – 3.31 (m, 2H), 2.89 – 2.70 (m, 1H), 2.51 – 
2.34 (m, 1H), 1.70 – 1.54 (m, 2H), 1.47 – 1.30 (m, 2H), 0.94 (t, J = 7.4 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 156.8, 134.2, 130.5, 128.8, 127.9, 93.8, 67.4, 47.8, 40.6, 33.1, 32.5, 20.8, 
14.1. 
IR: 2958 (w), 2932 (w), 2872 (w), 1710 (s), 1550 (s), 1351 (w), 1181 (w), 1030 (m), 703 (w).  
HRMS: (ESI) calcd for C15H21N2O3
+
 [M+H]
+
 277.1547; found 277.1547. 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.37 – 7.29 (m, 5H), 7.06 – 6.97 (m, 2H), 6.97 – 6.83 (m, 1H), 4.38 (td, J = 
9.3, 6.3 Hz, 1H), 4.27 (td, J = 8.7, 2.1 Hz, 1H), 4.16 (d, J = 14.6 Hz, 1H), 3.44 (d, J = 14.6 Hz, 1H), 2.94 (ddd, J 
= 14.6, 6.3, 2.2 Hz, 1H), 2.56 (ddd, J = 14.5, 9.8, 8.7 Hz, 1H), 2.08 (s, 6H). 
13
C NMR (100.62 MHz, CDCl3): δ 155.8, 143.6, 133.9, 130.4, 129.0, 128.1, 128.0, 127.9, 124.0, 94.3, 68.4, 
41.1, 33.2, 18.1. 
IR: 2921 (w), 2363 (w), 1715 (s), 1551 (s), 1472 (w), 1213 (w), 1182 (w), 1027 (m), 768 (w), 703 (w).  
HRMS: (ESI) calcd for C19H21N2O3
+
 [M+H]
+
 325.1547; found 325.1547. 
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1
H NMR (400.13 MHz, CDCl3): δ 7.33 – 7.24 (m, 3H), 7.17 – 7.04 (m, 2H), 6.96 (s, 1H), 3.83 – 3.70 (m, 2H), 
3.63 (d, J = 13.9 Hz, 1H), 3.48 (d, J = 13.9 Hz, 1H), 3.33 – 3.20 (m, 2H), 2.50 (t, J = 6.0 Hz, 2H), 1.88 (s, 1H), 
1.54 – 1.35 (m, 2H), 1.35 – 1.17 (m, 2H), 0.90 (t, J = 7.3 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 166.1, 133.3, 130.1, 128.8, 128.1, 97.5, 58.7, 44.3, 40.2, 38.5, 31.1, 20.1, 
13.8. 
IR: 3362 (w), 2959 (w), 2932 (w), 2868 (w), 1659 (m), 1548 (s), 1457 (w), 1048 (w), 743 (w), 703 (w).  
HRMS: (ESI) calcd for C12H19NNaO2
+
 [M+Na]
+
 232.1308; found 232.1314. 
Part II 
Chapter 3 
General procedures 
 
General procedure A: 
To a solution of -disubstituted -isocyanoacetate X (0.1 mmol, 1 equiv) and primary amine X (0.12 mmol, 
1.2 equiv) in toluene (1 mL) was added AgNO3 (0.01 mmol, 0.1 equiv). The reaction mixture was stirred at 60 
°C until complete consumption of the starting material (TLC monitoring, around 12 hours). The reaction mixture 
was cooled down to room temperature and concentrated under reduced pressure. The residue was purified by 
flash chromatography on silica gel to afford the pure product. 
 
 
General procedure B: 
To a solution of -disubstituted -isocyanoacetate X (0.1 mmol, 1 equiv), primary amine X (0.15 mmol, 1.5 
equiv), aryl iodide (0.2 mmol, 2 equiv) and PPh3 (0.01 mmol, 0.1 mmol) in DMF (1 mL) were added Pd(OAc)2 
(0.005 mmol, 0.05 equiv) and Cu2O (0.1 mmol, 1 equiv). The reaction was performed in a sealed tube under 
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inert atmosphere. The reaction mixture was stirred at 130 °C for 12h. The reaction mixture was cooled down to 
room temperature, diluted with AcOEt (10 mL), washed with a 1:1 mixture of aqueous ammonia and brine (2 
times) and brine only (3 times). The organic layer was dried over Na2SO4, filtered and concentrated under 
reduced pressure. The crude product was purified by flash chromatography on silica gel to afford the pure 
product. 
 
General procedure C: 
To a solution of methyl -isopropyl -isocyanoacetate (1 equiv) in DMF (0.1 M) was added portion-wise NaH 
(1.5 equiv), After 30 minutes, the corresponding alkyl halide (1.5 equiv) was added drop-wise. The reaction 
mixture was stirred at 50 °C for 12 hours. The reaction mixture was cooled to room temperature, quenched with 
a saturated aqueous solution of NaHCO3 and extracted with DCM (3 times). The combined organic layers were 
washed with brine, dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product was 
purified by flash chromatography on silica gel. 
 
General procedure D: 
To a solution of methyl -phenyl -isocyanoacetate (1 equiv) in DCE (0.1 M) were added DBU (1.1 equiv) and 
the corresponding alkyl halide (1.5 equiv). The reaction mixture was stirred at 80 °C for 12 hours. The reaction 
mixture was cooled to room temperature, quenched with a saturated aqueous solution of NaHCO3 and extracted 
with DCM (3 times). The combined organic layers were washed with brine, dried over Na2SO4, filtered and 
concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel. 
 
General procedure E, following the literature report
[215]
: 
To a solution of methyl -isocyanoacetate (1 equiv) in MeCN (0.1 M) were added K2CO3 (4.4 equiv), TBAHS 
(0.1 equiv.) and the corresponding alkyl halide (2 equiv). The reaction mixture was stirred at 70 °C for 12 hours. 
The reaction mixture was cooled to room temperature, quenched with a saturated aqueous solution of NaHCO3 
and extracted with DCM (3 times). The combined organic layers were washed with brine, dried over Na2SO4, 
filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on 
silica gel. 
haracterisation data 
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To a solution of leucine in methanol was added SOCl2. The reaction mixture was stirred at RT for 2 hours and 
evaporated to dryness to give the corresponding methyl ester hydrochloride which was washed with NaOH (3M) 
and extraceted with DCM (3 times). The combined organic layers were washed with brine, dried over Na2SO4, 
filtered and concentrated under reduced pressure. The resulting amine was directly used without further 
purification. 
To a solution formic acid (100 equiv) was added Ac2O (10 equiv). The reaction mixture was stirred at 60 °C for 
1 hour. After cooling down the reaction mixture the ammonium salt was added. The reaction mixture was stirred 
at RT for 2 hour and evaporated to dryness to give the corresponding formamide which was directly used 
without further purification. 
To a solution of formamide in DCM (0.3 M) was added triethylamine (2.7 equiv). The reaction mixture was 
cooled to -30 °C. POCl3 (1.2 equiv) was added and the solution was stirred at -30 °C with TLC monitoring 
(around 3h). The reaction mixture was cooled to room temperature, quenched with a saturated aqueous solution 
of NaHCO3 and extracted with DCM (3 times). The combined organic layers were washed with brine, dried over 
Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by flash 
chromatography on silica gel (Eluent: PE/AcOEt: 9/1 to 7/3) to afford the desire isocyanoacetate. 
Characterization data 
 
Yield: 30% yield over three steps 
 
1
H NMR (400.13 MHz, CDCl3): δ 4.29 (dd, J = 10.0, 4.6 Hz, 1H), 3.82 (s, 2H), 2.02 – 1.77 (m, 2H), 1.73 – 
1.55 (m, 1H), 0.99 (d, J = 6.6 Hz, 3H), 0.96 (d, J = 6.6 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 167.8, 160.1, 55.2 (t, J = 7.0 Hz), 53.5, 41.4, 24.9, 22.7, 21.0. 
IR: 2960 (w), 2148 (m), 1756 (s), 1439 (w), 1274 (m), 1235 (m), 1207 (m), 1142 (w), 1011 (w).  
HRMS: (ESI) calcd for C8H14NO2
+
 [M+H]
+
 156.1019; found 156.1021. 
-disubstituted -isocyanoacetate 
 
From literature report
[215] 
Aspect: white solid 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.37 – 7.30 (m, 6H), 7.29 – 7.25 (m, 4H), 3.59 (s, 3H), 3.38 (d, J = 13.5 Hz, 
2H), 3.07 (d, J = 13.5 Hz, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 168.6, 161.4, 133.6, 130.3, 128.6, 128.1, 70.6, 53.3, 45.0. 
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IR: 3030 (w), 2142 (w), 1740 (m), 1497 (w), 1441 (w), 1236 (m), 1208 (m), 1088 (m), 1036 (w), 958 (w), 748 
(m), 701 (s). 
HRMS: (ESI) calcd for C18H18NO2
+
 [M+H]
+
 280.1332; found 280.1339. 
 
From
 
literature report
 [216] 
Aspect: yellow oil 
 
1
H NMR (400.13 MHz, CDCl3): δ 3.83 (s, 3H), 1.67 (s, 6H). 
13
C NMR (100.62 MHz, CDCl3): δ 170.2, 158.0, 59.7 (t, J = 6 Hz), 53.7, 27.7. 
IR: 2958 (w), 2141 (w), 1748 (s), 1437 (w), 1284 (m), 1193 (m), 1153 (s), 992 (w), 864 (w), 783 (w), 767 (w).  
HRMS: (ESI) calcd for C6H10NO2
+
 [M+H]
+
 128.0706; found 128.0705. 
 
General procedure D 
Yield: 76% yield (with benzyl bromide) 
Aspect: yellow oil 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.63 – 7.53 (m, 2H), 7.47 – 7.37 (m, 3H), 7.30 – 7.24 (m, 3H), 7.17 – 7.08 
(m, 2H), 3.77 (s, 3H), 3.73 (d, J = 13.7 Hz, 1H), 3.33 (d, J = 13.7 Hz, 1H). 
13
C NMR (100.62 MHz, CDCl3): δ 168.1, 162.2, 135.1, 133.6, 130.7, 129.2, 129.0, 128.4, 127.9, 125.4, 72.0, 
54.0, 46.0. 
IR: 2138 (w), 1746 (m), 1498 (w), 1436 (w), 1260 (m), 1035 (w), 732 (m), 697 (s). 
HRMS: (ESI) calcd for C17H15NNaO2
+
 [M+Na]
+
 288.0995; found 288.0996. 
 
General procedure D 
Aspect: yellow oil 
Yield: 82% yield (with benzyl bromide) 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.60 – 7.55 (m, 2H), 7.47 – 7.34 (m, 3H), 7.30 – 7.23 (m, 3H), 7.21 – 7.13 
(m, 2H), 3.70 (d, J = 13.7 Hz, 1H), 3.29 (d, J = 13.8 Hz, 1H), 1.41 (s, 9H). 
13
C NMR (100.62 MHz, CDCl3): δ 166.3, 161.3, 135.7, 134.0, 130.8, 128.9, 128.8, 128.2, 127.7, 125.4, 84.4, 
72.3, 45.7, 27.7. 
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IR: 2980 (w), 2137 (w), 1735 (m), 1497 (w), 1450 (w), 1371 (w), 1262 (m), 1259 (m), 1150 (s), 839 (m), 738 
(m), 697 (s). 
HRMS: (ESI) calcd for C20H21NNaO2
+
 [M+Na]
+
 330.1464; found 330.1472. 
 
General procedure D 
Aspect: yellow oil 
Yield: 76% yield (with ethyl iodide) 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.63 – 7.51 (m, 2H), 7.48 – 7.33 (m, 3H), 3.78 (s, 3H), 2.44 (dq, J = 14.3, 
7.1 Hz, 1H), 2.19 (dq, J = 14.5, 7.3 Hz, 1H), 1.02 (t, J = 7.3 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 168.5, 160.9, 135.2, 129.0, 129.0, 125.3, 71.9, 53.9, 33.5, 8.7. 
IR: 2138 (m), 1747 (s), 1450 (w), 1242 (s), 1139 (w), 1011 (w), 759 (w), 731 (m), 696 (s), 613 (w). 
HRMS: (ESI) calcd for C12H13NO2 [M+] 203.0941; found 203.0940. 
 
From
 
literature report
 [217] 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.50 – 7.30 (m, 8H), 7.21 – 7.08 (m, 2H), 3.68 (s, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 169.7, 162.3, 154.6, 137.8, 137.4, 130.3, 129.9, 129.6, 129.1, 128.4, 128.2, 
113.7, 52.9. 
IR: 2113 (w), 1729 (m), 1697 (w), 1445 (w), 1332 (w), 1255 (m), 1115 (m), 765 (w), 747 (w), 699 (s).  
HRMS: (ESI) calcd for C17H14NO2
+
 [M+H]
+
 264.1019; found 264.1025. 
 
General procedure D 
Aspect: yellow oil 
Yield: 72% yield (with 1-bromo-3-methylbutane) 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.61 – 7.52 (m, 2H), 7.45 – 7.33 (m, 3H), 3.78 (s, 3H), 2.45 – 2.31 (ddd, J = 
6.3, 10.5, 13.8 Hz, 1H), 2.23 – 2.09 (ddd, J = 6.3, 10.5, 13.8 Hz, 1H), 1.65 – 1.49 (m, 1H), 1.36 – 1.20 (m, 2H), 
0.91 (d, J = 6.7 Hz, 3H), 0.89 (d, J = 6.7 Hz, 3H). 
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13
C NMR (100.62 MHz, CDCl3): δ 168.6, 160.8, 135.4, 129.0, 129.0, 125.2, 71.3, 53.9, 38.1, 33.1, 27.9, 22.6, 
22.4. 
IR: 2957 (w), 2872 (w), 2136 (m), 1748 (s), 1450 (w), 1436 (w), 1252 (s), 1144 (w), 1025 (w), 775 (w), 732 
(m), 697 (s). 
HRMS: (ESI) calcd for C15H20NO2
+
 [M+H]
+
 246.1489; found 246.1494. 
 
General procedure D 
Aspect: yellow oil 
Yield: 74% yield (with ethyl 4-iodobutanoate) 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.59 – 7.51 (m, 2H), 7.44 – 7.35 (m, 3H), 4.13 (q, J = 7.1 Hz, 2H), 3.78 (s, 
3H), 2.47 – 2.39 (m, 1H), 2.38 – 2.32 (m, 2H), 2.29 – 2.19 (m, 1H), 1.80 – 1.66 (m, 2H), 1.25 (t, J = 7.1 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 172.6, 168.2, 161.5, 134.8, 129.1, 129.0, 125.1, 70.8, 60.5, 54.0, 39.0, 33.4, 
19.7, 14.3. 
IR: 2981 (w), 2136 (m), 1731 (s), 1450 (w), 1249 (s), 1186 (s), 1097 (m), 1032 (w), 772 (w), 732 (m), 697 (s). 
HRMS: (ESI) calcd for C16H19NNaO4
+
 [M+Na]
+
 312.1206; found 312.1211. 
 
General procedure D 
Aspect: yellow oil 
Yield: 81% yield  (with (4-bromobutoxy)benzene) 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.60 – 7.52 (m, 2H), 7.47 – 7.36 (m, 3H), 7.32 – 7.24 (m, 2H), 6.98 – 6.91 
(m, 1H), 6.89 – 6.84 (m, 2H), 3.95 (t, J = 6.3 Hz, 2H), 3.78 (s, 3H), 2.55 – 2.39 (m, 1H), 2.29 – 2.20 (m, 1H), 
1.94 – 1.75 (m, 2H), 1.68 – 1.52 (m, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 168.4, 161.3, 159.0, 135.2, 129.6, 129.1, 129.1, 125.2, 120.8, 114.6, 71.1, 
67.3, 54.0, 39.7, 28.8, 21.2. 
IR: 2952 (w), 2136 (w), 1747 (m), 1599 (w), 1496 (m), 1243 (s), 1173 (m), 1034 (w), 754 (s), 731 (m), 693 (s). 
HRMS: (ESI) calcd for C20H21NNaO3
+
 [M+Na]
+
 346.1414; found 346.1418. 
 
220 
 
General procedure E 
Aspect: yellow oil 
Yield: 65% yield (with methyl acrylate) 
 
1
H NMR (400.13 MHz, CDCl3): δ 3.78 (s, 3H), 3.65 (s, 6H), 2.60 – 2.47 (ddd, J = 5.4, 10.8, 17.2 Hz, 2H), 2.40 
– 2.20 (m, 4H), 2.20 – 2.08 (ddd, J = 5.4, 10.8, 14.1 Hz, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 172.0, 168.1, 161.3, 66.7, 53.8, 52.0, 33.8, 29.0. 
IR: 2956 (w), 2136 (w), 1735 (s), 1438 (m), 1200 (s), 1174 (s), 1094 (m), 975 (w), 915 (w), 816 (w), 733 (m).  
HRMS: (ESI) calcd for C12H17NNaO6
+
 [M+Na]
+
 294.0948; found 294.0950. 
 
General procedure E 
Aspect: yellow oil 
Yield: 60% yield (with acrylonitrile) 
 
1
H NMR (400.13 MHz, CDCl3): δ 3.93 (s, 3H), 2.70 – 2.59 (m, 2H), 2.56 – 2.44 (m, 2H), 2.48 – 2.38 (m, 2H), 
2.26 – 2.14 (m, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 166.4, 164.2, 117.1, 65.7, 54.5, 34.4, 12.8. 
IR: 2960 (w), 2135 (m), 1733 (s), 1449 (m), 1375 (w), 1245 (s), 1219 (s), 1098 (m), 1046 (m), 737 (m). 
HRMS: (ESI) calcd for C10H11N3NaO2
+
 [M+Na]
+
 228.0743; found 228.0740. 
 
General procedure E 
Aspect: yellow oil 
Yield: 77% yield (with allyl bromide) 
 
1
H NMR (400.13 MHz, CDCl3): δ 5.87 – 5.7 (ddt, 7.26, 7.26, 10.31, 16.91, 2H), 5.27 – 5.25 (m, 1H), 5.25 – 
5.22 (m, 2H), 5.21 – 5.18 (m, 1H), 3.79 (s, 3H), 2.65 (dd, J = 14.0, 7.4 Hz, 2H), 2.55 (dd, J = 13.9, 7.1 Hz, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 168.4, 159.8, 129.9, 121.1, 67.8, 53.3, 42.6. 
IR: 2956 (w), 2138 (m), 1748 (s), 1439 (m), 1222 (s), 1155 (m), 1030 (m), 994 (s), 928 (s), 669 (m).  
HRMS: (ESI) calcd for C10H14NO2
+
 [M+H]
+
 180.1019; found 180.1020. 
221 
 
 
From literature report
 [218] 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.59 – 7.51 (m, 2H), 7.48 – 7.36 (m, 3H), 3.81 (s, 3H), 3.61 – 3.31 (m, 2H), 
2.76 (ddd, J = 14.0, 8.5, 7.3 Hz, 1H), 2.40 (ddd, J = 14.0, 8.5, 4.8 Hz, 1H). 
13
C NMR (100.62 MHz, CDCl3): δ 167.7, 162.7, 134.5, 129.5, 129.3, 125.0, 68.9, 54.3, 47.0, 38.5. 
IR: 2134 (m), 1748 (s), 1450 (w), 1436 (w), 1249 (s), 1214 (m), 1103 (w), 760 (w), 730 (m), 697 (s).  
HRMS: (ESI) calcd for C12H12N4NaO2
+
 [M+Na]
+
 267.0852; found 267.0857. 
 
From literature report
 [219] 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 3.82 (s, 3H), 1.70 – 1.62 (m, 2H), 1.59 – 1.53 (m, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 168.4, 158.0, 53.7, 34.7 (t, J = 12.0 Hz), 20.0. 
IR: 2958 (w), 2363 (w), 2139 (w), 1742 (s), 1440 (m), 1332 (s), 1202 (s), 1163 (s). 
HRMS: (ESI) calcd for C6H8NO2
+
 [M+H]
+
 126.0550; found 126.0549. 
 
From literature report
 [219] 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 3.82 (s, 3H), 2.05 – 1.94 (m, 2H), 1.89 – 1.78 (m, 2H), 1.76 – 1.64 (m, 5H), 
1.34 – 1.19 (m, 1H). 
13
C NMR (100.62 MHz, CDCl3): δ 170.3, 158.8, 64.5, 53.6, 34.4, 24.5, 21.0. 
IR: 2940 (w), 2864 (w), 2136 (m), 1746 (s), 1452 (w), 1437 (w), 1280 (s), 1245 (s), 1151 (m), 1069 (m).  
HRMS: (ESI) calcd for C9H14NO2
+
 [M+H]
+
 168.1019; found 168.1019. 
 
General procedure D  
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Aspect: yellow oil 
Yield: 85% yield (with methyl acrylate) 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.58 – 7.47 (m, 2H), 7.47 – 7.33 (m, 3H), 3.78 (s, 3H), 3.65 (s, 3H), 2.78 – 
2.66 (ddd, J = 5.0, 10.9, 13.7, 1H), 2.62 – 2.52 (ddd, 5.0, 10.9, 13.7 Hz, 1H), 2.52 – 2.42 (m, 1H), 2.41 – 2.29 
(ddd, J = 5.0, 10.9, 16.20 Hz, 1H). 
13
C NMR (100.62 MHz, CDCl3): δ 172.2, 167.8, 162.1, 134.3, 129.3, 129.2, 125.1, 70.1, 54.1, 52.0, 34.8, 29.3. 
IR: 2955 (w), 2135 (m), 1738 (s), 1437 (m), 1249 (s), 1200 (m), 1176 (m), 1073 (w), 733 (m), 697 (m).  
HRMS: (ESI) calcd for C14H15NNaO4
+
 [M+Na]
+
 284.0893; found 284.0892. 
  
General procedure D 
Aspect: yellow oil 
Yield: 82% yield (with acrylonitrile) 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.56 – 7.49 (m, 2H), 7.48 – 7.39 (m, 3H), 3.81 (s, 3H), 2.82 – 2.71 (m, 1H), 
2.65 – 2.47 (m, 2H), 2.44 – 2.30 (m, 1H). 
13
C NMR (100.62 MHz, CDCl3): δ 167.0, 163.5, 133.2, 129.8, 129.5, 124.8, 117.7, 69.5, 54.4, 35.4, 12.9. 
IR: 2957 (w), 2133 (m), 1748 (s), 1450 (m), 1253 (s), 1218 (m), 1089 (w), 1071 (m), 913 (w), 731 (s), 697 (s).  
HRMS: (ESI) calcd for C13H12N2NaO2
+
 [M+Na]
+
 251.0791; found 251.0792. 
 
General procedure C 
Aspect: yellow oil 
Yield: 68% yield (with isobutyl bromide) 
 
1
H NMR (400.13 MHz, CDCl3): δ 3.79 (s, 3H), 1.95 – 1.77 (m, 4H), 1.80 – 1.60 (m, 2H), 1.00 (d, J = 6.3 Hz, 
6H), 0.84 (d, J = 6.3 Hz, 6H). 
13
C NMR (100.62 MHz, CDCl3): δ 170.4, 159.9 (br. s), 66.9 (t J = 6.0 Hz), 53.2, 49.0, 25.0, 23.9, 22.4. 
IR: 2959 (m), 2365 (w), 2343 (w), 2137 (m), 1748 (s), 1473 (w), 1440 (w), 1235 (s), 1150 (s). 
HRMS: (ESI) calcd for C12H21NNaO2
+
 [M+Na]
+
 234.1464; found 234.1469. 
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General procedure C 
Aspect: yellow oil 
Yield: 71% yield (with ethyl 4-iodobutanoate) 
 
1
H NMR (400.13 MHz, CDCl3): δ 4.13 (q, J = 7.1 Hz, 2H), 3.81 (s, 3H), 2.38 – 2.28 (m, 2H), 2.01 – 1.82 (m, 
4H), 1.80 – 1.72 (m, 2H), 1.63 – 1.48 (m, 1H), 1.25 (t, J = 7.1 Hz, 3H), 1.00 (d, J = 6.3 Hz, 3H), 0.85 (d, J = 6.3 
Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 172.7, 169.8, 159.9, 67.5, 60.7, 53.5, 47.2, 40.0, 33.5, 25.1, 23.8, 22.2, 19.6, 
14.4. 
IR: 2960 (w), 2137 (w), 1733 (s), 1450 (w), 1235 (m), 1172 (s), 1136 (m), 1028 (w). 
HRMS: (ESI) calcd for C14H23NNaO4
+
 [M+Na]
+
 292.1519; found 292.1524. 
 
General procedure C 
Aspect: yellow oil 
Yield: 60% yield (with 1,5-dibromopentane) 
 
1
H NMR (400.13 MHz, CDCl3): δ 3.80 (s, 3H), 3.40 (t, J = 6.7 Hz, 2H), 1.96 – 1.81 (m, 5H), 1.80 – 1.70 (m, 
2H), 1.67 – 1.54 (m, 1H), 1.45 (p, J = 7.5 Hz, 2H), 1.28 – 1.15 (m, 1H), 1.00 (d, J = 6.3 Hz, 3H), 0.85 (d, J = 6.3 
Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 169.9, 159.5, 67.6, 53.3, 47.3, 40.6, 33.6, 32.3, 27.6, 25.0, 23.7, 23.2, 22.1. 
IR: 2959 (m), 2873 (w), 2137 (m), 1749 (s), 1440 (w), 1235 (s), 1162 (m), 1009 (w). 
HRMS: (ESI) calcd for C13H22BrNNaO2
+
 [M+Na]
+
 326.0726; found 326.0723. 
 
To a solution of alkyl bromide X in DCM were added K2CO3 (5 eqiv.) and N,N-(benzyl)methyl (2 equiv.). The 
reaction mixture was stirred at RT for 24 hours. The reaction mixture was quenched with a saturated aqueous 
solution of NaHCO3 and extracted with DCM (3 times). The combined organic layers were washed with brine, 
dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified by flash 
chromatography on silica gel. 
Yield: 54% yield 
Aspect: yellow oil 
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1
H NMR (400.13 MHz, CDCl3): δ 7.34 – 7.29 (m, 4H), 7.25 – 7.21 (m, 1H), 3.79 (s, 3H), 3.48 (s, 2H), 2.36 (t, J 
= 7.3 Hz, 2H), 2.18 (s, 3H), 1.94 – 1.80 (m, 3H), 1.79 – 1.66 (m, 2H), 1.64 – 1.57 (m, 1H), 1.56 – 1.48 (m, 2H), 
1.37 – 1.27 (m, 2H), 1.24 – 1.14 (m, 1H), 1.00 (d, J = 6.4 Hz, 3H), 0.85 (d, J = 6.3 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 170.1, 159.5, 139.2, 129.2, 128.4, 127.1, 67.8, 62.4, 57.3, 53.3, 47.4, 42.3, 
40.9, 27.1, 27.0, 25.1, 24.0, 23.8, 22.2. 
IR: 3247 (w), 2955 (m), 2934 (m), 2865 (w), 2787 (w), 2361 (w), 2341 (w), 2137 (s), 1746 (s), 1455 (m), 1370 
(w), 1235 (s), 1148 (m), 1019 (w), 741 (m), 700 (m). 
HRMS: (ESI) calcd for C34H44N3O
+
 [M+H]
+
 510.3479; found 510.3481. 
 
General procedure C 
Aspect: yellow oil 
Yield: 78% yield (with allyl bromide) 
 
1
H NMR (400.13 MHz, CDCl3): δ 5.78 (ddt, J = 17.3, 10.3, 7.3 Hz, 1H), 5.37 – 5.05 (m, 2H), 3.79 (s, 3H), 
2.62 (dd, J = 13.9, 7.3 Hz, 1H), 2.50 (dd, J = 13.9, 7.3 Hz, 1H), 1.95 – 1.81 (m, 2H), 1.81 – 1.72 (m, 1H), 1.01 
(d, J = 6.3 Hz, 3H), 0.86 (d, J = 6.3 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 169.6, 159.9, 130.1, 121.2, 67.6 (t, J = 6.0 Hz), 53.4, 46.6, 45.0, 25.1, 23.8, 
22.1. 
IR: 2959 (w), 2136 (m), 1747 (s), 1440 (w), 1222 (s), 1157 (m), 995 (w), 928 (m). 
HRMS: (ESI) calcd for C11H18NO2
+
 [M+H]
+
 196.1332; found 196.1334. 
 
 
From literature report
 [220] 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 8.07 – 7.91 (m, 1H), 7.57 (m, 1H), 7.47 (m, 2H), 3.97 (s, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 169.6, 164.6, 133.2, 131.5, 129.3, 129.0, 127.2, 125.7, 52.8. 
IR: 2125 (w), 1722 (m), 1693 (m), 1585 (w), 1516 (w), 1449 (w), 1435 (m), 1297 (m), 1254 (s), 1134 (m), 1081 
(s), 962 (w), 753 (s), 700 (w). 
HRMS: (ESI) calcd for C9H8NO2
+
 [M+H]
+
 162.0550; found 162.0551. 
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- Silver-catalyzed isocyanide insertion/lactamization 
3,5,5-trisubstituted-3,5-dihydro-4H-imidazol-4-one 
 
General procedure A 
Yield: 32 mg, 90% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: white amorphous solid 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.25 – 7.17 (m, 10H), 7.16 – 7.11 (m, 1H), 7.10 – 7.04 (m, 2H), 7.04 (s, 
1H), 6.35 – 6.24 (m, 2H), 4.12 (s, 2H), 3.27 (d, J = 13.1 Hz, 2H), 3.21 (d, J = 13.1 Hz, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 182.2, 151.8, 135.0, 134.7, 130.3, 128.7, 127.9, 127.5, 126.8, 126.8, 77.1, 
43.6, 43.0. 
IR: 3062 (w), 2919 (w), 1706 (s), 1618 (m), 1455 (w), 1357 (w), 1141 (m), 942 (w), 739 (m), 697 (s).  
HRMS: (ESI) calcd for C24H23N2O
+
 [M+H]
+
 355.1805; found 355.1803. 
 
General procedure A 
Yield: 27 mg, 98% yield, Eluent AcOEt/PE: 10:90 to 30:70 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.23 – 7.12 (m, 10H), 7.07 (s, 1H), 3.18 (d, J = 13.1 Hz, 2H), 3.11 (d, J = 
13.1 Hz, 2H), 2.53 (s, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 183.2, 152.5, 135.1, 130.1, 127.7, 126.7, 76.9, 42.7, 26.7. 
IR: 3030 (w), 1716 (m), 1611 (m), 1495 (w), 1293 (m), 1089 (w), 742 (m), 700 (s). 
HRMS: (ESI) calcd for C18H19N2O
+
 [M+H]
+
 279.1492; found 279.1499. 
 
General procedure A 
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Yield: 31 mg, 97% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: white amorphous solid 
1
H NMR (400.13 MHz, CDCl3): δ 7.22 – 7.12 (m, 10H), 7.09 (s, 1H), 3.19 (d, J = 13.1 Hz, 2H), 3.13 (d, J = 
13.1 Hz, 2H), 2.92 (t, J = 7.0 Hz, 2H), 1.02 – 0.84 (m, 2H), 0.72 – 0.59 (m, 5H). 
13
C NMR (100.62 MHz, CDCl3): δ 182.6, 152.3, 135.1, 130.2, 127.7, 126.7, 77.0, 42.8, 40.2, 30.3, 19.2, 13.4. 
IR: 2922 (w), 1715 (m), 1612 (m), 1495 (w), 1351 (w), 1284 (w), 934 (w), 741 (m), 701 (s).  
HRMS: (ESI) calcd for C21H25N2O
+
 [M+H]
+
 321.1961; found 321.1963. 
 
General procedure A 
Yield: 29.2 mg, 96% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: white amorphous solid 
1
H NMR (400.13 MHz, CDCl3): δ 7.23 – 7.14 (m, 10H), 7.12 (s, 1H), 5.06 (ddt, J = 17.1, 10.5, 5.3 Hz, 1H), 
4.79 (ddt, J = 10.3, 2.4, 0.8 Hz, 1H), 4.30 (ddt, J = 17.1, 1.7, 0.8 Hz, 1H), 3.56 (dt, J = 5.4, 1.6 Hz, 2H), 3.22 (d, 
J = 13.1 Hz, 2H), 3.16 (d, J = 13.1 Hz, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 182.2, 151.9, 135.1, 131.0, 130.3, 127.8, 126.8, 117.5, 77.2, 42.8, 42.2. 
IR: 3030 (w), 2921 (w), 1721 (s), 1611 (m), 1495 (w), 1351 (w), 935 (w), 742 (m), 702 (s). 
HRMS: (ESI) calcd for C20H21N2O
+
 [M+H]
+
 305.1648; found 305.1655. 
 
General procedure A 
Yield: 14.6 mg, 95% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: white amorphous solid 
1
H NMR (400.13 MHz, CDCl3): δ 7.72 (s, 1H), 4.15 (sept, J = 6.9 Hz, 1H), 1.33 (s, 3H), 1.31 (s, 3H), 1.31 (s, 
6H). 
13
C NMR (100.62 MHz, CDCl3): δ 184.9, 149.5, 68.9, 43.3, 23.6, 21.7. 
IR: 2978 (w), 2929 (w), 1707 (s), 1605 (s), 1373 (w), 1295 (w), 1245 (w), 1221 (w).  
HRMS: (ESI) calcd for C8H15N2O
+
 [M+H]
+
 155.1179; found 155.1179. 
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General procedure A 
Yield: 29.1 mg, 95% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: white amorphous solid 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.22 – 7.10 (m, 11H), 3.66 (sept, J = 6.9 Hz, 1H, 1H), 3.20 (d, J = 13.0 Hz, 
2H), 3.13 (d, J = 13.0 Hz, 2H), 0.66 (d, J = 6.9 Hz, 6H). 
13
C NMR (100.62 MHz, CDCl3): δ 182.0, 150.0, 135.1, 130.2, 127.6, 126.6, 77.5, 42.6, 20.8. 
IR: 3058 (w), 2972 (w), 1728 (w), 1707 (s), 1609 (m), 1375 (w), 1251 (m), 1076 (w), 880 (w), 743 (m), 699 (s).  
HRMS: (ESI) calcd for C20H23N2O
+
 [M+H]
+
 307.1805; found 307.1799. 
 
General procedure A 
Yield: 30.5 mg, 88% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: white amorphous solid 
1
H NMR (400.13 MHz, CDCl3): δ 7.21 – 7.11 (m, 11H), 3.27 (tt, J = 12.5, 3.9 Hz, 1H), 3.21 (d, J = 13.0 Hz, 
2H), 3.13 (d, J = 13.0 Hz, 2H), 1.65 – 1.49 (m, 3H), 1.19 – 1.06 (m, 2H), 1.06 – 0.97 (m, 2H), 0.98 – 0.88 (m, 
1H), 0.87 – 0.74 (m, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 182.2, 150.3, 135.2, 130.2, 127.7, 126.6, 50.1, 77.5, 42.7, 31.3, 25.2, 25.0. 
IR: 3031 (w), 2933 (m), 2856 (w), 1725 (s), 1607 (s), 1496 (w), 1454 (w), 1264 (w), 1124 (m), 894 (w), 738 
(m), 701 (s). 
HRMS: (ESI) calcd for C23H27N2O
+
 [M+H]
+
 347.2118; found 347.2114. 
 
General procedure A 
Yield: 21.8 mg, 68% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: white amorphous solid 
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1
H NMR (400.13 MHz, CDCl3): δ 7.24 (s, 1H), 7.22 – 7.11 (m, 10H), 3.19 (d, J = 13.0 Hz, 2H), 3.11 (d, J = 
13.2 Hz, 2H), 0.96 (s, 9H). 
13
C NMR (100.62 MHz, CDCl3): δ 183.2, 151.0, 135.2, 130.4, 127.6, 126.6, 77.5, 54.2, 43.0, 27.4. 
IR: 2922 (w), 1709 (s), 1602 (w), 1456 (w), 1281 (m), 1240 (m), 1170 (m), 1145 (w), 870 (w), 791 (w), 741 (m), 
696 (s). 
HRMS: (ESI) calcd for C21H25N2O
+
 [M+H]
+
 321.1961; found 321.1969. 
 
General procedure A 
Yield: 33.2 mg, 90% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: white amorphous solid 
1
H NMR (400.13 MHz, CDCl3): δ 7.25 – 7.16 (m, 10H), 7.16 – 7.11 (m, 1H), 7.10 – 7.04 (m, 2H), 6.96 (s, 1H), 
6.38 – 6.32 (m, 2H), 4.76 (q, J = 7.1 Hz, 1H), 3.30 (d, J = 13.1 Hz, 4H), 3.28 (d, J = 13.1 Hz, 4H), 3.25 (d, J = 
13.1 Hz, 4H), 3.23 (d, J = 13.1 Hz, 1H), 0.89 (d, J = 7.1 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 181.5, 150.6, 138.8, 135.1, 134.9, 130.4, 130.4, 128.5, 128.0, 127.7, 127.4, 
126.8, 126.8, 126.0, 77.6, 48.4, 43.2, 42.5, 18.2. 
IR: 3061 (w), 2917 (w), 1710 (m), 1609 (m), 1455 (w), 1366 (w), 1160 (w), 743 (m), 699 (s).  
HRMS: (ESI) calcd for C25H25N2O
+
 [M+H]
+
 369.1961; found 369.1951. 
[𝛂]𝐃
𝟐𝟓= - 43.8 (c 0.94, CHCl3) 
 
General procedure A 
Yield: 30.0 mg, 78% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: white amorphous solid 
1
H NMR (400.13 MHz, MeOD): 7.58 (s, 1H), 7.25 – 7.18 (m, 3H), 7.17 – 7.05 (m, 10H), 6.56 – 6.40 (m, 2H), 
4.63 (t, J = 5.4 Hz, 1H), 3.52 (dd, J = 11.6, 5.4 Hz, 1H), 3.30 – 3.25 (m, 1H), 3.24 (dd, J = 10.7, 2.5 Hz, 2H), 
3.17 (dd, J = 13.2, 3.1 Hz, 2H). 
13
C NMR (100.62 MHz, MeOD): 183.7, 154.5, 137.3, 136.1, 136.0, 131.3, 129.6, 129.1, 129.0, 128.5, 128.2, 
128.1, 127.8, 78.0, 62.9, 57.1, 44.3, 43.5, 30.8. 
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IR: 2923 (w), 2363 (w), 1729 (m), 1609 (m), 1496 (w), 1456 (w), 1362 (w), 743 (w), 700 (s).  
HRMS: (ESI) calcd for C25H25N2O2
+
 [M+H]
+
 385.1911; found 385.1910. 
[𝛂]𝐃
𝟐𝟓= - 10.6 (c 0.43, CHCl3) 
 
General procedure A 
Yield: 34.7 mg, 94% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: white amorphous solid 
1
H NMR (400.13 MHz, CDCl3): δ 7.25 – 7.15 (m, 10H), 7.01 (s, 1H), 6.38 (d, J = 8.4 Hz, 2H), 6.13 (d, J = 8.4 
Hz, 2H), 3.99 (s, 2H), 3.25 (d, J = 13.1 Hz, 2H), 3.19 (d, J = 13.1 Hz, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 182.1, 152.0, 145.8, 135.1, 130.3, 128.3, 127.9, 126.7, 124.3, 115.1, 77.2, 
43.3, 42.9. 
IR: 3424 (w), 3344 (w), 1699 (s), 1609 (s), 1519 (m), 1365 (m), 1272 (m), 1177 (m), 1147 (m), 829 (m), 734 (s).  
HRMS: (ESI) calcd for C24H24N3O
+
 [M+H]
+
 370.1914; found 370.1905. 
 
General procedure A 
Yield: 39.9 mg, 98% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: white amorphous solid 
1
H NMR (400.13 MHz, CDCl3): δ 7.91 – 7.88 (br. s, 1H), 7.44 – 7.36 (m, 1H), 7.32 – 7.28 (m, 1H), 7.25 – 7.17 
(m, 10H), 7.17 – 7.14 (m, 1H), 7.10 – 7.05 (m, 1H), 6.58 (s, 1H), 5.94 (d, J = 2.3 Hz, 1H), 3.28 (t, J = 6.7 Hz, 
2H), 3.23 (d, J = 13.1 Hz, 2H), 3.15 (d, J = 13.1 Hz, 2H), 2.42 (t, J = 6.7 Hz, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 182.6, 152.6, 136.2, 135.3, 130.5, 127.8, 126.8, 126.3, 122.7, 122.2, 119.5, 
118.3, 111.4, 111.3, 76.6, 42.9, 40.5, 24.7. 
IR: 3031 (w), 2920 (w), 1716 (m), 1607 (m), 1456 (w), 1355 (w), 1088 (w), 908 (m), 730 (s), 700 (s). 
HRMS: (ESI) calcd for C27H26N3O
+
 [M+H]
+
 408.2070; found 408.2076. 
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General procedure A 
Yield: 29.9 mg, 70% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: white amorphous solid 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.32 – 7.26 (m, 2H), 7.25 – 7.18 (m, 3H), 7.18 – 7.07 (m, 8H), 6.69 (s, 1H), 
6.44 – 6.34 (m, 2H), 4.69 (dd, J = 6.8, 4.7 Hz, 1H), 3.44 (s, 3H), 3.17 (d, J = 13.1 Hz, 1H), 3.13 (s, 2H), 3.11 (d, 
J = 13.1 Hz, 1H), 3.08 (d, J = 13.1 Hz, 1H), 2.78 (dd, J = 13.8, 4.7 Hz, 1H), 2.44 (dd, J = 13.8, 6.8 Hz, 1H). 
13
C NMR (100.62 MHz, CDCl3): δ 181.9, 169.0, 150.7, 135.3, 134.8, 134.6, 130.7, 130.3, 129.4, 128.7, 128.0, 
127.7, 127.4, 127.1, 126.7, 76.0, 53.5, 52.5, 43.0, 42.5, 37.6. 
IR: 3030 (w), 2922 (w), 1730 (s), 1609 (m), 1496 (w), 1456 (w), 1226 (w), 741 (w), 701 (s). 
HRMS: (ESI) calcd for C27H27N2O3
+
 [M+H]
+
 427.2016; found 427.2017. 
[𝛂]𝐃
𝟐𝟓= + 20.3 (c 0.96, CHCl3) 
 
General procedure A 
Yield: 34.7 mg, 74% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: white amorphous solid 
1
H NMR (400.13 MHz, CDCl3): δ 7.32 – 7.27 (m, 2H), 7.25 – 7.18 (m, 3H), 7.18 – 7.07 (m, 8H), 6.86 (s, 1H), 
6.45 – 6.43 (m, 2H), 4.57 (dd, J = 7.3, 4.6 Hz, 1H), 3.17 (d, J = 13.1 Hz, 1H), 3.14 (s, 2H), 3.11 (d, J = 13.1 Hz, 
1H), 2.65 (dd, J = 13.8, 4.6 Hz, 1H), 2.37 (dd, J = 13.7, 7.4 Hz, 1H), 1.21 (s, 9H). 
13
C NMR (100.62 MHz, CDCl3): δ 182.0, 167.5, 151.1, 135.3, 134.9, 134.7, 130.7, 130.2, 129.6, 128.4, 127.9, 
127.8, 127.3, 127.1, 126.8, 82.9, 75.9, 54.0, 42.9, 42.6, 38.0, 27.7. 
IR: 2899 (w), 1737 (m), 1720 (s), 1614 (m), 1370 (w), 1233 (w), 1146 (s), 741 (w), 700 (m).  
HRMS: (ESI) calcd for C30H33N2O3
+
 [M+H]
+
 469.2486; found 469.2487. 
[𝛂]𝐃
𝟐𝟓= + 36.5 (c 0.85, CHCl3) 
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General procedure A 
Yield: 20.6 mg, 81% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: white amorphous solid 
1
H NMR (400.13 MHz, CDCl3): δ 7.58 (s, 1H), 7.39 – 7.28 (m, 3H), 7.25 – 7.17 (m, 2H), 5.70 – 5.42 (m, 2H), 
5.10 (dd, J = 17.1, 1.7 Hz, 2H), 5.02 (dd, J = 10.2, 2.0 Hz, 2H), 4.58 (s, 2H), 2.57 (d, J = 13.6 Hz, 1H), 2.55 (d, 
J = 13.6 Hz, 1H), 2.49 (d, J = 13.6 Hz, 1H), 2.47 (d, J = 13.6 Hz, 1H) 
13
C NMR (100.62 MHz, CDCl3): δ 182.9, 152.1, 135.5, 131.4, 128.9, 128.2, 127.9, 119.4, 74.9, 44.5, 40.4. 
IR: 2934 (w), 1727 (s), 1608 (s), 1437 (w), 1350 (m), 1166 (m), 923 (m), 720 (m), 700 (m).  
HRMS: (ESI) calcd for C16H19N2O
+
 [M+H]
+
 255.1492; found 255.1499. 
 
General procedure A 
Yield: 15.5 mg, 79% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: white amorphous solid 
1
H NMR (400.13 MHz, CDCl3): δ 7.85 (s, 1H), 3.90 – 3.68 (m, 2H), 3.68 – 3.55 (m, 2H), 2.78 (s, 1H), 1.86 – 
1.60 (m, 7H), 1.55 – 1.33 (m, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 185.9, 152.8, 71.1, 60.9, 43.5, 33.0, 25.1, 21.5. 
IR: 2934 (m), 2855 (w), 1720 (s), 1609 (s), 1448 (w), 1362 (m), 1291 (w), 1181 (w), 1054 (m), 1012 (w).  
HRMS: (ESI) calcd for C10H17N2O2
+
 [M+H]
+
 197.1285; found 197.1285. 
 
 
General procedure A 
Yield: 30.6 mg, 95% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: white amorphous solid 
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1
H NMR (400.13 MHz, CDCl3): δ 7.76 – 7.67 (m, 2H), 7.62 (s, 1H), 7.42 – 7.34 (m, 2H), 7.33 – 7.27 (m, 1H), 
7.23 – 7.17 (m, 3H), 7.16 – 7.09 (m, 2H), 4.06 (d, J = 17.9 Hz, 1H), 3.92 (d, J = 17.9 Hz, 1H), 3.64 (s, 3H), 3.43 
(d, J = 13.2 Hz, 1H), 3.37 (d, J = 13.2 Hz, 1H). 
13
C NMR (100.62 MHz, CDCl3): δ 181.5, 167.6, 151.7, 138.3, 134.8, 130.6, 128.6, 128.0, 127.9, 127.0, 126.2, 
76.6, 52.9, 46.3, 41.5. 
IR: 3031 (w), 1730 (s), 1617 (m), 1496 (w), 1438 (w), 1377 (w), 1334 (w), 1277 (m), 1218 (s), 1163 (m), 955 
(m), 767 (w), 700 (s). 
HRMS: (ESI) calcd for C19H19N2O3
+
 [M+H]
+
 323.1390; found 323.1390. 
 
 
General procedure A 
Yield: 20.9 mg, 69% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: white amorphous solid 
1
H NMR (400.13 MHz, CDCl3): δ 7.81 (s, 1H), 7.70 – 7.53 (m, 2H), 7.48 – 7.29 (m, 6H), 7.23 – 7.16 (m, 2H), 
4.68 (d, J = 15.1 Hz, 1H), 4.58 (d, J = 15.2 Hz, 1H), 2.57 – 2.46 (m, 1H), 2.43 – 2.29 (m, 1H), 2.29 – 2.17 (m, 
2H). 
13
C NMR (100.62 MHz, CDCl3): δ 181.5, 153.6, 136.5, 135.1, 129.4, 129.0, 128.7, 128.6, 127.9, 126.1, 119.0, 
74.3, 45.1, 35.3, 12.6. 
IR: 3064 (w), 1727 (s), 1611 (s), 1448 (m), 1346 (m), 1265 (m), 1167 (m), 720 (m), 699 (s).  
 HRMS: (ESI) calcd for C19H17N3NaO
+
 [M+Na]
+
 326.1264; found 326.1268. 
 
General procedure A 
Yield: 27.6 mg, 82% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: white amorphous solid 
1
H NMR (400.13 MHz, CDCl3): δ 7.74 (s, 1H), 7.68 – 7.59 (m, 2H), 7.39 – 7.27 (m, 6H), 7.23 – 7.16 (m, 2H), 
4.66 (d, J = 15.2 Hz, 1H), 4.55 (d, J = 15.2 Hz, 1H), 3.60 (s, 3H), 2.58 – 2.43 (m, 1H), 2.39 – 2.16 (m, 3H). 
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13
C NMR (100.62 MHz, CDCl3): δ 182.0, 173.0, 152.7, 137.5, 135.2, 129.1, 128.5, 128.3, 127.9, 127.7, 126.0, 
74.9, 51.6, 44.7, 34.7, 28.9. 
IR: 2947 (w), 1726 (s), 1612 (m), 1437 (m), 1347 (m), 1265 (m), 1165 (m), 762 (w), 727 (m), 699 (s). 
HRMS: (ESI) calcd for C20H21N2O3
+
 [M+H]
+
 337.1547; found 337.1547. 
 
General procedure A 
Yield: 31.0 mg, 97% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: white amorphous solid 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.79 (s, 1H), 7.70 – 7.56 (m, 2H), 7.43 – 7.29 (m, 6H), 7.25 – 7.20 (m, 2H), 
4.69 (d, J = 15.1 Hz, 1H), 4.56 (d, J = 15.1 Hz, 1H), 3.26 – 3.21 (m, 2H), 2.50 – 2.36 (m, 1H), 2.36 – 2.25 (m, 
1H). 
13
C NMR (100.62 MHz, CDCl3): δ 181.8, 153.1, 137.8, 135.1, 129.2, 128.7, 128.4, 128.1, 127.8, 125.8, 73.9, 
47.0, 45.0, 38.6. 
IR: 2931 (w), 2096 (s), 1726 (s), 1611 (s), 1448 (w), 1346 (m), 1266 (m), 1167 (m), 762 (w), 699 (s).  
 HRMS: (ESI) calcd for C18H17N5NaO
+
 [M+Na]
+
 342.1325; found 342.1326. 
[𝛂]𝐃
𝟐𝟓= - 11.7 (c 2.73, CHCl3) 
 
General procedure A 
Yield: 27.1 mg, 80% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: white amorphous solid 
1
H NMR (400.13 MHz, CDCl3): δ 7.65 (s, 1H), 7.54 – 7.48 (m, 2H), 7.47 – 7.40 (m, 3H), 7.39 – 7.31 (m, 8H), 
7.31 – 7.27 (m, 2H), 4.69 (s, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 167.6, 151.3, 150.1, 139.1, 137.2, 135.9, 135.7, 132.3, 130.6, 129.7, 129.5, 
129.0, 128.2, 128.0, 127.9, 127.8, 44.9. 
IR: 3057 (w), 1701 (s), 1597 (m), 1444 (w), 1267 (m), 1166 (m), 761 (m), 721 (m), 696 (s).  
HRMS: (ESI) calcd for C23H19N2O
+
 [M+H]
+
 339.1492; found 339.1495. 
234 
 
 
General procedure A 
Yield: 24.8 mg, 80% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: white amorphous solid 
1
H NMR (400.13 MHz, CDCl3): δ 7.79 (s, 1H), 5.66 – 5.37 (m, 2 H), 5.11 (dq, J = 17.1, 1.6 Hz, 2H),  5.05 (br. 
d, J = 10.2 Hz, 2H), 5.01 – 4.96 (m, 2H), 4.71 (dd, J = 10.3, 4.4 Hz, 1H), 3.70 (s, 3H), 2.58 – 2.47 (m, 2H), 2.47 
– 2.37 (m, 3H), 2.36 – 2.19 (m, 2H), 2.09 – 2.03 (m, 1H), 2.02 (s, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 182.3, 170.0, 150.8, 131.4, 131.2, 119.7, 119.4, 74.9, 52.9, 52.2, 40.7, 40.2, 
30.0, 29.9, 15.3. 
IR: 2917 (w), 1733 (s), 1610 (m), 1436 (w), 1377 (w), 1242 (m), 1201 (w), 998 (w), 924 (w).  
HRMS: (ESI) calcd for C15H23N2O3S
+
 [M+H]
+
 311.1424; found 311.1424. 
[𝛂]𝐃
𝟐𝟓= - 9.7 (c 0.96, CHCl3) 
 
General procedure A 
Yield: 31.9 mg, 92% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: white amorphous solid 
1
H NMR (400.13 MHz, CDCl3): δ 7.65 (s, 1H), 7.48 – 7.32 (m, 3H), 7.31 – 7.20 (m, 2H), 4.61 (s, 2H), 3.64 (s, 
6H), 2.33 – 2.03 (m, 8H). 
13
C NMR (100.62 MHz, CDCl3): δ 182.8, 172.8, 153.0, 135.2, 129.2, 128.5, 127.9, 73.0, 51.7, 44.8, 31.1, 28.3. 
IR: 2952 (w), 1727 (s), 1607 (m), 1437 (m), 1350 (w), 1264 (m), 1199 (m), 1168 (m), 705 (m).  
HRMS: (ESI) calcd for C18H23N2O5
+
 [M+H]
+
 347.1601; found 347.1613. 
 
 General procedure A 
Yield: 14.8 mg, 74% yield, Eluent AcOEt/PE: 10:90 to 30:70 
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Aspect: white amorphous solid 
1
H NMR (400.13 MHz, CDCl3): δ 7.65 (s, 1H), 7.41 – 7.31 (m, 3H), 7.30 – 7.26 (m, 2H), 4.72 (s, 2H), 1.81 – 
1.73 (m, 2H), 1.73 – 1.67 (m, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 180.8, 151.9, 135.6, 129.1, 128.2, 51.9, 45.2, 19.4. 
IR: 3032 (w), 1714 (s), 1585 (s), 1456 (w), 1378 (w), 1347 (m), 1294 (m), 1142 (m), 1046 (m), 956 (m), 737 
(m), 716 (s), 697 (s). 
HRMS: (ESI) calcd for C12H13N2O
+
 [M+H]
+
 201.1022; found 201.1028. 
 
General procedure A 
Yield: 16.3 mg, 48% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.41 (s, 1H), 7.31 – 7.27 (m, 2H), 7.26 – 7.20 (m, 11H), 6.63 – 6.54 (m, 2H), 
3.36 (d, J = 13.1 Hz, 2H), 3.30 (d, J = 13.2 Hz, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 180.7, 151.6, 134.8, 132.8, 130.3, 129.4, 128.7, 127.9, 127.0, 123.2, 77.5, 
42.9. 
IR: 2923 (w), 1723 (s), 1615 (w), 1597 (w), 1503 (m), 1456 (w), 1378 (w), 1191 (w), 911 (w), 760 (w), 741 (m), 
702 (s), 689 (m). 
HRMS: (ESI) calcd for C23H21N2O
+
 [M+H]
+
 341.1648; found 341.1651. 
 
General procedure A 
Yield: 16.3 mg, 46% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: yellow oil 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.30 (s, 1H), 7.25 – 7.18 (m, 10H), 7.05 (d, J = 8.0 Hz, 2H), 6.47 (d, J = 8.0 
Hz, 2H) 3.33 (d, J = 13.1 Hz, 2H), 3.25 (d, J = 13.1 Hz, 2H), 2.28 (s, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 180.9, 151.8, 138.0, 134.8, 130.3, 129.9, 127.9, 127.0, 125.2, 123.2, 75.0, 
42.9, 21.0. 
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IR: 3031 (w), 1733 (m), 1608 (m), 1516 (m), 1377 (w), 1188 (m), 915 (w), 818 (w), 743 (m), 701 (s).  
HRMS: (ESI) calcd for C24H23N2O
+
 [M+H]
+
 355.1805; found 355.1805. 
 
General procedure A 
Yield: 19.7 mg, 51% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: yellow oil 
 
1
H NMR (400.13 MHz, CDCl3): δ 8.13 (d, J = 9.0 Hz, 2H), 7.46 (s, 1H), 7.24 – 7.14 (m, 10H), 6.94 (d, J = 9.0 
Hz, 2H), 3.34 (d, J = 13.2 Hz, 2H), 3.27 (d, J = 13.2 Hz, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 180.6, 149.3, 146.1, 138.5, 134.7, 130.3, 128.1, 127.3, 125.1, 122.1, 78.5, 
43.1. 
IR: 2924 (w), 1737 (m), 1618 (w), 1594 (s), 1521 (s), 1498 (s), 1344 (s), 1177 (m), 851 (m), 741 (m), 702 (s). 
HRMS: (ESI) calcd for C23H20N3O3
+
 [M+H]
+
 386.1499; found 386.1502. 
 
General procedure A 
Yield: 20.4 mg, 55% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: yellow oil 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.25 (s, 1H), 7.25 – 7.18 (m, 10H), 6.80 – 6.72 (m, 2H), 6.49 – 6.41 (m, 
2H), 3.74 (s, 3H), 3.32 (d, J = 13.1 Hz, 2H), 3.24 (d, J = 13.1 Hz, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 181.2, 159.1, 151.9, 135.0, 130.3, 127.9, 126.9, 125.6, 125.2, 114.6, 70.6, 
55.5, 42.9. 
IR: 2923 (w), 1733 (s), 1614 (m), 1250 (s), 1185 (m), 1032 (w), 831 (w), 745 (w), 703 (s). 
HRMS: (ESI) calcd for C24H23N2O2
+
 [M+H]
+
 371.1754; found 371.1769. 
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General procedure A 
Yield: 41.6 mg, 75% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: white amorphous solid 
1
H NMR (400.13 MHz, CDCl3): δ 7.20 – 7.11 (m, 12H), 7.10 – 7.03 (m, 8H), 5.08 (s, 2H), 3.10 (d, J = 2.4 Hz, 
8H), 2.46 (s, 4H) 
13
C NMR (100.62 MHz, CDCl3): δ 182.5, 151.5, 135.0, 130.5, 128.0, 127.2, 76.7, 42.7, 39.6. 
IR: 3030 (w), 2922 (w), 1730 (s), 1608 (s), 1455 (m), 1364 (m), 913 (m), 741 (m), 702 (s). 
HRMS: (ESI) calcd for C36H35N4O2
+
 [M+H]
+
 555.2755; found 555.2756. 
 
General procedure A 
Yield: 45.5 mg, 80% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: white amorphous solid 
1
H NMR (400.13 MHz, CDCl3): δ 7.13 – 7.06 (m, 16H), 7.08 – 6.99 (m, 4H), 6.84 (s, 2H), 3.11 (s, 8H), 1.97 – 
1.89 (m, 4H), 0.75 – 0.65 (m, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 182.4, 152.2, 135.0, 130.2, 127.7, 126.8, 77.1, 42.7, 36.1, 26.5. 
IR: 3030 (w), 2921 (w), 1722 (m), 1609 (m), 1354 (w), 1088 (w), 740 (m), 700 (s). 
HRMS: (ESI) calcd for C18H23N2O5
+
 [M+H]
+
 347.1601; found 347.1613. 
 
General procedure A 
Yield: 46.2 mg, 73% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: white amorphous solid 
1
H NMR (400.13 MHz, CDCl3): δ 7.68 (s, 1H), 7.24 – 7.10 (m, 10H), 5.06 – 5.04 (m, 1H), 3.79 – 3.71 (m, 1H), 
3.16 – 3.07 (m, 4H), 2.50 – 2.32 (m, 1H), 2.04 – 1.96 (m, 1H), 1.95 – 1.77 (m, 2H), 1.62 – 1.20 (m, 13H), 1.18 – 
0.94 (m, 9H), 0.92 (d, J = 6.5 Hz, 3H), 0.88 (d, J = 6.6 Hz, 3H), 0.86 (d, J = 6.6 Hz, 3H), 0.84 (s, 3H), 0.70 – 
0.65 (m, 1H), 0.63 (s, 3H), 0.06 – -0.13 (m, 1H). 
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13
C NMR (100.62 MHz, CDCl3): δ 183.1, 152.0, 139.0, 135.4, 135.3, 130.5, 130.4, 127.8, 127.8, 126.9, 126.8, 
123.9, 75.7, 56.8, 56.2, 49.9, 47.5, 43.0, 42.4, 42.4, 39.8, 39.7, 36.8, 36.3, 35.9, 35.0, 31.9, 31.8, 31.6, 28.3, 28.2, 
25.2, 24.3, 23.9, 23.0, 22.7, 20.6, 19.3, 18.9, 12.0. 
IR: 2934 (w), 2867 (w), 1725 (m), 1602 (w), 1456 (w), 1364 (w), 1283 (w), 738 (m), 700 (s).  
HRMS: (ESI) calcd for C44H61N2O
+
 [M+H]
+
 633.4778; found 633.4778. 
[𝛂]𝐃
𝟐𝟓= - 24 (c 0.42, CHCl3) 
 
General procedure A 
Yield: 32.9 mg, 70% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: white amorphous solid 
1
H NMR (400.13 MHz, MeOD): 8.69 – 8.60 (m, 1H), 8.03 (s, 1H), 7.97 – 7.90 (m, 1H), 7.75 (br. s, 1H), 7.61 – 
7.52 (m, 1H), 7.47 – 7.40 (m, 1H), 6.04 – 5.89 (m, 1H), 5.74 – 5.60 (m, 2H), 5.57 – 5.43 (m, 1H), 5.22 – 5.14 
(m, 1H), 5.14 – 5.09 (m, 1H), 5.06 – 4.97 (m, 2H), 4.92 – 4.83 (m, 2H), 4.02 (s, 3H), 3.30 – 3.21 (m, 1H), 3.11 – 
3.00 (m, 2H), 2.99 – 2.89 (m, 2H), 2.86 – 2.72 (m, 2H), 2.69 – 2.53 (m, 2H), 2.38 – 2.28 (m, 1H), 1.70 – 1.53 
(m, 3H), 1.26 – 1.17 (m, 1H), 1.16 – 1.05 (m, 1H). 
13
C NMR (100.62 MHz, MeOD): 173.5, 163.0, 161.4, 159.6, 148.2, 144.9, 142.2, 133.4, 133.3, 131.1, 130.3, 
123.8, 121.0, 119.5, 119.4, 115.0, 103.1, 63.9, 60.6, 56.3, 51.0, 50.1, 48.2, 40.5, 40.1, 39.6, 28.9, 27.7, 26.7. 
IR: 2936 (w), 1652 (s), 1622 (m), 1509 (s), 1476 (s), 1229 (s), 1030 (w), 995 (w), 919 (m), 850 (w), 829 (w), 
736 (w), 715 (w). 
HRMS: (ESI) calcd for C29H35N4O2
+
 [M+H]
+
 471.2755; found 471.2755. 
[𝛂]𝐃
𝟐𝟓= + 59.8 (c 1.13, CHCl3) 
 
General procedure A 
Yield: 20.3 mg, 86% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: white amorphous solid 
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1
H NMR (400.13 MHz, CDCl3): δ 8.33 (ddd, J = 8.0, 1.5, 0.6 Hz, 1H), 8.11 (s, 1H), 7.76 (ddd, J = 8.0, 6.9, 1.5 
Hz, 1H), 7.71 (ddd, J = 8.0, 1.5, 0.6 Hz, 1H), 7.51 (ddd, J = 8.0, 6.9, 1.5 Hz, 1H), 7.38 – 7.33 (m, 4H), 7.33 – 
7.28 (m, 1H), 5.20 (s, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 161.0, 148.0, 146.3, 135.7, 134.3, 129.0, 128.3, 128.0, 127.5, 127.4, 126.9, 
122.2, 49.6. 
IR: 3062 (w), 1733 (w), 1673 (s), 1474 (m), 1370 (m), 1323 (w), 775 (m), 750 (w), 711 (m), 696 (m).  
HRMS: (ESI) calcd for C15H13N2O
+
 [M+H]
+
 237.1022; found 237.1027. 
 
General procedure A 
Yield: 23.7 mg, 82% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: white amorphous solid 
1
H NMR (400.13 MHz, CDCl3): δ 8.37 (dd, J = 8.1, 1.5 Hz, 1H), 8.16 (br. s, 1H), 7.75 (ddd, J = 8.5, 7.1, 1.6 
Hz, 1H), 7.68 – 7.62 (m, 2H), 7.54 (s, 1H), 7.53 – 7.50 (m, 1H), 7.36 (dt, J = 8.1, 0.9 Hz, 1H), 7.21 (ddd, J = 8.2, 
7.1, 1.2 Hz, 1H), 7.13 (ddd, J = 8.0, 7.1, 1.0 Hz, 1H), 6.87 (d, J = 2.2 Hz, 1H), 4.30 (t, J = 6.7 Hz, 2H), 3.27 (t, J 
= 6.7 Hz, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 161.0, 147.8, 146.8, 136.5, 134.3, 127.2, 127.2, 126.8, 126.7, 122.8, 122.5, 
122.0, 119.8, 118.4, 111.6, 111.3, 47.6, 24.9. 
IR: 3312 (w), 1666 (s), 1610 (s), 1474 (m), 1376 (w), 1158 (w), 774 (m), 744 (m), 699 (w). 
HRMS: (ESI) calcd for C18H16N3O
+
 [M+H]
+
 290.1288; found 290.1288. 
Natural products synthesis: 
 
Procedure: To a solution of compound X (57.9 mg, 0.2 mmol, 1 equiv) in MeCN (2 mL) was added TFAA (42 
L, 0.3 mmol, 1.5 equiv). The reaction mixture was stirred 1 hour at RT and NaBH4 ( 0.4 nnol, 2 equiv) was 
added. The reaction mixture was stirred 1 hour at RT and quenched with a saturated aqueous solution of 
NaHCO3 and extracted with AcOEt (5 times). The organic layer was dried over Na2SO4, filtered and 
concentrated under reduced pressure to afford the desired product without further purification. 
Yield: 80% overall yield 
Aspect: yellow amorphous solid 
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1
H NMR (400.13 MHz, DMSO-d6): δ 10.90 (s, 1H), 7.76 (dd, J = 7.8, 1.5 Hz, 1H), 7.51 (dd, J = 7.8, 1.1 Hz, 
1H), 7.42 (dt, J = 8.1, 0.9 Hz, 1H), 7.35 (ddd, J = 8.4, 7.2, 1.6 Hz, 1H), 7.14 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H), 7.04 
(ddd, J = 8.0, 7.1, 1.0 Hz, 1H), 6.90 (s, 1H), 6.89 – 6.77 (m, 2H), 6.05 (t, J = 1.5 Hz, 1H), 4.86 – 4.74 (m, 1H), 
3.08 – 2.97 (m, 1H), 2.88 – 2.72 (m, 2H). 
13
C NMR (100.62 MHz, DMSO-d6): δ 163.8, 147.3, 136.4, 133.4, 130.8, 128.2, 125.9, 122.0, 119.1, 118.7, 
118.6, 116.1, 115.3, 111.7, 109.5, 63.8, 38.8, 20.1. 
IR: 3305 (w), 2925 (w), 2360 (w), 1731 (w), 1615 (s), 1489 (m), 1419 (m), 1308 (m), 1169 (m), 738 (s), 695 
(m). 
HRMS: (ESI) calcd for C18H16N3O
+
 [M+H]
+
 290.1288; found 290.1298. 
 
Aspect: yellow amorphous solid 
1
H NMR (400.13 MHz, MeOD) δ 9.00 (s, 1H), 8.50 (dd, J = 7.9, 1.6 Hz, 1H), 8.12 (t, J = 7.6 Hz, 1H), 7.90 (t, J 
= 7.7 Hz, 1H), 7.86 (d, J = 8.4 Hz, 1H), 7.38 (d, J = 8.3 Hz, 1H), 7.31 (d, J = 8.0 Hz, 1H), 7.07 (t, J = 7.6 Hz, 
1H), 6.80 (t, J = 7.5 Hz, 1H), 4.43 (t, J = 7.0 Hz, 2H), 3.75 (s, 3H), 3.33 – 3.28 (m, 2H). 
13
C NMR (100.62 MHz, MeOD): δ 159.0, 154.0, 139.3, 138.2, 138.0, 131.4, 129.6, 128.5, 125.0, 122.9, 121.4, 
120.2, 119.1, 118.5, 112.7, 110.6, 51.9, 49.6, 40.6, 24.9. 
IR: 3320 (w), 1713 (s), 1662 (m), 1276 (s), 1260 (s), 1171 (m), 1031 (s), 756 (s). 
HRMS: (ESI) calcd for C19H18N3O [M+] 304.1444; found 304.1449.. 
 
 
Yield: 18.8 mg, 62% yield Eluent DCM/MeOH: 100:0 to 95:5 
Aspect: yellow amorphous solid 
1
H NMR (400.13 MHz, CDCl3): δ 8.24 (s, 1H), 8.12 (d, J = 7.6 Hz, 1H), 7.60 (d, J = 7.8 Hz, 1H), 7.49 (t, J = 
7.5 Hz, 1H), 7.42 (d, J = 8.1 Hz, 1H), 7.26 – 7.24 (m, 1H), 7.23 – 7.17 (m, 2H), 7.14 (d, J = 8.1 Hz, 1H), 5.92 (s, 
1H), 5.03 – 4.66 (m, 1H), 3.44 – 3.21 (m, 1H), 3.05 – 2.81 (m, 2H), 2.50 (s, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 164.9, 150.8, 136.8, 133.2, 129.1, 128.4, 126.4, 124.3, 123.9, 123.2, 122.6, 
120.2, 119.1, 113.8, 111.5, 69.0, 39.7, 37.4, 20.3. 
IR: 3248 (w), 2922 (w), 1732 (w), 1638 (s), 1606 (m), 1481 (m), 1424 (s), 1168 (m), 910 (m), 744 (s), 617 (m). 
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HRMS: (ESI) calcd for C19H18N3O
+
 [M+H]
+
 304.1444; found 304.1438. 
 
Procedure: To a solution of tryptamine (32.0 mg, 0.2 mmol, 1 equiv) and methyl o-isocyanobenzoate (35.5 mg, 
0.22 mmol, 1.1 equiv) in MeCN (2 mL) was added AgNO3 (3.4 mg, 0.02 mmol, 0.1 equiv). The reaction mixture 
was stirred at 60 °C until complete consumption of the starting material (TLC monitoring, 12 hours). The 
reaction mixture was cooled to RT and TFAA (42 L, 0.3 mmol, 1.5 equiv) was added. The reaction mixture 
was stirred 1 hour at RT and EtOH (2 mL) and a 3M aqueous solution of KOH (0.2 mL) was added. The reaction 
mixture was stirred 1 hour at 60 °C. The reaction was cooled to RT and H2O2 (1 mL) was added. The reaction 
mixture was stirred 12 hour at 60 °C. The reaction was quenched with a saturated aqueous solution of NaHCO3 
and extracted with AcOEt (3 times). The organic layer was dried over Na2SO4, filtered and concentrated under 
reduced pressure. The crude product was purified by flash chromatography on silica gel (7:3 to 1:1 PE/AcOEt) 
to afford the pure product. 
Yield: 43% overall yield 
Aspect: yellow amorphous solid 
1
H NMR (400.13 MHz, CDCl3): δ 9.44 (s, 1H), 8.39 – 8.21 (m, 1H), 7.77 – 7.66 (m, 2H), 7.65 – 7.62 (m, 1H), 
7.47 – 7.38 (m, 2H), 7.36 – 7.30 (m, 1H), 7.23 – 7.14 (m, 1H), 4.59 (t, J = 6.9 Hz, 2H), 3.24 (t, J = 6.9 Hz, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 161.4, 147.1, 145.0, 138.5, 134.5, 127.3, 126.7, 126.4, 126.2, 125.8, 125.5, 
121.0, 120.7, 120.1, 118.8, 112.2, 41.2, 19.7. 
IR: 2958 (w), 2359 (m), 2343 (w), 1732 (s), 1677 (m), 1596 (s), 1471 (m), 1330 (w), 1234 (w), 1167 (m), 1149 
(w), 771 (w), 749 (w), 738 (w). 
HRMS: (ESI) calcd for C18H14N3O
+
 [M+H]
+
 288.1131; found 288.1132. 
- Pd/Cu-catalyzed 3-CR reaction 
2,3,5,5-tetrasubstituted-3,5-dihydro-4H-imidazol-4-one 
 
General procedure B 
Yield: 32.0 mg, 72% yield, Eluent AcOEt/PE: 10:90 to 30:70  
Aspect: yellow oil 
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1
H NMR (400.13 MHz, CDCl3): δ 7.31 – 7.19 (m, 10H), 7.10 – 7.03 (m, 1H), 7.01 – 6.94 (m, 4H), 6.68 (d, J = 
7.6 Hz, 2H), 6.09 (d, J = 7.6 Hz, 2H), 4.04 (s, 2H), 3.37 (s, 4H), 2.28 (s, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 183.7, 162.3, 140.8, 135.9, 135.5, 130.8, 130.5, 129.1, 128.4, 128.0, 127.6, 
127.0, 126.9, 126.1, 76.6, 44.3, 43.5, 21.5. 
IR: 3030 (w), 2919 (w), 1729 (s), 1625 (w), 1495 (w), 1455 (m), 1379 (w), 1356 (m), 1125 (m), 968 (w), 821 
(w), 750 (w), 724 (m), 701 (s). 
HRMS: (ESI) calcd for C31H29N2O
+
 [M+H]
+
 445.2274; found 445.2284. 
 
General procedure B 
Yield: 19.5 mg, 51% yield, Eluent AcOEt/PE: 10:90 to 30:70 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.42 – 7.34 (m, 1H), 7.34 – 7.25 (m, 2H), 7.27 – 7.18 (m, 10H), 6.74 (d, J = 
7.1 Hz, 2H), 3.32 (d, J = 12.8 Hz, 2H), 3.23 (d, J = 12.6 Hz, 2H), 3.16 (sept, J = 6.8 Hz 1H), 0.76 (d, J = 6.9 Hz, 
6H). 
13
C NMR (100.62 MHz, CDCl3): δ 183.7, 162.6, 135.4, 130.6, 130.1, 129.8, 128.5, 127.6, 127.4, 126.7, 75.7, 
46.2, 43.1, 19.0. 
IR: 3030 (w), 1722 (m), 1631 (w), 1495 (w), 1455 (w), 1356 (w), 1342 (w), 1287 (w), 1190 (w), 1094 (w), 1071 
(w), 1030 (w), 771 (w), 752 (m), 698 (s). 
HRMS: (ESI) calcd for C26H27N2O
+
 [M+H]
+
 383.2118; found 383.2112. 
 
General procedure B 
Yield: 34.9 mg, 82% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.25 – 7.14 (m, 11H), 6.91 (dd, J = 8.4, 2.6 Hz, 1H), 6.37 (d, J = 7.5 Hz, 
1H), 6.29 (br. s, 1H), 3.75 (s, 3H), 3.32 (d, J = 12.9 Hz, 2H), 3.26 (d, J = 13.0 Hz, 2H), 2.81 (t, J = 7.2 Hz, 2H), 
0.71 – 0.62 (m, 2H), 0.62 – 0.56 (m, 2H), 0.52 (t, J = 6.4 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 183.6, 162.1, 159.4, 135.5, 131.3, 130.5, 129.8, 127.8, 126.8, 119.6, 116.5, 
112.7, 76.2, 55.4, 43.2, 40.5, 29.9, 19.3, 13.5. 
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IR: 2957 (w), 1725 (m), 1598 (w), 1580 (w), 1494 (w), 1455 (m), 1354 (m), 1289 (m), 1097 (w), 1046 (m), 793 
(w), 750 (m), 715 (m), 700 (s). 
HRMS: (ESI) calcd for C28H31N2O2
+
 [M+H]
+
 427.2380; found 427.2379. 
 
General procedure B 
Yield: 24.2 mg, 54% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: yellow oil 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.26 – 7.22 (m, 10H), 7.09 – 7.01 (m, 1H), 6.99 – 6.92 (m, 2H), 6.88 – 6.80 
(m, 2H), 6.71 – 6.63 (m, 2H), 6.09 – 6.02 (m, 2H), 4.03 (s, 2H), 3.39 (d, J = 12.9 Hz, 2H), 3.35 (d, J = 13.0 Hz, 
2H). 
13
C NMR (100.62 MHz, CDCl3): 183.4, 163.9 (d, J =251.1 Hz), 161.3, 135.6, 135.5, 130.5, 129.8 (d, J = 8.7 
Hz), 128.5, 128.0, 127.1, 126.2, 125.9, 115.6 (d, J = 22.0 Hz), 76.8, 44.2, 43.5. 
IR: 3031 (w), 1730 (m), 1630 (w), 1603 (w), 1510 (m), 1455 (w), 1354 (m), 1236 (w), 1124 (m), 1090 (w), 1031 
(w), 840 (m), 750 (m), 700 (s). 
HRMS: (ESI) calcd for C30H26FN2O
+
 [M+H]
+
 449.2024; found 449.2017. 
 
General procedure B 
Yield: 37.5 mg, 79% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: yellow oil 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.34 – 7.26 (m, 5H), 7.24 – 7.17 (m, 5H), 7.13 – 7.05 (m, 1H), 7.04 – 6.96 
(m, 2H), 6.64 (d, J = 8.6 Hz, 2H), 6.50 (d, J = 8.3 Hz, 2H), 6.29 (d, J = 7.6 Hz, 2H), 4.59 (q, J = 7.2 Hz, 1H), 
3.74 (s, 3H), 3.34 (s, 2H), 3.33 (s, 2H), 0.87 (d, J = 7.2 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 183.3, 162.6, 160.7, 139.7, 135.4, 135.4, 130.7, 130.5, 129.2, 128.1, 127.8, 
127.8, 126.9, 126.8, 126.7, 126.1, 122.9, 113.5, 75.7, 55.2, 50.9, 43.5, 43.4, 16.9. 
IR: 2920 (w), 1725 (m), 1626 (w), 1513 (m), 1495 (w), 1455 (w), 1343 (w), 1298 (w), 1252 (s), 1176 (m), 1029 
(m), 836 (w), 749 (m), 700 (s). 
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HRMS: (ESI) calcd for C32H31N2O2
+
 [M+H]
+
 475.2380; found 475.2383. 
[𝛂]𝐃
𝟐𝟓= - 9.0 (c 1.58, CHCl3) 
 
General procedure B 
Yield: 33.0 mg, 72% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.33 – 7.27 (m, 5H), 7.12 – 7.05 (m, 1H), 7.02 – 6.97 (m, 2H), 6.96 – 6.89 
(m, 2H), 6.50 – 6.43 (m, 2H), 6.31 – 6.25 (m, 2H), 4.55 (q, J = 7.2 Hz, 1H), 3.34 (s, 2H), 3.33 (s, 2H), 2.27 (s, 
3H), 0.87 (d, J = 7.2 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 183.3, 162.9, 140.1, 139.7, 135.5, 130.9, 130.7, 128.9, 128.2, 128.0, 128.0, 
127.7, 127.6, 127.0, 126.9, 126.8, 126.3, 75.9, 51.1, 43.6, 21.5, 17.0. 
IR: 3030 (w), 1725 (m), 1628 (w), 1495 (w), 1341 (w), 1145 (w), 1093 (w), 821 (w), 748 (m), 699 (s). 
HRMS: (ESI) calcd for C32H31N2O
+
 [M+H]
+
 459.2431; found 459.2432. 
[𝛂]𝐃
𝟐𝟓= - 11.4 (c 1.82, CHCl3) 
 
General procedure B 
Yield: 32.8 mg, 65% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.80 – 7.73 (m, 2H), 7.50  – 7.46 (m, 2H), 7.38 – 7.36 (m, 2H), 7.35 – 7.26 
(m, 2H), 7.26 – 7.24 (m, 1H), 7.21 – 7.19 (m, 3H), 7.05 – 6.97 (m, 2H), 6.97 – 6.88 (m, 3H), 6.88 – 6.81 (m, 
2H), 4.75 (d, J = 15.8 Hz, 1H), 4.69 (d, J = 15.9 Hz, 1H), 3.87 (t, J = 6.5 Hz, 2H), 3.85 (s, 3H), 2.36 – 2.18 (m, 
2H), 1.84 – 1.70 (m, 2H), 1.50 – 1.37 (m, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 184.5, 162.2, 161.9, 159.1, 139.8, 136.6, 130.1, 129.5, 128.8, 128.6, 127.7, 
127.7, 127.1, 126.2, 122.2, 120.6, 114.6, 114.2, 75.3, 67.6, 55.6, 45.4, 40.7, 29.4, 21.1. 
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IR: 2940 (w), 1726 (m), 1601 (m), 1514 (m), 1496 (m), 1301 (m), 1247 (s), 1174 (m), 1032 (m), 840 (m), 755 
(s), 734 (m), 693 (s). 
HRMS: (ESI) calcd for C33H33N2O3
+
 [M+H]
+
 505.2486; found 505.2484. 
 
General procedure B 
Yield: 30.9 mg, 63% yield, Eluent AcOEt/PE: 5:95 to 20:80 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.72 – 7.64 (m, 2H), 7.34 (d, J = 8.1 Hz, 2H), 7.32 – 7.25 (m, 2H), 7.27 – 
7.20 (m, 1H), 7.19 – 7.11 (m, 5H), 6.95 – 6.88 (m, 2H), 4.73  (d, J = 16.0 Hz, 1 H), 4.69 (d, J = 16.0 Hz, 1H), 
4.02 (q, J = 7.1 Hz, 2H), 2.33 (s, 3H), 2.28 – 2.17 (m, 3H), 2.12 – 2.03 (m, 1H), 1.64 – 1.49 (m, 2H), 1.15 (t, J = 
7.1 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 184.0, 173.2, 162.8, 141.6, 139.4, 136.5, 129.5, 128.9, 128.8, 128.6, 128.4, 
127.8, 127.7, 127.1, 126.2, 75.1, 60.4, 45.3, 40.0, 34.3, 21.7, 20.0, 14.4. 
IR: 2979 (w), 1728 (s), 1622 (w), 1495 (w), 1447 (m), 1377 (m), 1329 (m), 1253 (m), 1179 (m), 1073 (m), 1031 
(m), 934 (w), 824 (m), 722 (m), 699 (s). 
HRMS: (ESI) calcd for C29H31N2O3
+
 [M+H]
+
 455.2329; found 455.2326. 
 
General procedure B 
Yield: 21.4 mg, 58% yield, Eluent AcOEt/PE: 5:95 to 20:80 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.84 – 7.69 (m, 2H), 7.43 – 7.34 (m, 4H), 7.32 – 7.27 (m, 1H), 7.24 – 7.21 
(m, 5H), 7.03 – 6.98 (m, 2H), 4.75 (d, J = 15.8 Hz, 1H), 4.67 (d, J = 15.8 Hz, 1H), 2.41 (s, 3H), 2.29 – 2.21 (m, 
2H), 0.88 (t, J = 7.3 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 184.4, 162.8, 141.6, 139.7, 136.6, 129.5, 128.8, 128.5, 128.4, 127.7, 127.7, 
127.2, 126.2, 75.8, 45.3, 34.0, 21.7, 8.8. 
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IR: 2970 (w), 1728 (s), 1623 (m), 1448 (w), 1377 (m), 1332 (m), 1118 (w), 826 (w), 765 (w), 720 (w), 699 (m).  
HRMS: (ESI) calcd for C25H25N2O
+
 [M+H]
+
 369.1961; found 369.1957. 
 
General procedure B 
Yield: 36.8 mg, 82% yield, Eluent AcOEt/PE: 5:95 to 20:80 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 8.08 (s, 1H), 8.00 – 7.88 (m, 3H), 7.64 – 7.53 (m, 3H), 4.20 – 4.02 (m, 3H), 
2.28 (t, J = 7.6 Hz, 2H), 2.24 – 2.15 (m, 2H), 1.96 – 1.73 (m, 8H), 1.70 – 1.55 (m, 2H), 1.53 – 1.40 (m, 3H), 1.24 
(t, J = 7.1 Hz, 3H), 0.91 (d, J = 6.7 Hz, 3H), 0.87 (d, J = 6.6 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 185.7, 173.3, 163.3, 134.2, 132.9, 128.9, 128.7, 128.5, 128.0, 127.9, 127.8, 
127.2, 124.5, 73.7, 60.4, 56.0, 46.2, 38.4, 34.4, 29.3, 29.0, 25.3, 25.2, 24.9, 24.5, 23.6, 18.9, 14.4. 
IR: 2955 (w), 2871 (w), 1726 (s), 1619 (w), 1470 (w), 1325 (w), 1281 (w), 1180 (w), 822 (w), 755 (w).  
HRMS: (ESI) calcd for C28H37N2O3
+
 [M+H]
+
 449.2799; found 449.2799. 
 
General procedure B 
Yield: 21.8 mg, 50% yield, Eluent AcOEt/PE: 5:95 to 20:80 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.92 – 7.81 (m, 2H), 7.40 (dd, J = 8.5, 6.8 Hz, 2H), 7.36 – 7.27 (m, 3H), 7.26 
– 7.21 (m, 5H), 7.15 – 7.08 (m, 2H), 3.51 (d, J = 12.8 Hz, 1H), 3.40 (d, J = 13.2 Hz, 1H), 3.36 – 3.27 (m, 1H), 
2.40 (s, 3H), 2.04 – 1.88 (m, 1H), 1.83 – 1.73 (m, 1H), 1.61 – 1.49 (m, 2H), 1.43 – 1.33 (m, 4H), 1.16 – 1.01 (m, 
2H), 0.98 – 0.84 (m, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 183.1, 163.3, 140.8, 139.8, 135.3, 131.2, 129.4, 128.6, 128.0, 127.8, 127.0, 
126.3, 75.5, 56.8, 47.0, 32.3, 31.8, 27.5, 27.4, 25.4, 25.3, 21.7. 
IR: 2924 (w), 2858 (w), 1722 (s), 1627 (w), 1495 (w), 1448 (w), 1344 (m), 1272 (w), 1121 (w), 823 (w), 700 (s). 
247 
 
HRMS: (ESI) calcd for C30H33N2O
+
 [M+H]
+
 437.2587; found 437.2598. 
 
General procedure B 
Yield: 30.9 mg, 63% yield, Eluent AcOEt/PE: 5:95 to 20:80  
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 8.00 – 7.84 (m, 2H), 7.47 – 7.40 (m, 2H), 7.38 – 7.31 (m, 3H), 7.30 –7.22 
(m, 3H), 7.16 – 7.07 (m, 4H), 6.65 – 6.56 (m, 1H), 6.55 – 6.48 (m, 1H), 6.01 – 5.90 (m, 1H), 4.46 (d, J = 16.5 
Hz, 1H), 4.34 (d, J = 16.6 Hz, 1H), 3.58 (d, J = 13.1 Hz, 1H), 3.52 (d, J = 13.2 Hz, 1H), 2.35 (s, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 183.0, 162.1 (dd, J = 248.7, 12.0 Hz), 161.8, 159.6 (dd, J = 249.4, 12.0 Hz), 
141.3, 139.5, 135.3, 130.9, 129.3, 129.0 (dd, J = 9.6, 5.2 Hz), 128.6, 128.0, 127.9, 127.6, 127.1, 126.5, 126.1, 
119.0 (dd, J = 14.4, 3.7 Hz), 111.5 (dd, J = 21.3, 3.6 Hz), 103.5 (t, J = 25.4 Hz), 76.3, 46.8, 38.3 (d, J = 4.7 Hz), 
21.5.  
IR: 2928 (w), 1731 (s), 1622 (m), 1607 (m), 1506 (s), 1431 (m), 1382 (m), 1338 (m), 1274 (m), 1140 (m), 1093 
(m), 967 (m), 848 (w), 824 (m), 702 (s). 
HRMS: (ESI) calcd for C30H25F2N2O
+
 [M+H]
+
 467.1929; found 467.1948. 
 
General procedure B 
Yield: 32.6 mg, 75% yield, Eluent AcOEt/PE: 5:95 to 20:80 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.36 (d, J = 7.8 Hz, 2H), 7.24 – 7.21 (m, 5H), 7.11 – 7.00 (m, 2H), 4.74 (d, J 
= 15.7 Hz, 1H), 4.68 (d, J = 15.7 Hz, 1H), 4.09 (q, J = 7.1 Hz, 2H), 2.40 (s, 3H), 2.24 (t, J = 7.6 Hz, 2H), 1.95 – 
1.76 (m, 4H), 1.59 – 1.50 (m, 2H), 1.48 – 1.38 (m, 1H), 1.23 (t, J = 7.1 Hz, 3H), 0.86 (d, J = 6.7 Hz, 3H), 0.80 
(d, J = 6.6 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 186.1, 173.2, 162.1, 141.5, 136.6, 129.6, 128.8, 128.2, 127.8, 127.5, 127.1, 
73.9, 60.4, 46.2, 45.4, 38.1, 34.4, 24.8, 24.4, 23.8, 21.7, 19.2, 14.4. 
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IR: 2955 (w), 1730 (s), 1623 (w), 1456 (w), 1376 (w), 1355 (w), 1182 (w), 822 (w), 729 (w), 702 (w).  
HRMS: (ESI) calcd for C27H35N2O3
+
 [M+H]
+
 435.2642; found 435.2649. 
 
General procedure B 
Yield: 32.9 mg, 76% yield, Eluent AcOEt/PE: 5:95 to 20:80 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 8.20 (d, J = 8.3 Hz, 2H), 7.75 – 7.64 (m, 4H), 7.36 (m, 2H), 7.33 – 7.26 (m, 
1H), 3.97 (s, 3H), 3.97 – 3.90 (m, 1H), 2.25 – 2.02 (m, 4H), 1.93 – 1.84 (m, 2H), 1.83 – 1.76 (m, 1H), 1.74 – 
1.65 (m, 1H), 1.57 – 1.42 (m, 3H), 1.17 – 1.07 (m, 2H), 0.85 (t, J = 6.3 Hz, 6H). 
13
C NMR (100.62 MHz, CDCl3): δ 183.9, 166.3, 162.9, 139.8, 134.6, 132.4, 130.2, 128.6, 128.5, 127.7, 126.1, 
75.4, 55.9, 52.6, 39.2, 32.8, 29.5, 29.4, 28.2, 25.4, 25.4, 22.7, 22.5. 
IR: 2952 (w), 2870 (w), 1723 (s), 1606 (w), 1352 (w), 1276 (s), 1106 (m), 1020 (w), 865 (w), 777 (w), 714 (m), 
700 (m). 
HRMS: (ESI) calcd for C27H33N2O3
+
 [M+H]
+
 433.2486; found 433.2502. 
 
General procedure B 
Yield: 21.4 mg, 52% yield, Eluent AcOEt/PE: 5:95 to 20:80 
Aspect: yellow oil 
 
1
H NMR (400.13 MHz, CDCl3): δ 7.86 – 7.75 (m, 2H), 7.51 – 7.38 (m, 4H), 7.37 – 7.31 (m, 1H), 7.29 – 7.23 
(m, 5H), 7.05 – 7.00 (m, 2H), 4.79 (d, J = 15.8 Hz, 1H), 4.71 (d, J = 15.8 Hz, 1H), 2.45 (s, 3H), 2.32 – 2.14 (m, 
2H), 1.55 (sept, J = 6.6 Hz, 1H), 1.15 (m, 2H), 0.88 (d, J = 6.6 Hz, 3H), 0.87 (d, J = 6.6 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 184.6, 162.3, 141.5, 140.0, 136.6, 129.5, 128.8, 128.5, 128.4, 127.9, 127.7, 
127.6, 127.2, 126.2, 75.4, 45.3, 39.1, 33.0, 28.3, 22.7, 22.5, 21.7. 
IR: 2954 (w), 2925 (w), 1729 (s), 1623 (w), 1448 (w), 1378 (w), 1329 (w), 826 (w), 722 (w), 699 (m).  
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HRMS: (ESI) calcd for C28H31N2O
+
 [M+H]
+
 411.2431; found 411.2445. 
 
General procedure B 
Yield: 27.9 mg, 74% yield, Eluent AcOEt/PE: 5:95 to 20:80 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.40 – 7.32 (m, 2H), 7.26 – 7.21 (m, 5H), 7.09 – 7.00 (m, 2H), 4.70 (s, 2H), 
2.40 (s, 3H), 1.86  (dd, J = 13.8, 5.8 Hz, 2H), 1.78 (dd, J = 13.8, 6.2 Hz, 2H), 1.52 (sept, J = 6.6 Hz, 2H), 0.85 
(d, J = 6.7 Hz, 6H), 0.81 (d, J = 6.6 Hz, 6H). 
13
C NMR (100.62 MHz, CDCl3): δ 186.9, 161.2, 141.3, 136.7, 129.6, 128.7, 128.2, 127.8, 127.7, 127.3, 74.3, 
47.5, 45.4, 24.6, 24.5, 24.1, 21.7. 
IR: 2954 (w), 2869 (w), 1728 (s), 1623 (w), 1456 (w), 1356 (m), 1329 (m), 1119 (w), 1074 (w), 948 (w), 821 
(m), 729 (m), 702 (m). 
HRMS: (ESI) calcd for C25H33N2O
+
 [M+H]
+
 377.2587; found 377.2591. 
 
General procedure B 
Yield: 18.3 mg, 55% yield, Eluent AcOEt/PE: 5:95 to 20:80 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.33 – 7.28 (m, 2H), 7.28 – 7.21 (m, 3H), 7.18 (d, J = 7.9 Hz, 2H), 7.03 – 
6.94 (m, 2H), 4.69 (s, 2H), 2.37 (s, 3H), 1.90 – 1.79 (m, 6H), 1.78 – 1.69 (m, 1H), 1.61 (d, J = 4.9 Hz, 2H), 1.52 
(s, 1H). 
13
C NMR (100.62 MHz, CDCl3): δ 187.0, 161.4, 141.2, 136.9, 129.4, 128.8, 128.4, 127.6, 126.9, 70.5, 44.7, 
33.6, 25.4, 21.6, 21.6. 
IR: 2932 (m), 2854 (w), 2361 (w), 1727 (s), 1624 (w), 1378 (w), 1353 (m), 1329 (w), 981 (w), 824 (w), 723 (w), 
697 (w). 
HRMS: (ESI) calcd for C22H25N2O
+
 [M+H]
+
 333.1961; found 333.1957. 
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General procedure B 
Yield: 21.5 mg, 61% yield, Eluent AcOEt/PE: 5:95 to 20:80 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.85 (s, 1H), 7.79 (m, 2H), 7.65 (t, J = 7.8 Hz, 1H), 3.55 – 3.44 (m, 2H), 1.86 
– 1.69 (m, 7H), 1.58 – 1.45 (m, 3H), 1.42 – 1.31 (m, 2H), 1.22 – 1.11 (m, 2H), 0.79 (t, J = 7.3 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 186.4, 160.1, 131.6 (q, J = 33.0 Hz), 131.5, 129.6, 127.7, 127.6 (br. s), 
125.2 (q, J = 3.8 Hz), 124.2 (q, J = 272.6 Hz) 122.3, 119.6, 70.9, 41.0, 33.5, 31.0, 25.3, 21.6, 19.7, 13.6. 
IR: 2934 (w), 2860 (w), 1729 (m), 1447 (w), 1329 (s), 1279 (m), 1237 (m), 1169 (m), 1129 (s), 1072 (m), 970 
(w), 910 (w), 811 (w), 699 (w). 
HRMS: (ESI) calcd for C19H24F3N2O
+
 [M+H]
+
 353.1835; found 353.1838. 
 
General procedure B 
Yield: 16.1 mg, 44% yield, Eluent AcOEt/PE: 5:95 to 20:80  
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 8.44 – 8.38 (m, 2H), 7.90 – 7.85 (m, 2H), 7.72 – 7.67 (m, 2H), 7.42 – 7.34 
(m, 3H), 7.33 – 7.27 (m, 1H), 3.64 – 3.44 (m, 2H), 2.34 – 2.09 (m, 2H), 1.48 – 1.28 (m, 2H), 1.21 – 1.10 (m, 
2H), 0.87 (t, J = 7.3 Hz, 3H), 0.78 (t, J = 7.3 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 183.7, 160.9, 149.4, 139.1, 136.2, 129.4, 128.7, 127.9, 126.0, 124.3, 76.3, 
41.5, 34.2, 31.1, 19.9, 13.6, 8.7. 
IR: 2962 (w), 2934 (w), 2362 (w), 1729 (s), 1594 (m), 1524 (s), 1350 (s), 1075 (w), 864 (m), 854 (m), 760 (m), 
703 (s). 
HRMS: (ESI) calcd for C21H24N3O3
+
 [M+H]
+
 366.1812; found 366.1825. 
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General procedure B 
Yield: 30.9 mg, 63% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.97 – 7.84 (m, 3H), 7.51 – 7.43 (m, 1H), 7.47 – 7.39 (m, 2H), 7.40 – 7.31 
(m, 5H), 7.30 – 7.21 (m, 4H), 7.19 – 7.11 (m, 2H), 7.10 (ddd, J = 8.2, 5.7, 2.4 Hz, 1H), 6.98 – 6.88 (m, 2H), 6.59 
(br. s, 1H), 3.60 (d, J = 13.0 Hz, 1H), 3.54 – 3.32 (m, 3H), 3.49 (d, J = 13.0 Hz, 1H), 2.53 (ddd, J = 14.5, 10.0, 
6.4 Hz, 1H), 2.23 (ddd, J = 14.5, 10.0, 5.3 Hz, 1H). 
13
C NMR (100.62 MHz, CDCl3): δ 182.9, 162.7, 139.2, 136.2, 135.2, 131.0, 130.8, 128.8, 128.7, 128.0, 127.9, 
127.2, 127.0, 126.3, 122.2, 122.1, 119.5, 118.4, 111.7, 111.2, 76.2, 47.1, 41.8, 24.0. 
IR: 3059 (w), 1723 (m), 1627 (w), 1597 (w), 1496 (w), 1448 (w), 1339 (w), 772 (w), 738 (s), 698 (s).  
HRMS: (ESI) calcd for C32H28N3O
+
 [M+H]
+
 470.2227; found 470.2244. 
 
General procedure B 
Yield: 34.0 mg, 52% yield, Eluent AcOEt/PE: 5:95 to 20:80 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.48 – 7.34 (m, 2H), 7.30 – 7.26 (m, 2H), 5.28 (br. s, 1H), 4.04 – 3.91 (m, 
1H), 2.59 – 2.47 (m, 1H), 2.42 (s, 3H), 2.37 – 2.29 (m, 1H), 2.20 – 2.10 (m, 1H), 2.02 – 1.90 (m, 3H), 1.85 – 
1.68 (m, 7H), 1.61 – 1.44 (m, 6H), 1.41 – 1.30 (m, 2H), 1.29 – 1.20 (m, 2H), 1.19 – 0.98 (m, 10H), 0.92 – 0.79 
(m, 25H), 0.66 (s, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 186.3, 162.6, 140.7, 138.9, 129.6, 128.5, 127.9, 123.0, 73.8, 56.9, 56.2, 
51.8, 48.2, 47.7, 47.7, 42.6, 39.9, 39.6, 36.4, 36.3, 36.0, 35.4, 34.5, 32.1, 31.7, 28.4, 28.2, 24.7, 24.7, 24.6, 24.6, 
24.5, 24.3, 24.3, 24.0, 24.0, 23.0, 22.7, 21.8, 21.7, 21.2, 18.8, 12.1. 
IR: 2952 (s), 2934 (s), 2868 (m), 1730 (s), 1625 (w), 1466 (w), 1352 (w), 1169 (w), 1113 (w), 820 (w).  
HRMS: (ESI) calcd for C44H69N2O
+
 [M+H]
+
 641.5404; found -.0005. 
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[𝛂]𝐃
𝟐𝟓= - 1.9 (c 1.88, CHCl3) 
 
General procedure B 
Yield: 30.9 mg, 63% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.30 (m, 1H), 7.23 – 7.17 (m, 4H), 7.07 (t, J = 7.5 Hz, 1H), 6.96 – 6.88 (m, 
2H), 6.57 (br. s, 1H), 4.04 (dd, J = 10.4, 5.0 Hz, 1H), 3.38 (dd, J = 14.3, 10.4 Hz, 1H), 3.32 (dd, J =14.3, 5.0 Hz, 
1H), 2.03 (s, 3H), 1.80 – 1.75 (m, 3H), 1.71 – 1.61 (m, 2H), 1.56 – 1.50 (m, 1H), 1.49 (s, 9H), 0.94 (d, J = 6.6 
Hz, 3H), 0.92 (d, J =6.6 Hz, 6H), 0.88 (d, J = 6.6 Hz, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 185.9, 167.9, 160.6, 137.4, 137.3, 130.6, 130.2, 129.6, 129.0, 128.8, 128.6, 
127.0, 125.8, 83.1, 74.9, 58.5, 46.0, 45.9, 34.4, 28.1, 25.0, 24.9, 24.8, 24.8, 24.5, 24.4, 19.2. 
IR: 2953 (w), 1727 (s), 1633 (w), 1456 (w), 1365 (m), 1277 (m), 1155 (s), 847 (w), 768 (w), 749 (w), 701 (m). 
 
HRMS: (ESI) calcd for C31H43N2O3
+
 [M+H]
+
 491.3268; found 491.3268. 
[𝛂]𝐃
𝟐𝟓= - 52.0 (c 2.65, CHCl3) 
 
General procedure B 
Yield: 26 mg, 51% yield, Eluent AcOEt/PE: 40:60 to 80:20 
Aspect: yellow oil 
1
H NMR (400.13 MHz, MeOD): δ 7.45 – 7.36 (m, 7H), 7.36 – 7.32 (m, 2H), 7.24 – 7.21 (m, 3H), 7.00 – 6.96 
(m, 2H), 4.78 (d, J = 15.6 Hz, 1H), 4.72 (d, J = 15.6 Hz, 1H), 3.90 (s, 2H), 2.74 – 2.64 (m, 2H), 2.47 (s, 3H), 
2.43 (s, 3H), 1.88 – 1.77 (m, 4H), 1.61 – 1.55 (m, 2H), 1.53 – 1.45 (m, 1H), 1.32 – 1.25 (m, 2H), 1.21 – 1.13 (m, 
1H), 1.08 – 0.99 (m, 1H), 0.87 (d, J = 6.6 Hz, 3H), 0.81 (d, J = 6.6 Hz, 3H). 
13
C NMR (100.62 MHz, MeOD): δ 187.1, 164.8, 143.4, 137.7, 131.4, 130.7, 129.9, 129.9, 129.6, 129.2, 128.9, 
128.9, 127.8, 75.1, 61.9, 57.5, 47.4, 46.0, 41.2, 39.6, 27.9, 26.2, 25.7, 24.7, 24.3, 24.1, 21.5. 
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IR: 2946 (w), 2365 (w), 1728 (s), 1623 (w), 1456 (w), 1377 (w), 1356 (w), 1329 (w), 1118 (w), 822 (w), 743 
(w), 731 (w), 700 (m). 
HRMS: (ESI) calcd for C34H44N3O
+
 [M+H]
+
 510.3479; found 510.3481. 
 
General procedure B 
Yield: 36.7 mg, 78% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.54 (br s., 1H), 7.25 (d, J = 4.1 Hz, 4H), 7.24 – 7.17 (m, 6H), 7.16 (d, J = 
7.9 Hz, 2H), 7.10 (d, J = 7.6 Hz, 3H), 7.04 (t, J = 7.5 Hz, 2H), 6.18 (d, J = 7.6 Hz, 2H), 5.84 (d, J = 15.9 Hz, 
1H), 4.22 (s, 2H), 3.44 – 3.28 (m, 4H), 2.32 (s, 3H). 
13
C NMR (100.62 MHz, CDCl3): δ 182.4, 159.2, 140.2, 138.9, 135.3, 132.0, 130.3, 129.5, 128.7, 128.5, 127.9, 
127.6, 127.2, 126.8, 125.7, 112.2, 76.3, 43.5, 42.8, 21.4. 
IR: 3029 (w), 2360 (w), 1730 (m), 1639 (w), 1593 (m), 1495 (w), 1455 (w), 1387 (w), 1356 (m), 1183 (w), 976 
(w), 807 (w), 757 (w), 701 (s). 
HRMS: (ESI) calcd for C33H31N2O
+
 [M+H]
+
 471.2431; found 471.2452. 
 
General procedure B 
Yield: 30.1 mg, 58% yield, Eluent AcOEt/PE: 20:80 to 40:60 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.76 – 7.71 (m, 1H), 7.71 – 7.66 (m, 2H), 7.49 – 7.42 (m, 1H), 7.41 – 7.33 
(m, 2H), 7.33 – 7.27 (m, 3H), 7.26 – 7.22 (m, 1H), 7.20 – 7.14 (m, 1H), 7.11 – 7.03 (m, 1H), 6.97 – 6.90 (m, 
1H), 6.84 (d, J = 8.1 Hz, 2H), 6.70 (s, 1H), 3.88 (t, J = 6.3 Hz, 2H), 3.74 – 3.58 (m, 2H), 3.09 – 2.92 (m, 2H), 
2.15 (dq, J = 15.3, 7.9, 7.2 Hz, 2H), 1.79 – 1.72 (m, 2H), 1.69 (s, 3H), 1.62 (s, 3H), 1.53 (s, 3H), 1.47 – 1.36 (m, 
2H). 
13
C NMR (100.62 MHz, CDCl3): δ 184.1, 165.2, 159.1, 140.1, 137.4, 136.5, 129.6, 128.5, 127.6, 127.2, 126.1, 
122.8, 122.3, 120.7, 119.6, 118.4, 114.6, 111.7, 111.4, 74.9, 67.6, 41.8, 40.4, 29.4, 24.4, 22.3, 21.2, 20.0, 17.3. 
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IR: 2944 (w), 1727 (s), 1600 (m), 1496 (m), 1448 (m), 1358 (m), 1356 (m), 1246 (s), 1109 (w), 1035 (w), 758 
(s), 746 (s), 694 (m). 
HRMS: (ESI) calcd for C34H38N3O2
+
 [M+H]
+
 520.2959; found 520.2663. 
 
General procedure B 
Yield: 23.4 mg, 55% yield, Eluent AcOEt/PE: 20:80 to 40:60 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.56 – 7.31 (m, 5H), 5.86 (s, 1H), 5.76 (s, 1H), 4.12 (q, J = 7.1 Hz, 2H), 3.12 
– 3.00 (m, 1H), 2.31 (t, J = 7.5 Hz, 2H), 1.93 – 1.80 (m, 2H), 1.79 – 1.62 (m, 6H), 1.61 – 1.48 (m, 3H), 1.24 (t, J 
= 7.1 Hz, 3H), 0.99 (d, J = 6.3 Hz, 3H), 0.93 (d, J = 6.2 Hz, 3H), 0.58 (t, J = 7.4 Hz, 3H), 0.57(t, J = 7.4 Hz, 3H) 
13
C NMR (100.62 MHz, CDCl3): δ 185.9, 173.1, 163.6, 140.9, 136.5, 129.2, 129.1, 126.7, 121.5, 74.0, 60.4, 
59.8, 46.1, 37.7, 34.6, 24.9, 24.8, 24.7, 24.6, 24.3, 19.7, 14.4, 11.5. 
IR: 2962 (w), 2934 (w), 2875 (w), 2363 (w), 1726 (s), 1609 (w), 1461 (m), 1350 (m), 1214 (m), 1181 (m), 1072 
(w), 1030 (w), 924 (w), 780 (w), 700 (m). 
HRMS: (ESI) calcd for C26H39N2O3
+
 [M+H]
+
 427.2955; found 427.2961. 
 
General procedure B 
Yield: 14.9 mg, 44% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 8.09 (m, J = 16.6 Hz, 1H), 7.91 – 7.82 (m, 2H), 7.59 – 7.48 (m, 2H), 7.45 – 
7.36 (m, 3H), 7.35 – 7.31 (m, 1H), 7.31 – 7.26 (m, 2H), 7.14 – 7.09 (m, 2H), 7.08 – 7.03 (m, 1H), 4.47 (d, J = 
16.5 Hz, 1H), 4.23 (d, J = 16.4 Hz, 1H), 3.57 (d, J = 13.2 Hz, 1H), 3.51 (d, J = 13.6 Hz, 1H). 
13
C NMR (100.62 MHz, CDCl3): δ 179.3, 165.1, 145.4, 135.0, 133.1, 130.5, 129.1, 128.9, 128.7, 128.2, 128.1, 
127.8, 127.1, 126.3, 126.2, 124.5, 84.5, 46.7, 44.6. 
IR: 3060 (w), 2925 (w), 1724 (s), 1448 (m), 1343 (m), 1308 (w), 736 (m), 721 (m), 700 (s).  
HRMS: (ESI) calcd for C23H19N2O
+
 [M+H]
+
 339.1492; found 339.1498. 
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General procedure B 
Yield: 17.4 mg, 48% yield, Eluent AcOEt/PE: 10:90 to 30:70 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 8.10 (s, 1H), 7.77 – 7.69 (m, 2H), 7.65 – 7.60 (m, 1H), 7.58 – 7.55 (m, 1H), 
7.54 – 7.49 (m, 1H), 7.38 – 7.33 (m, 2H), 7.31 – 7.27 (m, 1H), 4.74 (d, J = 16.4 Hz, 1H), 4.62 (d, J = 16.4 Hz, 
1H), 4.07 (q, J = 7.1 Hz, 3H), 2.33 – 2.25 (m, 2H), 2.26 – 2.12 (m, 2H), 1.70 – 1.60 (m, 2H), 1.21 (t, J = 7.1 Hz, 
3H). 
13
C NMR (100.62 MHz, CDCl3): δ 179.5, 173.3, 165.9, 145.6, 139.6, 133.0, 129.1, 128.7, 128.6, 127.9, 126.0, 
124.7, 123.9, 83.8, 60.5, 44.8, 39.8, 34.2, 20.0, 14.3. 
IR: 2930 (w), 1727 (s), 1664 (m), 1447 (w), 1337 (m), 1252 (w), 1180 (m), 1159 (m), 1033 (w), 737 (m), 700 
(m). 
HRMS: (ESI) calcd for C22H23N2O3
+
 [M+H]
+
 363.1703; found 363.1701. 
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Chapter 4 
Characterization data 
 
Yield: 40% over two steps 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.77 – 7.69 (m, 1H), 7.68 – 7.62 (m, 1H), 7.57 – 7.45 (m, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 171.6, 133.9, 133.3, 129.8, 128.7 (t, J = 12.9 Hz), 127.5, 114.6, 111.1. 
IR: 2234 (w), 2124 (s), 1711 (w), 1668 (w), 1594 (w), 1485 (w), 1453 (m), 766 (s), 738 (s), 714 (m).  
HRMS: (ESI) calcd for C8H5N2
+
 [M+H]
+
 129.0447; found 129.0446. 
 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 3.81 (s, 3H), 2.01 – 1.81 (m, 3H), 1.76 (dd, J = 13.6, 4.8 Hz, 1H), 1.66 – 
1.56 (m, 1H), 1.00 (d, J = 6.5 Hz, 3H), 0.93 – 0.87 (m, 1H), 0.85 (d, J = 6.4 Hz, 3H), 0.66 – 0.52 (m, 1H), 0.50 – 
0.41 (m, 1H), 0.22 – 0.14 (m, 1H), 0.09 – -0.01 (m, 1H). 
13
C NMR (100.62 MHz, CDCl3): δ 170.1, 159.9, 67.9, 53.3, 47.2, 45.7, 25.1, 23.9, 22.1, 6.1, 4.0, 4.0. 
IR: 2361 (w), 2341 (w), 1617 (s), 1579 (s), 1477 (m), 1388 (m), 1145 (w), 952 (w), 770 (m), 730 (m). 
HRMS: (ESI) calcd for C22H18N2O [M+] 326.1419; found 326.1650. 
 
Yield: 82% yield 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 3.81 (s, 3H), 2.01 – 1.81 (m, 3H), 1.76 (dd, J = 13.6, 4.8 Hz, 1H), 1.66 – 
1.56 (m, 1H), 1.00 (d, J = 6.5 Hz, 3H), 0.93 – 0.87 (m, 1H), 0.85 (d, J = 6.4 Hz, 3H), 0.66 – 0.52 (m, 1H), 0.50 – 
0.41 (m, 1H), 0.22 – 0.14 (m, 1H), 0.09 – -0.01 (m, 1H). 
13
C NMR (100.62 MHz, CDCl3): δ 170.1, 159.9, 67.9, 53.3, 47.2, 45.7, 25.1, 23.9, 22.1, 6.1, 4.0, 4.0. 
IR: 2957 (m), 2362 (w), 1745 (s), 1625 (w), 1436 (w), 1267 (m), 1206 (m), 1013 (w).  
257 
 
HRMS: (ESI) calcd for C15H22N2NaO4
+
 [M+Na]
+
 317.1472; found 317.1476. 
 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.31 – 7.27 (m, 2H), 7.16 – 7.09 (m, 2H), 3.76 (s, 3H), 2.65 (d, J = 12.9 Hz, 
1H), 2.34 (s, 3H), 2.07 (d, J = 12.9 Hz, 1H), 2.06 – 1.97 (m, 1H), 1.89 – 1.80 (m, 2H), 1.18 – 1.11 (m, 1H), 1.08 
– 1.01 (m, 1H), 0.96 (s, 3H), 0.95 (s, 3H), 0.95 – 0.84 (m, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 177.9, 175.6, 139.5, 130.7, 129.0, 127.7, 79.2, 52.4, 48.1, 43.6, 32.2, 25.2, 
24.2, 24.0, 21.5, 13.1, 12.5. 
IR: 2951 (w), 1732 (s), 1596 (w), 1451 (w), 1359 (w), 1221 (m), 1133 (w), 819 (w). 
HRMS: (ESI) calcd for C19H26NO2
+
 [M+H]
+
 300.1958; found 300.1961. 
 
Aspect: yellow oil 
1
H NMR (400.13 MHz, CDCl3): δ 7.92 (d, J = 8.2 Hz, 2H), 7.35 – 7.28 (m, 2H), 2.44 (s, 3H), 2.03 (dd, J = 
13.9, 5.9 Hz, 1H), 1.94 – 1.75 (m, 2H), 1.69 – 1.59 (m, 2H), 0.88 (d, J = 6.7 Hz, 3H), 0.84 (d, J = 6.6 Hz, 3H), 
0.65 – 0.54 (m, 1H), 0.38 – 0.32 (m, 2H), 0.10 (ddd, J = 8.8, 5.1, 1.3 Hz, 2H). 
13
C NMR (100.62 MHz, CDCl3): δ 181.7, 159.9, 143.4, 129.7, 128.0, 123.5, 73.7, 46.4, 43.8, 25.1, 24.2, 23.3, 
21.8, 5.7, 4.1, 3.8. 
IR: 2957 (w), 1816 (s), 1735 (w), 1654 (s), 1316 (w), 1302 (w), 1181 (w), 1047 (m), 988 (m), 885 (w), 729 (w).  
HRMS: (ESI) calcd for C18H23NO2 [M+] 285.1723; found 285.1724. 
 (m), 1698 (w), 1651 (s), 1608 (w), 1330 (m), 1244 (s), 1179 (w), 758 (w). 
HRMS: (ESI) calcd for C18H23NO2 [M+] 285.1723; found 285.1724. 
 
Aspect: yellow oil 
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1
H NMR (400.13 MHz, CDCl3): δ 7.78 – 7.69 (m, 2H), 7.46 (s, 1H), 7.29 – 7.21 (m, 2H), 3.82 (s, 3H), 2.78 
(dd, J = 14.1, 5.9 Hz, 1H), 2.67 (dd, J = 14.0, 5.1 Hz, 1H), 2.40 (s, 3H), 1.71 (dd, J = 14.0, 7.9 Hz, 1H), 1.65 – 
1.56 (m, 2H), 1.55 – 1.47 (m, 1H), 0.88 (d, J = 6.6 Hz, 3H), 0.78 (d, J = 6.6 Hz, 3H), 0.58 – 0.46 (m, 1H), 0.40 – 
0.25 (m, 2H), 0.10 – 0.02 (m, 1H), -0.04 – -0.15 (m, 1H). 
13
C NMR (100.62 MHz, CDCl3): δ 176.2, 166.2, 141.9, 132.6, 129.4, 127.0, 65.0, 52.6, 43.7, 40.8, 24.9, 24.0, 
22.6, 21.6, 6.3, 3.7, 3.6. 
IR: 3418 (w), 2955 (w), 1730 (m), 1664 (s), 1494 (s), 1445 (m), 1232 (s), 1192 (m), 830 (m), 750 (s). 
HRMS: (ESI) calcd for C19H28NO3
+
 [M+H]
+
 318.2064; found 318.2065. 
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